![]() |
![]() |
My Amedeo
![]() ![]() ![]() |
![]() |
|||||||||
C49 + CC Journal Club For more information, please refer to our special emails from April 13 and May 19. |
Bladder Cancer, January 2023
Retrieve all available abstracts of the following 2497 articles:
|
Single Articles |
AMEDEO Bladder Cancer is free of charge.
Lymph node assessment technique matters in radical cystectomy for bladder cancer.
ANZ J Surg. 2023 Mar 3. doi: 10.1111/ans.18292.
Abstract
COMPARATIVE RESULTS OF MODERN EXAMINATION METHODS IN EARLY DIAGNOSIS OF BLADDER
CANCER, DETERMINATION OF THE DEGREE OF INVASION AND SELECTION OF RADICAL
TREATMENT TACTICS.
Georgian Med News. 2023;:98-102.
Abstract
Epigenetically regulated gene expression profiles recognized three molecular
classifications with prognostic and therapeutic implications in bladder cancer.
Clin Transl Med. 2023;13:e1145.
Abstract
[A Case of Long-Term Survival Following Multidisciplinary Therapy for Small
Intestinal Metastasis of Bladder Cancer].
Hinyokika Kiyo. 2023;69:55-58.
Abstract
Chemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus
capecitabine: a nationwide cohort study.
Radiother Oncol. 2023 Feb 28:109584. doi: 10.1016/j.radonc.2023.109584.
Abstract
Evaluation of predictive factors in patients with bladder cancer undergoing
atezolizumab treatment: Case reports.
Indian J Cancer. 2022;59:556-559.
Abstract
Retraction: CircRNA circPDSS1 promotes bladder cancer by downregulating miR-16.
Biosci Rep. 2023;43:BSR-2019-1961.
Abstract
A bispecific glycopeptide spatiotemporally regulates tumor microenvironment for
inhibiting bladder cancer recurrence.
Sci Adv. 2023;9:eabq8225.
Abstract
A serum miRNAs signature for early diagnosis of bladder cancer.
Ann Med. 2023;55:736-745.
Abstract
Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical
Challenge in the Current Therapeutic Scenario.
Technol Cancer Res Treat. 2023;22:15330338231159753.
Abstract
RNA-seq reveals novel mechanistic targets of Livin in bladder cancer.
BMC Urol. 2023;23:26.
Abstract
Down-regulation and clinical significance of Sorbin and SH3 domain-containing
protein 1 in bladder cancer tissues.
IET Syst Biol. 2023 Feb 28. doi: 10.1049/syb2.12060.
Abstract
The PSCA rs2294008 (C/T) Polymorphism Increases the Risk of Gastric and Bladder
Cancer: A Meta-Analysis.
Genet Test Mol Biomarkers. 2023;27:44-55.
Abstract
Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus
Calmette-Guerin for the Treatment of Patients With High-Risk Non-Muscle-Invasive
Bladder Cancer.
JAMA Netw Open. 2023;6:e230849.
Abstract
Trimodality Therapy in which Concurrent Chemoradiation with Concomitant Boost in
Muscle Invasive TCC Urinary Bladder Cancer.
Asian Pac J Cancer Prev. 2023;24:517-524.
Abstract
Cancer-associated fibroblast-derived extracellular vesicles mediate immune escape
of bladder cancer via PD-L1/PD-1 expression.
Endocr Metab Immune Disord Drug Targets. 2023.
Abstract
Apatinib Inhibits Bladder Cancer through Suppression of The VEGFR2-PI3K-AKT
Signaling Pathway as revealed by Network Pharmacology and In Vitro Experimental
Verification.
Comb Chem High Throughput Screen. 2023.
Abstract
A case of Avelumab response to multiple bone and lymph node metastases of
plasmacytoid variant bladder cancer.
Urol Case Rep. 2023;47:102358.
Abstract
The role of smoking in explaining racial/ethnic disparities in bladder cancer
incidence in the United States.
Urol Oncol. 2023 Feb 25:S1078-1439(23)00051.
Abstract
Assessing the Increased Variability in Individual Lesion Kinetics During
Immunotherapy: Does It Exist, and Does It Matter?
JCO Precis Oncol. 2023;7:e2200368.
Abstract
Intraoperative complication of radical cystectomy for muscle-invasive bladder
cancer: does the surgical approach matter? A retrospective multicenter study
using the EAUiaiC classification.
World J Urol. 2023 Feb 27. doi: 10.1007/s00345-023-04340.
Abstract
Occupational asbestos exposure and urinary bladder cancer: a systematic review
and meta-analysis.
World J Urol. 2023 Feb 27. doi: 10.1007/s00345-023-04327.
Abstract
To determine correlation between VIRADS scoring and pathological staging in
bladder cancer: A prospective study and review of literature.
Urologia. 2023 Feb 27:3915603231151738. doi: 10.1177/03915603231151738.
Abstract
Inhibitor of apoptosis proteins as therapeutic targets in bladder cancer.
Front Oncol. 2023;13:1124600.
Abstract
Bladder mucinous adenocarcinoma as a diagnostic challenge: a case report.
Pan Afr Med J. 2022;42:221.
Abstract
Case report: Urothelial carcinoma of the renal pelvis with trophoblastic
differentiation: A rare case report and review of literature.
Pathol Oncol Res. 2023;29:1610856.
Abstract
BCG unresponsive non-muscle invasive bladder cancer: The beginning of a new era?
Actas Urol Esp (Engl Ed). 2023 Feb 24:S2173-5786(23)00018.
Abstract
Low expression of ZSCAN4 predicts unfavorable outcome in urothelial carcinoma of
upper urinary tract and urinary bladder.
World J Surg Oncol. 2023;21:62.
Abstract
Kavalactone Kawain Impedes Urothelial Tumorigenesis in UPII-Mutant Ha-Ras Mice
via Inhibition of mTOR Signaling and Alteration of Cancer Metabolism.
Molecules. 2023;28:1666.
Abstract
Combined Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer: How
(Should) We Do It? A Narrative Review.
J Clin Med. 2023;12:1560.
Abstract
Development and Validation of Nomograms Predicting the 5- and 8-Year Overall and
Cancer-Specific Survival of Bladder Cancer Patients Based on SEER Program.
J Clin Med. 2023;12:1314.
Abstract
Nanoparticle-Based Techniques for Bladder Cancer Imaging: A Review.
Int J Mol Sci. 2023;24:3812.
Abstract
HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic,
and Predictive Role.
Int J Mol Sci. 2023;24:3720.
Abstract
Melatonin-Assisted Cisplatin Suppresses Urinary Bladder Cancer Cell Proliferation
and Growth through Inhibiting PrP(C)-Regulated Cell Stress and Cell Proliferation
Signaling.
Int J Mol Sci. 2023;24:3353.
Abstract
Replacement Instead of Discontinuation of Bacillus Calmette-Guerin Instillation
in Non-Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2023;15:1345.
Abstract
Development of Deep Learning with RDA U-Net Network for Bladder Cancer
Segmentation.
Cancers (Basel). 2023;15:1343.
Abstract
Approaches to Clinical Complete Response after Neoadjuvant Chemotherapy in
Muscle-Invasive Bladder Cancer: Possibilities and Limitations.
Cancers (Basel). 2023;15:1323.
Abstract
Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients with
No Progression and with No More than Five Residual Metastatic Lesions Following
First-Line Systemic Therapy: A Retrospective Analysis.
Cancers (Basel). 2023;15:1161.
Abstract
RNA-Binding Proteins in Bladder Cancer.
Cancers (Basel). 2023;15:1150.
Abstract
The Diagnostic and Therapeutic Role of snoRNA and lincRNA in Bladder Cancer.
Cancers (Basel). 2023;15:1007.
Abstract
Overexpression of KMT9alpha Is Associated with Aggressive Basal-like Muscle-Invasive
Bladder Cancer.
Cells. 2023;12:589.
Abstract
The Current Progress and Future Options of Multiple Therapy and Potential
Biomarkers for Muscle-Invasive Bladder Cancer.
Biomedicines. 2023;11:539.
Abstract
Development of a Sensitive Digital Droplet PCR Screening Assay for the Detection
of GPR126 Non-Coding Mutations in Bladder Cancer Urine Liquid Biopsies.
Biomedicines. 2023;11:495.
Abstract
Oxidative Stress Markers in Urine and Serum of Patients with Bladder Cancer.
Antioxidants (Basel). 2023;12:277.
Abstract
[SENTIERI - Epidemiological Study of Residents in National Priority Contaminated
Sites. Sixth Report].
Epidemiol Prev. 2023;47.
Abstract
Reporting perioperative complications of radical cystectomy: the influence of
using standard methodology based on ICARUS and EAU quality criteria.
World J Surg Oncol. 2023;21:58.
Abstract
Micro-mechanical fingerprints of the rat bladder change in actinic cystitis and
tumor presence.
Commun Biol. 2023;6:217.
Abstract
Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant
durvalumab in patients with localized urothelial cancer of bladder: results from
phase II study, BTCRC-GU15-023.
J Immunother Cancer. 2023;11:e006551.
Abstract
Comprehensive genomic profiling of upper tract urothelial carcinoma and
urothelial carcinoma of the bladder identifies distinct molecular
characterizations with potential implications for targeted therapy &
immunotherapy.
Front Immunol. 2023;13:1097730.
Abstract
Molecular genetic and clinical characteristic analysis of primary signet ring
cell carcinoma of urinary bladder identified by a novel OR2L5 mutation.
Cancer Med. 2023;12:3931-3951.
Abstract
News in the classification of WHO 2022 bladder tumors.
Pathologica. 2022;115:32-40.
Abstract
Nectin-4: a Tumor Cell Target and Status of Inhibitor Development.
Curr Oncol Rep. 2023;25:181-188.
Abstract
Quantitative MRI in distinguishing bladder paraganglioma from bladder leiomyoma.
Abdom Radiol (NY). 2023;48:1051-1061.
Abstract
Influence of luminal and basal subtype in prognosis of high-grade non muscle
invasive urothelial carcinoma.
Ann Diagn Pathol. 2023;63:152081.
Abstract
Invasive urothelial carcinoma with squamous differentiation and associated
high-risk human papilloma virus infection: Clinical, cytologic, and histologic
features of a rare entity.
Ann Diagn Pathol. 2023;63:152103.
Abstract
Pediatric inflammatory myofibroblastic tumor of the bladder with ALK-FN1 fusion
successfully treated by alectinib.
Pediatr Blood Cancer. 2023;70:e30172.
Abstract
The feasibility of robot-assisted radical cystectomy: an experimental study.
World J Urol. 2023;41:477-482.
Abstract
Prognostic significance of minor high grade component in non-invasive papillary
urothelial carcinoma of urinary bladder: (A study of 273 consecutive cases over a
period of 3 years).
Ann Diagn Pathol. 2023;63:152079.
Abstract
Effects of Holliday Junction-Recognition Protein-Mediated C-Jun N-Terminal
Kinase/ Signal Transducer and Activator of Transcription 3 Signaling Pathway on
Cell Proliferation, Cell Cycle and Cell Apoptosis in Bladder Urothelial
Carcinoma.
Tohoku J Exp Med. 2023;259:209-219.
Abstract
Bladder EpiCheck urine test in the follow-up of NMIBC: a cost analysis.
World J Urol. 2023;41:471-476.
Abstract
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results
from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.
Ann Oncol. 2023;34:289-299.
Abstract
Register-based research. Accurate data and analysis, crucial for correct
conclusions. Comment on "Incidence, mortality, and relative survival of patients
with cancer of the bladder and upper urothelial tract in the Nordic countries
between 1990 and 20
Scand J Urol. 2023;57.
Abstract
Leiomyoma: a case of a rare benign mesenchymal neoplasm of the urinary bladder.
Pol Arch Intern Med. 2023;133:16381.
Abstract
Incidence, mortality and relative survival of patients with cancer of the bladder
and upper urothelial tract in the Nordic countries between 1990 and 2019.
Scand J Urol. 2023;57.
Abstract
The prognostic role of p53 and its correlation with CDK9 in urothelial carcinoma.
Clin Transl Oncol. 2023;25:830-840.
Abstract
Dietary Capsaicin Reduces Chemically Induced Rat Urinary Bladder Carcinogenesis.
Plant Foods Hum Nutr. 2023;78:93-99.
Abstract
Functional evaluation of a spiral neobladder with an angled chimney; A
prospective randomized comparative study.
Eur J Surg Oncol. 2023;49:491-496.
Abstract
Urachal carcinoma: A novel staging system utilizing the National Cancer Database.
Cancer Med. 2023;12:2752-2760.
Abstract
Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to
evaluate enfortumab vedotin versus chemotherapy in subjects with previously
treated locally advanced or metastatic urothelial carcinoma.
Cancer Med. 2023;12:2761-2771.
Abstract
Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial
carcinoma.
Cancer Immunol Immunother. 2023;72:775-782.
Abstract
Association between cannabis use with urological cancers: A population-based
cohort study and a mendelian randomization study in the UK biobank.
Cancer Med. 2023;12:3468-3476.
Abstract
Using machine learning for mortality prediction and risk stratification in
atezolizumab-treated cancer patients: Integrative analysis of eight clinical
trials.
Cancer Med. 2023;12:3744-3757.
Abstract
Discontinuation of pembrolizumab for advanced urothelial carcinoma without
disease progression: Nationwide cohort study.
Cancer Med. 2023;12:2325-2332.
Abstract
Vulvar pagetoid urothelial intraepithelial neoplasia: a case report.
Acta Chir Belg. 2023;123:174-177.
Abstract
LONG-TERM FOLLOW-UP OF ASYMMETRIC BILATERAL DIFFUSE UVEAL MELANOCYTIC
PROLIFERATION IN A PATIENT WITH METASTASIZED UROTHELIAL CARCINOMA.
Retin Cases Brief Rep. 2023;17:105-110.
Abstract
Current Status of Perioperative Therapy in Muscle-Invasive Bladder Cancer and
Future Directions.
Curr Oncol Rep. 2023 Mar 10. doi: 10.1007/s11912-023-01390.
Abstract
En Bloc Resection Versus Conventional TURBT for T1HG Bladder Cancer: A Propensity
Score-Matched Analysis.
Ann Surg Oncol. 2023 Mar 10. doi: 10.1245/s10434-023-13227.
Abstract
Evaluating the cost-utility of intravesical bacillus calmette-guerin versus
radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer
in the UK.
J Med Econ. 2023 Mar 10:1-19. doi: 10.1080/13696998.2023.2189860.
Abstract
Contrast-enhanced Ultrasound Combined With Elastography for the Evaluation of
Muscle-invasive Bladder Cancer in Rats.
J Ultrasound Med. 2023 Mar 10. doi: 10.1002/jum.16216.
Abstract
Comparative Effectiveness of Radiation Versus Radical Cystectomy for Localized
Muscle-Invasive Bladder Cancer.
Adv Radiat Oncol. 2022;8:101157.
Abstract
Comprehensive analysis of cuproptosis-related genes on bladder cancer prognosis,
tumor microenvironment invasion, and drug sensitivity.
Front Oncol. 2023;13:1116305.
Abstract
Artificial intelligence-based model for lymph node metastases detection on whole
slide images in bladder cancer: a retrospective, multicentre, diagnostic study.
Lancet Oncol. 2023 Mar 6:S1470-2045(23)00061.
Abstract
Critical Appraisal of Decision Models Used for the Economic Evaluation of Bladder
Cancer Screening and Diagnosis: A Systematic Review.
Pharmacoeconomics. 2023 Mar 8. doi: 10.1007/s40273-023-01256.
Abstract
Phenotype of Urine Sediment Cells in Patients with Bladder Cancer.
Bull Exp Biol Med. 2023 Mar 9. doi: 10.1007/s10517-023-05732.
Abstract
Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic
Opportunities.
Eur Urol Oncol. 2023 Mar 6:S2588-9311(23)00043-3. doi: 10.1016/j.euo.2023.
Abstract
[Frailty and surgical tolerability in elderly patients undergoing robot-assisted
radical cystectomy (RARC)].
Nihon Ronen Igakkai Zasshi. 2023;60:38-42.
Abstract
In vivo detection of circulating tumor cells predicts high-risk features in
patients with bladder cancer.
Med Oncol. 2023;40:113.
Abstract
Systematic radiomics analysis based on multiparameter MRI to preoperatively
predict the expression of Ki67 and histological grade in patients with bladder
cancer.
Br J Radiol. 2023 Mar 8:20221086. doi: 10.1259/bjr.20221086.
Abstract
Enfortumab Vedotin in metastatic bladder cancer: a case report of durable
clinical efficacy in a pretreated patient.
Acta Biomed. 2023;94.
Abstract
Disparities in cause-specific mortality by race and sex among bladder cancer
patients from the SEER database.
Cancer Causes Control. 2023 Mar 8. doi: 10.1007/s10552-023-01679.
Abstract
Adenocarcinoma of the Bladder: Assessment of Survival Advantage Associated With
Radical Cystectomy and Comparison With Urothelial Bladder Cancer.
Urol Oncol. 2023 Mar 5:S1078-1439(23)00015-7. doi: 10.1016/j.urolonc.2023.
Abstract
EffectiveNess of a multimodal preHAbilitation program in patieNts with bladder
canCEr undergoing radical cystectomy: protocol of the ENHANCE multicentre
randomised controlled trial.
BMJ Open. 2023;13:e071304.
Abstract
Treatment strategies for the Bacillus Calmette-Guerin-unresponsive non-muscle
invasive bladder cancer.
Investig Clin Urol. 2023;64:103-106.
Abstract
Efficacy of Combined Pembrolizumab and Pelvic Radiotherapy for Bladder Cancer
With Rectal Metastases.
In Vivo. 2023;37:912-915.
Abstract
PABPN1 regulates mRNA alternative polyadenylation to inhibit bladder cancer
progression.
Cell Biosci. 2023;13:45.
Abstract
A new biomarker panel of ultraconserved long non-coding RNAs for bladder cancer
prognosis by a machine learning based methodology.
BMC Bioinformatics. 2023;23.
Abstract
Gemcitabine-cisplatin versus MVAC chemotherapy for urothelial carcinoma: a
nationwide cohort study.
Sci Rep. 2023;13:3682.
Abstract
Improved protocol for single-nucleus RNA-sequencing of frozen human bladder tumor
biopsies.
Nucleus. 2023;14:2186686.
Abstract
In vivo detection demonstrates circulating tumor cell reduction instead of
baseline number has prognostic value in bladder cancer patients receiving
neoadjuvant chemotherapy.
Cell Oncol (Dordr). 2023 Mar 6. doi: 10.1007/s13402-023-00785.
Abstract
In brief: Adstiladrin - a gene therapy for bladder cancer.
Med Lett Drugs Ther. 2023;65:e40-e41.
Abstract
Drug-induced interstitial pneumonia after intravesical Bacillus Calmette-Guerin
administration for bladder cancer with scleroderma.
IJU Case Rep. 2023;6:133-136.
Abstract
Patient Preferences for Treatment of Bacillus Calmette-Guerin-unresponsive
Non-muscle-invasive Bladder Cancer: A Cross-country Choice Experiment.
Eur Urol Open Sci. 2023;49:92-99.
Abstract
Cytoskeleton regulator RNA expression on cancer-associated fibroblasts is
associated with prognosis and immunotherapy response in bladder cancer.
Heliyon. 2023;9:e13707.
Abstract
Prediction of immune infiltration and prognosis for patients with urothelial
bladder cancer based on the DNA damage repair-related genes signature.
Heliyon. 2023;9:e13661.
Abstract
Comprehensive Analysis of the Expression, Prognosis, and Biological Significance
of PLOD Family in Bladder Cancer.
Int J Gen Med. 2023;16:707-722.
Abstract
Where To Draw the Line: Stratifying Risk for High-grade Ta Bladder Cancer.
Eur Urol Oncol. 2023 Mar 3:S2588-9311(23)00035-4. doi: 10.1016/j.euo.2023.
Abstract
EDIT Software: A tool for the semi-automatic 3D reconstruction of bladder cancer
and urinary bladder of animal models.
Comput Methods Programs Biomed. 2023;232:107448.
Abstract
Anticancer properties of cannabidiol and Delta(9)-tetrahydrocannabinol and
synergistic effects with gemcitabine and cisplatin in bladder cancer cell lines.
J Cannabis Res. 2023;5:7.
Abstract
Biochemical network analysis of protein-protein interactions to follow-up T1
bladder cancer patients.
J Proteomics. 2023 Mar 2:104865. doi: 10.1016/j.jprot.2023.104865.
Abstract
Single-Cell Phenotyping of CD73 Expression Reveals the Diversity of the Tumor
Immune Microenvironment and Reflects the Prognosis of Bladder Cancer.
Lab Invest. 2023;103:100040.
Abstract
Which data subset should be augmented for deep learning? a simulation study using
urothelial cell carcinoma histopathology images.
BMC Bioinformatics. 2023;24:75.
Abstract
Global Meta-analysis of Urine Microbiome: Colonization of Polycyclic Aromatic
Hydrocarbon-degrading Bacteria Among Bladder Cancer Patients.
Eur Urol Oncol. 2023 Mar 1:S2588-9311(23)00036-6. doi: 10.1016/j.euo.2023.
Abstract
Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder
cancer.
Urol Oncol. 2023 Mar 1:S1078-1439(23)00009-1. doi: 10.1016/j.urolonc.2023.
Abstract
Adenoviral gene therapy for bladder cancer.
Cell. 2023;186:893.
Abstract
Transurethral en bloc resection of a bladder perivascular epithelioid cell tumor
(PEComa): a case report.
BMC Urol. 2023;23:28.
Abstract
Progression-associated molecular changes in basal/squamous and sarcomatoid
bladder carcinogenesis.
J Pathol. 2023;259:455-467.
Abstract
Actionable genomic landscapes from a real-world cohort of urothelial carcinoma
patients.
Urol Oncol. 2023;41:148.
Abstract
Immunohistochemical analysis of expression of VEGFR2, KIT, PDGFR-beta, and CDK4 in
canine urothelial carcinoma.
J Vet Diagn Invest. 2023;35:109-115.
Abstract
Switch-maintenance avelumab immunotherapy following first-line chemotherapy for
patients with advanced, unresectable or metastatic urothelial carcinoma: the
first Japanese real-world evidence from a multicenter study.
Jpn J Clin Oncol. 2023;53:253-262.
Abstract
Conditional survival after radical cystectomy for non-metastatic muscle-invasive
squamous cell carcinoma of the urinary bladder: A population-based analysis.
Urol Oncol. 2023;41:147.
Abstract
Early experience with UGN-101 for the treatment of upper tract urothelial cancer
- A multicenter evaluation of practice patterns and outcomes.
Urol Oncol. 2023;41:147.
Abstract
Probiotics enhances anti-tumor immune response induced by gemcitabine plus
cisplatin chemotherapy for urothelial cancer.
Cancer Sci. 2023;114:1118-1130.
Abstract
Cutoff values of PD-L1 expression in urinary cytology samples for predicting
response to immune checkpoint inhibitor therapy in upper urinary tract urothelial
carcinoma.
Cancer Cytopathol. 2023;131:179-187.
Abstract
Pulmonary thrombotic microangiopathy caused by neoplastic urothelial carcinoma
cells.
Med Clin (Barc). 2023;160:226-227.
Abstract
Comparison between renal pelvic and ureteral tumors in muscle-invasive upper
tract urothelial carcinoma.
Cancer Sci. 2023;114:984-994.
Abstract
DNA methylation analysis in urinary samples: A useful method to predict the risk
of neoplastic recurrence in patients with urothelial carcinoma of the bladder in
the high-risk group.
Cancer Cytopathol. 2023;131:158-164.
Abstract
Prevalence and risk estimation of cancer-predisposing genes for upper urinary
tract urothelial carcinoma in Japanese.
Jpn J Clin Oncol. 2022;52:1441-1445.
Abstract
Expression of p53 Protein Associates with Anti-PD-L1 Treatment Response on
Human-Derived Xenograft Model of GATA3/CR5/6-Negative Recurrent Nonmuscular
Invasive Bladder Urothelial Carcinoma.
Int J Mol Sci. 2021;22:9856.
Abstract
Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic
Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic
Signaling and the Tumor Immune Microenvironment.
Int J Mol Sci. 2021;22:9526.
Abstract
Blood-based protein biomarkers in bladder urothelial tumors.
J Proteomics. 2021;247:104329.
Abstract
Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After
Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label,
Single-Arm, Phase 2 ARCADIA Trial.
Clin Genitourin Cancer. 2021;19:457-465.
Abstract
Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial
Carcinoma Treated With First-line PD1/L1 Inhibitors.
Clin Genitourin Cancer. 2021;19:425-433.
Abstract
The Diagnostic Value of FDG-PET/CT for Urachal Cancer.
Clin Genitourin Cancer. 2021;19:373-380.
Abstract
Three-Dimensional Deep Noninvasive Radiomics for the Prediction of Disease
Control in Patients With Metastatic Urothelial Carcinoma treated With
Immunotherapy.
Clin Genitourin Cancer. 2021;19:396-404.
Abstract
Mining The Cancer Genome Atlas gene expression data for lineage markers in
distinguishing bladder urothelial carcinoma and prostate adenocarcinoma.
Sci Rep. 2021;11:6765.
Abstract
Comparison of clinical outcomes in patients with localized or locally advanced
urothelial carcinoma treated with neoadjuvant chemotherapy involving
gemcitabine-cisplatin and high dose-intensity MVAC.
J Cancer Res Clin Oncol. 2021;147:3421-3429.
Abstract
Coexistent urothelial papilloma and ureteric calculus in an 8-year-old child: A
rare co-occurrence.
J Postgrad Med. 2021;67:182-183.
Abstract
Prognostic factors and nomogram for the overall survival of bladder cancer bone
metastasis: A SEER-based study.
Medicine (Baltimore). 2023;102:e33275.
Abstract
Tumour microenvironment as a predictive factor for immunotherapy in
non-muscle-invasive bladder cancer.
Cancer Immunol Immunother. 2023 Mar 16. doi: 10.1007/s00262-023-03376.
Abstract
SNHG18 inhibits bladder cancer cell proliferation by increasing p21 transcription
through destabilizing c-Myc protein.
Cancer Cell Int. 2023;23:48.
Abstract
Predicting bladder cancer risk in patients with hematuria. A single-centre
retrospective study.
Arch Ital Urol Androl. 2023 Mar 15. doi: 10.4081/aiua.2023.11026.
Abstract
Anthropometric characteristics and relationship with non-muscle invasive bladder
cancer in Greece: A case-control study.
Arch Ital Urol Androl. 2023 Mar 15. doi: 10.4081/aiua.2023.11266.
Abstract
An m7G-related lncRNA signature predicts prognosis and reveals the immune
microenvironment in bladder cancer.
Sci Rep. 2023;13:4302.
Abstract
Added Clinical Value of (18)F-FDG-PET/CT to Stage Patients With High-Risk
Non-Muscle Invasive Bladder Cancer Before Radical Cystectomy.
Clin Genitourin Cancer. 2023 Feb 22:S1558-7673(23)00037.
Abstract
Multiple directional DWI combined with T2WI in predicting muscle layer and Ki-67
correlation in bladder cancer in 3.0-T MRI.
Cancer Med. 2023 Mar 14. doi: 10.1002/cam4.5782.
Abstract
Prognostic value of galectin-1 and galectin-3 expression in localized urothelial
bladder cancer.
Transl Androl Urol. 2023;12:228-240.
Abstract
Neoadjuvant and adjuvant chemotherapy share equivalent efficacy in improving
overall survival and cancer-specific survival among muscle invasive bladder
cancer patients who undergo radical cystectomy: a retrospective cohort study
based on SEER databas
Transl Androl Urol. 2023;12:330-346.
Abstract
Identification and validation of immunohistochemical marker panels to predict the
prognosis of muscle invasive bladder cancer.
Transl Androl Urol. 2023;12:176-186.
Abstract
Exosomal miR-93-5p as an important driver of bladder cancer progression.
Transl Androl Urol. 2023;12:286-299.
Abstract
Nitidine chloride regulates cell function of bladder cancer in vitro through
downregulating Lymphocyte antigen 75.
Naunyn Schmiedebergs Arch Pharmacol. 2023.
Abstract
Global trends in the epidemiology of bladder cancer: challenges for public health
and clinical practice.
Nat Rev Clin Oncol. 2023 Mar 13. doi: 10.1038/s41571-023-00744.
Abstract
Fibronectin-1: A Predictive Immunotherapy Response Biomarker for Muscle‑Invasive
Bladder Cancer.
Arch Esp Urol. 2023;76:70-83.
Abstract
Robotic Radical Cystectomy with Intracorporeal Urinary Diversion - Tips and
Tricks.
Chirurgia (Bucur). 2023;118:63-72.
Abstract
Identification of a glutamine metabolism reprogramming signature for predicting
prognosis, immunotherapy efficacy, and drug candidates in bladder cancer.
Front Immunol. 2023;14:1111319.
Abstract
Prognostic nomogram for estimating survival in patients with resected
muscle-invasive bladder cancer receiving chemotherapy.
Front Surg. 2023;10:1121184.
Abstract
Association of regional anesthesia with oncological outcomes in patients
receiving surgery for bladder cancer: A meta-analysis of observational studies.
Front Oncol. 2023;13:1097637.
Abstract
Recreating heterogeneity of bladder cancer microenvironment to study its
recurrences and progression.
Stem Cell Investig. 2023;10:5.
Abstract
Trends and risk factors of global incidence, mortality, and disability of
genitourinary cancers from 1990 to 2019: Systematic analysis for the Global
Burden of Disease Study 2019.
Front Public Health. 2023;11:1119374.
Abstract
ASO Author Reflections: Is T1HG Bladder Cancer a Good Candidate for En Bloc
Resection?
Ann Surg Oncol. 2023 Mar 12. doi: 10.1245/s10434-023-13291.
Abstract
Predicting muscle invasion in bladder cancer based on MRI: A comparison of
radiomics, and single-task and multi-task deep learning.
Comput Methods Programs Biomed. 2023;233:107466.
Abstract
A Systematic Review of Oncological Outcomes Associated with Bladder-sparing
Strategies in Patients Achieving Complete Clinical Response to Initial Systemic
Treatment for Localized Muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2023 Mar 9:S2588-9311(23)00040-8. doi: 10.1016/j.euo.2023.
Abstract
Differences in Quality of Life and Toxicity for Male and Female Patients
following Chemo(radiotherapy) for Bladder Cancer.
Clin Oncol (R Coll Radiol). 2023 Feb 11:S0936-6555(23)00052.
Abstract
Effect of isorhamnetin on carbonic anhydrase IX expression and tumorigenesis of
bladder cancer by activating PPARgamma/PTEN/AKT pathway.
Tissue Cell. 2023;82:102048.
Abstract
Glutathione S-transferase zeta 1 alters the HMGB1/GPX4 axis to drive ferroptosis
in bladder cancer cells.
Hum Exp Toxicol. 2023;42:9603271231161606.
Abstract
Effective-by-method for the preparation of folic acid coated TiO(2) nanoparticles
with high targeting potential for apoptosis induction against bladder cancer
cells (T24).
Biotechnol Appl Biochem. 2023 Mar 11. doi: 10.1002/bab.2456.
Abstract
LncRNA JHDM1D-AS1 Is a Key Biomarker for Progression and Modulation of
Gemcitabine Sensitivity in Bladder Cancer Cells.
Molecules. 2023;28:2412.
Abstract
Clinical Significance and Tumor Microenvironment Characterization of a Novel
Immune-Related Gene Signature in Bladder Cancer.
J Clin Med. 2023;12:1892.
Abstract
The Effect of Sex on Disease Stage and Survival after Radical Cystectomy in
Non-Urothelial Variant-Histology Bladder Cancer.
J Clin Med. 2023;12:1776.
Abstract
Association of SNPs in the PAI1 Gene with Disease Recurrence and Clinical Outcome
in Bladder Cancer.
Int J Mol Sci. 2023;24:4943.
Abstract
Crosstalk between Mesenchymal Stem Cells and Cancer Stem Cells Reveals a Novel
Stemness-Related Signature to Predict Prognosis and Immunotherapy Responses for
Bladder Cancer Patients.
Int J Mol Sci. 2023;24:4760.
Abstract
Emerging RNA-Based Therapeutic and Diagnostic Options: Recent Advances and Future
Challenges in Genitourinary Cancers.
Int J Mol Sci. 2023;24:4601.
Abstract
Focus on the Use of Resveratrol in Bladder Cancer.
Int J Mol Sci. 2023;24:4562.
Abstract
Correction: Zhu et al. A Feedback Loop Formed by ATG7/Autophagy, FOXO3a/miR-145
and PD-L1 Regulates Stem-like Properties and Invasion in Human Bladder Cancer.
Cancers 2019, 11, 349.
Cancers (Basel). 2023;15:1403.
Abstract
Evaluating the Protective Effect of Intravesical Bacillus Calmette-Guerin against
SARS-CoV-2 in Non-Muscle Invasive Bladder Cancer Patients: A Multicenter
Observational Trial.
Cancers (Basel). 2023;15:1618.
Abstract
A Comprehensive Analysis of Immune Response in Patients with Non-Muscle-Invasive
Bladder Cancer.
Cancers (Basel). 2023;15:1364.
Abstract
Clinical Characteristics and Current Status of Treatment for Recurrent Bladder
Cancer after Surgeries on Upper Tract Urothelial Carcinoma.
Diagnostics (Basel). 2023;13:1004.
Abstract
Methylation analysis of histone 4-related gene HIST1H4F and its effect on gene
expression in bladder cancer.
Gene. 2023;866:147352.
Abstract
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.
Cancer Treat Rev. 2023;115:102530.
Abstract
A novel microfluidic system for enrichment of functional circulating tumor cells
in cancer patient blood samples by combining cell size and invasiveness.
Biosens Bioelectron. 2023;227:115159.
Abstract
Urachal carcinoma: The journey so far and the road ahead.
Pathol Res Pract. 2023;243:154379.
Abstract
UCseek: ultrasensitive early detection and recurrence monitoring of urothelial
carcinoma by shallow-depth genome-wide bisulfite sequencing of urinary sediment
DNA.
EBioMedicine. 2023;89:104437.
Abstract
Efficacy and safety of enfortumab vedotin in the treatment of advanced urothelial
carcinoma: a systematic review and meta-analysis.
Anticancer Drugs. 2023;34:473-478.
Abstract
Complete response to tislelizumab in a metastatic urothelial carcinoma after
surgery associated with high tumor mutational burden: a case report.
Anticancer Drugs. 2023;34:595-598.
Abstract
Nested Subtype of Urothelial Carcinoma in the Upper Urinary Tract: A Series of 15
Cases.
Am J Surg Pathol. 2023;47:461-468.
Abstract
Robot-assisted laparoscopic cystectomy with non-continent urinary diversion for
neurogenic lower urinary tract dysfunction: Midterm outcomes.
Neurourol Urodyn. 2023;42:586-596.
Abstract
Application of Transvaginal Natural Orifice Specimen Extraction Surgery in
Urological Surgery.
J Laparoendosc Adv Surg Tech A. 2023;33:231-235.
Abstract
MiR-9 promotes proliferation and inhibits apoptosis of bladder cancer cells via
notch signaling pathway.
Panminerva Med. 2023;65:114-115.
Abstract
Evidence for virus-mediated oncogenesis in bladder cancers arising in solid organ
transplant recipients.
Elife. 2023;12:e82690.
Abstract
A Comprehensive View on the Quercetin Impact on Bladder Cancer: Focusing on
Oxidative stress, Cellular, and Molecular Mechanisms.
Fundam Clin Pharmacol. 2023 Mar 24. doi: 10.1111/fcp.12896.
Abstract
Anlotinib Enhances the Therapeutic Effect of Bladder Cancer with GSDMB
Expression: Analyzed from TCGA Bladder Cancer Database & Mouse Bladder Cancer
Cell Line.
Pharmgenomics Pers Med. 2023;16:219-228.
Abstract
The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells
infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer.
Front Immunol. 2023;14:1085476.
Abstract
Adjuvant intravesical treatment in patients with intermediate and high-risk
non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or
EMDA. Results of a prospective study.
J Cancer Res Clin Oncol. 2023 Mar 23:1-7. doi: 10.1007/s00432-023-04688.
Abstract
Implications for diagnosis and treatment strategies in non-muscle invasive
bladder cancer with variant histology: a systematic review.
Minerva Urol Nephrol. 2023 Mar 22. doi: 10.23736/S2724-6051.23.05091.
Abstract
Corrigendum to "The Significance of Squamous Histology on Clinical Outcomes and
PD-L1 Expression in Bladder Cancer".
Int J Surg Pathol. 2023 Mar 22:10668969231164482. doi: 10.1177/10668969231164482
Abstract
Attenuation of cancer proliferation by suppression of glypican-1 and its
pleiotropic effects in neoplastic behavior.
Oncotarget. 2023;14:219-235.
Abstract
P4HA2-mediated HIF-1alpha stabilization promotes erdafitinib-resistance in
FGFR3-alteration bladder cancer.
FASEB J. 2023;37:e22840.
Abstract
Antioxidant status in patients with bladder cancer regarding cancer stage and
grade.
Asian J Urol. 2023;10:182-188.
Abstract
Vascular graft infections caused by Mycobacterium bovis BCG after BCG
immunotherapy for non-muscle-invasive bladder cancer: Case report and review of
literature.
J Clin Tuberc Other Mycobact Dis. 2023;31:100360.
Abstract
Geriatric nutritional risk index as a prognostic marker for patients with upper
tract urothelial carcinoma receiving radical nephroureterectomy.
Sci Rep. 2023;13:4554.
Abstract
Development of a predictive model for recurrence-free survival in pTa low-grade
bladder cancer.
Urol Oncol. 2023 Mar 18:S1078-1439(23)00047.
Abstract
Urinary BLACAT1 as a non-invasive biomarker for bladder cancer.
Mol Biol Rep. 2023 Mar 20. doi: 10.1007/s11033-023-08370.
Abstract
Examining the Role of Microbiota-Centered Interventions in Cancer Therapeutics:
Applications for Urothelial Carcinoma.
Technol Cancer Res Treat. 2023;22:15330338231164196.
Abstract
Anti-tumor effect of AZD8055 against bladder cancer and bladder cancer-associated
macrophages.
Heliyon. 2023;9:e14272.
Abstract
Serum metabolites as early detection markers of non-muscle invasive bladder
cancer in Chinese patients.
Front Oncol. 2023;13:1061083.
Abstract
Plasmacytoid Variant Urothelial Cell Carcinoma: A Case of a Histological Variant
of Urinary Bladder Cancer With Aggressive Behavior.
Cureus. 2023;15:e36278.
Abstract
ACER2 forms a cold tumor microenvironment and predicts the molecular subtype in
bladder cancer: Results from real-world cohorts.
Front Genet. 2023;14:1148437.
Abstract
Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy.
BMC Urol. 2023;23:38.
Abstract
High expression of ABCF1 is an independent predictor of poor prognosis in bladder
cancer.
BMC Urol. 2023;23:37.
Abstract
Management of the patient with urostomy: Caregiver needs during the three months
after discharge. A qualitative study.
Arch Ital Urol Androl. 2023;95.
Abstract
TULA DUAL: Trans Urethral Laser Ablation of recurrent bladder tumors in
outpatient setting.
Arch Ital Urol Androl. 2023;95.
Abstract
Reprint of: Female Urethral Carcinoma: A contemporary review of the
clinicopathologic features, with emphasis on the histo-anatomic landmarks and
potential staging issues.
Hum Pathol. 2023;133:126-135.
Abstract
Possible etiological association of ovine papillomaviruses with bladder tumors in
cattle.
Virus Res. 2023;328:199084.
Abstract
o-Toluidine metabolism and effects in the urinary bladder of humanized-liver
mice.
Toxicology. 2023;488:153483.
Abstract
iATMEcell: identification of abnormal tumor microenvironment cells to predict the
clinical outcomes in cancer based on cell-cell crosstalk network.
Brief Bioinform. 2023;24:bbad074.
Abstract
Nadofaragene Firadenovec: First Approval.
Drugs. 2023;83:353-357.
Abstract
Biological knowledge graph-guided investigation of immune therapy response in
cancer with graph neural network.
Brief Bioinform. 2023;24:bbad023.
Abstract
Is high accuracy of Vesical Imaging-Reporting and Data System (VI-RADS)
sufficient for its implementation in the urological practice?
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2023;167:85-90.
Abstract
Comparison of different methods of obturator nerve block in transurethral
resection of bladder tumors: A systematic review and network meta-analysis.
Cancer Med. 2023;12:5420-5435.
Abstract
Implications of the non-specific effect induced by Bacillus Calmette-Guerin (BCG)
vaccine on vaccine recommendations.
J Pediatr (Rio J). 2023;99 Suppl 1:S22-S27.
Abstract
Effectiveness of pembrolizumab in trial-ineligible patients with metastatic
urothelial carcinoma.
Cancer Immunol Immunother. 2023;72:841-849.
Abstract
Clinicopathologic analysis of patients undergoing repeat transurethral resection
of bladder tumour following an initial diagnosis of urothelial carcinoma with
lamina propria invasion and variant/divergent histology.
J Clin Pathol. 2023;76:256-260.
Abstract
MiR-9 promotes proliferation and inhibits apoptosis of bladder cancer cells via
notch signaling pathway.
Panminerva Med. 2023;65:114-115.
Abstract
A comprehensive analysis of immunogenic cell death and its key gene HSP90AA1 in
bladder cancer.
Clin Transl Oncol. 2023 Mar 31. doi: 10.1007/s12094-023-03143.
Abstract
Nutrient Patterns and Bladder Cancer: A Case-Control Study in Iran.
Nutr Cancer. 2023 Mar 31:1-7. doi: 10.1080/01635581.2023.2191383.
Abstract
Selective Cellular Uptake and Cytotoxicity of Curcumin-encapsulated SPC and HSPC
Liposome Nanoparticles on Human Bladder Cancer Cells.
Curr Pharm Des. 2023 Mar 31. doi: 10.2174/1381612829666230331084848.
Abstract
Bioengineered bacterial outer membrane vesicles encapsulated Polybia-mastoparan I
fusion peptide as a promising nanoplatform for bladder cancer immune-modulatory
chemotherapy.
Front Immunol. 2023;14:1129771.
Abstract
Bladder Preservation After Bilateral Kidney Loss and Bladder Cancer After Renal
Transplantation: A Case Report.
Transplant Proc. 2023 Mar 28:S0041-1345(23)00087.
Abstract
The iBLAD app protocol - a national, exploratory study on a multimodality
smartphone app in bladder cancer for better understanding symptoms, quality of
life and need for supportive care.
Acta Oncol. 2023 Mar 30:1-5. doi: 10.1080/0284186X.2023.2194031.
Abstract
The prognostic and immunological role of MYB: from bladder cancer validation to
pan-cancer analysis.
Biosci Rep. 2023 Mar 30:BSR20222627. doi: 10.1042/BSR20222627.
Abstract
Impact of previous malignancy at diagnosis on oncological outcomes of upper tract
urothelial carcinoma.
BMC Urol. 2023;23:49.
Abstract
The effect of treatment on work productivity in patients with bladder cancer.
Urol Oncol. 2023 Mar 27:S1078-1439(23)00056.
Abstract
KRT13-expressing epithelial cell population predicts better response to
chemotherapy and immunotherapy in bladder cancer: Comprehensive evidences based
on BCa database.
Comput Biol Med. 2023;158:106795.
Abstract
Canadian Bladder Cancer Forum 2023 Meeting Abstracts - Poster Presentations.
Can Urol Assoc J. 2023;17.
Abstract
Canadian Bladder Cancer Forum 2023 Meeting Abstracts - Podium Presentations.
Can Urol Assoc J. 2023;17.
Abstract
Letter to the Editor: "Prospective assessment of VI-RADS score in multiparametric
MRI in bladder cancer: accuracy and the factors affecting the results".
Diagn Interv Radiol. 2023;29:412-413.
Abstract
Chondrosarcoma of Ureter in an Elderly Patient: A Case Report.
Medicina (Kaunas). 2023;59:454.
Abstract
The Urinary Microbiome and Bladder Cancer.
Life (Basel). 2023;13:812.
Abstract
Bladder Cancer and Risk Factors: Data from a Multi-Institutional Long-Term
Analysis on Cardiovascular Disease and Cancer Incidence.
J Pers Med. 2023;13:512.
Abstract
Blood-Based Biomarkers as Prognostic Factors of Recurrent Disease after Radical
Cystectomy: A Systematic Review and Meta-Analysis.
Int J Mol Sci. 2023;24:5846.
Abstract
HSPA5 Promotes the Proliferation, Metastasis and Regulates Ferroptosis of Bladder
Cancer.
Int J Mol Sci. 2023;24:5144.
Abstract
Elevated Baseline Neutrophil Count Correlates with Worse Outcomes in Patients
with Muscle-Invasive Bladder Cancer Treated with Chemoradiation.
Cancers (Basel). 2023;15:1886.
Abstract
New Approaches to Targeting Epigenetic Regulation in Bladder Cancer.
Cancers (Basel). 2023;15:1856.
Abstract
Body Composition of Patients Undergoing Radical Cystectomy for Bladder Cancer:
Sarcopenia, Low Psoas Muscle Index, and Myosteatosis Are Independent Risk Factors
for Mortality.
Cancers (Basel). 2023;15:1778.
Abstract
Refining the Characterization and Outcome of Pathological Complete Responders
after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from
the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
Cancers (Basel). 2023;15:1742.
Abstract
Performing Automatic Identification and Staging of Urothelial Carcinoma in
Bladder Cancer Patients Using a Hybrid Deep-Machine Learning Approach.
Cancers (Basel). 2023;15:1673.
Abstract
Pyruvate Dehydrogenase Kinase 4 Deficiency Increases Tumorigenesis in a Murine
Model of Bladder Cancer.
Cancers (Basel). 2023;15:1654.
Abstract
Circulating Tumor Cells Predict Response of Neoadjuvant Chemotherapy in Patients
with Bladder Cancer: A Preliminary Study.
Diagnostics (Basel). 2023;13:1032.
Abstract
Differential Occupancy and Regulatory Interactions of KDM6A in Bladder Cell
Lines.
Cells. 2023;12:836.
Abstract
The Significance of Matrix Metalloproteinase 9 (MMP-9) and Metalloproteinase 2
(MMP-2) in Urinary Bladder Cancer.
Biomedicines. 2023;11:956.
Abstract
Ubiquitin-Specific Proteases as Potential Therapeutic Targets in Bladder
Cancer-In Vitro Evaluation of Degrasyn and PR-619 Activity Using Human and Canine
Models.
Biomedicines. 2023;11:759.
Abstract
Kawain Inhibits Urinary Bladder Carcinogenesis through Epigenetic Inhibition of
LSD1 and Upregulation of H3K4 Methylation.
Biomolecules. 2023;13:521.
Abstract
Development of a Molecular-Subtype-Associated Immune Prognostic Signature That
Can Be Recognized by MRI Radiomics Features in Bladder Cancer.
Bioengineering (Basel). 2023;10:318.
Abstract
Predictive Value of 18F-FDG PET/CT for Assessment of Tumor Response to
Neoadjuvant Chemotherapy in Bladder Cancer.
Clin Nucl Med. 2023 Mar 27. doi: 10.1097/RLU.0000000000004639.
Abstract
Investigation of Atypical Cell Parameter in the Surveillance of Patients with
NMIBC; Initial Outcomes of a Single Center Prospective Study.
J Med Syst. 2023;47:41.
Abstract
Real-Time Urethral and Ureteral Assessment during Radical Cystectomy Using
Ex-Vivo Optical Imaging: A Novel Technique for the Evaluation of Fresh Unfixed
Surgical Margins.
Curr Oncol. 2023;30:3421-3431.
Abstract
Survival Benefits of Adjuvant Chemotherapy for Positive Soft Tissue Surgical
Margins Following Radical Cystectomy in Bladder Cancer with Extravesical
Extension.
Curr Oncol. 2023;30:3223-3231.
Abstract
Predictive Value of Inflammatory and Nutritional Indexes in the Pathology of
Bladder Cancer Patients Treated with Radical Cystectomy.
Curr Oncol. 2023;30:2582-2597.
Abstract
Retraction: MiR-301b promotes the proliferation, mobility, and
epithelial-to-mesenchymal transition of bladder cancer cells by targeting EGR1.
Biochem Cell Biol. 2023 Mar 28. doi: 10.1139/bcb-2023-0074.
Abstract
Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in
the tumor immune microenvironment of bladder cancer and establishes a prognostic
model.
J Transl Med. 2023;21:223.
Abstract
Identification and validation of tumor-infiltrating lymphocyte-related prognosis
signature for predicting prognosis and immunotherapeutic response in bladder
cancer.
BMC Bioinformatics. 2023;24:118.
Abstract
Patient and Caregiver Perceptions of Advanced Bladder Cancer Systemic Treatments:
Infodemiology Study Based on Social Media Data.
JMIR Cancer. 2023;9:e45011.
Abstract
Noncoding RNAs as a potential biomarker for the prognosis of bladder cancer: a
systematic review and meta-analysis.
Expert Rev Mol Diagn. 2023 Mar 27. doi: 10.1080/14737159.2023.2195554.
Abstract
Latency period of aristolochic acid-induced upper urinary tract urothelial
carcinoma.
Front Public Health. 2023;11:1072864.
Abstract
Corrigendum to 'Atomic force microscopy-based assessment of multimechanical
cellular properties for classification of graded bladder cancer cells and cancer
early diagnosis using machine learning analysis' Acta Biomaterialia 2023, 158,
358‒373.
Acta Biomater. 2023 Mar 23:S1742-7061(23)00152.
Abstract
Partial and radical cystectomy provides equivalent oncologic outcomes in bladder
cancer when combined with adequate lymph node dissection: A population-based
study.
Urol Oncol. 2023 Mar 23:S1078-1439(23)00078.
Abstract
A case of bilateral synchronous double primary lung cancer secondary to bladder
cancer: From the next-generation sequencing prospect.
Thorac Cancer. 2023 Mar 25. doi: 10.1111/1759-7714.14864.
Abstract
Utilising alternative cystoscopic schedules to minimise cost and patient burden
after trimodality therapy for muscle-invasive bladder cancer.
Cancer Med. 2023 Mar 25. doi: 10.1002/cam4.5840.
Abstract
India Ink Tattooing of Ureteroenteric Anastomoses.
Tomography. 2023;9:449-458.
Abstract
Tailored immunotherapy approach with nivolumab with or without ipilimumab in
patients with advanced transitional cell carcinoma after platinum-based
chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.
Lancet Oncol. 2023;24:347-359.
Abstract
Aristolochic acid induces an inflammatory response with prostaglandin E2
production and apoptosis in NRK-52E proximal tubular cells.
Toxicol Lett. 2023;378:39-50.
Abstract
Short term outcomes after robot assisted and open cystectomy - A nation-wide
population-based study.
Eur J Surg Oncol. 2023;49:868-874.
Abstract
ATR Inhibition in Advanced Urothelial Carcinoma.
Clin Genitourin Cancer. 2023;21:203-207.
Abstract
Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial
Carcinoma.
Clin Genitourin Cancer. 2023;21:286-294.
Abstract
The exstrophy experience: A national survey assessing urinary continence, bladder
management, and oncologic outcomes in adults.
J Pediatr Urol. 2023;19:178.
Abstract
Uretero-enteric Strictures After Robot Assisted Radical Cystectomy: Prevalence
and Management Over Two Decades.
Clin Genitourin Cancer. 2023;21:e19-e26.
Abstract
Disparities in Access to Novel Systemic Therapies in Patients With Urinary Tract
Cancer: Propagating Access, Policies and Resources Uniformly.
Clin Genitourin Cancer. 2023;21:301-308.
Abstract
Bladder tumor Resection Weight as a Prognostic Factor for Recurrence and
Progression in Patients With High-Risk Non-Muscle Invasive Bladder Treated With
BCG.
Clin Genitourin Cancer. 2023;21:e70-e77.
Abstract
Identification of endothelial-related molecular subtypes for bladder cancer
patients.
Front Oncol. 2023;13:1101055.
Abstract
Additional oncological benefit of photodynamic diagnosis with blue light
cystoscopy in transurethral resection for primary non-muscle-invasive bladder
cancer: A comparative study from experienced institutes.
BJUI Compass. 2023;4:305-313.
Abstract
Hyperthermic intravesical chemotherapy with mitomycin-C for the treatment of
high-risk non-muscle-invasive bladder cancer patients.
BJUI Compass. 2022;4:314-321.
Abstract
PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent
non-muscle-invasive bladder cancer.
BJUI Compass. 2023;4:322-330.
Abstract
External beam radiotherapy combination is a risk factor for bladder cancer in
patients with prostate cancer treated with brachytherapy.
World J Urol. 2023 Apr 6. doi: 10.1007/s00345-023-04380.
Abstract
Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients
with muscle-invasive bladder cancer: A multi-center, single-arm, phase 2 study.
Cancer Med. 2023 Apr 6. doi: 10.1002/cam4.5900.
Abstract
PLCepsilon promotes the Warburg effect and tumorigenesis through AKT/GSK3beta/Cdc25a in
bladder cancer.
Biotechnol Genet Eng Rev. 2023 Apr 5:1-15. doi: 10.1080/02648725.2023.2199188.
Abstract
Immune Co-inhibitory Receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in Upper
Tract Urothelial Carcinomas: A Large Cohort Study.
J Immunother. 2023;46:154-159.
Abstract
Comprehensive proteomics and platform validation of urinary biomarkers for
bladder cancer diagnosis and staging.
BMC Med. 2023;21:133.
Abstract
Blood-based liquid biopsy: insights into early detection, prediction, and
treatment monitoring of bladder cancer.
Cell Mol Biol Lett. 2023;28:28.
Abstract
Comparison of the survival outcomes between primary and secondary muscle-invasive
bladder cancer: a propensity score-matched study.
Chin Med J (Engl). 2023 Apr 5. doi: 10.1097/CM9.0000000000002512.
Abstract
Smoking-related epigenetic modifications are associated with the prognosis and
chemotherapeutics of patients with bladder cancer.
Int J Immunopathol Pharmacol. 2023;37:3946320231166774.
Abstract
Correction: Pharmacologic Activation of STING in the Bladder Induces Potent
Antitumor Immunity in Non-Muscle Invasive Murine Bladder Cancer.
Mol Cancer Ther. 2023;22:551.
Abstract
An MRI-based radiomics nomogram in predicting histologic grade of
non-muscle-invasive bladder cancer.
Front Oncol. 2023;13:1025972.
Abstract
Should continuous bladder irrigation be recommended when single instillation of
intravesical chemotherapy cannot be used after transurethral resection in
low-risk non-muscle invasive bladder cancer?
Bladder (San Franc). 2023;10:e21200002.
Abstract
Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune
cells in urothelial bladder cancer: A comprehensive study based on bioinformatics
and clinical analysis validation.
Front Immunol. 2023;14:955949.
Abstract
Influence of the grade and invasiveness of bladder cancer on disease course
severity in patients with bladder tamponade resulting from a bleeding bladder
cancer.
Urol Ann. 2023;15:27-30.
Abstract
Identification of essential genes and drug discovery in bladder cancer and
inflammatory bowel disease via text mining and bioinformatics analysis.
Curr Comput Aided Drug Des. 2023 Mar 30. doi: 10.2174/1573409919666230330154008.
Abstract
Radiation-based Therapy for Muscle-invasive Bladder Cancer: Contemporary Outcomes
Across Tertiary Centers.
Eur Urol Oncol. 2023 Mar 31:S2588-9311(23)00068.
Abstract
A Restaging Transurethral Resection of the Bladder Is Always Necessary for
High-grade T1 Non-muscle-invasive Bladder Cancer: Con.
Eur Urol Focus. 2023 Mar 31:S2405-4569(23)00076.
Abstract
Targeted m(6)A demethylation of ITGA6 mRNA by a multisite dCasRx-m(6)A editor
inhibits bladder cancer development.
J Adv Res. 2023 Mar 30:S2090-1232(23)00092-9. doi: 10.1016/j.jare.2023.
Abstract
Voiding patterns following radical cystectomy and orthotopic neobladder: is
intermittent self-catheterization worth the hype?
Minerva Urol Nephrol. 2023;75:246-247.
Abstract
Animal model assessment of a new design for a coated mitomycin-eluting
biodegradable ureteral stent for intracavitary instillation as an adjuvant
therapy in upper urothelial carcinoma.
Minerva Urol Nephrol. 2023;75:194-202.
Abstract
Incidence of urological cancers in neurological patients: a review of the
literature from the EAU Young Academic Urologist Functional Group.
Minerva Urol Nephrol. 2023;75:163-171.
Abstract
A systematic review and meta-analysis of robot-assisted vs. open radical
cystectomy: where do we stand and future perspective.
Minerva Urol Nephrol. 2023;75:134-143.
Abstract
Paraganglioma in The Urinary Bladder: A Pitfall in Histopathologic Diagnosis.
Acta Med Indones. 2023;55:95-100.
Abstract
[Perioperative systemic treatment of urothelial cancer].
Urologie. 2023;62:407-417.
Abstract
Highlights into historical and current immune interventions for cancer.
Int Immunopharmacol. 2023;117:109882.
Abstract
Establishment of a risk score model for bladder urothelial carcinoma based on
energy metabolism-related genes and their relationships with immune infiltration.
FEBS Open Bio. 2023;13:736-750.
Abstract
Which Patients To Consider for Bladder Preservation After a Complete Response to
Neoadjuvant Chemotherapy.
Eur Urol Focus. 2023;9:229-231.
Abstract
Impact of Performance Status on Oncologic Outcomes in Patients with Advanced
Urothelial Carcinoma Treated with Immune Checkpoint Inhibitor: A Systematic
Review and Meta-analysis.
Eur Urol Focus. 2023;9:264-274.
Abstract
GNRI Sustainability during One Cycle of First-Line Chemotherapy as a Prognostic
Indicator in Patients with Metastatic Urothelial Carcinoma.
Oncology. 2023;101:224-233.
Abstract
Optimizing Lymph Node Dissection at the Time of Nephroureterectomy for High-risk
Upper Tract Urothelial Carcinoma.
Eur Urol Focus. 2023;9:280-282.
Abstract
Long-Term Retention Microbubbles with Three-Layer Structure for Floating
Intravesical Instillation Delivery.
Small. 2023;19:e2205630.
Abstract
[One clip too many].
Urologie. 2023;62:389-391.
Abstract
Management of metastatic urothelial carcinoma: Current approach, emerging agents,
and future perspectives.
Urologia. 2023;90:3-10.
Abstract
Oncologic and Safety Outcomes for Endoscopic Surgery Versus Radical
Nephroureterectomy for Upper Tract Urothelial Carcinoma: An Updated Systematic
Review and Meta-analysis.
Eur Urol Focus. 2023;9:236-240.
Abstract
Comparison of hexaminolevulinate (HAL) -guided versus white light transurethral
resection for NMIBC: A systematic review and meta-analysis of randomized
controlled trials.
Photodiagnosis Photodyn Ther. 2023;41:103220.
Abstract
Does immune cell exhaustion lie at the heart of BCG-unresponsive disease?
Nat Rev Urol. 2023;20:201-202.
Abstract
Oncologic and Safety Outcomes for Retrograde and Antegrade Endoscopic Surgeries
for Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-analysis.
Eur Urol Focus. 2023;9:258-263.
Abstract
Cutaneous toxicity with suprabasal blisters and dyskeratosis following
administration of enfortumab vedotin.
J Dermatol. 2022 Nov 22. doi: 10.1111/1346-8138.16646.
Abstract
The diagnostic utility of trichorhinophalangeal syndrome type 1
immunohistochemistry for metastatic breast carcinoma in effusion cytology
specimens.
Cancer Cytopathol. 2023;131:226-233.
Abstract
[Cystoscopy in the outpatient clinical routine: things to keep in mind].
Aktuelle Urol. 2023;54:129-134.
Abstract
Outcome of transurethral resection of bladder tumour under spinal anaesthesia
combined with obturator nerve block in Sri Lanka.
Urologia. 2023;90:80-82.
Abstract
Patient tolerability during office cystoscopy and bladder tumor cauterization: a
multivariate analysis of risk factors.
Actas Urol Esp (Engl Ed). 2023;47:165-171.
Abstract
Urachal mucinous cystadenocarcinoma: A case report.
Asian J Surg. 2023;46:1759-1760.
Abstract
Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in
predicting progression in a large cohort of HG T1 NMIBC patients treated with
BCG.
Minerva Urol Nephrol. 2023;75:180-187.
Abstract
Long-term Recurrence and Progression Patterns in a Contemporary Series of
Patients with Carcinoma In Situ of the Bladder With or Without Associated Ta/T1
Disease Treated with Bacillus Calmette-Guerin: Implications for Risk-adapted
Follow-up.
Eur Urol Focus. 2023;9:325-332.
Abstract
Melanosis of the urinary bladder.
Ann R Coll Surg Engl. 2023;105:386-387.
Abstract
Transurethral resection of bladder tumour (TURBT) as a day-case: A real-world
practice and patients' perspective from a district general hospital (DGH).
Urologia. 2023;90:68-74.
Abstract
The impact of socio-economic deprivation on recovery following robotic assisted
radical cystectomy.
Urologia. 2023;90:136-140.
Abstract
Dual-Energy CT applications in urinary tract cancers: an update.
Tumori. 2023;109:148-156.
Abstract
Disease management in a patient diagnosed with COVID-19 disease during induction
intravesical BCG therapy: A case report and review of the literature.
Urologia. 2023;90:195-197.
Abstract
[Sigmoid colon conduit volvulus: an extremely rare complication of a sigmoid
colon conduit].
Aktuelle Urol. 2023;54:148-150.
Abstract
The current status of gene therapy in bladder cancer.
Expert Rev Anticancer Ther. 2023 Apr 13. doi: 10.1080/14737140.2023.2203385.
Abstract
An Overview of Angiogenesis in Bladder Cancer.
Curr Oncol Rep. 2023 Apr 13. doi: 10.1007/s11912-023-01421.
Abstract
Correction to: Bladder Cancer Progression Is Suppressed Through the Heart and
Neural Crest Derivatives Expressed 2‑Antisense RNA 1/microRNA‑93‑5p/Defective in
Cullin Neddylation 1 Domain Containing 3 Axis.
Appl Biochem Biotechnol. 2023 Apr 13. doi: 10.1007/s12010-023-04478.
Abstract
CT Evaluation of the Findings of Nutcracker Syndrome in Patients with Bladder
Cancer after Radical Cystectomy and Ileal Neobladder Formation: A Correlation
with Hematuria.
J Korean Soc Radiol. 2023;84:409-417.
Abstract
Extracellular Vesicles as Potential Bladder Cancer Biomarkers: Take It or Leave
It?
Int J Mol Sci. 2023;24:6757.
Abstract
Clinicopathological Features and Survival Analysis in Molecular Subtypes of
Muscle-Invasive Bladder Cancer.
Int J Mol Sci. 2023;24:6610.
Abstract
Variability, Expression, and Methylation of IL-6 and IL-8 Genes in Bladder Cancer
Pathophysiology.
Int J Mol Sci. 2023;24:6266.
Abstract
3D Tumor Models in Urology.
Int J Mol Sci. 2023;24:6232.
Abstract
Evodiamine Exhibits Anti-Bladder Cancer Activity by Suppression of Glutathione
Peroxidase 4 and Induction of Ferroptosis.
Int J Mol Sci. 2023;24:6021.
Abstract
Risk Classification of Bladder Cancer by Gene Expression and Molecular Subtype.
Cancers (Basel). 2023;15:2149.
Abstract
Retrospective Analysis of a Cohort of Patients with Metastatic Bladder Cancer
with Metastatic Sites Limited to the Pelvis and Retroperitoneum Treated at a
Single Institution between 2009 and 2020.
Cancers (Basel). 2023;15:2069.
Abstract
Efficacy of Different Bacillus of Calmette-Guerin (BCG) Strains on Recurrence
Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs):
Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis.
Cancers (Basel). 2023;15:1937.
Abstract
Novel utility of Vesical Imaging-Reporting and Data System in multimodal
treatment for muscle-invasive bladder cancer.
Eur Radiol. 2023 Apr 13. doi: 10.1007/s00330-023-09627.
Abstract
The Pursuit of Intravesical and Systemic Therapies in Non-muscle-invasive Bladder
Cancer: Challenges and Opportunities.
Eur Urol Oncol. 2023 Apr 10:S2588-9311(23)00071.
Abstract
Associations of dietary isothiocyanate exposure from cruciferous vegetable
consumption with recurrence and progression of non-muscle invasive bladder
cancer: Findings from The Be-Well Study.
Am J Clin Nutr. 2023 Apr 10:S0002-9165(23)46835.
Abstract
Molecular subtypes, tumor microenvironment infiltration characterization and
prognosis model based on cuproptosis in bladder cancer.
PeerJ. 2023;11:e15088.
Abstract
ASO Visual Abstract: En Bloc Resection Versus Conventional TURBT for T1HG Bladder
Cancer: A Propensity Score-Matched Analysis.
Ann Surg Oncol. 2023 Apr 11. doi: 10.1245/s10434-023-13395.
Abstract
Exploring the application of bladder-preservation treatment in patients with
T2N0M0 bladder cancer and establish a nomogram model: A SEER-based study.
Asian J Surg. 2023 Apr 8:S1015-9584(23)00486.
Abstract
Clinical utility of checkpoint inhibitors against metastatic bladder cancer:
overcoming challenges to find a way forward.
Expert Opin Biol Ther. 2023 Apr 10:1-12. doi: 10.1080/14712598.2023.2201371.
Abstract
Healthcare Resource Utilization and Cost Burden of BCG-Treated Non-Muscle
Invasive Bladder Cancer Patients in Germany: A Retrospective Claims Analysis.
Clinicoecon Outcomes Res. 2023;15:227-237.
Abstract
Survival prediction among pathologic T4 bladder cancer patients following
cytoreductive cystectomy: A retrospective single-center study.
Front Surg. 2023;10:1121357.
Abstract
Endothelial cells are a key target of IFN-g during response to combined
PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer.
bioRxiv. 2023 Mar 29:2023.03.28.534561. doi: 10.1101/2023.03.28.534561.
Abstract
An innovative risk index based on neutrophils and macrophages can effectively
predict prognosis and immunotherapy response in patients with muscle-invasive
bladder cancer.
Transl Cancer Res. 2023;12:536-549.
Abstract
The Short- and Long-Term Effect of Radical Cystectomy in Frail Patients With
Bladder Cancer.
Clin Genitourin Cancer. 2023 Mar 11:S1558-7673(23)00063.
Abstract
TJP1 promotes vascular mimicry in bladder cancer by facilitating VEGFA expression
and transcriptional activity through TWIST1.
Transl Oncol. 2023;32:101666.
Abstract
Re: Wei Shan Tan, Gary Steinberg, J. Alfred Witjes, et al. Intermediate-risk
Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management
Recommendations from the International Bladder Cancer Group. Eur Urol Oncol
2022;5:505-16.
Eur Urol Oncol. 2023 Apr 6:S2588-9311(23)00073-1. doi: 10.1016/j.euo.2023.
Abstract
Mycoplasma infection mimicking a malignancy in a waldenstrom macroglobulinemia
patient.
BMC Infect Dis. 2023;23:219.
Abstract
Bladder Cancer Carcinogens: Opportunities for Risk Reduction.
Eur Urol Focus. 2023 Apr 5:S2405-4569(23)00086-X. doi: 10.1016/j.euf.2023.
Abstract
circSOBP Inhibits Bladder Cancer Proliferation and Metastasis by Regulating the
miR-200a-3p/PTEN Axis and Participating in the Immune Response.
Cell Transplant. 2023;32:9636897231165874.
Abstract
Melatonin inhibits bladder tumorigenesis by suppressing PPARgamma/ENO1-mediated
glycolysis.
Cell Death Dis. 2023;14:246.
Abstract
Correlation of Clinician- and Patient-Reported Outcomes in the BC2001 Trial.
Clin Oncol (R Coll Radiol). 2023;35:331-338.
Abstract
Does Therapeutic Repurposing in Cancer Meet the Expectations of Having Drugs at a
Lower Price?
Clin Drug Investig. 2023;43:227-239.
Abstract
Emerging monoclonal antibody therapies in the treatment of metastatic urothelial
carcinoma.
Expert Opin Emerg Drugs. 2023;28:17-26.
Abstract
Open vs robotic intracorporeal Padua ileal bladder: functional outcomes of a
single-centre RCT.
World J Urol. 2023;41:739-746.
Abstract
Subclassification of pT3 upper tract urothelial carcinoma: a multicenter
retrospective study.
World J Urol. 2023;41:767-776.
Abstract
Immunotherapy in Genitourinary Cancers: Role of Surgical Pathologist for
Detection of Immunooncologic Predictive Factors.
Adv Anat Pathol. 2023;30:203-210.
Abstract
Optimizing decision-making process of benign uretero-enteric anastomotic
stricture treatment after radical cystectomy.
World J Urol. 2023;41:733-738.
Abstract
Assessment of association between lower ureteric excision technique and
oncological outcomes for upper urinary tract urothelial carcinoma: retrospective
analysis from the Scottish Renal Cancer Consortium.
World J Urol. 2023;41:757-765.
Abstract
Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive
Urothelial Carcinoma of the Bladder.
Cancer Res Treat. 2023;55:636-642.
Abstract
Predicting prognosis and clinical efficacy of immune checkpoint blockade therapy
via interferon-alpha response in muscle-invasive bladder cancer.
Pathol Oncol Res. 2023;29:1611117.
Abstract
Detection of the ADGRG6 hotspot mutations in urine for bladder cancer early
screening by ARMS-qPCR.
Cancer Med. 2023 Apr 20. doi: 10.1002/cam4.5879.
Abstract
Lifestyle Factors in Patients with Bladder Cancer: A Contemporary Picture of
Tobacco Smoking, Electronic Cigarette Use, Body Mass Index, and Levels of
Physical Activity.
Eur Urol Focus. 2023 Apr 18:S2405-4569(23)00101.
Abstract
TNM-Based Head-to-Head Comparison of Urachal Carcinoma and Urothelial Bladder
Cancer : Stage-Matched Analysis of a Large Multicenter National Cohort.
Cancer Res Treat. 2023 Apr 17. doi: 10.4143/crt.2023.
Abstract
Correction to: Current Status of Perioperative Therapy in Muscle‑Invasive Bladder
Cancer and Future Directions.
Curr Oncol Rep. 2023 Apr 20. doi: 10.1007/s11912-023-01409.
Abstract
Characterization and treatment of gemcitabine- and cisplatin-resistant bladder
cancer cells with a pan-RAS inhibitor.
FEBS Open Bio. 2023 Apr 20. doi: 10.1002/2211-5463.13616.
Abstract
Reduced- vs full-dose BCG in bladder cancer: A systematic review and
meta-analysis.
Actas Urol Esp (Engl Ed). 2023;47:4-14.
Abstract
Development of an immune-nutritional prognostic index in patients with
muscle-infiltrating bladder cancer candidates for radical cystectomy.
Actas Urol Esp (Engl Ed). 2023;47:34-40.
Abstract
Histopathological spectrum of adult renal tumours: A single center experience and
review of literature.
Indian J Pathol Microbiol. 2023;66:307-313.
Abstract
Intratumoral Heterogeneity of Molecular Subtypes in Muscle-invasive Bladder
Cancer-An Extensive Multiregional Immunohistochemical Analysis.
Eur Urol Focus. 2023 Apr 17:S2405-4569(23)00080.
Abstract
Sequential Treatment With Bacillus Calmette-Guerin (BCG) and Mitomycin C
Administered With Electromotive Drug Administration (EMDA) in Patients With
High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure.
Clin Genitourin Cancer. 2023 Mar 17:S1558-7673(23)00061.
Abstract
Bladder squamous cell carcinoma in situ in the background of condyloma acuminatum
in a kidney transplant recipient.
Can J Urol. 2023;30:11505-11508.
Abstract
Correction to: HYOU1 promotes cell proliferation, migration, and invasion via the
PI3K/AKT/FOXO1 feedback loop in bladder cancer.
Mol Biol Rep. 2023 Apr 18. doi: 10.1007/s11033-023-08325.
Abstract
The androgen receptor in bladder cancer.
Nat Rev Urol. 2023 Apr 18. doi: 10.1038/s41585-023-00761.
Abstract
Bladder cancer organoids as a functional system to model different disease stages
and therapy response.
Nat Commun. 2023;14:2214.
Abstract
Association of patient-reported pain with survival in bladder cancer: a post-hoc
analysis of the iBLAD trial.
Acta Oncol. 2023 Apr 18:1-6. doi: 10.1080/0284186X.2023.2199461.
Abstract
YTHDC1 positively regulates PTEN expression and plays a critical role in
cisplatin resistance of bladder cancer.
Cell Prolif. 2023 Apr 17:e13404. doi: 10.1111/cpr.13404.
Abstract
Potential mechanisms of osthole against bladder cancer cells based on network
pharmacology, molecular docking, and experimental validation.
BMC Complement Med Ther. 2023;23:122.
Abstract
Going in circles: circMGA-HNRNPL feedback loop in bladder cancer.
Nat Rev Urol. 2023 Apr 17. doi: 10.1038/s41585-023-00771.
Abstract
Using AI to assist pathologists in bladder cancer metastases detection.
Nat Rev Urol. 2023 Apr 14. doi: 10.1038/s41585-023-00769.
Abstract
The prognostic value of hedgehog signaling in bladder cancer by integrated
bioinformatics.
Sci Rep. 2023;13:6241.
Abstract
T cell subsets, regulatory T, regulatory B cells and proinflammatory cytokine
profile in Schistosoma haematobium associated bladder cancer: First report from
Upper Egypt.
PLoS Negl Trop Dis. 2023;17:e0011258.
Abstract
Cytomorphologic visualization of circulating tumor cells in urinary bladder
cancer patients using ScreenCell technology: Potential as a simple cytology
test.
Diagn Cytopathol. 2023 Apr 17. doi: 10.1002/dc.25141.
Abstract
Image quality evaluation of diffusion-weighted imaging in bladder cancer: a
comparison between integrated slice-specific dynamic shimming and single-shot
echo-planar imaging.
Quant Imaging Med Surg. 2023;13:2526-2537.
Abstract
The impact of antithrombotic therapy on the time of detection of bladder cancer.
Cent European J Urol. 2023;76:33-37.
Abstract
Identification of a novel defined inflammation-related long noncoding RNA
signature contributes to predicting prognosis and distinction between the cold
and hot tumors in bladder cancer.
Front Oncol. 2023;13:972558.
Abstract
Identifying novel biomarkers associated with bladder cancer treatment outcomes.
Front Oncol. 2023;13:1114203.
Abstract
Machine learning-based identification of tumor-infiltrating immune
cell-associated model with appealing implications in improving prognosis and
immunotherapy response in bladder cancer patients.
Front Immunol. 2023;14:1171420.
Abstract
BSA modification of bacterial surface: a promising anti-cancer therapeutic
strategy.
BMC Microbiol. 2023;23:105.
Abstract
Singe intraoperative instillation of chemotherapy during radical cystectomy for
bladder cancer: Oncological outcome and survival predictors.
Cancer Med. 2023 Apr 16. doi: 10.1002/cam4.5895.
Abstract
Telocytes and ezrin expression in normal-appearing tissues adjacent to urothelial
bladder carcinoma as predictors of invasiveness and recurrence.
Sci Rep. 2023;13:6179.
Abstract
Heterogeneity of BCG unresponsive bladder cancer clinical trials limits patients'
access to novel therapeutics.
Urol Oncol. 2023 Apr 13:S1078-1439(23)00094.
Abstract
Transmembrane protein 132A (TMEM132A) predicts overall survival for bladder
cancer patients.
Asian J Surg. 2023 Apr 13:S1015-9584(23)00423.
Abstract
Osteoclast-rich undifferentiated carcinoma of the bladder and the diagnostic
usefulness of immunohistochemistry. A case report.
Rev Esp Patol. 2023;56:132-135.
Abstract
When and How To Perform Active Surveillance for Low-risk Non-muscle-invasive
Bladder Cancer.
Eur Urol Focus. 2023 Apr 12:S2405-4569(23)00095.
Abstract
Androgen receptor transcriptionally inhibits programmed death ligand-1 (PD-L1)
expression and influences immune escape in bladder cancer.
Lab Invest. 2023 Apr 12:100148. doi: 10.1016/j.labinv.2023.100148.
Abstract
Uptake of Maintenance Immunotherapy and Changes in Upstream Treatment Selection
Among Patients With Urothelial Cancer.
JAMA Netw Open. 2023;6:e238395.
Abstract
The prognostic impact of lymphovascular invasion for upper urinary tract
urothelial carcinoma: A propensity score-weighted analysis.
Medicine (Baltimore). 2023;102:e33485.
Abstract
A pan-cancer analysis of the oncogenic role of YKT6 in human tumors.
Medicine (Baltimore). 2023;102:e33546.
Abstract
[Not Available].
Ugeskr Laeger. 2023;185:V02230082.
Abstract
[Investigation of the mutational status of the FGFR3 gene in urothelial bladder
carcinoma].
Arkh Patol. 2023;85:5-12.
Abstract
Single-cell transcriptomic analysis of tumor heterogeneity and intercellular
networks in human urothelial carcinoma.
Chin Med J (Engl). 2023;136:690-706.
Abstract
Rapid geriatric screening tools predict inability to manage stoma by oneself
after urinary diversion: G8 and IADL-modified G8.
J Geriatr Oncol. 2023;14:101468.
Abstract
Use of a physical activity monitor to track perioperative activity of radical
cystectomy patients. Our first glimpse at what our patients are doing before and
after surgery.
Urol Oncol. 2023;41:206.
Abstract
Variant histology in upper tract carcinomas: Analysis of the National Cancer
Database.
Urol Oncol. 2023;41:206.
Abstract
Characteristics Contributing to Survival Differences Between Black and White
Patients Following Cystectomy.
Urol Oncol. 2023;41:207.
Abstract
Radical cystectomy and urinary diversion outcomes in patients with single vs.
double renal unit: A 2:1 matched-pair analysis.
Urol Oncol. 2023;41:207.
Abstract
Clinical and economic impact of blue light cystoscopy in the management of NMIBC
at US ambulatory surgical centers: what is the site-of-service disparity?
Urol Oncol. 2023;41:207.
Abstract
Long non-coding RNA UCA1 regulates MPP(+)-induced neuronal damage through the
miR-671-5p/KPNA4 pathway in SK-N-SH cells.
Metab Brain Dis. 2023;38:961-972.
Abstract
A Urine-based Genomic Assay Improves Risk Stratification for Patients with
High-risk Hematuria Stratified According to the American Urological Association
Guidelines.
Eur Urol Oncol. 2023;6:183-189.
Abstract
ANXA10 Expression Is Inversely Associated with Tumor Stage, Grade, and TP53
Expression in Upper and Lower Urothelial Carcinoma.
Pathobiology. 2023;90:94-103.
Abstract
Hydraulic Detrusor for Artificial Bladder Active Voiding.
Soft Robot. 2023;10:269-279.
Abstract
Genetic Polymorphisms of Gene Methionine Synthase Reductase (MTRR) and Risk of
Urinary Bladder Cancer.
Asian Pac J Cancer Prev. 2023;24:1137-1141.
Abstract
[Research in bladder cancer: translation into the clinic-report of 13th annual
meeting of the German Research Group on Bladder Cancer (DFBK) in Berlin].
Urologie. 2023 Apr 28. doi: 10.1007/s00120-023-02093.
Abstract
A prognostic model for bladder cancer based on cytoskeleton-related genes.
Medicine (Baltimore). 2023;102:e33538.
Abstract
The Efficacy and Safety of Tislelizumab as Adjuvant Treatment for Advanced or
Metastatic Bladder Cancer in People Living With HIV: A Retrospective Multi-Center
Study.
Cancer Control. 2023;30:10732748231173475.
Abstract
Adherence to guidelines in the follow-up of non-muscle-invasive bladder cancer
among urology trainers and trainees in Jordan: a cross-sectional study.
Ann Med Surg (Lond). 2023;85:763-766.
Abstract
Natural Products as New Approaches for Treating Bladder Cancer: From Traditional
Medicine to Novel Drug Discovery.
Pharmaceutics. 2023;15:1117.
Abstract
PET Imaging in Bladder Cancer: An Update and Future Direction.
Pharmaceuticals (Basel). 2023;16:606.
Abstract
Altered Glycosylation in Progression and Management of Bladder Cancer.
Molecules. 2023;28:3436.
Abstract
MTX-211 Inhibits GSH Synthesis through Keap1/NRF2/GCLM Axis and Exerts Antitumor
Effects in Bladder Cancer.
Int J Mol Sci. 2023;24:7608.
Abstract
YTHDF1 Promotes Bladder Cancer Cell Proliferation via the
METTL3/YTHDF1-RPN2-PI3K/AKT/mTOR Axis.
Int J Mol Sci. 2023;24:6905.
Abstract
VI-RADS for the diagnosis and management of urinary bladder cancer.
Eur Radiol. 2023 Apr 28. doi: 10.1007/s00330-023-09677.
Abstract
DNA polymerase POLD1 promotes proliferation and metastasis of bladder cancer by
stabilizing MYC.
Nat Commun. 2023;14:2421.
Abstract
Expression-based subtypes define pathologic response to neoadjuvant
immune-checkpoint inhibitors in muscle-invasive bladder cancer.
Nat Commun. 2023;14:2126.
Abstract
Cost of Bladder Cancer Care: A Single Centre Comparison of Radical Cystectomy and
Trimodal Therapy.
Urol Pract. 2023 Apr 4:101097UPJ0000000000000403.
Abstract
Sarcopenia Predicts Disease Progression in Patients with T1 High-grade
Non-muscle-invasive Bladder Cancer Treated with Adjuvant Intravesical Bacillus
Calmette-Guerin: Implications for Decision-making?
Eur Urol Open Sci. 2023;50:17-23.
Abstract
Circular RNA Ubiquitin-associated Protein 2 Silencing Suppresses Bladder Cancer
Progression by Downregulating DNA Topoisomerase 2-alpha Through Sponging miR-496.
Eur Urol Open Sci. 2023;50:31-42.
Abstract
STIL/AURKA axis promotes cell proliferation by influencing primary cilia
formation in bladder cancer.
J Transl Med. 2023;21:281.
Abstract
Symptoms and signs of urogenital cancer in primary care.
BMC Prim Care. 2023;24:107.
Abstract
Impact of Minimally Invasive Approach to Radical Cystectomy in Bladder Cancer
Patients with Malnutrition.
Nutr Cancer. 2023 Apr 26:1-6. doi: 10.1080/01635581.2023.2202432.
Abstract
Serum lactate dehydrogenase level predicts the prognosis in bladder cancer
patients.
BMC Urol. 2023;23:65.
Abstract
Discovery of a novel dual functional phenylpyrazole-styryl hybrid that induces
apoptotic and autophagic cell death in bladder cancer cells.
Eur J Med Chem. 2023;254:115335.
Abstract
Latent heterogeneity of muscle-invasive bladder cancer in patient characteristics
and survival: A population-based nation-wide study in the Bladder Cancer Data
Base Sweden (BladderBaSe).
Cancer Med. 2023 Apr 25. doi: 10.1002/cam4.5981.
Abstract
Utilizing the Lactate Dehydrogenase-to-Albumin Ratio for Survival Prediction in
Patients with Bladder Cancer After Radical Cystectomy.
J Inflamm Res. 2023;16:1733-1744.
Abstract
Single-Dose Post-Office Fulguration Mitomycin C Instillation Appears to Improve
Recurrence-Free Survival in Patients With Low-Grade Noninvasive Bladder Cancer.
Clin Genitourin Cancer. 2023 Mar 23:S1558-7673(23)00066.
Abstract
Comprehensive characterization of endoplasmic reticulum stress in bladder cancer
revealing the association with tumor immune microenvironment and prognosis.
Front Genet. 2023;14:1097179.
Abstract
Impact of intravesical Bacillus Calmette-Guerin and chemotherapy on the bladder
microbiome in patients with non-muscle invasive bladder cancer.
Front Cell Infect Microbiol. 2023;13:1125809.
Abstract
Downregulated ESRP1/2 promotes lung metastasis of bladder carcinoma through
altering FGFR2 splicing and macrophage polarization.
Front Immunol. 2023;14:1161273.
Abstract
A reevaluation of selected mortality risks in the updated NCI/NIOSH acrylonitrile
cohort study.
Front Public Health. 2023;11:1122346.
Abstract
Cost-Effectiveness and Economic Impact of Bladder Cancer Management: An Updated
Review of the Literature.
Pharmacoeconomics. 2023 Apr 23. doi: 10.1007/s40273-023-01273.
Abstract
NEDD4L inhibits migration, invasion, cisplatin resistance and promotes apoptosis
of bladder cancer cells by inactivating the p62/Keap1/Nrf2 pathway.
Environ Toxicol. 2023 Apr 23. doi: 10.1002/tox.23796.
Abstract
[Current diagnostic and treatment strategies for urachal cancer].
Orv Hetil. 2023;164:602-609.
Abstract
[Intravesical instillation of bacillus Calmette-Guerin for non-muscle invasive
bladder cancer: outcomes of 421 patients in a single center].
Nan Fang Yi Ke Da Xue Xue Bao. 2023;43:488-494.
Abstract
Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant
Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314.
Eur Urol Oncol. 2023 Apr 20:S2588-9311(23)00074.
Abstract
Electronic cigarette: is it a risk factor for the development of bladder cancer?
Actas Urol Esp (Engl Ed). 2023 Apr 20:S2173-5786(23)00047.
Abstract
Cucurbitacin IIb Extracted from Hemsleya penxianensis Induces Cell Cycle Arrest
and Apoptosis in Bladder Cancer Cells by Regulating Cell Cycle Checkpoints and
Mitochondrial Apoptotic Pathway.
Plant Foods Hum Nutr. 2023 Apr 22. doi: 10.1007/s11130-023-01058.
Abstract
How has the COVID-19 pandemic affected patients with primary bladder cancer?
Cir Cir. 2023;91:204-211.
Abstract
Recent advances in the understanding of urothelial tumorigenesis.
Expert Rev Anticancer Ther. 2023;23:485-493.
Abstract
Safety and efficacy of cobimetinib plus atezolizumab in patients with solid
tumors: a phase II, open-label, multicenter, multicohort study.
ESMO Open. 2023;8:100877.
Abstract
Metabolic Modulation of Intracellular Ammonia via Intravesical Instillation of
Nanoporter-Encased Hydrogel Eradicates Bladder Carcinoma.
Adv Sci (Weinh). 2023;10:e2206893.
Abstract
Progress in the treatment of urethral adenocarcinoma.
J Cancer Res Clin Oncol. 2023;149:2693-2698.
Abstract
Ectopic prostate tissue at the bladder trigone accompanied by cystitis
glandularis and hemorrhage detected by multiparametric MRI.
Asian J Androl. 2023;25:438-439.
Abstract
Evaluation of short-term outcomes of neoadjuvant chemotherapy followed by radical
cystectomy in muscle-invasive bladder cancer: a single Egyptian institution
experience.
J Egypt Natl Canc Inst. 2023;35:13.
Abstract
Real-world outcomes of first-line chemotherapy for unresectable stage III and IV
bladder cancer.
World J Urol. 2023 May 5. doi: 10.1007/s00345-023-04408.
Abstract
Detection of Plasma Antibodies Against CD25-Derived Peptide Antigens in Bladder
Cancer.
Clin Lab. 2023;69.
Abstract
A risk signature of necroptosis-related lncRNA to predict prognosis and probe
molecular characteristics for male with bladder cancer.
Medicine (Baltimore). 2023;102:e33664.
Abstract
Xanthogranulomatous Ureteritis: A Diagnostic Challenge in a Patient with Bladder
Cancer.
Int J Surg Pathol. 2023 May 4:10668969231169049. doi: 10.1177/10668969231169049.
Abstract
ARID1A Inactivation Increases Expression of circ0008399 and Promotes Cisplatin
Resistance in Bladder Cancer.
Curr Med Sci. 2023 May 5. doi: 10.1007/s11596-023-2731.
Abstract
Pelvic Organ Preservation in Non-muscle-invasive Bladder Cancer: Less Is More.
Eur Urol Focus. 2023 May 2:S2405-4569(23)00103-7. doi: 10.1016/j.euf.2023.
Abstract
Short-course treatment after complete response to pembrolizumab in metastatic
urothelial bladder cancer: a case series.
Immunotherapy. 2023 May 4. doi: 10.2217/imt-2022-0283.
Abstract
Berberine Affects the Proliferation, Migration, Invasion, Cell Cycle, and
Apoptosis of Bladder Cancer Cells T24 and 5637 by Down-Regulating the
HER2/PI3K/AKT Signaling Pathway.
Arch Esp Urol. 2023;76:152-160.
Abstract
Higher Serum Endothelial-Specific Molecule-1 (ESM-1/Endocan) Levels are
Associated with Poor Pathological Outcomes in Primary Bladder Cancer: A
Non-randomized, Prospective, Case-Control Study.
Arch Esp Urol. 2023;76:132-138.
Abstract
Impact of a One-Stop Hematuria Clinic on Overall Survival and Bladder Tumor
Recurrence.
Arch Esp Urol. 2023;76:114-122.
Abstract
Long-term effect of transurethral partial cystectomy with a 2-micrometer
continuous-wave laser for non-muscle-invasive bladder cancer.
Front Surg. 2023;10:1117997.
Abstract
Integrative multi-omics analysis depicts the methylome and hydroxymethylome in
recurrent bladder cancers and identifies biomarkers for predicting PD-L1
expression.
Biomark Res. 2023;11:47.
Abstract
The potential crosstalk between tumor and plasma cells and its association with
clinical outcome and immunotherapy response in bladder cancer.
J Transl Med. 2023;21:298.
Abstract
The efficacy and safety outcomes of lower dose BCG compared to intravesical
chemotherapy in non-muscle-invasive bladder cancer: A network meta-analysis.
Urol Oncol. 2023 May 1:S1078-1439(23)00118-7. doi: 10.1016/j.urolonc.2023.
Abstract
Association of human papillomavirus (HPV), p16, p53 and p63 expression with
non-bilharzia-associated squamous cell carcinoma of the bladder and algorithm
construction for histopathological grading prediction.
Einstein (Sao Paulo). 2023;21:eAO0109.
Abstract
Evaluation of IGF2, KRT14, and KRT20 as Urinary Biomarkers in Patients with
Bladder Cancer.
Rep Biochem Mol Biol. 2023;11:710-719.
Abstract
Synergistic augmentation of osimertinib-induced autophagic death by proguanil or
rapamycin in bladder cancer.
MedComm (2020). 2023;4:e236.
Abstract
Cost of bladder cancer in Lebanon before and after the economic collapse: a
probabilistic modeling study.
Int J Equity Health. 2023;22:77.
Abstract
Development and validation of a tobacco smoking-related index for predicting
overall survival and immunotherapy response in bladder cancer.
Environ Sci Pollut Res Int. 2023 May 2. doi: 10.1007/s11356-023-27132.
Abstract
Metastasis to the penis from a bladder carcinoma invading only the lamina
propria: case report and description of the morphological aspects.
Rom J Morphol Embryol. 2023;64:89-94.
Abstract
Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG)
in the treatment of non-muscle invasive bladder cancer: A preliminary
cost-effectiveness analysis.
Urol Oncol. 2023 Apr 29:S1078-1439(23)00119.
Abstract
Histopathological bladder cancer gene mutation prediction with hierarchical deep
multiple-instance learning.
Med Image Anal. 2023;87:102824.
Abstract
Using chitosan-stabilized, hyaluronic acid-modified selenium nanoparticles to
deliver CD44-targeted PLK1 siRNAs for treating bladder cancer.
Nanomedicine (Lond). 2023 Apr 26. doi: 10.2217/nnm-2022-0198.
Abstract
Comprehensive analysis of a novel RNA modifications-related model in the
prognostic characterization, immune landscape and drug therapy of bladder cancer.
Front Genet. 2023;14:1156095.
Abstract
Case Report: PD-L1-negative advanced bladder cancer effectively treated with
anlotinib and tislelizumab: A report of two cases.
Front Oncol. 2023;13:1164368.
Abstract
Emerging trends of BCG immunotherapy for bladder cancer in last decade: a
bibliometric and visualization analysis.
Front Oncol. 2023;13:1092969.
Abstract
Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder
cancer: A case report.
Heliyon. 2023;9:e15157.
Abstract
Transurethral resection of bladder tumor-based bladder preservation therapy for
refractory high risk non-muscle invasive bladder cancer: Current landscape and
future directions.
Front Surg. 2023;10:1143219.
Abstract
Uncovering the potential functions of lymph node metastasis-associated aberrant
methylation differentially expressed genes and their association with the immune
infiltration and prognosis in bladder urothelial carcinoma.
PeerJ. 2023;11:e15284.
Abstract
Comment on "telomerase reverse transcriptase rs2736098 and rs2736100 in bladder
cancer".
Rep Pract Oncol Radiother. 2023;28:135.
Abstract
Why has sexuality research in women with bladder cancer undergoing radical
cystectomy been ignored for so long?
J Sex Med. 2023;20:580-583.
Abstract
Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive
advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.
Cancer Med. 2023 Apr 29. doi: 10.1002/cam4.5893.
Abstract
Hypermethylated ITGA8 Facilitate Bladder Cancer Cell Proliferation and
Metastasis.
Appl Biochem Biotechnol. 2023 Apr 29. doi: 10.1007/s12010-023-04512.
Abstract
The correlation of EMT and p53 immunohistochemical markers with cisplatin
resistance in muscle invasive bladder cancer patients: A single-centred study.
Malays J Pathol. 2023;45:19-29.
Abstract
Clinical characteristics and treatment outcomes of kidney transplant recipients
with de novo urothelial carcinoma: thirty years of experience from a single
center.
BMC Urol. 2023;23:71.
Abstract
Apoptosis related genes mediated molecular subtypes depict the hallmarks of the
tumor microenvironment and guide immunotherapy in bladder cancer.
BMC Med Genomics. 2023;16:88.
Abstract
Cell senescence-associated porphyrin metabolism affects the efficacy of
aminolevulinic acid-photodynamic diagnosis in bladder cancer.
Photodiagnosis Photodyn Ther. 2023 Apr 26:103581.
Abstract
Perioperative mortality for radical cystectomy in the modern Era: experience from
a tertiary referral center.
Int Braz J Urol. 2023;49:351-358.
Abstract
Inflammatory Myofibroblastic Tumour of the Urinary Bladder in a Middle-Aged Man-A
Case Report of an Unusual Localization of a Rare Tumour.
Medicina (Kaunas). 2023;59:791.
Abstract
VCAN Hypomethylation and Expression as Predictive Biomarkers of Drug Sensitivity
in Upper Urinary Tract Urothelial Carcinoma.
Int J Mol Sci. 2023;24:7486.
Abstract
SPAG9 Expression Predicts Good Prognosis in Patients with Clear-Cell Renal Cell
Carcinoma: A Bioinformatics Analysis with Experimental Validation.
Genes (Basel). 2023;14:944.
Abstract
Geographic variation in urinary tract and genital cancers in Iran: a hypothesis
involving exposure to solar radiation.
BMC Res Notes. 2023;16:65.
Abstract
[Tumor cell-based glycolytic metabolism and single-cell sequencing of urinary
exfoliated cells for the diagnosis and molecular profiling of urothelial
carcinoma].
Zhonghua Bing Li Xue Za Zhi. 2023;52:472-479.
Abstract
Urinary Bladder Masslike Lesions.
Radiographics. 2023;43:e230012.
Abstract
Hemoglobin, Albumin, Lymphocyte, and Platelet Count is a Significant Biomarker
Surrogate for Nutritional Status to Predict Overall Survival in Patients
Post-radical Cystectomy.
Urol Pract. 2023;10:262-269.
Abstract
Bladder and Kidney Cancer Diagnosis and Survival Increase With Medicare
Eligibility at Age 65.
Urol Pract. 2023;10:59-65.
Abstract
18F-FDG PET-Positive Large Pelvic Granuloma Mimicking Malignant Bladder Tumor.
Clin Nucl Med. 2023 Apr 25. doi: 10.1097/RLU.0000000000004676.
Abstract
IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who
are ctDNA+ post-surgery.
Future Oncol. 2023;19:509-515.
Abstract
Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274
study): a plain language summary.
Future Oncol. 2023;19:413-426.
Abstract
Preferences for first-line treatment of advanced urothelial carcinoma among US
practicing oncologists and patients.
Future Oncol. 2023;19:369-383.
Abstract
Urothelial carcinoma metastases impacting the CNS: A 20-year retrospective
series.
Ann Diagn Pathol. 2023;64:152109.
Abstract
BCG shortage for intravesical instillation is associated with early tumoral
recurrence in patients with high-risk non-muscle invasive bladder tumours.
Actas Urol Esp (Engl Ed). 2023;47:250-258.
Abstract
Clinical sequencing identifies potential actionable alterations in a high rate of
urachal and primary bladder adenocarcinomas.
Cancer Med. 2023;12:9041-9054.
Abstract
Kidney-sparing surgery for distal high-risk ureteral carcinoma: Clinical efficacy
and preliminary experiences in 22 patients.
Cancer Med. 2023;12:7835-7843.
Abstract
Multiple urinary bladder tumors: A case report.
Asian J Surg. 2023;46:2221-2222.
Abstract
Metabolic acidosis after ileal urinary diversion and radical cystectomy. Do we
know as much as we think we do? A systematic review.
Actas Urol Esp (Engl Ed). 2023;47:195-210.
Abstract
Management of primary upper urinary tract carcinoma in situ diagnosed by
ureteroscopic biopsy: Is bacillus Calmette-Guerin an alternative to
nephroureterectomy?
Actas Urol Esp (Engl Ed). 2023;47:221-228.
Abstract
Peritoneal tuberculosis caused by intravesical instillation with Bacillus
Calmette-Guerin (BCG) following nephroureterectomy in a patient with bladder and
upper tract urothelial cancer: a case report.
Acta Clin Belg. 2023;78:257-260.
Abstract
Development and evaluation of an adenosine-to-inosine RNA editing-based
prognostic model for survival prediction of bladder cancer patients.
Medicine (Baltimore). 2023;102:e33719.
Abstract
Guidance of adjuvant instillation in intermediate-risk non-muscle invasive
bladder cancer by drug screens in patient derived organoids: a single center,
open-label, phase II trial.
BMC Urol. 2023;23:89.
Abstract
Clinical application and efficacy analysis of partial cystectomy combined with
intravesical chemotherapy in muscle-invasive bladder cancer.
BMC Urol. 2023;23:91.
Abstract
Single-cell RNA sequencing reveals the cellular and molecular characteristics of
high-grade and metastatic bladder cancer.
Cell Oncol (Dordr). 2023 May 11. doi: 10.1007/s13402-023-00820.
Abstract
Comparison of Bacillus Calmette-Guerin Maintenance Therapy with Monthly
Instillations and the Southwest Oncology Group Protocol in the Treatment of
Non-muscle-invasive Bladder Cancer.
Eur Urol Focus. 2023 May 9:S2405-4569(23)00110-4. doi: 10.1016/j.euf.2023.
Abstract
Mechanistic review of sulforaphane as a chemoprotective agent in bladder cancer.
Am J Clin Exp Urol. 2023;11:103-120.
Abstract
Extramural venous invasion: a novel magnetic resonance imaging biomarker for
adverse pathology in bladder cancer.
Am J Clin Exp Urol. 2023;11:185-193.
Abstract
A deep learning model for drug screening and evaluation in bladder cancer
organoids.
Front Oncol. 2023;13:1064548.
Abstract
Retroperitoneal urothelial carcinoma arising after bladder diverticulectomy: a
case report.
BMC Urol. 2023;23:88.
Abstract
Mistletoe for Bladder Cancer: Call for More Case Reports Using the Intravesical
Route.
Altern Ther Health Med. 2023;29:18-19.
Abstract
Cervical lymph node metastasis of bladder cancer: a case report and review of
literature.
Aging Male. 2023;26:2205935.
Abstract
The function of guanylate binding protein 3 (GBP3) in human cancers by pan-cancer
bioinformatics.
Math Biosci Eng. 2023;20:9511-9529.
Abstract
Impact of Chart-Derived Frailty Index on 1-Year Mortality After Radical
Cystectomy in 1004 Patients with Bladder Cancer.
Ann Surg Oncol. 2023 May 9. doi: 10.1245/s10434-023-13565.
Abstract
The application of gemcitabine and pirarubicin in patients with non-muscle
invasive bladder cancer.
J Cancer Res Clin Oncol. 2023 May 9. doi: 10.1007/s00432-023-04739.
Abstract
Promoting post-discharge telephone follow-up of patients with transurethral
resection for bladder cancer: a best practice implementation project.
JBI Evid Implement. 2023 May 10. doi: 10.1097/XEB.0000000000000374.
Abstract
An innovative model based on N7-methylguanosine-related lncRNAs for forecasting
prognosis and tumor immune landscape in bladder cancer.
Cancer Cell Int. 2023;23:85.
Abstract
PCBP1 protects bladder cancer cells from mitochondria injury and ferroptosis by
inducing LACTB mRNA degradation.
Mol Carcinog. 2023 May 8. doi: 10.1002/mc.23533.
Abstract
Cryoablation inhibits the recurrence and progression of bladder cancer by
enhancing tumour-specific immunity.
Clin Transl Med. 2023;13:e1255.
Abstract
Anti-cancer activity of Chaga mushroom (Inonotus obliquus) against dog bladder
cancer organoids.
Front Pharmacol. 2023;14:1159516.
Abstract
Effect of renin-angiotensin-aldosterone system inhibitors on survival outcomes in
cancer patients treated with immune checkpoint inhibitors: a systematic review
and meta-analysis.
Front Immunol. 2023;14:1155104.
Abstract
LDL receptor related protein 1 is an adverse prognostic biomarker that correlates
with stromal remodeling and macrophages infiltration in bladder cancer.
Front Immunol. 2023;14:1113756.
Abstract
Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic
signature and immune infiltration characteristics in bladder cancer based on a
machine learning survival framework.
Front Endocrinol (Lausanne). 2023;14:1180404.
Abstract
Association of IL-17A promoter region SNP-rs2275913 with urinary bladder cancer.
Int J Health Sci (Qassim). 2023;17:33-38.
Abstract
Correlation between fibroblast growth factor receptor mutation, programmed death
ligand-1 expression and survival in urinary bladder cancer based on real-world
data.
Pathol Oncol Res. 2023;29:1611077.
Abstract
Identification of a novel de novo mutation of SETBP1 and new findings of SETBP1
in tumorgenesis.
Orphanet J Rare Dis. 2023;18:107.
Abstract
Primary aortoenteric fistula after intravesical instillation of Bacillus
Calmette-Guerin for bladder cancer.
Vascular. 2023 May 6:17085381231174923. doi: 10.1177/17085381231174923.
Abstract
Utility of GATA-3 and associated immunohistochemical markers in the differential
diagnosis of poorly differentiated urothelial carcinoma.
J Cancer Res Ther. 2023;19.
Abstract
Analysis of PPI networks of transcriptomic expression identifies hub genes
associated with Newcastle disease virus persistent infection in bladder cancer.
Sci Rep. 2023;13:7323.
Abstract
Diagnostic accuracy of bimanual palpation in bladder cancer patients undergoing
cystectomy: A prospective study.
Urol Oncol. 2023 May 3:S1078-1439(23)00122-9. doi: 10.1016/j.urolonc.2023.
Abstract
Melatonin induces cell cycle arrest and suppresses tumor invasion in urinary
bladder urothelial carcinoma.
Aging (Albany NY). 2023;15:3107-3119.
Abstract
Transcriptional-translational conflict is a barrier to cellular transformation
and cancer progression.
Cancer Cell. 2023;41:853-870.
Abstract
[Neoadjuvant chemotherapy in patients with high-risk upper tract urothelial
carcinoma: current evidence].
Urologie. 2023;62:522-524.
Abstract
Complete Remission of BCG-Refractory High-grade Bladder CIS with Pharmacologic
Ascorbate and Mistletoe.
Altern Ther Health Med. 2023;29:6-17.
Abstract
Population characteristics, management, and survival outcomes in muscle-invasive
urothelial carcinoma undergoing radical resection: the MINOTAUR study.
World J Urol. 2023;41:1069-1075.
Abstract
A 6-month maintenance schedule of mitomycin C after radical nephroureterectomy
for upper tract urothelial carcinoma for the prevention of intravesical
recurrence: a retrospective, single center study.
World J Urol. 2023;41:1077-1083.
Abstract
Biofilm Potentiates Cancer-Promoting Effects of Tumor-Associated Macrophages in a
3D Multi-Faceted Tumor Model.
Small. 2023;19:e2205904.
Abstract
Preoperative accuracy of diagnostic evaluation of urachal carcinoma.
Cancer Med. 2023;12:9106-9115.
Abstract
Impact of sex on outcomes after surgery for non-muscle-invasive and
muscle-invasive bladder urothelial carcinoma: a systematic review and
meta-analysis.
World J Urol. 2023;41:909-919.
Abstract
Aristolochic acid-containing Chinese herbal medicine and upper urinary tract
urothelial carcinoma in Taiwan: a narrative review.
World J Urol. 2023;41:899-907.
Abstract
Study Protocol of the Bladder Adjuvant RadioTherapy (BART) Trial: A Randomised
Phase III Trial of Adjuvant Radiotherapy Following Cystectomy in Bladder Cancer.
Clin Oncol (R Coll Radiol). 2023 May 5:S0936-6555(23)00178.
Abstract
Clock gene NR1D1 might be a novel target for the treatment of bladder cancer.
Urol Oncol. 2023 May 18:S1078-1439(23)00141.
Abstract
Editorial: Tumor microenvironment in bladder cancer.
Front Oncol. 2023;13:1208196.
Abstract
Synergistic ferroptosis-starvation therapy for bladder cancer based on hyaluronic
acid modified metal-organic frameworks.
Bioeng Transl Med. 2023;8:e10515.
Abstract
Association of BCG Vaccine Treatment With Death and Dementia in Patients With
Non-Muscle-Invasive Bladder Cancer.
JAMA Netw Open. 2023;6:e2314336.
Abstract
Physical activity, obesity, and bladder cancer incidence.
Cancer Causes Control. 2023 May 18. doi: 10.1007/s10552-023-01711.
Abstract
Immune Checkpoint Inhibitor Toxicity Management in Non-muscle-invasive Bladder
Cancer: What Urologists Need To Know.
Eur Urol Focus. 2023 May 16:S2405-4569(23)00109.
Abstract
The c-MYC transcription factor conduces to resistance to cisplatin by regulating
MMS19 in bladder cancer cells.
Tissue Cell. 2023;82:102096.
Abstract
Sig1R activates extracellular matrix-induced bladder cancer cell proliferation
and angiogenesis by combing beta-integrin.
Aging (Albany NY). 2023;15.
Abstract
International Society of Urological Pathology Consensus Conference on Current
Issues in Bladder Cancer. Working Group 4: Molecular Subtypes of Bladder
Cancer-Principles of Classification and Emerging Clinical Utility.
Am J Surg Pathol. 2023 May 18. doi: 10.1097/PAS.0000000000002053.
Abstract
Prognostic nutritional index combined with NLR to construct a survival prediction
model and decision analysis of patients with muscle-invasive bladder cancer after
surgery.
Cancer Med. 2023 May 18. doi: 10.1002/cam4.6088.
Abstract
The Impact of Blue Light Cystoscopy Use Among Nonmuscle Invasive Bladder Cancer
Patients in an Equal Access Setting: Implications on Recurrence and Time to
Recurrence.
Clin Genitourin Cancer. 2023 Apr 28:S1558-7673(23)00098.
Abstract
Adjuvant vs. progression-triggered treatment with gemcitabine in
platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a
randomized phase 3 trial.
Urol Oncol. 2023 May 15:S1078-1439(23)00134.
Abstract
Molecular vasculogenic mimicry-Related signatures predict clinical outcomes and
therapeutic responses in bladder cancer: Results from real-world cohorts.
Front Pharmacol. 2023;14:1163115.
Abstract
Risk Factors for Bladder Cancer: Results of a Survey of Hospital Patients.
J Cancer Allied Spec. 2023;9:485.
Abstract
Efficacy and safety of Bladder Preservation Therapy in combination with
Atezolizumab and Radiation Therapy (BPT-ART) for invasive bladder cancer: Interim
analysis from a multicenter, open-label, prospective phase II trial.
Int J Radiat Oncol Biol Phys. 2023 May 15:S0360-3016(23)00461.
Abstract
Increased Burden of Second Bladder Cancer and Rectal Cancer in Prostate Cancer
Treated With Radiotherapy: Results From Surveillance, Epidemiology, and End
Results.
Cancer Control. 2023;30:10732748231177544.
Abstract
Urothelial Bladder Cancer: Genomic Alterations in Fibroblast Growth Factor
Receptor.
Mol Diagn Ther. 2023 May 17. doi: 10.1007/s40291-023-00647.
Abstract
The accuracy of cystoscopy in predicting muscle invasion in newly diagnosed
bladder cancer patients.
World J Urol. 2023 May 17. doi: 10.1007/s00345-023-04428.
Abstract
Anna Karenina principle in personalized treatment of bladder cancer according to
oncogram: which drug for which patient?
Per Med. 2023 May 17. doi: 10.2217/pme-2022-0134.
Abstract
Between the Hammer and Anvil: Resolution of unresectable muscle invasive bladder
cancer in a renal transplant patient after cessation of immunosuppressive
therapy.
Urol Case Rep. 2023;48:102399.
Abstract
Association of 5alpha-Reductase Inhibitor Prescription With Bladder Cancer
Progression in Males in South Korea.
JAMA Netw Open. 2023;6:e2313667.
Abstract
Non-Invasive Imaging Modalities in Intravesical Murine Models of Bladder Cancer.
Cancers (Basel). 2023;15:2381.
Abstract
P2X1 and P2X7 Receptor Overexpression Is a Negative Predictor of Survival in
Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2023;15:2321.
Abstract
The Evaluation of Vascular Endothelial Growth Factor A (VEGFA) and VEGFR2
Receptor as Prognostic Biomarkers in Bladder Cancer.
Diagnostics (Basel). 2023;13:1471.
Abstract
Identification of the Prognostic Biomarkers CBX6 and CBX7 in Bladder Cancer.
Diagnostics (Basel). 2023;13:1393.
Abstract
Pelvic lymph node dissection for cervical or bladder cancer: embedding residual
fat tissue offers no added value.
Virchows Arch. 2023 May 15. doi: 10.1007/s00428-023-03559.
Abstract
Single-nucleus and Spatially Resolved Intratumor Subtype Heterogeneity in Bladder
Cancer.
Eur Urol Open Sci. 2023;51:78-88.
Abstract
Carboplatin Induction Chemotherapy in Clinically Lymph Node-positive Bladder
Cancer.
Eur Urol Open Sci. 2023;51:39-46.
Abstract
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer:
a multi-institutional propensity score matched and weighted analysis.
Lancet Oncol. 2023 May 12:S1470-2045(23)00170.
Abstract
Proton beam therapy for muscle-invasive bladder cancer: A systematic review and
analysis with Proton-Net, a multicenter prospective patient registry database.
J Radiat Res. 2023 Apr 25:rrad027. doi: 10.1093.
Abstract
Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) of First-Line
Therapies (1L) for Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC).
Curr Oncol. 2023;30:3637-3647.
Abstract
ASO Visual Abstract: Impact of Chart-Derived Frailty Index (CFI) on 1-Year
Mortality After Radical Cystectomy in 1004 Patients with Bladder Cancer.
Ann Surg Oncol. 2023 May 15. doi: 10.1245/s10434-023-13618.
Abstract
Chen, Y, Zhang, W, Kadier, A, Zhang, H, Yao, X. MicroRNA-769-5p suppresses cell
growth and migration via targeting NUSAP1 in bladder cancer. J Clin Lab Anal.
2020; 34:e23193.
J Clin Lab Anal. 2023 May 14:e24893. doi: 10.1002/jcla.24893.
Abstract
[A Case of Primary Signet Ring Cell Carcinoma of the Urinary Bladder Showing
Effectiveness of Chemotherapy with Gemcitabine and Cisplatin].
Hinyokika Kiyo. 2023;69:107-112.
Abstract
EIF4A3 serves as a prognostic and immunosuppressive microenvironment factor and
inhibits cell apoptosis in bladder cancer.
PeerJ. 2023;11:e15309.
Abstract
Prognostic analysis and validation of lncRNAs in bladder cancer on the basis of
neutrophil extracellular traps.
J Gene Med. 2023 May 13:e3525. doi: 10.1002/jgm.3525.
Abstract
The Clinical Significance of Serum Free Light Chains in Bladder Cancer.
J Clin Med. 2023;12:3294.
Abstract
Diagnostic Value of the Sentinel Lymph Node Technique in Patients with
Muscle-Invasive Bladder Cancer.
J Clin Med. 2023;12:3092.
Abstract
Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in
Recurrent Bladder Cancer.
Int J Mol Sci. 2023;24:8418.
Abstract
Bladder Cancer Cells Interaction with Lectin-Coated Surfaces under Static and
Flow Conditions.
Int J Mol Sci. 2023;24:8213.
Abstract
MDR1 Inhibition Reverses Doxorubicin-Resistance in Six Doxorubicin-Resistant
Canine Prostate and Bladder Cancer Cell Lines.
Int J Mol Sci. 2023;24:8136.
Abstract
Special Issue "Cisplatin in Cancer Therapy: Molecular Mechanisms of Action 3.0".
Int J Mol Sci. 2023;24:7917.
Abstract
Comprehensive Analysis of the Prognostic Value of Circulating MMP-7 Levels in
Urothelial Carcinoma: A Combined Cohort Analysis, Systematic Review, and
Meta-Analysis.
Int J Mol Sci. 2023;24:7859.
Abstract
Mutation Hotspots Found in Bladder Cancer Aid Prediction of Carcinogenic Risk in
Normal Urothelium.
Int J Mol Sci. 2023;24:7852.
Abstract
Diagnostic and Prognostic Roles of Urine Nectin-2 and Nectin-4 in Human Bladder
Cancer.
Cancers (Basel). 2023;15:2565.
Abstract
Genome-Wide Screening Identifies Gene AKR1C1 Critical for Resistance to
Pirarubicin in Bladder Cancer.
Cancers (Basel). 2023;15:2487.
Abstract
Photostable Cascade Activatable Peptide Self-assembly on a Cancer Cell Membrane
for High-Performance Identification of Human Bladder Cancer.
Adv Mater. 2023 May 12:e2210732. doi: 10.1002/adma.202210732.
Abstract
A case report and literature review on primary solitary fibrous tumor of the
bladder.
Medicine (Baltimore). 2023;102:e33708.
Abstract
Effects of dose and human N-acetyltransferase 1 genetic polymorphism in benzidine
metabolism and genotoxicity.
Arch Toxicol. 2023;97:1765-1772.
Abstract
ASO Author Reflections: Comparison of Perioperative Outcomes and Complications of
Laparoscopic and Robotic Nephroureterectomy Approaches in Patients with
Upper-Tract Urothelial Carcinoma.
Ann Surg Oncol. 2023;30:3817-3818.
Abstract
Preoperative fibrinogen/CRP score predicts survival in upper urothelial tract
carcinoma patients undergoing radical curative surgery.
World J Urol. 2023;41:1359-1364.
Abstract
Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for
advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis.
Urol Oncol. 2023;41:256.
Abstract
Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits
from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a
second BCG induction cycle?
World J Urol. 2023;41:1329-1335.
Abstract
The efficacy of ultrasonography for the detection of upper tract urothelial
carcinoma.
J Med Ultrason (2001). 2023;50:197-203.
Abstract
Diagnostic value of Xpert(R) BC Detection, Bladder Epicheck(R), Urovysion(R) FISH and
cytology in the detection of upper urinary tract urothelial carcinoma.
World J Urol. 2023;41:1323-1328.
Abstract
ASO Visual Abstract: Comparison of Perioperative Outcomes and Complications of
Laparoscopic and Robotic Nephroureterectomy Approaches in Patients with
Upper-Tract Urothelial Carcinoma.
Ann Surg Oncol. 2023;30:3819.
Abstract
Comparison of Perioperative Outcomes and Complications of Laparoscopic and
Robotic Nephroureterectomy Approaches in Patients with Upper-Tract Urothelial
Carcinoma.
Ann Surg Oncol. 2023;30:3805-3816.
Abstract
Comparison of clinicopathological characteristics, gene expression profiles,
mutational analysis, and clinical outcomes of pure and mixed small-cell carcinoma
of the bladder.
Histopathology. 2023;82:991-1002.
Abstract
Case report: durable complete response to pembrolizumab plus lenvatinib in a
metastatic upper tract urothelial carcinoma patient with high tumor mutational
burden and an immune-active tumor microenvironment.
Anticancer Drugs. 2023;34:797-802.
Abstract
Detection and resection of carcinoma in situ of the bladder: Implications for
clinical trial design.
Urol Oncol. 2023;41:254.
Abstract
Oncological and functional outcomes of female reproductive organ-sparing radical
cystectomy and ileal neobladder construction.
Urol Oncol. 2023;41:254.
Abstract
Urothelial carcinoma of the bladder with isolated lymph node metastasis: Natural
history and outcomes following surgical resection.
Urol Oncol. 2023;41:255.
Abstract
Combination of radiation and immunotherapy in the treatment of genitourinary
malignancies: A systematic review and meta-analysis.
Urol Oncol. 2023;41:219-232.
Abstract
Discriminative capacity of guideline recommendations in the assessment of
patients with asymptomatic microhematuria.
Urol Oncol. 2023;41:254.
Abstract
Rare periorbital, pseudocystic metastasis of squamous cell carcinoma of the
bladder: Case report and review of the literature.
Orbit. 2023;42:336-342.
Abstract
Intravesical Contrast-Enhanced MRI: A Potential Tool for Bladder Cancer
Surveillance and Staging.
Curr Oncol. 2023;30:4632-4647.
Abstract
Targeting bladder cancer with Trigonella foenum-graecum: a computational study
using network pharmacology and molecular docking.
J Biomol Struct Dyn. 2023 May 26:1-8. doi: 10.1080/07391102.2023.2217926.
Abstract
Off the fog to find the optimal choice: Research advances in biomarkers for early
diagnosis and recurrence monitoring of bladder cancer.
Biochim Biophys Acta Rev Cancer. 2023 May 23:188926.
Abstract
MiR-3960 inhibits bladder cancer progression via targeting of DEXI.
Biochem Biophys Res Commun. 2023;668:8-18.
Abstract
Targeted and untargeted urinary metabolic profiling of bladder cancer.
J Pharm Biomed Anal. 2023;233:115473.
Abstract
Health care resource utilization, quality metrics, and costs of bladder cancer
within the Oncology Care Model.
Am J Manag Care. 2023;29:e136-e142.
Abstract
Plasmacytoid bladder cancer: a rare case report.
Ann Med Surg (Lond). 2023;85:1885-1887.
Abstract
Nature's hidden gem: quercitrin's promising role in preventing prostate and
bladder cancer.
Future Sci OA. 2023;9:FSO867.
Abstract
Late-onset enteric fistula following radical cystectomy for bladder cancer: A
case report.
Urol Case Rep. 2023;49:102431.
Abstract
Urinary shedding of common DNA viruses and their possible association with
bladder cancer: a qPCR-based study.
Neoplasma. 2023;70:311-318.
Abstract
Real-world retrospective review of monotherapy following platinum-based
chemotherapy for metastatic urothelial cancer.
J Int Med Res. 2023;51:3000605231173319.
Abstract
Urine biomarkers in bladder cancer - current status and future perspectives.
Nat Rev Urol. 2023 May 24. doi: 10.1038/s41585-023-00773.
Abstract
Acute Toxicity of Hypofractionated and Conventionally Fractionated
(Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the
RAIDER Trial.
Clin Oncol (R Coll Radiol). 2023 May 9:S0936-6555(23)00180.
Abstract
[National Registries for Urothelial Cancer (UroNAT) and Prostate Cancer (ProNAT)
by d-uo].
Aktuelle Urol. 2023;54:202-207.
Abstract
[The cancer registry notification seen from the perspective of the German Society
of Uro-Oncologists (d-uo)].
Aktuelle Urol. 2023;54:189-195.
Abstract
[Not Available].
Aktuelle Urol. 2023;54:185.
Abstract
Non-muscle-invasive bladder cancer molecular subtypes predict differential
response to intravesical Bacillus Calmette-Guerin.
Sci Transl Med. 2023;15:eabn4118.
Abstract
Machine learning models combining computed tomography semantic features and
selected clinical variables for accurate prediction of the pathological grade of
bladder cancer.
Front Oncol. 2023;13:1166245.
Abstract
Comment on: "Accuracy of the European Association of Urology (EAU) NMIBC 2021
scoring model in predicting progression in a large cohort of HG T1 NMIBC patients
treated with BCG".
Minerva Urol Nephrol. 2023;75:407-409.
Abstract
Comment on: "Animal model assessment of a new design for a coated
mitomycin-eluting biodegradable ureteral stent for intracavitary instillation as
an adjuvant therapy in upper urothelial carcinoma".
Minerva Urol Nephrol. 2023;75:401-403.
Abstract
Thymoquinone enhanced the antitumor activity of cisplatin in human bladder cancer
5637 cells in vitro.
Mol Biol Rep. 2023 May 23. doi: 10.1007/s11033-023-08472.
Abstract
Mucoadhesive gellan gum-based and carboxymethyl cellulose -based hydrogels
containing gemcitabine and papain for bladder cancer treatment.
Int J Biol Macromol. 2023 May 20:124957. doi: 10.1016/j.ijbiomac.2023.124957.
Abstract
LncRNA UCA1 Participates in De Novo Synthesis of Guanine Nucleotides in Bladder
Cancer by Recruiting TWIST1 to Increase IMPDH1/2.
Int J Biol Sci. 2023;19:2599-2612.
Abstract
A potential biological signature of 7-methylguanosine-related lncRNA to predict
the immunotherapy effects in bladder cancer.
Heliyon. 2023;9:e15897.
Abstract
Quality of life of muscle-invasive bladder cancer patients after
brachytherapy-based treatment: A cross-sectional study.
J Contemp Brachytherapy. 2023;15:110-116.
Abstract
The role of E3 ubiquitin ligases and deubiquitinases in bladder cancer
development and immunotherapy.
Front Immunol. 2023;14:1202633.
Abstract
Analysis of the Regulatory Effect of ACTG2 on Biological Behavior of Bladder
Cancer Cells Based on Database Screening.
Cell Mol Biol (Noisy-le-grand). 2023;69:125-130.
Abstract
LncRNA BCLET variant confers bladder cancer susceptibility through alternative
splicing of MSANTD2 exon 1.
Cancer Med. 2023 May 21. doi: 10.1002/cam4.6072.
Abstract
Patterns of Utilization and Outcomes of Perioperative Chemotherapy in Patients
With Locally Advanced-urothelial Bladder Cancer (LABC)-Real World Data From an
Indian Tertiary Care Cancer Center.
Clin Genitourin Cancer. 2023 Apr 11:S1558-7673(23)00082.
Abstract
Survival outcomes in patients with muscle invasive bladder cancer undergoing
radical vs. partial cystectomy.
Urol Oncol. 2023 May 18:S1078-1439(23)00137.
Abstract
Roles of non-coding RNAs in the metabolism and pathogenesis of bladder cancer.
Hum Cell. 2023 May 20. doi: 10.1007/s13577-023-00915.
Abstract
The cuproptosis-associated 11 gene signature as a predictor for outcomes and
response to Bacillus Calmette-Guerin and immune checkpoint inhibitor therapies in
bladder carcinoma.
Front Immunol. 2023;14:1126247.
Abstract
Pathogenesis of psoriasis via miR-149-5p/AKT1axis by long noncoding RNA BLACAT1.
Skin Res Technol. 2023;29:e13339.
Abstract
Gene-occupation interactions: a review of the literature on bladder and prostate
cancer.
Med Pr. 2023;74:127-144.
Abstract
Conditional survival for non-metastatic muscle-invasive adenocarcinoma of the
urinary bladder after radical cystectomy.
Surg Oncol. 2023;48:101947.
Abstract
Evolving systemic management of urothelial cancers.
Curr Opin Oncol. 2023;35:186-199.
Abstract
Regional differences in total hospital costs for radical cystectomy in the United
States.
Surg Oncol. 2023;48:101924.
Abstract
Integrating Molecular Sequencing Into the Pathological Diagnosis of Clinically
Suspected Non-Small Cell Lung Carcinomas.
Mod Pathol. 2023;36:100126.
Abstract
Targeted Next-Generation Sequencing of Flat Urothelial Lesions Reveals Putative
Pathobiological Pathways, Potential Biomarkers, and Rational Therapeutic Targets.
Mod Pathol. 2023;36:100120.
Abstract
Differential operation of MLH1/MSH2 and FANCD2 crosstalk in chemotolerant bladder
carcinoma: a clinical and therapeutic intervening study.
Mol Cell Biochem. 2023;478:1599-1610.
Abstract
Long-term oncologic outcomes of robot-assisted radical cystectomy: update series
from a high-volume robotic center beyond 10 years of follow-up.
J Robot Surg. 2023;17:1143-1150.
Abstract
Centralization and prospective audit of cystectomy are necessary: a commentary on
the case for centralization, supported by a contemporary series utilizing the
ANZUP cystectomy database.
Asia Pac J Clin Oncol. 2023;19:290-295.
Abstract
Noninferior oncological outcomes in adults aged 80 years or older compared with
younger patients who underwent radical nephroureterectomy for upper tract
urothelial carcinoma.
Asia Pac J Clin Oncol. 2023;19:305-311.
Abstract
[Cystectomy of a young patient with squamous cell metaplasia of the bladder and
manifestation of condyloma].
Aktuelle Urol. 2023;54:223-227.
Abstract
Oncological outcomes of visibly complete transurethral resection prior to
neoadjuvant chemotherapy for bladder cancer.
Int Braz J Urol. 2023;49:479-489.
Abstract
Bladder preservation by neoadjuvant chemotherapy followed by concurrent
chemoradiation for muscle-invasive bladder cancer.
Contemp Oncol (Pozn). 2023;27:1-9.
Abstract
Correction for: Circular RNA circRGNEF promotes bladder cancer progression via
miR-548/KIF2C axis regulation.
Aging (Albany NY). 2023;undefined.
Abstract
[Sequential therapy of advanced bladder cancer after prior perioperative systemic
treatment : Recommendations from the Interdisciplinary Bladder Carcinoma Working
Group (IABC) of the DKG e. V.].
Urologie. 2023 Jun 1. doi: 10.1007/s00120-023-02098.
Abstract
A non-G-Quadruplex DNA Aptamer Targeting NCL for Diagnosis and Therapy in Bladder
Cancer.
Adv Healthc Mater. 2023 Jun 1:e2300791. doi: 10.1002/adhm.202300791.
Abstract
History of infantile BCG immunization did not predict lamina propria invasion
and/or high-grade in patients with non-muscle invasive bladder cancer.
Arch Ital Urol Androl. 2023 May 31:11380. doi: 10.4081/aiua.2023.11380.
Abstract
Retraction Note: LncRNA BRE-AS1 acts as a tumor suppressor factor in bladder
cancer via mediating STAT3.
Eur Rev Med Pharmacol Sci. 2023;27:4326.
Abstract
Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive
bladder cancer.
World J Urol. 2023 May 31:1-9. doi: 10.1007/s00345-023-04443.
Abstract
The YTHDC1/GLUT3/RNF183 axis forms a positive feedback loop that modulates
glucose metabolism and bladder cancer progression.
Exp Mol Med. 2023 Jun 1. doi: 10.1038/s12276-023-00997.
Abstract
Readmissions trends following radical cystectomy for bladder cancer unchanged in
the era of enhanced recovery after surgery (ERAS) protocols.
Urol Oncol. 2023 May 29:S1078-1439(23)00172.
Abstract
Comment on "The prognostic impact of tumor necrosis in non-muscle invasive
bladder cancer".
Rev Assoc Med Bras (1992). 2023;69:e20230295.
Abstract
The association between serum hypoxia inducible factor-1alpha level and urothelial
bladder cancer: A preliminary study.
Arch Ital Urol Androl. 2023 May 29:11292. doi: 10.4081/aiua.2023.11292.
Abstract
CD24 targeting with NK-CAR immunotherapy in testis, prostate, renal and
(luminal-type) bladder cancer and identification of direct CD24 interaction
partners.
FEBS J. 2023 May 31. doi: 10.1111/febs.16880.
Abstract
Surveillance of prognostic risk factors in patients with SCCB using artificial
intelligence: a retrospective study.
Sci Rep. 2023;13:8727.
Abstract
Hyperthermia intravesical chemotherapy acts as a promising alternative to
bacillus Calmette-Guerin instillation in non-muscle-invasive bladder cancer: a
network meta-analysis.
Front Oncol. 2023;13:1164932.
Abstract
Corrigendum: The epithelial to mesenchymal transition related gene calumenin is
an adverse prognostic factor of bladder cancer correlated with tumor
microenvironment remodeling, gene mutation, and ferroptosis.
Front Oncol. 2023;13:1185029.
Abstract
Peritoneal and pulmonary tuberculosis following intravesical administration of
Bacillus Calmette-Guerin for bladder cancer.
Int Cancer Conf J. 2023;12:221-225.
Abstract
A long-term survival case of bladder cancer with distant metastases: abscopal
effect of brain metastases after stereotactic radiotherapy with immune checkpoint
blockade therapy to lung metastases.
Int Cancer Conf J. 2023;12:205-209.
Abstract
Penile metastasis secondary to urothelial bladder cancer.
Urol Case Rep. 2023;49:102428.
Abstract
A genome-wide CRISPR screen maps endogenous regulators of PPARG gene expression
in bladder cancer.
iScience. 2023;26:106525.
Abstract
Health outcomes and budget impact projection of anti-PD-(L)1s in cancer care in
Portugal.
Front Public Health. 2023;11:1133959.
Abstract
Tripartite motif-containing 9 promoted proliferation and migration of bladder
cancer cells through CEACAM6-Smad2/3 axis.
J Cell Commun Signal. 2023 May 30. doi: 10.1007/s12079-023-00766.
Abstract
miR-383-5p serves as a tumor suppressor in bladder cancer by suppressing PI3K/AKT
signaling pathway.
Cancer Biomark. 2023 May 18. doi: 10.3233/CBM-220379.
Abstract
Perioperative and oncologic outcomes of transperitoneal versus retroperitoneal
laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma: a
systematic review and pooled analysis of comparative outcomes.
World J Surg Oncol. 2023;21:163.
Abstract
Clinical Exome Gene Panel Analysis of a Cohort of Urothelial Bladder Cancer
Patients from Sri Lanka.
Asian Pac J Cancer Prev. 2023;24:1533-1542.
Abstract
Methylseleninic acid induces apoptosis of human bladder cancer cells through the
ROS-mediated mitochondrial pathway.
J Biochem Mol Toxicol. 2023 May 29:e23387. doi: 10.1002/jbt.23387.
Abstract
International Society of Urological Pathology (ISUP) Consensus Conference on
Current Issues in Bladder Cancer. Working Group 1: Comparison of Bladder Cancer
Grading System Performance.
Am J Surg Pathol. 2023 May 29. doi: 10.1097/PAS.0000000000002059.
Abstract
The Role of Fascin-1 in Human Urologic Cancers: A Promising Biomarker or
Therapeutic Target?
Technol Cancer Res Treat. 2023;22:15330338231175733.
Abstract
The Role of Dual-Energy CT in the Study of Urinary Tract Tumors: Review of Recent
Literature.
Semin Ultrasound CT MR. 2023;44:136-144.
Abstract
Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature
based on T-cell marker genes to predict prognosis and immunotherapy response in
bladder cancer.
J Cancer Res Clin Oncol. 2023 May 27. doi: 10.1007/s00432-023-04881.
Abstract
The Utility of Inflammatory Serum Markers in the Assessment of Perioperative
Morbidity after Radical Cystectomy for Bladder Cancer.
Medicina (Kaunas). 2023;59:926.
Abstract
Precision Medicine in Bladder Cancer: Present Challenges and Future Directions.
J Pers Med. 2023;13:756.
Abstract
The Implementation of FDG PET/CT for Staging Bladder Cancer: Changes in the
Detection and Characteristics of Occult Nodal Metastases at Upfront Radical
Cystectomy?
J Clin Med. 2023;12:3367.
Abstract
"ThermoTRP" Channel Expression in Cancers: Implications for Diagnosis and
Prognosis (Practical Approach by a Pathologist).
Int J Mol Sci. 2023;24:9098.
Abstract
Spatial Gene Expression Analysis Reveals Characteristic Gene Expression Patterns
of De Novo Neuroendocrine Prostate Cancer Coexisting with Androgen Receptor
Pathway Prostate Cancer.
Int J Mol Sci. 2023;24:8955.
Abstract
Hypoxia Is Associated with Increased Immune Infiltrates and Both Anti-Tumour and
Immune Suppressive Signalling in Muscle-Invasive Bladder Cancer.
Int J Mol Sci. 2023;24:8956.
Abstract
Relationship between the Reduced Expression of Zinc Finger Protein 668 in Bladder
Cancer and Its Invasiveness.
Int J Mol Sci. 2023;24:8668.
Abstract
Impacts of Mir146a Genotypes on Bladder Cancer Risk in Taiwan.
Biomedicines. 2023;11:1396.
Abstract
Differential Expression of LncRNA in Bladder Cancer Development.
Diagnostics (Basel). 2023;13:1745.
Abstract
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with
advanced solid tumors, including dose expansion in patients with advanced
urothelial carcinoma.
J Immunother Cancer. 2023;11:e005813.
Abstract
PHB promotes bladder cancer cell epithelial-mesenchymal transition via the
Wnt/beta-catenin signaling pathway.
Pathol Res Pract. 2023;247:154536.
Abstract
One-Step Robot-Assisted Complete Urinary Tract Extirpation in Man with End-Stage
Renal Disease on Dialysis: The First Case Report.
Curr Oncol. 2023;30:5093-5102.
Abstract
Three-port approach vs conventional laparoscopic radical cystectomy with
orthotopic neobladder: a single-center retrospective study.
World J Surg Oncol. 2023;21:160.
Abstract
Mucoadhesive Emulsion Microgels for Intravesical Drug Delivery: Preparation,
Retention at Urothelium, and Biodistribution Study.
ACS Appl Mater Interfaces. 2023;15:25354-25368.
Abstract
Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic
urothelial carcinoma.
Int Immunopharmacol. 2023;119:110158.
Abstract
Autoimmune disorders caused by intravesical bacillus Calmette-Guerine treatment:
A systematic review.
Autoimmun Rev. 2023;22:103329.
Abstract
MLKL and other necroptosis-related genes promote the tumor immune cell
infiltration, guiding for the administration of immunotherapy in bladder
urothelial carcinoma.
Apoptosis. 2023;28.
Abstract
Urothelial carcinoma in situ with "overriding" features can evade detection by
mimicking umbrella cells.
Hum Pathol. 2023;136:56-62.
Abstract
Nitrated Polycyclic Aromatic Hydrocarbon (Nitro-PAH) Signatures and Somatic
Mutations in Diesel Exhaust-Exposed Bladder Tumors.
Cancer Epidemiol Biomarkers Prev. 2023;32:840-847.
Abstract
Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced
upper tract urothelial carcinoma: A multicenter, retrospective, real-world study.
Cancer Med. 2023;12:10587-10596.
Abstract
Clinical application of the anti-human telomerase reverse transcriptase (hTERT)
antibody (SCD-A7) immunocytochemistry in liquid-based urine cytology:
A prospective, single institute study.
Cancer Med. 2023;12:10363-10370.
Abstract
Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade
Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice.
Clin Genitourin Cancer. 2023;21:334-341.
Abstract
Development and Internal Validation of a Nomogram Predicting Overall Survival
Based on Log ODDS of Positive Lymph-Nodes for Post Radical Cystectomy Patients in
Muscle Invasive Carcinoma of Bladder.
Clin Genitourin Cancer. 2023;21:e153-e165.
Abstract
Mycobacterium bovis bacille Calmette-Guerin-derived extracellular vesicles as an
alternative to live BCG immunotherapy.
Clin Exp Med. 2023;23:519-527.
Abstract
[Retracted] KIF4A promotes the development of bladder cancer by transcriptionally
activating the expression of CDCA3.
Int J Mol Med. 2023;52:62.
Abstract
International Society of Urological Pathology (ISUP) Consensus Conference on
Current Issues in Bladder Cancer: Progresses and Challenges.
Am J Surg Pathol. 2023 Jun 8. doi: 10.1097/PAS.0000000000002066.
Abstract
Comparative transcriptomic analysis and mechanistic characterization revealed the
use of formononetin for bladder cancer treatment.
Food Funct. 2023 Jun 8. doi: 10.1039/d2fo03962.
Abstract
Absence of detrusor muscle in TUR-BT specimen - can we predict who is at highest
risk?
BMC Urol. 2023;23:106.
Abstract
Can pelvic diameter measurement have an effect on surgical outcomes in radical
cystectomy?
BMC Urol. 2023;23:105.
Abstract
Perivesical Fat Invasive Pattern as Prognostic Factor and Predictor of Response
to Adjuvant Chemotherapy in T3 Stage Bladder Cancer.
Clin Genitourin Cancer. 2023 May 7:S1558-7673(23)00105.
Abstract
Novel sequential treatment strategy for patients with muscle-invasive bladder
cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant
chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant
immunotherapy - protocol
BMJ Open. 2023;13:e067634.
Abstract
Corrigendum: MicroRNA-153 decreases tryptophan catabolism and inhibits
angiogenesis in bladder cancer by targeting indoleamine 2,3-dioxygenase 1.
Front Oncol. 2023;13:1208728.
Abstract
Real-world retrospective study of immune checkpoint inhibitors in combination
with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy
for muscle-invasive bladder urothelial cancer.
Front Immunol. 2023;14:1162580.
Abstract
Inhibition of FGFR3 upregulates MHC-I and PD-L1 via TLR3/NF-kB pathway in
muscle-invasive bladder cancer.
Cancer Med. 2023 Jun 7. doi: 10.1002/cam4.6172.
Abstract
Construction of prognostic risk model of bladder cancer based on
cuproptosis-related long non-coding RNAs.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023;52:139-147.
Abstract
Sex hormones influence survival of patients with metastatic urothelial carcinoma
undergoing immune checkpoint therapy.
Biol Sex Differ. 2023;14:38.
Abstract
Single-cell RNA sequencing reveals sexual diversity in the human bladder and its
prospective impacts on bladder cancer and urinary tract infection.
BMC Med Genomics. 2023;16:122.
Abstract
Identification of MDM2 as a prognostic and immunotherapeutic biomarker in a
comprehensive pan-cancer analysis: A promising target for breast cancer, bladder
cancer and ovarian cancer immunotherapy.
Life Sci. 2023 Jun 3:121832. doi: 10.1016/j.lfs.2023.121832.
Abstract
Fluoxetine inactivates STAT3/NF-kappaB signaling and promotes sensitivity to
cisplatin in bladder cancer.
Biomed Pharmacother. 2023;164:114962.
Abstract
Clinical value of anoikis-related genes and molecular subtypes identification in
bladder urothelial carcinoma and in vitro validation.
Front Immunol. 2023;14:1122570.
Abstract
Bladder cancer patients have increased NETosis and impaired DNaseI-mediated NET
degradation that can be therapeutically restored in vitro.
Front Immunol. 2023;14:1171065.
Abstract
Inflammatory myofibroblastic tumor of the urinary bladder: a case report.
Pan Afr Med J. 2023;44:119.
Abstract
Screening of immunotherapy-related genes in bladder cancer based on GEO datasets.
Front Oncol. 2023;13:1176637.
Abstract
LaSOM 335, active against bladder cancer cells, interferes with Let-60 (hRas) and
reduces CD73 expression/activity.
Chem Biol Drug Des. 2023 Jun 5. doi: 10.1111/cbdd.14273.
Abstract
Evaluation of incidence, predictive factors and treatment considerations for
asymptomatic genitourinary granulomas after intravesical bacillus Calmette-Guerin
therapy.
Actas Urol Esp (Engl Ed). 2023;47:317-326.
Abstract
High risk of non-cancer mortality in bladder cancer patients: evidence from
SEER-Medicaid.
J Cancer Res Clin Oncol. 2023 Jun 3. doi: 10.1007/s00432-023-04867.
Abstract
A Restaging Transurethral Resection of Bladder Tumor Is Always Necessary For
High-grade T1 Non-muscle-invasive Bladder Cancer.
Eur Urol Focus. 2023 Jun 1:S2405-4569(23)00121-9. doi: 10.1016/j.euf.2023.
Abstract
Artificial intelligence-based model for lymph node metastases detection in
bladder cancer - Authors' reply.
Lancet Oncol. 2023;24:e234.
Abstract
Artificial intelligence-based model for lymph node metastases detection in
bladder cancer.
Lancet Oncol. 2023;24:e233.
Abstract
Artifical intelligence-based model for lymph node metastases detection in bladder
cancer.
Lancet Oncol. 2023;24:e232.
Abstract
CircHIPK3 negatively regulates autophagy by blocking VCP binding to the Beclin 1
complex in bladder cancer.
Discov Oncol. 2023;14:86.
Abstract
Identification of necroptosis-related long non-coding RNAs prognostic signature
and the crucial lncRNA in bladder cancer.
J Cancer Res Clin Oncol. 2023 Jun 3. doi: 10.1007/s00432-023-04886.
Abstract
TROP2 translation mediated by dual m(6)A/m(7)G RNA modifications promotes bladder
cancer development.
Cancer Lett. 2023 May 31:216246. doi: 10.1016/j.canlet.2023.216246.
Abstract
Effects of different combinations of radical nephroureterectomy and bladder cuff
excision procedures for upper tract urothelial carcinoma on bladder recurrence.
Int Braz J Urol. 2023;49:469-478.
Abstract
[Urothelial carcinoma of the upper urinary tract].
Urologie. 2023;62:640-650.
Abstract
Obturator Nerve Block for Transurethral Resection of Bladder Tumors.
Med Arch. 2023;77:118-122.
Abstract
Response to M. Brehmer: Register-based research. Accurate data and analysis,
crucial for correct conclusions. Comment on 'Incidence, mortality, and relative
survival of patients with cancer of the bladder and upper urothelial tract in the
Nordic count
Scand J Urol. 2023;58:20.
Abstract
Urinary microbiota and metabolic signatures associated with inorganic
arsenic-induced early bladder lesions.
Ecotoxicol Environ Saf. 2023;259:115010.
Abstract
Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with
muscle-invasive urothelial cancer of the bladder.
World J Urol. 2023;41:1697-1698.
Abstract
Assessing postradical cystectomy outcomes in the enhanced recovery era:
"enhancing" the corresponding research outlook.
Urol Oncol. 2023;41:292.
Abstract
[Interstitial cystitis/bladder pain syndrome (IC/BPS)].
Urologie. 2023;62:582-589.
Abstract
Impact of smoking on urologic cancers: a snapshot of current evidence.
World J Urol. 2023;41:1473-1479.
Abstract
Cytokeratin 20 expression is linked to stage progression and to poor prognosis in
advanced (pT4) urothelial carcinoma of the bladder.
Exp Mol Pathol. 2023;131:104860.
Abstract
Development and validation of a prognostic nomogram for overall and
disease-specific survival in patients with sarcomatoid urothelial carcinoma.
Urol Oncol. 2023;41:296.
Abstract
Primary intestinal adenocarcinoma after orthotopic ileal neobladder.
Asian J Surg. 2023;46:2321-2322.
Abstract
Nuclear membrane irregularity in high-grade urothelial carcinoma cells can be
measured by using circularity and solidity as morphometric shape definitions in
digital image analysis of urinary tract cytology specimens.
Cancer Cytopathol. 2023;131:351-359.
Abstract
Clinical and treatment characteristics of secondary bladder malignancies
following low dose rate brachytherapy for prostate cancer.
Urol Oncol. 2023;41:296.
Abstract
Treatment progress of cystitis glandularis.
Asian J Surg. 2023;46:2444.
Abstract
Multiple primary trans-systemic triple carcinoma: A rare case report.
Asian J Surg. 2023;46:2466-2467.
Abstract
Disparities in access to high-volume centers and in hospital discharge status
following radical cystectomy in Florida.
Urol Oncol. 2023;41:294.
Abstract
Topical instillation of BCG immunotherapy for biopsy-proven primary upper urinary
tract carcinoma in situ: A single institution series and systematic review.
Urol Oncol. 2023;41:274-283.
Abstract
Advanced chronic kidney disease; A comparison between nephroureterectomy and
nephron-sparing surgery for upper tract urothelial carcinoma.
Urol Oncol. 2023;41:295.
Abstract
Multi-omics analysis of the oncogenic value of copper Metabolism-Related protein
COMMD2 in human cancers.
Cancer Med. 2023;12:11941-11959.
Abstract
Urine Cytology Findings in Cases of Pseudocarcinomatous Urothelial Hyperplasia of
the Bladder Often Represent a Diagnostic Challenge.
Arch Pathol Lab Med. 2023;147:716-721.
Abstract
The Effect of Complete Prostate Examination of Radical Cystoprostatectomy
Specimen on the Final Stage of Urothelial Carcinoma of the Urinary Bladder and
the Detection of Prostate Cancer.
Arch Pathol Lab Med. 2023;147:665-675.
Abstract
Competition between p53 and YY1 determines PHGDH expression and malignancy in
bladder cancer.
Cell Oncol (Dordr). 2023 Jun 16. doi: 10.1007/s13402-023-00823.
Abstract
[Corrigendum] Celecoxib inhibits the epithelial‑to‑mesenchymal transition in
bladder cancer via the miRNA‑145/TGFBR2/Smad3 axis.
Int J Mol Med. 2023;52:64.
Abstract
Leveraging a disulfidptosis-based signature to improve the survival and drug
sensitivity of bladder cancer patients.
Front Immunol. 2023;14:1198878.
Abstract
Construction of T cell exhaustion model for predicting survival and immunotherapy
effect of bladder cancer based on WGCNA.
Front Oncol. 2023;13:1196802.
Abstract
Dietary vitamin D intake and the bladder cancer risk: A pooled analysis of
prospective cohort studies.
Clin Nutr. 2023 May 22:S0261-5614(23)00152-8. doi: 10.1016/j.clnu.2023.
Abstract
Brazilin inhibits bladder cancer by promoting cell necroptosis.
Clin Exp Pharmacol Physiol. 2023 Jun 15. doi: 10.1111/1440-1681.13800.
Abstract
Audit, Feedback, and Education to Improve Quality and Outcomes in Transurethral
Resection and Single-Instillation Intravesical Chemotherapy for Nonmuscle
Invasive Bladder Cancer Treatment: Protocol for a Multicenter International
Observational Study W
JMIR Res Protoc. 2023;12:e42254.
Abstract
CD44 is a potential immunotherapeutic target and affects macrophage infiltration
leading to poor prognosis.
Sci Rep. 2023;13:9657.
Abstract
Cisplatin-induced increase in heregulin 1 and its attenuation by the monoclonal
ErbB3 antibody seribantumab in bladder cancer.
Sci Rep. 2023;13:9617.
Abstract
The Risk of Catastrophic Healthcare Expenditures Among Prostate and Bladder
Cancer Survivors in the United States.
Clin Genitourin Cancer. 2023 May 27:S1558-7673(23)00135.
Abstract
SCARA5 as a downstream factor of PCAT29, inhibits proliferation, migration, and
invasion of bladder cancer.
Genomics. 2023 Jun 12:110667. doi: 10.1016/j.ygeno.2023.110667.
Abstract
Medicaid Expansion and Racial Disparity in Timely Multidisciplinary Treatment in
Muscle Invasive Bladder Cancer.
J Natl Cancer Inst. 2023 Jun 14:djad112. doi: 10.1093.
Abstract
Targeted hollow pollen silica nanoparticles for enhanced intravesical therapy of
bladder cancer.
Biomater Sci. 2023 Jun 14. doi: 10.1039/d3bm00631.
Abstract
Cutaneous metastasis in bladder cancer.
J Cancer Res Ther. 2023;19:501-504.
Abstract
Chemotherapy or chemotherapy followed by consolidation chemoradiation in
postoperative (simple cholecystectomy) gall bladder cancer with residual disease,
unsuitable for revision surgery? Risk stratification and outcomes.
J Cancer Res Ther. 2023;19:259-264.
Abstract
PD1(hi) CD200(hi) CD4(+) exhausted T cell increase immunotherapy resistance and
tumour progression by promoting epithelial-mesenchymal transition in bladder
cancer.
Clin Transl Med. 2023;13:e1303.
Abstract
Systemic Interleukin-6 Response after Intravesical Instillation of Bacillus
Calmette-Guerin and Mitomycin C in Superficial Bladder Cancer.
Arch Razi Inst. 2023;78:353-360.
Abstract
[A Case of Refractory Lymphatic Leakage after Robot-Assisted Radical Cystectomy].
Hinyokika Kiyo. 2023;69:137-142.
Abstract
Effect of regional versus general anesthesia on recurrence of non-muscle invasive
bladder cancer: a systematic review and meta-analysis of eight retrospective
cohort studies.
BMC Anesthesiol. 2023;23:201.
Abstract
Letter to the Editor on the systematic review "Narrow band imaging versus white
light cystoscopy alone for transurethral resection of non-muscle invasive bladder
cancer".
World J Urol. 2023 Jun 13. doi: 10.1007/s00345-023-04435.
Abstract
Disparity of Bladder Cancer Incidence among Male Workers across Industries: A
Population-based Cohort Study from South Korea.
J Occup Environ Med. 2023 Jun 12. doi: 10.1097/JOM.0000000000002907.
Abstract
KIF20A as a potential biomarker of renal and bladder cancers based on
bioinformatics and experimental verification.
Aging (Albany NY). 2023;15.
Abstract
Establishment of a prognostic model to predict chemotherapy response and
identification of RAC3 as a chemotherapeutic target in bladder cancer.
Environ Toxicol. 2023 Jun 13. doi: 10.1002/tox.23860.
Abstract
Non-muscle-invasive Bladder Cancer: Side-by-Side Guideline Comparison.
Eur Urol Focus. 2023 Jun 10:S2405-4569(23)00115.
Abstract
Medicarpin induces G1 arrest and mitochondria-mediated intrinsic apoptotic
pathway in bladder cancer cells.
Acta Pharm. 2023;73:211-225.
Abstract
beta-asarone inhibits the migration, invasion, and EMT of bladder cancer through
activating ER stress.
Cancer Med. 2023 Jun 12. doi: 10.1002/cam4.6059.
Abstract
Use of machine learning to predict bladder cancer survival outcomes: a systematic
literature review.
Expert Rev Pharmacoecon Outcomes Res. 2023.
Abstract
N-acetyltransferase 2 haplotype modifies risks for both dyslipidemia and urinary
bladder cancer.
Pharmacogenet Genomics. 2023 May 29. doi: 10.1097/FPC.0000000000000500.
Abstract
Bladder-sparing approaches for muscle invasive bladder cancer: a narrative review
of current evidence and future perspectives.
Transl Androl Urol. 2023;12:802-808.
Abstract
Significance of the FGFR3 mutation in Chinese patients with bladder cancer.
Transl Androl Urol. 2023;12:761-769.
Abstract
Corrigendum to "Anti-tumor effect of AZD8055 against bladder cancer and bladder
cancer-associated macrophages" [Heliyon 9(3) (March 2023) e14272].
Heliyon. 2023;9:e15303.
Abstract
Assessment of the knowledge and awareness of urinary bladder cancer among the
general population in Western Saudi Arabia.
Urol Ann. 2023;15:220-225.
Abstract
Bladder cancer in young adults: Disease and treatment characteristics of patients
treated at a tertiary cancer center.
Urol Ann. 2023;15:207-210.
Abstract
A Th2-score in the tumor microenvironment as a predictive biomarker of response
to Bacillus Calmette Guerin in patients with non-muscle invasive bladder
carcinoma: A retrospective study.
Oncol Res. 2023;31:207-220.
Abstract
Urodrill - a novel MRI-guided endoscopic biopsy technique to sample and
molecularly classify muscle-invasive bladder cancer without fractionating the
specimen during transurethral resection.
Eur Urol Open Sci. 2023;53:78-82.
Abstract
SIRT4 is an independent prognostic factor in bladder cancer and inhibits bladder
cancer growth by suppressing autophagy.
Cell Div. 2023;18:9.
Abstract
FGFR3 mutation characterization identifies prognostic and immune-related gene
signatures in bladder cancer.
Comput Biol Med. 2023;162:106976.
Abstract
LncRNA LINC00885 promotes bladder cancer progression by targeting the
miR-98-5p/PBX3 axis.
Cell Mol Biol (Noisy-le-grand). 2023;69:163-168.
Abstract
Mechanisms of Resistance to Antibody-Drug Conjugates.
Int J Mol Sci. 2023;24:9674.
Abstract
Deregulated Expression of IL-37 in Patients with Bladder Urothelial Cancer: The
Diagnostic Potential of the IL-37e Isoform.
Int J Mol Sci. 2023;24:9258.
Abstract
Pevonedistat Inhibits SOX2 Expression and Sphere Formation but Also Drives the
Induction of Terminal Differentiation Markers and Apoptosis within
Arsenite-Transformed Urothelial Cells.
Int J Mol Sci. 2023;24:9149.
Abstract
Predicting Lymph Node Metastasis Status from Primary Muscle-Invasive Bladder
Cancer Histology Slides Using Deep Learning: A Retrospective Multicenter Study.
Cancers (Basel). 2023;15:3000.
Abstract
Assessing the Performance of 18F-FDG PET/CT in Bladder Cancer: A Narrative Review
of Current Evidence.
Cancers (Basel). 2023;15:2951.
Abstract
Inhibiting WEE1 Augments the Antitumor Efficacy of Cisplatin in Urothelial
Carcinoma by Enhancing the DNA Damage Process.
Cells. 2023;12:1471.
Abstract
Underutilization of intravesical chemotherapy and immunotherapy for high grade
non-muscle invasive bladder cancer in California between 2006-2018: Effect of
race, age and socioeconomic status on treatment disparities.
Urol Oncol. 2023 Jun 8:S1078-1439(23)00194-1. doi: 10.1016/j.urolonc.2023.
Abstract
HER2/neu expression status of post BCG recurrent non-muscle-invasive bladder
urothelial carcinomas in relation to their primary ones.
Arch Ital Urol Androl. 2023;95:11313.
Abstract
Sperm protein antigen 17 and Sperm flagellar 1 cancer testis antigens are
expressed in a rare case of ciliated foregut cyst of the common hepatic duct.
Pathol Res Pract. 2023;247:154546.
Abstract
New concept in urologic surgery: The total extended genital sparing radical
cystectomy in women.
Arch Ital Urol Androl. 2023;95:11058.
Abstract
Kidney Transplantation After Multiple Urinary Tract Conversion with an Ileal
Conduit: A Case Report.
Transplant Proc. 2023 May 14:S0041-1345(23)00252.
Abstract
Modulation of immune checkpoint regulators in interferon gamma induced urothelial
carcinoma and activated T-lymphocyte cells by cytostatics.
Genes Immun. 2023;24:149-153.
Abstract
Age represents the main driver of surgical decision making in patients candidate
to radical cystectomy.
J Surg Oncol. 2023;128:142-154.
Abstract
Elucidation of binding dynamics of tyrosine kinase inhibitor tepotinib, to human
serum albumin, using spectroscopic and computational approach.
Int J Biol Macromol. 2023;241:124656.
Abstract
First Comparison of Retroperitoneal Versus Transperitoneal Robot-Assisted
Nephroureterectomy with Bladder Cuff: A Single Center Study.
Ann Surg Oncol. 2023;30:4531-4539.
Abstract
Feasibility of Novel Technique of Flexible Cystoscopic En Bloc Snare Resection of
Bladder Tumor: f-ESRBT.
J Endourol. 2023;37:713-717.
Abstract
The usefulness of nuclear area in the diagnosis of high-grade urothelial
carcinoma cells in voided urine cytology.
Cytopathology. 2023;34:295-301.
Abstract
HER2-targeting antibody-drug conjugate RC48 alone or in combination with
immunotherapy for locally advanced or metastatic urothelial carcinoma: a
multicenter, real-world study.
Cancer Immunol Immunother. 2023;72:2309-2318.
Abstract
The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors
independent of FGFR expression in a real-world metastatic urothelial carcinoma
cohort.
Cancer Immunol Immunother. 2023;72:2075-2086.
Abstract
Cisplatin resistance driver claspin is a target for immunotherapy in urothelial
carcinoma.
Cancer Immunol Immunother. 2023;72:2057-2065.
Abstract
Thulium laser enucleation of bladder tumour (Thulebt): Changing paradigm in the
management of nonmuscle invasive urinary bladder carcinoma.
Urologia. 2023;90:266-271.
Abstract
Expression of epidermal growth factor receptor and human epidermal growth factor
receptor 2 in urothelial bladder carcinoma in an Egyptian cohort: Clinical
implication and prognostic significance.
Urologia. 2023;90:248-260.
Abstract
Urine pH and Risk of Bladder Cancer in Northern New England.
Cancer Epidemiol Biomarkers Prev. 2023 Jun 23:EPI-22-0801.
Abstract
Inflammation-related research within the field of bladder cancer: a bibliometric
analysis.
Front Oncol. 2023;13:1126897.
Abstract
Estimates of bladder cancer burden attributable to high fasting plasma glucose:
Findings of the Global Burden of Disease Study 2019.
Cancer Med. 2023 Jun 23. doi: 10.1002/cam4.6219.
Abstract
Targeting bladder cancer: A sex sensitive perspective in mutations and outcomes.
Urol Oncol. 2023 Jun 20:S1078-1439(23)00166.
Abstract
Cancer Resource and Information Support (CRIS) for Bladder Cancer Survivors and
Their Caregivers: Development and Usability Testing Study.
JMIR Form Res. 2023;7:e41876.
Abstract
Comparison between different neoadjuvant chemotherapy regimens and local therapy
alone for bladder cancer: a systematic review and network meta-analysis of
oncologic outcomes.
World J Urol. 2023 Jun 22. doi: 10.1007/s00345-023-04478.
Abstract
Knockdown of ZNF280A inhibits cell proliferation and promotes cell apoptosis of
bladder cancer.
Histol Histopathol. 2023 Jun 13:18640. doi: 10.14670.
Abstract
Silencing of FGF6 hampers aerobic glycolysis and angiogenesis in bladder cancer
by regulating PI3K/Akt and MAPK signaling pathways.
J Biochem Mol Toxicol. 2023 Jun 22:e23399. doi: 10.1002/jbt.23399.
Abstract
Proteomic analysis reveals mechanisms underlying increased efficacy of bleomycin
by photochemical internalization in bladder cancer cells.
Mol Omics. 2023 Jun 22. doi: 10.1039/d2mo00337.
Abstract
Accurate Detection of Urothelial Bladder Cancer Using Targeted Deep Sequencing of
Urine DNA.
Cancers (Basel). 2023;15:2868.
Abstract
Survival in Kidney and Bladder Cancers in Four Nordic Countries through a Half
Century.
Cancers (Basel). 2023;15:2782.
Abstract
Extraperitoneal Versus Intraperitoneal Radical Cystectomy for Bladder Cancer: A
Systematic Review and Meta-Analysis.
Ann Surg Oncol. 2023 Jun 21. doi: 10.1245/s10434-023-13744.
Abstract
Why bladder cancer cells that shed their Y chromosome become more aggressive.
Nature. 2023 Jun 21. doi: 10.1038/d41586-023-02069.
Abstract
Retraction Note: Overexpression of ROCK1 promotes cancer cell proliferation and
is associated with poor prognosis in human urothelial bladder cancer.
Mamm Genome. 2023 Jun 21. doi: 10.1007/s00335-023-10002.
Abstract
Enhancing bladder cancer care through the multidisciplinary clinic approach.
Can J Urol. 2023;30:11526-11531.
Abstract
Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and
Trop-2 in Variant Histology: A Rapid Autopsy Study.
Clin Genitourin Cancer. 2023 May 25:S1558-7673(23)00132.
Abstract
Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma.
Oncology (Williston Park). 2023;37:256-261.
Abstract
Erdafitinib's Road to Approval and Use in Urothelial Carcinoma.
Oncology (Williston Park). 2023;37:260-261.
Abstract
ASO Author Reflections: A Safe and Feasible Procedure for Bladder
Cancer-Extraperitoneal Radical Cystectomy.
Ann Surg Oncol. 2023 Jun 21. doi: 10.1245/s10434-023-13789.
Abstract
Efficacy of recombinant Bacillus Calmette-Guerin containing dltA in in vivo
three-dimensional bio-printed bladder cancer-on-a-chip and ex vivo orthotopic
mouse model.
Investig Clin Urol. 2023;64:296-305.
Abstract
Therapeutic responses to chemotherapy or immunotherapy by molecular subtype in
bladder cancer patients: A meta-analysis and systematic review.
Investig Clin Urol. 2023;64:229-241.
Abstract
Perioperative systemic therapy in muscle invasive bladder cancer: Current
standard method, biomarkers and emerging strategies.
Investig Clin Urol. 2023;64:202-218.
Abstract
Atypical Recurrent Renal Cell Carcinoma of the Ipsilateral Ureter Showing Typical
Symptoms of Upper Urinary Tract Urothelial Carcinoma: A Case Report and
Literature Review.
Arch Esp Urol. 2023;76:238-244.
Abstract
Efficiency and Safety of Laparoscopic Radical Cystectomy for Muscle-Invasive
Bladder Cancer, and Postoperative Recurrence.
Arch Esp Urol. 2023;76:196-202.
Abstract
m(6)A-mediated upregulation of lncRNA RMRP boosts the progression of bladder
cancer via epigenetically suppressing SCARA5.
Epigenomics. 2023 Jun 20. doi: 10.2217/epi-2023-0062.
Abstract
Radiotherapy Use in Muscle-Invasive Bladder Cancer: Review of the Guidelines and
Impact of Increased Awareness in Patient Referral at a Tertiary Center in
Belgium.
Cancer Manag Res. 2023;15:511-521.
Abstract
A comprehensive analysis of FBN2 in bladder cancer: A risk factor and the tumour
microenvironment influencer.
IET Syst Biol. 2023 Jun 19. doi: 10.1049/syb2.12067.
Abstract
Prognostic and Immunological Role of Asporin across Cancers and Exploration in
Bladder Cancer.
Gene. 2023 Jun 17:147573. doi: 10.1016/j.gene.2023.147573.
Abstract
Comet-FISH analysis of urothelial cells. A screening opportunity for bladder
cancer?
Expert Rev Mol Diagn. 2023 Jun 21:1-11. doi: 10.1080/14737159.2023.2227381.
Abstract
Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of
epidemiology, burden, and unmet needs.
Front Oncol. 2023;13:1170124.
Abstract
Bladder cancer screening: The new selection and prediction model.
Open Med (Wars). 2023;18:20230723.
Abstract
Reprogramming the immunosuppressive tumor microenvironment results in successful
clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1.
Oncoimmunology. 2023;12:2223094.
Abstract
Circulating tumor DNA as a Predictive and Prognostic Biomarker in the
Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review.
Eur Urol Oncol. 2023 Jun 15:S2588-9311(23)00111.
Abstract
Evaluation of Sensitive Urine DNA-based PENK Methylation Test for Detecting
Bladder Cancer in Patients with Hematuria.
J Mol Diagn. 2023 Jun 15:S1525-1578(23)00131.
Abstract
Implications of the COVID19 pandemic on the need and timing of second
transurethral bladder tumour resection in high-grade non-muscle invasive bladder
cancer.
World J Urol. 2023 Jun 17. doi: 10.1007/s00345-023-04469.
Abstract
Comparison of the diagnostic performance of biparametric and multiparametric MRI
in detecting muscle invasion of bladder cancer located at the ureteral orifice.
Abdom Radiol (NY). 2023 Jun 16. doi: 10.1007/s00261-023-03979.
Abstract
Untargeted urinary metabolomics for bladder cancer biomarker screening with
ultrahigh-resolution mass spectrometry.
Sci Rep. 2023;13:9802.
Abstract
Clinical trial design for non-muscle-invasive bladder cancer.
Nat Rev Urol. 2023 Jun 16. doi: 10.1038/s41585-023-00789.
Abstract
Androgen dihydrotestosterone promotes bladder cancer cell proliferation and
invasion via EPPK1-mediated MAPK/JUP signalling.
Cell Death Dis. 2023;14:363.
Abstract
Optimizing outcomes and managing adverse events in locally advanced or metastatic
urothelial cancer: a clinical pharmacology perspective.
Expert Rev Clin Pharmacol. 2023;16:533-548.
Abstract
Exploring knowledge, perspectives, and misperceptions of palliative care: A mixed
methods analysis.
Urol Oncol. 2023;41:327.
Abstract
Urine cytology in patients with gender confirmation surgery and hormone therapy:
evaluation of urine cytology performance in an underserved patient population.
J Am Soc Cytopathol. 2023;12:267-274.
Abstract
Knockdown of kinesin family member 4A inhibits cell proliferation, migration, and
invasion while promoting apoptosis of urothelial bladder carcinoma cells.
Cancer Med. 2023;12:12581-12592.
Abstract
TRPS1 expression is sensitive and specific for primary extramammary Paget
disease.
Histopathology. 2023;83:104-108.
Abstract
Bladder preservation after neoadjuvant therapy - 2021 IBCN updates part 1.
Urol Oncol. 2023;41:307-312.
Abstract
Synthesis, characterization and antiproliferative effects of naphtho [2,3-b]
thiophen-4,9-quinone on bladder tumor cells.
Nat Prod Res. 2023;37:2285-2292.
Abstract
GATA3 positivity is associated with poor prognosis in patients with oesophageal
squamous cell carcinoma.
J Clin Pathol. 2023;76:474-479.
Abstract
Construction and experimental validation of a B cell-related gene signature to
predict the prognosis and immunotherapeutic sensitivity in bladder cancer.
Aging (Albany NY). 2023;15.
Abstract
Sequential Application and Post-Test Probability for Screening of Bladder Cancer
Using Urinary Proteomic Biomarkers: A Review based Probabilistic Analysis.
Asian Pac J Cancer Prev. 2023;24:2021-2027.
Abstract
Retraction: Long noncoding RNA SNHG1 activates autophagy and promotes cell
invasion in bladder cancer.
Front Oncol. 2023;13:1228367.
Abstract
Interethnic Differences in Bladder Cancer Incidence and the Association between
Type 2 Diabetes and Bladder Cancer in the Multiethnic Cohort Study.
Cancer Res Commun. 2023;3:755-762.
Abstract
Non-invasive detection of bladder cancer via microfluidic immunoassay of the
protein biomarker NMP22.
Anal Methods. 2023 Jun 28. doi: 10.1039/d3ay00664.
Abstract
Nationwide analysis of survival after radical cystectomy for bladder cancer in
Finland.
Acta Oncol. 2023 Jun 28:1-7. doi: 10.1080/0284186X.2023.2228446.
Abstract
Association of CD47 Expression with Clinicopathologic Characteristics and
Survival Outcomes in Muscle Invasive Bladder Cancer.
J Pers Med. 2023;13:885.
Abstract
Epigenetic and Immunological Features of Bladder Cancer.
Int J Mol Sci. 2023;24:9854.
Abstract
Protein Biomarker Discovery Studies on Urinary sEV Fractions Separated with
UF-SEC for the First Diagnosis and Detection of Recurrence in Bladder Cancer
Patients.
Biomolecules. 2023;13:932.
Abstract
Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective
Immunotherapy of Solid Malignancies.
Cells. 2023;12:1611.
Abstract
Endophytic upper tract urothelial carcinoma in a solitary kidney treated by
cryotherapy: an unorthodox case for successful management.
BMC Urol. 2023;23:111.
Abstract
Over-expression of Long Non-coding RNA Urothelial Cancer-associated 1 as a
Predictive Marker for Prostate Cancer.
In Vivo. 2023;37:1511-1516.
Abstract
Exposure to Agent Orange and Risk of Bladder Cancer Among US Veterans.
JAMA Netw Open. 2023;6:e2320593.
Abstract
Targeting Pro-Survival Autophagy Enhanced GSK-3beta Inhibition-Induced Apoptosis and
Retarded Proliferation in Bladder Cancer Cells.
Curr Oncol. 2023;30:5350-5365.
Abstract
Impairment in Activities of Daily Living Assessed by the Barthel Index Predicts
Adverse Oncological Outcomes After Radical Cystectomy for Bladder Cancer.
Clin Genitourin Cancer. 2023 Jun 9:S1558-7673(23)00141.
Abstract
Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy
for annexin family using multi-omics data.
Funct Integr Genomics. 2023;23:211.
Abstract
Examining longitudinal markers of bladder cancer recurrence through a
semiautonomous machine learning system for quantifying specimen atypia from urine
cytology.
Cancer Cytopathol. 2023 Jun 26. doi: 10.1002/cncy.22725.
Abstract
Physician reported treatment patterns and outcomes in metastatic bladder cancer
in the USA: the CancerMPact((R)) Survey 2020.
Future Oncol. 2023 Jun 26. doi: 10.2217/fon-2022-1066.
Abstract
Can Peripheral Blood Systemic Immune Response Parameters Predict Oncological
Outcomes in Patients with Non-Muscle-Invasive Bladder Cancer?
Niger J Clin Pract. 2023;26:591-598.
Abstract
[The preliminary efficacy of "quadri-combination" therapy on the treatment of
bladder cancer].
Zhonghua Yi Xue Za Zhi. 2023;103:1855-1859.
Abstract
Bladder cancer mortality trends in Spain: 1980-2021.
Actas Urol Esp (Engl Ed). 2023 Jun 22:S2173-5786(23)00070.
Abstract
The perioperative and long-term outcomes of patients with variant histology
bladder cancer undergoing radical cystectomy: A propensity score-matched analysis
with pure urothelial carcinoma.
Actas Urol Esp (Engl Ed). 2023 Jun 22:S2173-5786(23)00071.
Abstract
Systematic review and meta-analysis of completely retroperitoneoscopic
nephroureterectomy versus traditional retroperitoneoscopic nephroureterectomy in
upper tract urothelial carcinoma.
Medicine (Baltimore). 2023;102:e34112.
Abstract
The bladder microbiome of NMIBC and MIBC patients revealed by 2bRAD-M.
Front Cell Infect Microbiol. 2023;13:1182322.
Abstract
Antibody-Drug Conjugates in the Treatment of Urothelial Cancer.
BioDrugs. 2023;37:505-520.
Abstract
Rapid and precise detection of cancers via label-free SERS and deep learning.
Anal Bioanal Chem. 2023;415:3449-3462.
Abstract
Validation of a drug-based score in advanced urothelial carcinoma treated with
pembrolizumab.
Immunotherapy. 2023;15:827-837.
Abstract
Prognostic Value of Tumor Budding in Urothelial Carcinoma: A Meta-Analysis and
Systematic Review.
Lab Invest. 2023;103:100136.
Abstract
Renal Pelvic Urothelial Carcinoma With Invasion Into Renal Medulla Can Be
Redefined as pT2 to Improve Correlation With Survival.
Mod Pathol. 2023;36:100140.
Abstract
Robotic-assisted Versus Laparoscopic Versus Open Radical Cystectomy-A Systematic
Review and Network Meta-analysis of Randomized Controlled Trials.
Eur Urol Focus. 2023;9:480-490.
Abstract
[Research Progress in Preoperative Evaluation of Lymph Node Metastasis of Bladder
Cancer].
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2023;45:464-470.
Abstract
BTA stat(R), NMP22(R) BladderChek(R), UBC(R) Rapid Test, and CancerCheck(R) UBC(R) rapid
VISUAL as urinary marker for bladder cancer: Final results of a German
multicenter study.
Urol Oncol. 2023 Jul 3:S1078-1439(23)00225-9. doi: 10.1016/j.urolonc.2023.
Abstract
Prognosis of Patients Receiving Chemotherapy for Metastatic Upper Tract
Urothelial Carcinoma Compared With Metastatic Urinary Bladder Cancer.
Cancer Diagn Progn. 2023;3:484-490.
Abstract
A case of eosinophilic cystitis coexisting of superficial bladder cancer,
mimicking muscle-invasive cancer.
IJU Case Rep. 2023;6:230-234.
Abstract
Recurrent urethral tumor with neuroendocrine differentiation in a female patient
after radical cystectomy for bladder cancer.
IJU Case Rep. 2023;6:199-202.
Abstract
Transcriptome sequencing and single-cell sequencing analysis identify GARS1 as a
potential prognostic and immunotherapeutic biomarker for multiple cancers,
including bladder cancer.
Front Immunol. 2023;14:1169588.
Abstract
Lifestyle and occupational risks assessment of bladder cancer using machine
learning-based prediction models.
Cancer Rep (Hoboken). 2023 Jul 5:e1860. doi: 10.1002/cnr2.1860.
Abstract
Antibody Drug Conjugates in Bladder Cancer: Current Milestones and Future
Perspectives.
Curr Treat Options Oncol. 2023 Jul 5. doi: 10.1007/s11864-023-01114.
Abstract
[Experience in the use of confocal laser endomicroscopy for the diagnosis of
bladder papillary tumors].
Urologiia. 2023;:99-106.
Abstract
The Impact of an Enrolment in Clinical Trial on Tolerance and Pathological
Response for Patients Treated by Neoadjuvant MVAC Against an Invasive Bladder
Cancer. A Retrospective Comparative Study.
Clin Genitourin Cancer. 2023 Jun 15:S1558-7673(23)00145.
Abstract
Quality of life in bladder cancer: systematic review and meta-analysis.
BMJ Support Palliat Care. 2023 Jul 3:spcare-2023-004185.
Abstract
Survival nomogram for high-grade bladder cancer patients after surgery based on
the SEER database and external validation cohort.
Front Oncol. 2023;13:1164401.
Abstract
Development and validation of cancer-associated fibroblasts-related gene
landscape in prognosis and immune microenvironment of bladder cancer.
Front Oncol. 2023;13:1174252.
Abstract
Role of preoperative neutrophil to lymphocyte ratio in prediction of recurrence,
progression, and BCG failure in non-muscle invasive bladder cancer: a
retrospective study.
Pan Afr Med J. 2023;44:145.
Abstract
Ileal neobladder adenocarcinoma occurring twenty-five years post ileocystoplasty:
a case report.
Pan Afr Med J. 2023;44:149.
Abstract
Correction: Long non-coding RNA DANCR promotes malignant phenotypes of bladder
cancer cells by modulating the miR-149/MSI2 axis as a ceRNA.
J Exp Clin Cancer Res. 2023;42:157.
Abstract
LncRNA PVT1 promotes bladder cancer progression by forming a positive feedback
loop with STAT5B.
Pathol Res Pract. 2023;248:154635.
Abstract
Downregulation of circular RNA hsa_circ_0087856 sensitizes bladder cancer cells
to cisplatin through targeting miR-1184/CITED2 signaling.
Environ Mol Mutagen. 2023 Jul 1. doi: 10.1002/em.22561.
Abstract
Second malignant tumors and non-tumor causes of death for patients with localized
and regional kidney cancer after diagnosis.
Eur J Med Res. 2023;28:206.
Abstract
Bladder Epicheck(R) for surveillance in high-risk non-muscle-invasive bladder
cancer: Initial experience.
Actas Urol Esp (Engl Ed). 2023 Jun 28:S2173-5786(23)00075.
Abstract
Cell softness reveals tumorigenic potential via ITGB8/AKT/glycolysis signaling in
a mice model of orthotopic bladder cancer.
Chin Med J (Engl). 2023 Jun 30. doi: 10.1097/CM9.0000000000002710.
Abstract
Crosstalk between autophagy and bladder transitional cell carcinoma by
autophagy-related lncRNAs.
Medicine (Baltimore). 2023;102:e34130.
Abstract
Molecular classification of muscle-invasive bladder cancer based on a simplified
immunohistochemical panel using GATA3, CK5/6 and p16.
Biomol Biomed. 2023 Jun 21. doi: 10.17305/bb.2023.9242.
Abstract
Cost-Effectiveness of Robot-Assisted Radical Cystectomy vs Open Radical
Cystectomy for Patients With Bladder Cancer.
JAMA Netw Open. 2023;6:e2317255.
Abstract
Predictors of trimodality therapy in patients with muscle-invasive bladder cancer
and effect on survival.
Clin Transl Oncol. 2023 Jun 30. doi: 10.1007/s12094-023-03264.
Abstract
A case of mycotic infrarenal abdominal aortic aneurysm after bacillus
Calmette-Guerin immunotherapy for bladder cancer and a review of the literature.
J Vasc Surg Cases Innov Tech. 2023;9:101213.
Abstract
Retracted: LINC00958 Inhibits Autophagy of Bladder Cancer Cells via Sponge
Adsorption of miR-625-5p to Promote Tumor Angiogenesis and Oxidative Stress.
Oxid Med Cell Longev. 2023;2023:9812826.
Abstract
Y Chromosome Loss Drives Bladder Cancer Aggressiveness and Immune Evasion.
Cancer Discov. 2023 Jun 30:OF1. doi: 10.1158/2159-8290.CD-RW2023.
Abstract
Establishment of a prognostic model related to tregs and natural killer cells
infiltration in bladder cancer.
World J Clin Cases. 2023;11:3444-3456.
Abstract
Antisense lncRNA-RP11-498C9.13 promotes bladder cancer progression by enhancing
reactive oxygen species-induced mitophagy.
J Gene Med. 2023 Jun 29:e3527. doi: 10.1002/jgm.3527.
Abstract
Recognition Imaging of Trace E-cadherins on the Bladder Cancer Cells Surface
during Epithelial-Mesenchymal Transition by Force-Distance Curve-Based AFM.
Nano Lett. 2023 Jun 29. doi: 10.1021/acs.nanolett.3c01667.
Abstract
International Society of Urological Pathology (ISUP) Consensus Conference on
Current Issues in Bladder Cancer. Working Group 2: Grading of Mixed Grade,
Invasive Urothelial Carcinoma Including Histologic Subtypes and Divergent
Differentiations, and Non
Am J Surg Pathol. 2023 Jun 29. doi: 10.1097/PAS.0000000000002077.
Abstract
The useful technique of laparoscopic segmental ureterectomy with ureteral
reimplantation for distal upper tract urothelial carcinoma.
Asian J Endosc Surg. 2023;16:666-672.
Abstract
[Precision oncology options in urological cancers].
Urologie. 2023;62:696-704.
Abstract
[Antibody-drug conjugates as new therapeutic agents in uro-oncology].
Urologie. 2023;62:679-684.
Abstract
Robot-assisted low anterior resection for a rectal cancer patient with ileal
conduit: A case report.
Asian J Endosc Surg. 2023;16:608-612.
Abstract
A phase II open-label trial of avelumab plus axitinib in previously treated
non-small-cell lung cancer or treatment-naive, cisplatin-ineligible urothelial
cancer.
ESMO Open. 2023;8:101173.
Abstract
Association between lung immune prognostic index and survival of patients with
metastatic urothelial carcinoma treated with pembrolizumab.
Int J Clin Oncol. 2023;28:913-921.
Abstract
Intravesical BCG therapy with photodynamic diagnosis-guided transurethral
resection of bladder tumors improves recurrence-free survival.
Photodiagnosis Photodyn Ther. 2023;42:103574.
Abstract
Clinical practice of UroVysion(R) urine test in patients with bladder carcinoma in
situ treated with intravesical Bacillus Calmette-Guerin.
Jpn J Clin Oncol. 2023;53:629-632.
Abstract
Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower
tract and metastatic disease.
Nat Rev Urol. 2023;20:406-419.
Abstract
Clinical impact of the suspension of the ERAS protocol on patients undergoing
radical cystectomy during the COVID-19 pandemic.
Actas Urol Esp (Engl Ed). 2023;47:369-375.
Abstract
Quality of life in patients with non-muscle invasive bladder tumor undergoing
adjuvant intravesical treatment.
Actas Urol Esp (Engl Ed). 2023;47:360-368.
Abstract
Determination of potential sources of heavy metals in patients with urothelial
carcinoma in central Taiwan: a biomonitoring case-control study.
Environ Geochem Health. 2023;45:5401-5414.
Abstract
A rare case of perivascular epithelioid-cell tumor of the bladder.
Asian J Surg. 2023;46:2748-2749.
Abstract
Primary ALK-Negative TP63-Rearranged Anaplastic Large Cell Lymphoma in the
Bladder: Potential for Misdiagnosis.
Int J Surg Pathol. 2023;31:612-615.
Abstract
Detailed functional results after bladder-preserving surgery and high-dose-rate
brachytherapy in pediatric bladder/prostate rhabdomyosarcoma.
J Cancer Res Clin Oncol. 2023;149:3161-3170.
Abstract
Effect of concurrent beta-blocker use in patients receiving immune checkpoint
inhibitors for advanced solid tumors.
J Cancer Res Clin Oncol. 2023;149:2833-2841.
Abstract
Systemic Treatment-Decision Algorithms in Muscle-Invasive Bladder Cancer:
Clinical Complexities and Navigating for Improved Outcomes.
Res Rep Urol. 2023;15:321-331.
Abstract
A novel signature of aging-related genes associated with lymphatic metastasis for
survival prediction in patients with bladder cancer.
Front Oncol. 2023;13:1140891.
Abstract
Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive
Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes.
Eur Urol Open Sci. 2023;53:16-22.
Abstract
Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in
Participants with a First Suspected Diagnosis of Intermediate- or High-risk
Non-muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a
Randomised Controlled Tr
Eur Urol Open Sci. 2023;53:67-77.
Abstract
Complete remission following pembrolizumab therapy for a patient with
nephroureterectomy positive-margin carcinoma in situ and bladder cancer
unresponsive to Bacille Calmette-Guerin therapy.
SAGE Open Med Case Rep. 2023;11:2050313X231185444.
Abstract
Effect of SMYD3 on Biological Behavior and H3K4 Methylation in Bladder Cancer
[Retraction].
Cancer Manag Res. 2023;15:625-626.
Abstract
ASO Visual Abstract: Extraperitoneal Versus Intraperitoneal Radical Cystectomy
for Bladder Cancer: A Systematic Review and Meta-analysis.
Ann Surg Oncol. 2023 Jul 12. doi: 10.1245/s10434-023-13855.
Abstract
Key Molecules in Bladder Cancer Affect Patient Prognosis and Immunotherapy
Efficacy: Further Exploration for CNTN1 and EMP1.
JCO Precis Oncol. 2023;7:e2200630.
Abstract
Calcium electroporation as an adjunct therapy for pembrolizumab-resistant bladder
cancer: a case report.
Acta Oncol. 2023 Jul 12:1-7. doi: 10.1080/0284186X.2023.2226330.
Abstract
Evaluating the Effectiveness of Intravesical Instillation of BCG by Modified
Maintenance Method in Patients With High-Risk Ta and T1 Bladder Cancer: A
Randomized Clinical Trial.
Clin Med Insights Oncol. 2023;17:11795549231184682.
Abstract
Value of the application of computed tomography-based radiomics for preoperative
prediction of unfavorable pathology in initial bladder cancer.
Cancer Med. 2023 Jul 11. doi: 10.1002/cam4.6225.
Abstract
Pathologic collision of urinary bladder urothelial carcinoma with small cell
carcinoma: a case report.
Diagn Pathol. 2023;18:80.
Abstract
Senescence-related gene c-Myc affects bladder cancer cell senescence by
interacting with HSP90B1 to regulate cisplatin sensitivity.
Aging (Albany NY). 2023;15.
Abstract
Real-time Detection of Bladder Cancer Using Augmented Cystoscopy with Deep
Learning: a Pilot Study.
J Endourol. 2023 Jul 11. doi: 10.1089/end.2023.0056.
Abstract
Clinical characteristics of secondary bladder cancer developing after
low-/high-dose-rate brachytherapy to treat localized prostate cancer.
Int J Clin Oncol. 2023 Jul 11. doi: 10.1007/s10147-023-02383.
Abstract
TRAIL-mediated signaling in bladder cancer: realization of clinical efficacy of
TRAIL-based therapeutics in medical oncology.
Med Oncol. 2023;40:236.
Abstract
ITIH5, as a predictor of prognosis and immunotherapy response for P53-like
bladder cancer, is related to cell proliferation and invasion.
Mol Omics. 2023 Jul 11. doi: 10.1039/d2mo00322.
Abstract
Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer.
Curr Treat Options Oncol. 2023 Jul 10. doi: 10.1007/s11864-023-01113.
Abstract
Pneumovesicoscopic management of bladder neoplasms in children: three case
reports.
Pediatr Med Chir. 2023;45.
Abstract
Identification of a cancer-associated fibroblast signature for predicting
prognosis and immunotherapeutic responses in bladder urothelial carcinoma.
Aging Male. 2023;26:2233609.
Abstract
ACSM6 overexpression indicates a non-inflammatory tumor microenvironment and
predicts treatment response in bladder cancer: results from multiple real-world
cohorts.
Front Pharmacol. 2023;14:1222512.
Abstract
Gemcitabine as first-line therapy for high-grade non-muscle invasive bladder
cancer: results from a tertiary center in the contemporary BCG-shortage era.
Transl Androl Urol. 2023;12:960-966.
Abstract
Immune Checkpoint Inhibitors as a Treatment Option for Bladder Cancer: Current
Evidence.
Cureus. 2023;15:e40031.
Abstract
Exploring the correlation of glycolysis-related chondroitin polymerizing factor
(CHPF) with clinical characteristics, immune infiltration, and cuproptosis in
bladder cancer.
Am J Cancer Res. 2023;13:2213-2233.
Abstract
Anti-tumor activity of intratumoral xenogeneic urothelial cell monotherapy or in
combination with chemotherapy in syngeneic murine models of bladder cancer.
Am J Cancer Res. 2023;13:2285-2306.
Abstract
A novel cuproptosis-related lncRNAs signature predicts prognosis in bladder
cancer.
Aging (Albany NY). 2023;15.
Abstract
Construction and experimental validation of a macrophage cell senescence-related
gene signature to evaluate the prognosis, immunotherapeutic sensitivity, and
chemotherapy response in bladder cancer.
Funct Integr Genomics. 2023;23:228.
Abstract
The Role of Lymph Node Dissection in Patients With Muscle-Invasive Bladder Cancer
Who Underwent Radical Cystectomy Following Neoadjuvant Chemotherapy.
Clin Genitourin Cancer. 2023 Jun 28:S1558-7673(23)00155.
Abstract
CDK2 and CDK4 targeted liensinine inhibits the growth of bladder cancer T24
cells.
Chem Biol Interact. 2023 Jul 7:110624. doi: 10.1016/j.cbi.2023.110624.
Abstract
UBE2S interacting with TRIM21 mediates the K11-linked ubiquitination of LPP to
promote the lymphatic metastasis of bladder cancer.
Cell Death Dis. 2023;14:408.
Abstract
Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of
Intravesical Bacillus Calmette-Guerin (BCG) Versus Intravesical Docetaxel and
Gemcitabine Treatment in BCG-naive High-grade Non-muscle-invasive Bladder Cancer
(BRIDGE).
Eur Urol Focus. 2023 Jul 6:S2405-4569(23)00146-3. doi: 10.1016/j.euf.2023.
Abstract
Necroptosis inhibits autophagy by regulating the formation of RIP3/p62/Keap1
complex in shikonin-induced ROS dependent cell death of human bladder cancer.
Phytomedicine. 2023;118:154943.
Abstract
Female sexual function evaluation and intraoperative vaginal reconstruction in
bladder cancer.
World J Urol. 2023 Jul 7. doi: 10.1007/s00345-023-04502.
Abstract
Doing Less with More: Towards a New Paradigm of Non-muscle-invasive Bladder
Cancer Care.
Eur Urol Focus. 2023 Jul 5:S2405-4569(23)00147-5. doi: 10.1016/j.euf.2023.
Abstract
Schistosomiasis of the Urinary Bladder.
Mayo Clin Proc. 2023;98:1100-1101.
Abstract
Pyuria as an independent predictor of intravesical recurrence after radical
nephroureterectomy in patients with upper tract urothelial carcinoma.
Investig Clin Urol. 2023;64:353-362.
Abstract
Effect of decreased renal function on poor oncological outcome after radical
cystectomy.
Investig Clin Urol. 2023;64:346-352.
Abstract
SKELETAL MUSCLE SENSITIVITY TO WASTING INDUCED BY UROTHELIAL CARCINOMA.
Exp Oncol. 2023;45:107-119.
Abstract
COMPARISON OF 2D AND 3D PRIMARY CELL CULTURES OBTAINED FROM EXPLANT OF HIGH-GRADE
UROTHELIAL BLADDER CANCER.
Exp Oncol. 2023;45:130-136.
Abstract
Combined use of a 980‑nm diode laser and preoperative intravesical instillation
of pirarubicin for the prevention of short‑term recurrence of non‑muscle invasive
bladder cancer: A pilot study.
Oncol Lett. 2023;26:322.
Abstract
Network pharmacology and in vitro experiments reveal that Noscapine induces
ROS-mediated apoptosis and cell cycle arrest via PI3K/Akt/FoxO3a signaling
pathway in human bladder cancer cells.
Curr Cancer Drug Targets. 2023 Jul 6. doi: 10.2174/1568009623666230706153936.
Abstract
Shared hotspot mutations in oncogenes position dogs as an unparalleled
comparative model for precision therapeutics.
Sci Rep. 2023;13:10935.
Abstract
Clinical significance, tumor immune landscape and immunotherapy responses of ADAR
in pan-cancer and its association with proliferation and metastasis of bladder
cancer.
Aging (Albany NY). 2023;15.
Abstract
Analysis of ICAM-1 Expression on Bladder Carcinoma Cell Lines and Infectivity and
Oncolysis by Coxsackie Virus A21.
Methods Mol Biol. 2023;2684:319-327.
Abstract
Intravesical Infusion of Oncolytic Virus CG0070 in the Treatment of Bladder
Cancer.
Methods Mol Biol. 2023;2684:303-317.
Abstract
Antibody-Drug-Conjugates (ADC): A Novel Treatment Option in Urothelial Carcinoma.
Methods Mol Biol. 2023;2684:293-301.
Abstract
Evaluation of FGFR Alteration Status in Urothelial Tumors.
Methods Mol Biol. 2023;2684:283-291.
Abstract
Epigenetic Priming and Development of New Combination Therapy Approaches.
Methods Mol Biol. 2023;2684:259-281.
Abstract
Assessment of PD-L1 Status in Urothelial Cancer.
Methods Mol Biol. 2023;2684:249-255.
Abstract
Predictive Biomarkers of Response to Neoadjuvant Therapy in Muscle Invasive
Bladder Cancer.
Methods Mol Biol. 2023;2684:229-247.
Abstract
Simplex Droplet Digital PCR Assays for the Detection of TERT Promoter Mutations
in Urine Samples for the Non-invasive Diagnosis of Urothelial Cancer.
Methods Mol Biol. 2023;2684:213-228.
Abstract
Considering the Effects of Modern Point-of-Care Urine Biomarker Assays in
Follow-Up of Patients with High-Risk Non-muscle-Invasive Bladder Cancer.
Methods Mol Biol. 2023;2684:199-212.
Abstract
NGS-Based Tumor-Informed Analysis of Circulating Tumor DNA.
Methods Mol Biol. 2023;2684:179-197.
Abstract
Tissue Slice Culture and Analysis of Tumor-Associated Hyaluronan in Urothelial
Carcinoma.
Methods Mol Biol. 2023;2684:167-175.
Abstract
Genome-Wide CRISPR Screening for the Identification of Therapy
Resistance-Associated Genes in Urothelial Carcinoma.
Methods Mol Biol. 2023;2684:155-165.
Abstract
Identification of STAG2-Mutant Bladder Cancers by Immunohistochemistry.
Methods Mol Biol. 2023;2684:145-151.
Abstract
Using Sister Chromatid Exchange Assay to Detect Homologous Recombination
Deficiency in Epigenetically Deregulated Urothelial Carcinoma Cells.
Methods Mol Biol. 2023;2684:133-144.
Abstract
Reconstructing Phylogenetic Relationship in Bladder Cancer: A Methodological
Overview.
Methods Mol Biol. 2023;2684:113-132.
Abstract
Characterization of Native COMPASS Complex in Urothelial Carcinoma Cells by Size
Exclusion Chromatography.
Methods Mol Biol. 2023;2684:101-109.
Abstract
A Drug Repurposing Pipeline Based on Bladder Cancer Integrated
Proteotranscriptomics Signatures.
Methods Mol Biol. 2023;2684:59-99.
Abstract
A Panel-Based Method for the Reproduction of Distinct Molecular Subtype
Classifications of Muscle-Invasive Urothelial Bladder Cancer.
Methods Mol Biol. 2023;2684:27-43.
Abstract
Scoring Systems for Immunohistochemistry in Urothelial Carcinoma.
Methods Mol Biol. 2023;2684:3-25.
Abstract
Survival after sequential neoadjuvant chemotherapy followed by trimodal treatment
or radical cystectomy for muscle-invasive bladder cancer.
World J Urol. 2023 Jul 6. doi: 10.1007/s00345-023-04506.
Abstract
Low-dose or -number of BCG in non-muscle invasive bladder cancer: updated
systematic review and meta-analysis.
Immunotherapy. 2023;15:933-943.
Abstract
Human papillomaviruses and bladder cancer risk: first report in south of Iran.
Virusdisease. 2023;34:257-262.
Abstract
Getting specific: participation preference in urooncological decision-making.
BMC Med Inform Decis Mak. 2023;23:114.
Abstract
[Clinicopathological Features of Primary Small Cell Neuroendocrine Carcinoma of
the Bladder].
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2023;45:429-435.
Abstract
Vitamin C and catheter-related bladder discomfort after transurethral resection
of bladder tumor: A double-blind, randomized, placebo-controlled study.
J Clin Anesth. 2023;89:111191.
Abstract
Prognostic Implications of CD24, SOX2, and Nanog Expression in Invasive
Urothelial Carcinoma.
Appl Immunohistochem Mol Morphol. 2023;31:421-428.
Abstract
Atypical Oncologic Failure After Laparoscopic Radical Nephroureterectomy in a
Japanese Multicenter Study.
J Endourol. 2023;37:793-800.
Abstract
ASO Author Reflections: Chart-Derived Frailty Index and 1-Year Mortality After
Radical Cystectomy.
Ann Surg Oncol. 2023;30:5304-5305.
Abstract
Diversity, equity, and inclusion in genitourinary clinical trials leading to FDA
novel drug approval: An assessment of the FDA center for drug evaluation and
research drug trials snapshot.
Curr Probl Cancer. 2023;47:100958.
Abstract
Comprehensive Genomic Profiling of NF2-Mutated Kidney Tumors Reveals Potential
Targets for Therapy.
Oncologist. 2023;28:e508-e519.
Abstract
Single-Position Complete Retroperitoneoscopic Radical Nephroureterectomy with
Bladder Cuff Excision for Upper Urinary Tract Urothelial Carcinoma.
J Endourol. 2023;37:768-774.
Abstract
A Modified and Practical Surgical Technique for Pure Transperitoneal Laparoscopic
Radical Nephroureterectomy in a Single Position and Research Outcomes.
J Laparoendosc Adv Surg Tech A. 2023;33:691-697.
Abstract
Development of a dynamic risk system for predicting the risk of recurrence and
progression in patients with non-muscle-invasive bladder cancer after thulium
laser resection of bladder tumor or transurethral resection of bladder tumor
followed by intra
Front Oncol. 2023;13:1133161.
Abstract
The Role of Hypoxia-inducible Factor-1 in Bladder Cancer.
Curr Mol Med. 2023 Jul 20. doi: 10.2174/1566524023666230720163448.
Abstract
Homologous recombination mRNAs (RAD21, RAD50 and BARD1) have a potentially poor
prognostic role in ERBB2-low bladder cancer patients.
Sci Rep. 2023;13:11738.
Abstract
A machine learning model based on MRI for the preoperative prediction of bladder
cancer invasion depth.
Eur Radiol. 2023 Jul 20. doi: 10.1007/s00330-023-09960.
Abstract
Bladder cancer immunomodulatory effects of intravesical Nitazoxanide, Rapamycin,
Thalidomide and Bacillus Calmette-Guerin (BCG).
World J Urol. 2023 Jul 20. doi: 10.1007/s00345-023-04526.
Abstract
Delineating and sparing the ileal conduit in adjuvant radiotherapy for bladder
cancer with modulated radiotherapy.
J Cancer Res Ther. 2023;19:731-737.
Abstract
Management of surgically inoperable muscle-invasive bladder cancer in a resource
constraint setting at a tertiary care center by bladder preservation protocol:
Case series.
J Cancer Res Ther. 2023;19:725-730.
Abstract
Unusual histomorphological spectrum of urinary bladder cancers and their
treatment modalities revisited: Our experience with series of five cases.
J Cancer Res Ther. 2023;19:617-623.
Abstract
The efficacy of hyperthermic intravesical chemotherapy in high-risk
non-muscle-invasive bladder cancer patients with BCG intolerance.
Urologia. 2023 Jul 20:3915603231189022. doi: 10.1177/03915603231189022.
Abstract
Editorial: Identifying novel biomarkers in bladder cancer.
Front Oncol. 2023;13:1191736.
Abstract
Preclinical evaluation of singlet oxygen-cleavable prodrugs in combination with
protoporphyrin IX-photodynamic therapy in an orthotopic rat model of
non-muscle-invasive bladder cancer(dagger).
Photochem Photobiol. 2023 Jul 20. doi: 10.1111/php.13838.
Abstract
Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus
Calmette-Guerin for the Treatment of Intermediate-risk Non-muscle-invasive
Bladder Cancer.
Eur Urol Oncol. 2023 Jul 18:S2588-9311(23)00143.
Abstract
Uninvited guest, Balantidium coli in urine in a patient with bladder cancer: A
case report and review of the literature.
Clin Case Rep. 2023;11:e7494.
Abstract
Correction: Long non-coding RNA SOX2OT promotes the stemness phenotype of bladder
cancer cells by modulating SOX2.
Mol Cancer. 2023;22:115.
Abstract
Postoperative adjuvant radiotherapy for patients with upper tract urothelial
carcinoma (UTUC) who underwent kidney-sparing surgery (KSS): a single-center
study.
Radiat Oncol. 2023;18:120.
Abstract
Racial disparities in conditional survival of patients with bladder cancer: a
population-based study.
BMC Urol. 2023;23:122.
Abstract
Bladder carcinosarcoma treated by cystectomy and adjuvant chemotherapy with good
outcomes: a case report.
J Med Case Rep. 2023;17:320.
Abstract
Smoking, ethnicity and bladder cancer - implications for public health and
clinical practice.
Nat Rev Urol. 2023 Jul 18. doi: 10.1038/s41585-023-00804.
Abstract
Adenocarcinoma involving the urinary bladder.
BMJ Case Rep. 2023;16:e252747.
Abstract
A feed-forward loop based on aerobic glycolysis and TGF-beta between
tumor-associated macrophages and bladder cancer cells promoted malignant
progression and immune escape.
J Cancer Res Clin Oncol. 2023 Jul 18. doi: 10.1007/s00432-023-05164.
Abstract
The impact of Cancer-Associated Fibroblasts on drug resistance, stemness, and
epithelial-mesenchymal transition in Bladder Cancer: A comparison between
recurrent and non-recurrent patient-derived CAFs.
Cancer Invest. 2023 Jul 18:1-16. doi: 10.1080/07357907.2023.2237576.
Abstract
Impact of postoperative complications on long-term survival in bladder cancer
patients.
Jpn J Clin Oncol. 2023 Jul 17:hyad079. doi: 10.1093.
Abstract
TGF-beta1 dominates stromal fibroblast-mediated EMT via the FAP/VCAN axis in bladder
cancer cells.
J Transl Med. 2023;21:475.
Abstract
Targeted quantitative metabolomics with a linear mixed-effect model for analysis
of urinary nucleosides and deoxynucleosides from bladder cancer patients before
and after tumor resection.
Anal Bioanal Chem. 2023 Jul 18. doi: 10.1007/s00216-023-04826.
Abstract
Deep-profiling of phospholipidome via rapid orthogonal separations and
isomer-resolved mass spectrometry.
Nat Commun. 2023;14:4263.
Abstract
[The Effect of Naldemedine Tosylate on the Postoperative Course of Robot-Assisted
Radical Cystectomy].
Hinyokika Kiyo. 2023;69:147-150.
Abstract
Network pharmacology analysis of icariside II against bladder cancer.
Eur J Pharmacol. 2023 Jul 15:175914. doi: 10.1016/j.ejphar.2023.175914.
Abstract
Implication of KDM6A in bladder cancer.
Pharmacogenomics. 2023 Jul 17. doi: 10.2217/pgs-2023-0027.
Abstract
A retrospective study on expression and clinical significance of PHH3, Ki67 and
P53 in bladder exophytic papillary urothelial neoplasms.
PeerJ. 2023;11:e15675.
Abstract
Bibliometric analysis of the association between drinking water pollution and
bladder cancer.
Front Oncol. 2023;13:1170700.
Abstract
The relationship between inflammatory response markers and the prognosis of
non-muscle invasive bladder cancer and the development of a nomogram model.
Front Oncol. 2023;13:1189086.
Abstract
CCNB1 is involved in bladder cancer pathogenesis and silencing CCNB1 decelerates
tumor growth and improves prognosis of bladder cancer.
Exp Ther Med. 2023;26:382.
Abstract
Prediction of immune and targeted drug efficacy in pain-related risk subtypes for
bladder cancer patients.
Heliyon. 2023;9:e17690.
Abstract
The Relationship between VEGF and AGT Gene Single Nucleotide Polymorphisms and
Susceptibility to Renal and Bladder Cancers.
Arch Esp Urol. 2023;76:298-308.
Abstract
Fluorodeoxyglucose positron emission tomography (18F-FDG PET)-computed tomography
(CT) in the initial staging of bladder cancer: a single institution experience.
J Egypt Natl Canc Inst. 2023;35:21.
Abstract
Radical cystectomy in bladder cancer patients previously treated for prostate
cancer: Insights from a large European multicentric series.
Surg Oncol. 2023;50:101973.
Abstract
PLAGL2 promotes bladder cancer progression via RACGAP1/RhoA GTPase/YAP1
signaling.
Cell Death Dis. 2023;14:433.
Abstract
Deep learning for histopathological segmentation of smooth muscle in the urinary
bladder.
BMC Med Inform Decis Mak. 2023;23:122.
Abstract
Downstaging and Survival Associated with Neoadjuvant Immunotherapy Before Radical
Cystectomy for Muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2023 Jul 14:S2588-9311(23)00118.
Abstract
Chronic prednisone, metformin, and nonsteroidal anti-inflammatory drug use and
clinical outcome in a cohort of bladder cancer patients undergoing radical
cystectomy in Quebec, Canada.
BMC Urol. 2023;23:119.
Abstract
Cell-Free DNA, MicroRNAs, Proteins, and Peptides as Liquid Biopsy Biomarkers in
Prostate Cancer and Bladder Cancer.
Methods Mol Biol. 2023;2695:165-179.
Abstract
Liquid Biopsy in Bladder Cancer.
Methods Mol Biol. 2023;2695:111-120.
Abstract
Development of a butyrate metabolism-related gene-based molecular subtypes and
scoring system for predicting prognosis and immunotherapy response in bladder
cancer.
J Cancer Res Clin Oncol. 2023 Jul 14. doi: 10.1007/s00432-023-05067.
Abstract
Limited Value of Bladder Wash Cytology During Follow-Up of Patients With
Non-muscle Invasive Bladder Cancer.
Cureus. 2023;15:e40283.
Abstract
Urinary MicroRNAs as Biomarkers of Urological Cancers: A Systematic Review.
Int J Mol Sci. 2023;24:10846.
Abstract
The Impact of the Initial Clinical Presentation of Bladder Cancer on
Histopathological and Morphological Tumor Characteristics.
J Clin Med. 2023;12:4259.
Abstract
Conditional Reprogramming Modeling of Bladder Cancer for Clinical Translation.
Cells. 2023;12:1714.
Abstract
Artificial Intelligence in the Advanced Diagnosis of Bladder Cancer-Comprehensive
Literature Review and Future Advancement.
Diagnostics (Basel). 2023;13:2308.
Abstract
MRI-Based Radiomics in Bladder Cancer: A Systematic Review and Radiomics Quality
Score Assessment.
Diagnostics (Basel). 2023;13:2300.
Abstract
Vascular Enlargement as a Predictor of Nodal Involvement in Bladder Cancer.
Diagnostics (Basel). 2023;13:2227.
Abstract
Sequential intravesical gemcitabine and docetaxel for treatment-naive and
previously treated intermediate-risk nonmuscle invasive bladder cancer.
Urol Oncol. 2023 Jul 11:S1078-1439(23)00228.
Abstract
Long-term Recurrence Rates of Low-risk Non-muscle-invasive Bladder Cancer-How
Long Is Cystoscopic Surveillance Necessary?
Eur Urol Focus. 2023 Jul 11:S2405-4569(23)00153.
Abstract
Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in
Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2
Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with
Daily Irradiation.
Eur Urol Oncol. 2023 Jul 11:S2588-9311(23)00115.
Abstract
Differential expression of SLITRK6 gene as a potential therapeutic target for
urothelial carcinoma in particular upper tract cancer.
Gene. 2023;878:147583.
Abstract
Y chromosome loss in cancer drives growth by evasion of adaptive immunity.
Nature. 2023;619:624-631.
Abstract
Clinical and pathological predictors of persistent T1 HG at second resection.
Urologia. 2023;90:482-490.
Abstract
Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in
cancer patients: a systemic review and meta-analysis.
Clin Exp Metastasis. 2023;40:255-287.
Abstract
Impact of diagnostic ureteral catheterization on intravesical tumour recurrence
following radical nephroureterectomy for upper tract urothelial carcinoma.
World J Urol. 2023;41:1869-1875.
Abstract
Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and
urothelial cancers: a systematic review and meta-analysis.
World J Urol. 2023;41:1763-1774.
Abstract
HLA-G expression in transitional bladder carcinoma. Relationship with tumor
invasion level and patient survival: Experience in a public hospital in
Argentina.
Hum Immunol. 2023;84:423-427.
Abstract
The Clinical Safety and Efficacy of Targeted PD-L1 Therapy with Durvalumab in
Solid Tumors.
Curr Drug Targets. 2023;24:584-598.
Abstract
Gender-specific counselling of patients with upper tract urothelial carcinoma and
Lynch syndrome.
World J Urol. 2023;41:1741-1749.
Abstract
The autocrine glycosylated-GREM1 interacts with TGFB1 to suppress
TGFbeta/BMP/SMAD-mediated EMT partially by inhibiting MYL9 transactivation in
urinary carcinoma.
Cell Oncol (Dordr). 2023;46:933-951.
Abstract
Mini-laparotomy radical cystectomy with limited bowel externalization during
ileal conduit urinary diversion reduces the rate of postoperative complications:
a match-paired, single centered analysis.
Acta Chir Belg. 2023;123:362-368.
Abstract
Radical cystectomy and orthotopic neobladder in a patient with a preexisting
three-components inflatable penile prosthesis.
Urologia. 2023;90:584-586.
Abstract
The Effect of Statins on the Incidence and Prognosis of Bladder Cancer: A
Systematic Review and Meta-Analysis.
Curr Oncol. 2023;30:6648-6665.
Abstract
The Management of Bacillus Calmette-Guerin (BCG) Failure in High-Risk Non-muscle
Invasive Bladder Cancer: A Review Article.
Cureus. 2023;15:e40962.
Abstract
Feasibility of Raman spectroscopic identification of gall bladder cancer using
extracellular vesicles extracted from bile.
Analyst. 2023 Jul 28. doi: 10.1039/d3an00806.
Abstract
Comparative proteomics analysis in different stages of urothelial bladder cancer
for identification of potential biomarkers: highlighted role for antioxidant
activity.
Clin Proteomics. 2023;20:28.
Abstract
Circular RNA_0000326 accelerates breast cancer development via modulation of the
miR-9-3p/YAP1 axis.
Neoplasma. 2023;70:430-442.
Abstract
Cutaneous immune-related adverse events to immune checkpoint inhibitors: from
underlying immunological mechanisms to multi-omics prediction.
Front Immunol. 2023;14:1207544.
Abstract
E3 ubiquitin ligases and deubiquitinases in bladder cancer tumorigenesis and
implications for immunotherapies.
Front Immunol. 2023;14:1226057.
Abstract
Retraction Note: Acetyl-CoA synthetase 3 promotes bladder cancer cell growth
under metabolic stress.
Oncogenesis. 2023;12:39.
Abstract
Repeat Transurethral Resection for Non-muscle-invasive Bladder Cancer: An Updated
Systematic Review and Meta-analysis in the Contemporary Era.
Eur Urol Focus. 2023 Jul 24:S2405-4569(23)00173.
Abstract
Uncovering the Uncommon: Institutional Insights Into the Clinical and
Epidemiological Characteristics of Rarer Forms of Bladder Cancer Beyond
Transitional Cell Carcinoma.
Cureus. 2023;15:e40879.
Abstract
Surgical resection of retinoblastoma-associated bladder leiomyosarcoma during
pregnancy: a case report.
BMC Urol. 2023;23:125.
Abstract
Ultrasound versus Nerve Stimulator Guided Obturator Nerve Block in Patients
Undergoing Transurethral Resection of Bladder Tumor.
J Nepal Health Res Counc. 2023;20:998-1002.
Abstract
Lymph node dissection during radical cystectomy for bladder cancer: A two-center
comparative study of robotic versus open surgery.
Asian J Endosc Surg. 2023 Jul 25. doi: 10.1111/ases.13234.
Abstract
Integrated single-cell and spatial transcriptomic profiling reveals higher
intratumour heterogeneity and epithelial-fibroblast interactions in recurrent
bladder cancer.
Clin Transl Med. 2023;13:e1338.
Abstract
Evaluation of sarcopenia in patients receiving intravesical Bacillus
Calmette-Guerin for non-muscle invasive bladder cancer.
Urol Oncol. 2023 Jul 22:S1078-1439(23)00198.
Abstract
Classification of formalin-fixed bladder cancer cells with laser tweezer Raman
spectroscopy.
Analyst. 2023 Jul 24. doi: 10.1039/d3an00119.
Abstract
Letter to the editor for the article "Real-world outcomes of first-line
chemotherapy for unresectable stage III and IV bladder cancer".
World J Urol. 2023 Jul 24. doi: 10.1007/s00345-023-04541.
Abstract
'I Had It. I Don't Think I Have It...But I Do Feel It Will Come Back Somewhere': A
Qualitative Investigation of the Experience of People With Non-Muscle Invasive
Bladder Cancer.
Qual Health Res. 2023 Jul 24:10497323231170089. doi: 10.1177/10497323231170089.
Abstract
Detection of the Vesical Arteries Using Three-dimensional Digital Subtraction
Angiography Relevant to Intra-arterial Infusion Chemotherapy for Bladder Cancer
Using Double-balloon Catheters.
Interv Radiol (Higashimatsuyama). 2023;8:64-69.
Abstract
Comprehensive Analysis of Differential Gene Expression and Correlated Immune
Infiltration in Bladder Cancer.
Iran J Public Health. 2023;52:1225-1237.
Abstract
Sarcopenia is an independent predictor of survival in patients undergoing radical
cystectomy for bladder cancer: a single-centre, retrospective study.
Cent European J Urol. 2023;76:81-89.
Abstract
Small bowel obstruction secondary to metastatic urothelial bladder cancer.
SAGE Open Med Case Rep. 2023;11:2050313X231176356.
Abstract
An HGF-dependent positive feedback loop between bladder cancer cells and
fibroblasts mediates lymphangiogenesis and lymphatic metastasis.
Cancer Commun (Lond). 2023 Jul 22. doi: 10.1002/cac2.12470.
Abstract
Comparison of holmium laser, bipolar and conventional monopolar transurethral
resection of bladder tumour in primary non-muscle invasive bladder cancer.
J Pak Med Assoc. 2023;73.
Abstract
The Value Of PD-L1 Immunohistochemical Expression In Egyptian Urinary Bladder
Carcinoma Patients.
J Pak Med Assoc. 2023;73.
Abstract
Self-polymerized platinum (II)-Polydopamine nanomedicines for photo-chemotherapy
of bladder Cancer favoring antitumor immune responses.
J Nanobiotechnology. 2023;21:235.
Abstract
Comparison of the Y-pouch orthotopic neobladder and the Studer technique after
radical cystectomy: surgical and functional outcomes from a single-center series.
World J Surg Oncol. 2023;21:218.
Abstract
[Bladder preservation treatments for bladder cancer: Trimodality therapy, an
overview of clinical practices in 2023].
Cancer Radiother. 2023 Jul 20:S1278-3218(23)00124.
Abstract
FLRT2 suppresses bladder cancer progression through inducing ferroptosis.
J Cell Mol Med. 2023 Jul 21. doi: 10.1111/jcmm.17855.
Abstract
MTHFD2 promotes PD-L1 expression via activation of the JAK/STAT signalling
pathway in bladder cancer.
J Cell Mol Med. 2023 Jul 21. doi: 10.1111/jcmm.17863.
Abstract
Comprehensive analysis of cuproptosis-related lncRNAs signature to predict
prognosis in bladder urothelial carcinoma.
BMC Urol. 2023;23:124.
Abstract
Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC
targeted therapy.
NPJ Precis Oncol. 2023;7:70.
Abstract
Identification of the diagnostic value of urine SLC1A5 in bladder cancer based on
GEO database.
Asian J Surg. 2023 Jul 19:S1015-9584(23)01045.
Abstract
Role and mechanisms of noncoding RNAs in the regulation of metabolic
reprogramming in bladder cancer (Review).
Int J Mol Med. 2023;52:79.
Abstract
Muscle invasive bladder cancer: where is the field headed?
Expert Opin Biol Ther. 2023 Jul 21:1-15. doi: 10.1080/14712598.2023.2238607.
Abstract
Procoagulant genes may affect angiogenesis, epithelial-mesenchymal transition,
survival prognosis and tumor immune microenvironment in patients with urothelial
carcinoma.
Aging (Albany NY). 2023;15:6429-6444.
Abstract
The Nova Scotia Community Cancer Matrix: A geospatial tool to support cancer
prevention.
Soc Sci Med. 2023;330:116038.
Abstract
Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases
and a review of the literature.
Autoimmun Rev. 2023;22:103375.
Abstract
The role of malnutrition universal screening tool in predicting outcomes after
radical cystectomy.
Surg Oncol. 2023;49:101962.
Abstract
Long Noncoding RNA UCA1 Correlates With Electropathology in Patients With Atrial
Fibrillation.
JACC Clin Electrophysiol. 2023;9.
Abstract
Clinicopathologic Analysis of Micropapillary Urothelial Carcinoma of the Upper
Urinary Tract: Implications for HER2-Targeted Therapy.
Clin Genitourin Cancer. 2023;21:508.
Abstract
Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to
Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical Cystectomy.
Clin Genitourin Cancer. 2023;21:507.
Abstract
Evaluating Real-World Characteristics of Patients With Advanced Urothelial
Carcinoma Eligible for Avelumab Maintenance Therapy: A Multicountry Retrospective
Medical Chart Review.
Clin Genitourin Cancer. 2023;21:459-466.
Abstract
Quantitative Nuclear Grading: An Objective, Artificial Intelligence-Facilitated
Foundation for Grading Noninvasive Papillary Urothelial Carcinoma.
Lab Invest. 2023;103:100155.
Abstract
Perioperative outcomes of open versus robot-assisted radical cystectomy in
octogenarians: a population based analysis.
J Robot Surg. 2023;17:1629-1635.
Abstract
Frequent Telomerase Reverse Transcriptase Promoter and Fibroblast Growth Factor
Receptor 3 Mutations Support the Precursor Nature of Papillary Urothelial
Hyperplasia of the Urinary Bladder.
Mod Pathol. 2023;36:100151.
Abstract
Comparison between robot-assisted versus open nephroureterectomy for upper tract
urothelial carcinoma: outcomes from a pooled analysis.
J Robot Surg. 2023;17:1227-1238.
Abstract
Practice Patterns Regarding Female Reproductive Organ-Sparing and Nerve-Sparing
Radical Cystectomy Among Urologic Oncologists in the United States.
Clin Genitourin Cancer. 2023;21:e236-e241.
Abstract
CD3 high and FoxP3 - tumor-infiltrating lymphocytes in the invasive margin as a
favorable prognostic marker in patients with invasive urothelial carcinoma of the
bladder.
Anticancer Drugs. 2023;34:844-851.
Abstract
Retracted: Clinical Value Analysis of Xiaozheng Decoction Combined with Bladder
Perfusion for Postoperative Treatment of Bladder Cancer and Its Effect on Serum
miR-143 and miR-92a.
J Healthc Eng. 2023;2023:9785158.
Abstract
FTO promotes proliferation and migration of bladder cancer via enhancing
stability of STAT3 mRNA in an m6A-dependent manner.
Epigenetics. 2023;18:2242688.
Abstract
Functional status analysis of RNH1 in bladder cancer for predicting immunotherapy
response.
Sci Rep. 2023;13:12625.
Abstract
Effect of four fluoroquinolones on the viability of bladder cancer cells in 2D
and 3D cultures.
Front Oncol. 2023;13:1222411.
Abstract
Pharmacological NF-kappaB inhibition decreases cisplatin chemoresistance in
muscle-invasive bladder cancer and reduces cisplatin-induced toxicities.
Mol Oncol. 2023 Aug 3. doi: 10.1002/1878-0261.13504.
Abstract
Progressive encephalomyelitis with rigidity and myoclonus (PERM) associated with
anti-glycine receptor antibodies and urothelial carcinoma: a case report.
J Med Case Rep. 2023;17:330.
Abstract
[Radical cystectomy versus trimodality therapy for muscle-invasive bladder
cancer].
Strahlenther Onkol. 2023 Aug 2. doi: 10.1007/s00066-023-02134.
Abstract
Circ_0000235 targets MCT4 to promote glycolysis and progression of bladder cancer
by sponging miR-330-5p.
Cell Death Discov. 2023;9:283.
Abstract
MicroRNA-30c-5p arrests bladder cancer G2/M phase and suppresses its progression
by targeting PRC1-mediated blocking of CDK1/Cyclin B1 axis.
Cell Signal. 2023 Jul 31:110836. doi: 10.1016/j.cellsig.2023.110836.
Abstract
Hsa_circ_0003098 promotes bladder cancer progression via miR-377-5p/ACAT2 axis.
Genomics. 2023 Jul 31:110692. doi: 10.1016/j.ygeno.2023.110692.
Abstract
A novel therapeutic strategy for non-muscle invasive bladder cancer: OncoTherad(R)
immunotherapy associated with platelet-rich plasma.
Int Immunopharmacol. 2023;123:110723.
Abstract
Molecular landscape of LncRNAs in bladder cancer: From drug resistance to novel
LncRNA-based therapeutic strategies.
Biomed Pharmacother. 2023;165:115242.
Abstract
The prognostic effect of immunohistochemical staining rates in patients with
non-muscle-invasive bladder cancer.
Indian J Pathol Microbiol. 2023;66:502-510.
Abstract
ZEB1-mediated biogenesis of circNIPBL sustains the metastasis of bladder cancer
via Wnt/beta-catenin pathway.
J Exp Clin Cancer Res. 2023;42:191.
Abstract
Genome-scale methylation analysis identifies immune profiles and age acceleration
associations with bladder cancer outcomes.
Cancer Epidemiol Biomarkers Prev. 2023 Aug 1:EPI-23-0331.
Abstract
Diagnostic and therapeutic effects of fluorescence cystoscopy and narrow-band
imaging in bladder cancer: A systematic review and network meta-analysis.
Int J Surg. 2023 Aug 1. doi: 10.1097/JS9.0000000000000592.
Abstract
Peptidase inhibitor (PI16) impairs bladder cancer metastasis by inhibiting NF-kappaB
activation via disrupting multiple-site ubiquitination of NEMO.
Cell Mol Biol Lett. 2023;28:62.
Abstract
Assessing utilities for muscle-invasive bladder cancer-related health states.
Urol Oncol. 2023 Jul 29:S1078-1439(23)00239.
Abstract
Prognosis Prediction of Disulfidptosis-Related Genes in Bladder Cancer and a
Comprehensive Analysis of Immunotherapy.
Crit Rev Eukaryot Gene Expr. 2023;33:73-86.
Abstract
Giant right hydronephrosis with underlying double malignancy: a case report.
Pan Afr Med J. 2023;45:21.
Abstract
Can we offer additional BCG therapy for three-month BCG refractory high grade/T1,
Tis bladder cancer patients?
Arab J Urol. 2023;21:142-149.
Abstract
Microscopic hematuria and pelvic ultrasonography could rule out flexible
cystoscopy during surveillance for T1-low grade non-muscle invasive bladder
cancer.
Arab J Urol. 2023;21:150-155.
Abstract
Intravesical BCG in bladder cancer induces innate immune responses against
SARS-CoV-2.
Front Immunol. 2023;14:1202157.
Abstract
LINC01137/miR-186-5p/WWOX: a novel axis identified from WWOX-related RNA
interactome in bladder cancer.
Front Genet. 2023;14:1214968.
Abstract
Identify and validate RUNX2 and LAMA2 as novel prognostic signatures and
correlate with immune infiltrates in bladder cancer.
Front Oncol. 2023;13:1191398.
Abstract
HEATR3 involved in the cell proliferation, metastasis and cell cycle development
of bladder cancer acts as a tumor suppressor.
Mol Genet Genomics. 2023 Jul 31. doi: 10.1007/s00438-023-02046.
Abstract
Disease-free survival of patients with muscle invasive bladder cancer treated
with radical cystectomy versus bladder preserving therapy: a nationwide study.
Int J Radiat Oncol Biol Phys. 2023 Jul 28:S0360-3016(23)07686.
Abstract
A Validation Study of cT-Categories in the Swedish National Urinary Bladder
Cancer Register-Norrland University Hospital.
J Pers Med. 2023;13:1163.
Abstract
Sertindole, an Antipsychotic Drug, Curbs the STAT3/BCL-xL Axis to Elicit Human
Bladder Cancer Cell Apoptosis In Vitro.
Int J Mol Sci. 2023;24:11852.
Abstract
Pesticides and Bladder Cancer: Mechanisms Leading to Anti-Cancer Drug
Chemoresistance and New Chemosensitization Strategies.
Int J Mol Sci. 2023;24:11395.
Abstract
Human Endogenous Retrovirus-H-Derived miR-4454 Inhibits the Expression of DNAJB4
and SASH1 in Non-Muscle-Invasive Bladder Cancer.
Genes (Basel). 2023;14:1410.
Abstract
Diminished Short-Term Efficacy of Reduced-Dose Induction BCG in the Treatment of
Non-Muscle Invasive Bladder Cancer.
Cancers (Basel). 2023;15:3746.
Abstract
Microtubule Dynamics Deregulation Induces Apoptosis in Human Urothelial Bladder
Cancer Cells via a p53-Independent Pathway.
Cancers (Basel). 2023;15:3730.
Abstract
Xpert Bladder Cancer Monitor for the Early Detection of Non-Muscle Invasive
Bladder Cancer Recurrences: Could Cystoscopy Be Substituted?
Cancers (Basel). 2023;15:3683.
Abstract
Evaluation of Whole-Tumor Texture Analysis Based on MRI Diffusion Kurtosis and
Biparametric VI-RADS Model for Staging and Grading Bladder Cancer.
Bioengineering (Basel). 2023;10:745.
Abstract
Novel ADCs and combination therapy in urothelial carcinoma: latest updates from
the 2023 ASCO-GU Cancers Symposium.
J Hematol Oncol. 2023;16:85.
Abstract
Correction: Up-regulation of long non-coding RNA PANDAR is associated with poor
prognosis and promotes tumorigenesis in bladder cancer.
J Exp Clin Cancer Res. 2023;42:185.
Abstract
The efficacy and timing of adjuvant chemotherapy in upper tract urothelial
carcinoma.
Urol Oncol. 2023;41:356.
Abstract
Stage-dependent survival in patients treated with neoadjuvant chemotherapy and
radical cystectomy.
Minerva Urol Nephrol. 2023;75:452-459.
Abstract
Low co-expression of PD-L1 and oncogenic receptor tyrosine kinases HER2 and cMET
in urothelial carcinoma is associated with discordant expression between primary
and metastatic sites.
Urol Oncol. 2023;41:357.
Abstract
Cancer Associated Fibroblasts: An Understudied but Critical Component of the
Tumor Microenvironment in Urothelial Cancer.
Eur Urol Oncol. 2023;6:376-377.
Abstract
Super acute-onset disseminated BCG infection: A case report.
J Infect Chemother. 2023;29:919-921.
Abstract
Copy number gain of ACTN4 is associated with poor prognosis in patients with
upper urinary tract urothelial carcinoma.
Cancer Sci. 2023;114:3411-3422.
Abstract
Real-world treatment patterns and clinical outcomes with first-line therapy in
patients with locally advanced/metastatic urothelial carcinoma by
cisplatin-eligibility.
Urol Oncol. 2023;41:357.
Abstract
Current Techniques for En Bloc Transurethral Resection of Bladder Tumor: A
Hands-on Guide Through the Energy Landscape.
Eur Urol Focus. 2023;9:567-570.
Abstract
Prognostic models for patients with metastatic urothelial carcinoma: why use
them?
Minerva Urol Nephrol. 2023;75:419-421.
Abstract
EpCAM tumor specificity and proteoform patterns in urothelial cancer.
J Cancer Res Clin Oncol. 2023;149:8913-8922.
Abstract
The impact of routine frozen section analysis during nephroureterectomy or
segmental ureterectomy for urothelial carcinoma on final surgical margin status
and long-term oncologic outcome.
Urol Oncol. 2023;41:357.
Abstract
The impact of histological variants in patients with upper tract urothelial
carcinoma treated with radical nephroureterectomy.
J Cancer Res Clin Oncol. 2023;149:8279-8288.
Abstract
Trends in the incidence of urothelial carcinoma in Taiwan after the ban on
aristolochic acid-containing Chinese herbal preparations, 2001-2018: a national
population-based cohort study.
J Cancer Res Clin Oncol. 2023;149:8201-8211.
Abstract
A case of rare metachronous four primary carcinoma.
J Cancer Res Clin Oncol. 2023;149:7471-7477.
Abstract
Comparison of sequential and joint nonlinear mixed effects modeling of tumor
kinetics and survival following Durvalumab treatment in patients with metastatic
urothelial carcinoma.
J Pharmacokinet Pharmacodyn. 2023;50:251-265.
Abstract
Tumor Biomarkers for Bacillus Calmette-Guerin Response: What We Get Is Not What
We Want.
Eur Urol Focus. 2023;9:582-583.
Abstract
Atypical Category of the Johns Hopkins Template Has Higher Risk of Malignancy
than the Paris System but the Paris System Is More Applicable for Suspicious
Category.
Acta Cytol. 2023;67:425-433.
Abstract
Quality Control Indicators for Transurethral Resection of Bladder Tumor: Results
from an Embedded Belgian Multicenter Prospective Registry.
Eur Urol Oncol. 2023;6:422-430.
Abstract
Correction to "G-protein-coupled receptor 137 accelerates proliferation of
urinary bladder cancer cells in vitro".
Biotechnol Appl Biochem. 2023;70:1560.
Abstract
Retraction Statement: KLF8 is required for bladder cancer cell proliferation and
migration.
Biotechnol Appl Biochem. 2023;70:1555.
Abstract
Development and validation a model for predicting overall survival of bladder
cancer with lung metastasis: a population-based study.
Eur J Med Res. 2023;28:279.
Abstract
RAB14 promotes epithelial-mesenchymal transition in bladder cancer through
autophagy‑dependent AKT signaling pathway.
Cell Death Discov. 2023;9:292.
Abstract
[Advanced Bladder Cancer with Multiple Pulmonary Metastases Treated with
Paclitaxel/Ifosfamide/Nedaplatin Therapy : Two Case Reports].
Hinyokika Kiyo. 2023;69:183-188.
Abstract
Oncological Outcomes for Patients with European Association of Urology Very
High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus
Calmette-Guerin or Early Radical Cystectomy.
Eur Urol Oncol. 2023 Aug 7:S2588-9311(23)00157-8. doi: 10.1016/j.euo.2023.
Abstract
RNA-seq profiling of upper tract urothelial carcinoma: bladder cancer consensus
classification relevance, molecular heterogeneity and differential immune
signatures.
Mod Pathol. 2023 Aug 7:100300. doi: 10.1016/j.modpat.2023.100300.
Abstract
Safety and efficacy of preoperative chemotherapy for muscle-invasive bladder
cancer in elderly patients.
World J Urol. 2023 Aug 9. doi: 10.1007/s00345-023-04561.
Abstract
Leiomyoma of the Bladder: A case report and review.
Ir Med J. 2023;116:792.
Abstract
Circular stable intronic RNAs possess distinct biological features and are
deregulated in bladder cancer.
NAR Cancer. 2023;5:zcad041.
Abstract
A novel in vitro prognostic model of bladder cancer based on urine-derived living
tumor cells.
Genes Dis. 2022;10:2586-2596.
Abstract
Relationship between testosterone and male bladder cancer.
Sci Rep. 2023;13:12881.
Abstract
Analysis of the efficacy of a single subumbilical stoma for bilateral cutaneous
ureterostomy after radical cystectomy.
Eur J Med Res. 2023;28:273.
Abstract
Specific subsets of urothelial bladder carcinoma infiltrating T cells associated
with poor prognosis.
Sci Rep. 2023;13:12801.
Abstract
Value-based healthcare for bladder cancer patients undergoing robot-assisted
radical cystectomy.
Eur J Surg Oncol. 2023;49:1329-1330.
Abstract
Unveiling nature's potential weapon: Magnolol's role in combating bladder cancer
by upregulating the miR-124 and inactivating PKC-delta/ERK axis.
Phytomedicine. 2023;119:154947.
Abstract
5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (alpha-B) for
Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer:
United States insurance claims data.
World J Urol. 2023 Aug 7. doi: 10.1007/s00345-023-04551.
Abstract
Tumor detection under cystoscopy with transformer-augmented deep learning
algorithm.
Phys Med Biol. 2023;68.
Abstract
A Survival Model for Patients with Upper Tract Urothelial Carcinoma.
Arch Esp Urol. 2023;76:357-362.
Abstract
Urothelium-specific expression of mutationally activated Pik3ca initiates early
lesions of non-invasive bladder cancer.
Am J Pathol. 2023 Aug 4:S0002-9440(23)00272-9. doi: 10.1016/j.ajpath.2023.
Abstract
Effect of neoadjuvant chemotherapy on survival in patients with T1 high-grade
non-muscle-invasive bladder cancer who underwent radical cystectomy.
Medicine (Baltimore). 2023;102:e34501.
Abstract
Integrated multiomics analysis of chromosome 19 miRNA cluster in bladder cancer.
Funct Integr Genomics. 2023;23:266.
Abstract
Robot-assisted radical cystectomy vs open radical cystectomy in patients with
bladder cancer: a systematic review and meta-analysis of randomized controlled
trials.
World J Surg Oncol. 2023;21:240.
Abstract
LncRNA AGAP2-AS1 interacts with IGF2BP2 to promote bladder cancer progression via
regulating LRG1 mRNA stability.
Cell Signal. 2023 Aug 2:110839. doi: 10.1016/j.cellsig.2023.110839.
Abstract
Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer:
further extensive evaluation needed - Authors' reply.
Lancet Oncol. 2023;24:e325-e326.
Abstract
Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer:
further extensive evaluation needed.
Lancet Oncol. 2023;24:e324.
Abstract
Erdafitinib in patients with advanced solid tumours with FGFR alterations
(RAGNAR): an international, single-arm, phase 2 study.
Lancet Oncol. 2023;24:925-935.
Abstract
[First-line maintenance therapy of adult patients with BCG-naive high-risk
non-muscle-invasive bladder cancer - A Phase 3, Open-Label, Multi-Center,
Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination
with Cetrelimab or TAR-2
Aktuelle Urol. 2023;54:272-273.
Abstract
Effects of intravenous chemotherapy after TURBT for high-risk nonmuscle invasive
bladder cancer: results of a retrospective study.
J Cancer Res Clin Oncol. 2023 Aug 4. doi: 10.1007/s00432-023-05206.
Abstract
Expression, Prognostic Value, and immune infiltration of MTHFD family in bladder
cancer.
Curr Cancer Drug Targets. 2023 Aug 4. doi: 10.2174/1568009623666230804152603.
Abstract
Robot-assisted laparoscopic enucleation in the treatment of leiomyosarcoma of
urinary bladder: A case report.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023;48:782-788.
Abstract
Uncommon but Clinically Significant: Bacillus Calmette-Guerin (BCG) Infection of
the Urinary Tract and its Impact on Quality of Life.
Am J Case Rep. 2023;24:e940375.
Abstract
Urachal xanthogranuloma: a rare but important case presenting as a urachal mass.
BMC Urol. 2023;23:132.
Abstract
Poly (ADP-ribose) Polymerase Inhibition in Advanced Urothelial Carcinoma.
JCO Precis Oncol. 2023;7:e2300293.
Abstract
From haematuria to nephroureterectomy via urine cytology-A case study.
Cytopathology. 2023;34:494-496.
Abstract
Clinical Outcomes of Pelvic Lymph Node Dissection Before Versus After
Robot-Assisted Laparoscopic Radical Cystectomy.
J Laparoendosc Adv Surg Tech A. 2023;33:776-781.
Abstract
Risk of urinary tract cancers following arsenic exposure and tobacco smoking: a
review.
Environ Geochem Health. 2023;45:5579-5598.
Abstract
HER2 Expression Associated with Clinical Characteristics and Prognosis of
Urothelial Carcinoma in a Chinese Population.
Oncologist. 2023;28:e617-e624.
Abstract
Wound dehiscence in enhanced recovery after open radical cystectomy: A
meta-analysis.
Int Wound J. 2023;20:2634-2639.
Abstract
Mucinous appendiceal adenocarcinoma invading the bladder: not always an easy
diagnosis. A case report.
Anticancer Drugs. 2023;34:967-969.
Abstract
A rare case of ulcerative colitis following Bacillus Calmette-Guerin therapy.
Rev Esp Enferm Dig. 2023;115:403.
Abstract
Cost-analysis of robot-assisted radical cystectomy in Europe: A cross-country
comparison.
Eur J Surg Oncol. 2023;49:1511-1518.
Abstract
Construction and comprehensive analysis of a novel prognostic signature
associated with immunogenic cell death molecular subtypes in patients with
bladder cancer.
Heliyon. 2023;9:e18848.
Abstract
The value of urinary exosomal lncRNA SNHG16 as a diagnostic biomarker for bladder
cancer.
Mol Biol Rep. 2023 Aug 17. doi: 10.1007/s11033-023-08667.
Abstract
Bladder cancer oligometastases - definition and treatment.
Nat Rev Urol. 2023 Aug 17. doi: 10.1038/s41585-023-00815.
Abstract
Predictive signature of response to neoadjuvant chemotherapy in muscle-invasive
bladder cancer integrating mRNA expression, taxonomic subtypes, and
clinicopathological features.
Front Oncol. 2023;13:1155244.
Abstract
Integrated multi-omics analyses reveal Jorunnamycin A as a novel suppressor for
muscle-invasive bladder cancer by targeting FASN and TOP1.
J Transl Med. 2023;21:549.
Abstract
Loneliness, spiritual well-being, and death perception, as well as their risk
factors in urological cancer patients.
Braz J Med Biol Res. 2023;56:e12915.
Abstract
Using the Multidimensional Health Locus of Control Scale Form C to Investigate
Health Beliefs About Bladder Cancer Prevention and Treatment Among Male Patients:
Cross-Sectional Study.
JMIR Form Res. 2023;7:e43345.
Abstract
Methionine orchestrates the metabolism vulnerability in cisplatin resistant
bladder cancer microenvironment.
Cell Death Dis. 2023;14:525.
Abstract
Real-life benchmarking bladder cancer care: A population-based study.
Can Urol Assoc J. 2023;17:268-273.
Abstract
Differentiation of bladder cancer stages using the vesical imaging -reporting and
data system and apparent diffusion coefficient.
Quant Imaging Med Surg. 2023;13:4897-4907.
Abstract
Application of nanotechnology in bladder cancer diagnosis and therapeutic drug
delivery.
J Mater Chem B. 2023 Aug 15. doi: 10.1039/d3tb01323.
Abstract
Codelivery of ERCC2 small interfering RNA and cisplatin with macrophage-derived
mimetic nanovesicles for enhanced bladder cancer treatment.
Anticancer Drugs. 2023 Aug 15. doi: 10.1097/CAD.0000000000001528.
Abstract
Cancer-Specific Survival of Patients with Non-Muscle-Invasive Bladder Cancer: A
Population-Based Analysis.
Ann Surg Oncol. 2023 Aug 14. doi: 10.1245/s10434-023-14051.
Abstract
A novel CD8(+) T cell-related gene signature for predicting the prognosis and
immunotherapy efficacy in bladder cancer.
Inflamm Res. 2023 Aug 14. doi: 10.1007/s00011-023-01772.
Abstract
Risk prediction of bladder cancer among diabetes patients: a derivation and
validation study.
Diabet Med. 2023 Aug 14:e15199. doi: 10.1111/dme.15199.
Abstract
Multiparameter interferometric polarization-enhanced imaging differentiates
carcinoma in situ from inflammation of the bladder: an ex vivo study.
J Biomed Opt. 2023;28:102907.
Abstract
Socio-economic, education, and insurance-related factors associated with the
treatment completion rates in patients with nonmetastatic urinary bladder cancer:
A Retrospective cohort study.
Indian J Urol. 2023;39:228-235.
Abstract
The APC/C E3 ligase subunit ANAPC11 mediates FOXO3 protein degradation to promote
cell proliferation and lymph node metastasis in urothelial bladder cancer.
Cell Death Dis. 2023;14:516.
Abstract
Correction: Hsu et al. Development of Folic Acid-Conjugated and Methylene
Blue-Adsorbed Au@TNA Nanoparticles for Enhanced Photodynamic Therapy of Bladder
Cancer Cells. Nanomaterials 2020, 10, 1351.
Nanomaterials (Basel). 2023;13:2233.
Abstract
Bladder Epicheck Test: A Novel Tool to Support Urothelial Carcinoma Diagnosis in
Urine Samples.
Int J Mol Sci. 2023;24:12489.
Abstract
The Bladder Tumor Microenvironment Components That Modulate the Tumor and Impact
Therapy.
Int J Mol Sci. 2023;24:12311.
Abstract
Effective and Selective Ru(II)-Arene Complexes Containing 4,4'-Substituted 2,2'
Bipyridine Ligands Targeting Human Urinary Bladder Cancer Cells.
Int J Mol Sci. 2023;24:11896.
Abstract
Neoadjuvant chemotherapy with dose-dense MVAC in muscle-invasive bladder cancer:
a tertiary center experience.
Clin Transl Oncol. 2023 Aug 11. doi: 10.1007/s12094-023-03277.
Abstract
Intratumoral PD1(+)CD38(+)Tim3(+) CD8(+) T Cells in Pre-BCG Tumor Tissues Are
Associated with Poor Responsiveness to BCG Immunotherapy in Patients with
Non-Muscle Invasive Bladder Cancer.
Cells. 2023;12:1939.
Abstract
Identification of Potential Key Genes Linked to Gender Differences in Bladder
Cancer Based on Gene Expression Omnibus (GEO) Database.
Adv Biomed Res. 2023;12:157.
Abstract
Lysine N-methyltransferase SETD7 promotes bladder cancer progression and immune
escape via STAT3/PD-L1 cascade.
Int J Biol Sci. 2023;19:3744-3761.
Abstract
Identification of potential DNA methylation biomarkers related to diagnosis in
patients with bladder cancer through integrated bioinformatic analysis.
BMC Urol. 2023;23:135.
Abstract
Subtypes in small cell bladder cancer.
Nat Rev Urol. 2023 Aug 10. doi: 10.1038/s41585-023-00813.
Abstract
Proteomic characterization of bladder cancer.
Nat Rev Urol. 2023 Aug 10. doi: 10.1038/s41585-023-00814.
Abstract
Proposal for a Novel Histological Scoring System as a Potential Grading Approach
for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease
Aggressiveness and Patient Outcomes.
Eur Urol Oncol. 2023 Aug 8:S2588-9311(23)00153-0. doi: 10.1016/j.euo.2023.
Abstract
NFYC-37 promotes tumor growth by activating the mevalonate pathway in bladder
cancer.
Cell Rep. 2023;42:112963.
Abstract
[A Case of Inflammatory Myofibroblastic Tumor of The Bladder Treated with Partial
Cystectomy].
Hinyokika Kiyo. 2023;69:179-182.
Abstract
An 80-Year-Old Man With Respiratory Insufficiency After Intravesical
Mycobacterium bovis BCG Immunotherapy.
Chest. 2023;164:e39-e43.
Abstract
Relationship between sex and immune checkpoint inhibitors in urothelial carcinoma
and renal cell carcinoma.
World J Urol. 2023;41:2301-2302.
Abstract
Application of a protocol for enhanced recovery after radical cystectomy: a
before-and-after cohort study.
World J Urol. 2023;41:2273-2280.
Abstract
Trends and sex-specific incidence of upper urinary tract cancer in Taiwan: A
birth cohort study.
Cancer Med. 2023;12:15350-15357.
Abstract
Epidemiology, treatments, and related biomarkers of locally advanced or
metastatic urothelial carcinoma in Chinese population: A scoping review.
Cancer Med. 2023;12:15384-15403.
Abstract
Liquid biopsy in urothelial carcinoma: Detection techniques and clinical
applications.
Biomed Pharmacother. 2023;165:115027.
Abstract
Development and validation of a preoperative nomogram to predict lymph node
metastasis in patients with bladder urothelial carcinoma.
J Cancer Res Clin Oncol. 2023;149:10911-10923.
Abstract
Real-world effectiveness of pembrolizumab as first-line therapy for
cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2
study.
Cancer Immunol Immunother. 2023;72:2961-2970.
Abstract
A robust gene prognostic index composed of GZMB, IRF1, and TP63 can stratify the
risk of two metastatic urothelial carcinoma cohorts based on immune checkpoint
blockade therapy.
J Cancer Res Clin Oncol. 2023;149:9877-9890.
Abstract
Ectopic prostate tissue at the bladder.
Am J Med Sci. 2023;366:e37.
Abstract
GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors.
Pathobiology. 2023;90:219-232.
Abstract
Synthesis, Solid State Structure, and Cytotoxic Activity of a Complex Dimer of
Yttrium with Anthranilic Acid against Cancer Cells.
Biol Trace Elem Res. 2023;201:4688-4696.
Abstract
Evaluation of the Implementation and Diagnostic Accuracy of the Paris
Classification for Reporting Urinary Cytology in Voided Urine Specimens: A
Cyto-Histological Correlation Study in a Cancer Center.
Pathobiology. 2023;90:233-240.
Abstract
Knockdown of Long Noncoding RNA Urothelial Carcinoma-Associated 1 Represses
Gallbladder Cancer Advancement by Regulating SPOCK1 Expression Through Sponging
miR-613.
Cancer Biother Radiopharm. 2023;38:354-363.
Abstract
Acquired haemophilia as a complicating factor in treatment of non-muscle invasive
bladder cancer: A case report.
World J Clin Cases. 2023;11:5338-5343.
Abstract
Construction and validation of cuproptosis-related lncRNA prediction signature
for bladder cancer and immune infiltration analysis.
Aging (Albany NY). 2023;15.
Abstract
[Retracted] KIF22 promotes bladder cancer progression by activating the
expression of CDCA3.
Int J Mol Med. 2023;52:92.
Abstract
Construction of a cuproptosis-associated lncRNA prognostic signature for bladder
cancer and experimental validation of cuproptosis-related lncRNA UBE2Q1-AS1.
Front Med (Lausanne). 2023;10:1222543.
Abstract
Intravesical urachal cyst masquerading as a bladder malignancy: a case report.
J Med Case Rep. 2023;17:364.
Abstract
Mechanisms of Xiaozheng decoction for anti-bladder cancer effects via affecting
the GSK3beta/beta-catenin signaling pathways: a network pharmacology-directed
experimental investigation.
Chin Med. 2023;18:104.
Abstract
Construction of a prediction model for prognosis of bladder cancer based on the
expression of ion channel-related genes.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023.
Abstract
Utility and safety of robot-assisted radical cystectomy in older patients with
bladder cancer.
Minim Invasive Ther Allied Technol. 2023.
Abstract
GREM1 is a potential biomarker for the progression and prognosis of bladder
cancer.
World J Surg Oncol. 2023;21:255.
Abstract
The sex gap in bladder cancer survival - a missing link in bladder cancer care?
Nat Rev Urol. 2023 Aug 21. doi: 10.1038/s41585-023-00806.
Abstract
A Plea for the Use of Video-recorded Cystoscopy for Blinded Independent Central
Review of Tumor Response in Open-label Non-muscle invasive Bladder Cancer Trials.
Eur Urol Oncol. 2023 Aug 19:S2588-9311(23)00147.
Abstract
Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of
bladder cancer (3rd report): cost impact of transurethral resection of bladder
tumor in Japan.
Photodiagnosis Photodyn Ther. 2023 Aug 19:103758.
Abstract
FGF13A interacts with NPM1 and UBF and inhibits the invasion of bladder cancer
cells.
Biochem Biophys Res Commun. 2023;678:1-10.
Abstract
Up-regulated serum lactate dehydrogenase could become a poor prognostic marker in
patients with bladder cancer by an evidence-based analysis of 2,182 patients.
Front Oncol. 2023;13:1233620.
Abstract
Hub gene associated with prognosis in bladder cancer is a novel therapeutic
target.
PeerJ. 2023;11:e15670.
Abstract
Integrating Bulk and Single-Cell RNA Sequencing Reveals Heterogeneity, Tumor
Microenvironment, and Immunotherapeutic Efficacy Based on Sialylation-Related
Genes in Bladder Cancer.
J Inflamm Res. 2023;16:3399-3417.
Abstract
Morphology, immunohistochemistry characteristics, and clinical presentation of
microcystic urothelial carcinoma: a series of 10 cases.
Diagn Pathol. 2023;18:94.
Abstract
Neoadjuvant Chemotherapy Prior to Radical Cystectomy for Muscle-Invasive Bladder
Cancer With Variant Histology: A Systematic Review and Meta-Analysis of Survival
Outcomes and Pathological Features.
Clin Genitourin Cancer. 2023 Jul 8:S1558-7673(23)00172.
Abstract
Discovery of a novel genetic variant in the N-acetyltransferase2 (NAT2) gene that
is associated with bladder cancer risk.
Acta Biochim Pol. 2023 Aug 18. doi: 10.18388/abp.2020_6590.
Abstract
A gene signature of cancer-associated fibroblasts predicts prognosis and
treatment response in bladder cancer.
Clin Transl Oncol. 2023 Aug 18. doi: 10.1007/s12094-023-03270.
Abstract
3D vascularized microphysiological system for investigation of tumor-endothelial
crosstalk in anti-cancer drug resistance.
Biofabrication. 2023;15.
Abstract
High-Field Asymmetric Waveform Ion Mobility Spectrometry Analysis of Carcinogenic
Aromatic Amines in Tobacco Smoke with an Orbitrap Tribrid Mass Spectrometer.
Chem Res Toxicol. 2023;36:1419-1426.
Abstract
Clinicopathologic Features of Noninvasive Inverted Urothelial Papillary Tumor.
Am J Clin Oncol. 2023;46:409-413.
Abstract
Development of a prediction model for gross residual in high-grade serous ovarian
cancer by combining preoperative assessments of abdominal and pelvic metastases
and multiparametric MRI.
Acad Radiol. 2023;30:1823-1831.
Abstract
Diagnostic accuracy of MUC7 expression for bladder cancer: A systematic review
and meta-analysis.
Medicine (Baltimore). 2023;102:e34828.
Abstract
Evaluation of non-vendor magnetic resonance imaging sequences for use in bladder
cancer magnetic resonance image guided radiotherapy.
Phys Imaging Radiat Oncol. 2023;27:100481.
Abstract
A novel Natural killer cell-related gene signature for improving the prediction
of prognosis and immunotherapy response in bladder cancer.
Comb Chem High Throughput Screen. 2023.
Abstract
Construction of enhanced CT radiomics model for noninvasive prediction of
CXCL13's expression and immune infiltrates in bladder cancer based on logistic
regression and support vector machine algorithm.
Asian J Surg. 2023 Aug 29:S1015-9584(23)01299.
Abstract
Clinical experience of modified percutaneous ureterostomy in bladder cancer
patients receiving radical cystectomy.
Asian J Surg. 2023 Aug 29:S1015-9584(23)01281.
Abstract
Orthotopic Mouse Models of Urinary Bladder Cancer.
In Vivo. 2023;37:2039-2043.
Abstract
Analysis of risk factors for recurrence after transurethral resection of bladder
tumor in patients with non-muscle invasive bladder cancer: 2-year follow-up
outcomes.
Oncology. 2023 Aug 30. doi: 10.1159/000533410.
Abstract
Generalized machine learning based on multi-omics data to profile the effect of
ferroptosis pathway on prognosis and immunotherapy response in patients with
bladder cancer.
Environ Toxicol. 2023 Aug 30. doi: 10.1002/tox.23949.
Abstract
Neoadjuvant systemic and intravesical chemotherapy with partial cystectomy for
muscle invasive bladder cancer with concomitant CIS.
Urol Case Rep. 2023;50:102516.
Abstract
Construction of a prediction model for prognosis of bladder cancer based on the
expression of ion channel-related genes.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023;52:499-509.
Abstract
A CASE OF RAPIDLY PROGRESSIVE RETINOPATHY ASSOCIATED WITH PEMBROLIZUMAB
IMMUNOTHERAPY FOR METASTATIC UROTHELIAL CARCINOMA.
Retin Cases Brief Rep. 2023;17:630-634.
Abstract
Primary high-grade urothelial carcinoma of prostate with prostatic hyperplasia: a
rare case report and review of the literature.
Aging Male. 2023;26:2252102.
Abstract
Prognostic Significance of PD-L2 Expression in Association with
Neutrophil-to-Lymphocyte Ratio in Urothelial Carcinoma of the Bladder.
Asian Pac J Cancer Prev. 2023;24:2673-2679.
Abstract
Oncological effectiveness of bladder-preserving trimodal therapy versus radical
cystectomy for the treatment of muscle-invasive bladder cancer: a system review
and meta-analysis.
World J Surg Oncol. 2023;21:271.
Abstract
Analysis of treatment of muscle invasive bladder cancer using the national cancer
database: Factors associated with receipt of aggressive therapy.
Urol Oncol. 2023 Aug 26:S1078-1439(23)00264.
Abstract
Gender and cystectomy for bladder cancer: A high-volume tertiary urologic care
center experience.
Eur J Surg Oncol. 2023;49:107034.
Abstract
Four types of adenine-related RNA modification writers -mediated molecular
subtypes contribute to predicting clinical outcomes and treatment options in
bladder cancer.
Front Immunol. 2023;14:1152806.
Abstract
Body composition as a predictor of oncological outcome in patients with
non-muscle-invasive bladder cancer receiving intravesical instillation after
transurethral resection of bladder tumor.
Front Oncol. 2023;13:1180888.
Abstract
Eph receptor B6 shapes a cold immune microenvironment, inhibiting anti-cancer
immunity and immunotherapy response in bladder cancer.
Front Oncol. 2023;13:1175183.
Abstract
Blue light transurethral resection and biopsy of bladder cancer with
hexaminolevulinate: Histopathological characteristics and recurrence rates in a
single UK centre study.
BJUI Compass. 2023;4:568-574.
Abstract
Primary mucosal melanomas of the urogenital tract: a clinical, pathological, and
genetic nationwide survey of Danish patients 1990-2019.
Scand J Urol. 2023;58:52-59.
Abstract
Cross-species oncogenomics offers insight into human muscle-invasive bladder
cancer.
Genome Biol. 2023;24:191.
Abstract
A simple and robust nanosystem for photoacoustic imaging of bladder cancer based
on alpha5beta1-targeted gold nanorods.
J Nanobiotechnology. 2023;21:301.
Abstract
The Diagnostic Accuracy of Cystoscopy for Detecting Bladder Cancer in Adults
Presenting with Haematuria: A Systematic Review from the European Association of
Urology Guidelines Office.
Eur Urol Focus. 2023 Aug 24:S2405-4569(23)00184.
Abstract
MRI-based radiomics analysis of bladder cancer: prediction of pathological grade
and histological variant.
Clin Radiol. 2023 Aug 12:S0009-9260(23)00327-6. doi: 10.1016/j.crad.2023.
Abstract
How I Do It: Maintenance avelumab.
Can J Urol. 2023;30:11633-11638.
Abstract
Prognosis analysis and validation of lipid metabolism-associated lncRNAs and
tumor immune microenvironment in bladder cancer.
Aging (Albany NY). 2023;15.
Abstract
Diagnostic and Prognostic Roles of GATA3 Immunohistochemistry in Urothelial
Carcinoma.
Medicina (Kaunas). 2023;59:1452.
Abstract
GPX3 rs8177412 Polymorphism Modifies Risk of Upper Urothelial Tumors in Patients
with Balkan Endemic Nephropathy.
Medicina (Kaunas). 2023;59:1421.
Abstract
BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape
and Novel Emerging Molecular Targets.
Int J Mol Sci. 2023;24:12596.
Abstract
Homeobox Gene Expression Dysregulation as Potential Diagnostic and Prognostic
Biomarkers in Bladder Cancer.
Diagnostics (Basel). 2023;13:2641.
Abstract
Differential Protein Expression Patterns of HOXA13 and HOXB13 Are Associated with
Bladder Cancer Progression.
Diagnostics (Basel). 2023;13:2636.
Abstract
A Study of DNA Methylation of Bladder Cancer Biomarkers in the Urine of Patients
with Neurogenic Lower Urinary Tract Dysfunction.
Biology (Basel). 2023;12:1126.
Abstract
Effects of Scaffolds on Urine- and Urothelial Carcinoma Tissue-Derived Organoids
from Bladder Cancer Patients.
Cells. 2023;12:2108.
Abstract
Diagnostic value of the combination of DAPK methylation in urinary sediment and B
ultrasound for recurrent urinary bladder cancer.
World J Surg Oncol. 2023;21:267.
Abstract
Integrating angiogenesis signature and tumor mutation burden for improved patient
stratification in immune checkpoint blockade therapy for muscle-invasive bladder
cancer.
Urol Oncol. 2023 Aug 23:S1078-1439(23)00254.
Abstract
miR-152-3p Inhibits Proliferation, Invasion and Autophagy in UMUC3 and TCCSUP
Bladder Cancer Cell Lines via Suppressing HMGA2 Expression.
Ann Clin Lab Sci. 2023;53:607-618.
Abstract
Comprehensive analysis of N1-methylandenosine regulators and m1A-related mRNAs
and lncRNAs as prognostic factors in bladder cancer.
Gene. 2023 Aug 23:147735. doi: 10.1016/j.gene.2023.147735.
Abstract
Reproductive factors in the risk of bladder cancer and upper urinary tract
cancer: The Japan Public Health Center-based Prospective Study.
Cancer Epidemiol Biomarkers Prev. 2023 Aug 25:EPI-23-0201.
Abstract
Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in
the Management of Advanced and Metastatic Urothelial Carcinoma.
Curr Oncol. 2023;30:7398-7411.
Abstract
Single-cell sequencing data reveals aggressive CD68-type macrophages and
prognostic models in bladder cancer.
Curr Med Chem. 2023 Aug 24. doi: 10.2174/0929867331666230824093312.
Abstract
A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in
HER2-positive colon cancer by triggering the cGAS-STING pathway.
Cell Death Dis. 2023;14:550.
Abstract
Preoperative Nutritional Status and Enhanced Recovery after Surgery (ERAS) Prior
to Radical Cystectomy: A Review of the Literature.
Nutr Cancer. 2023;75:1743-1751.
Abstract
Molecular classification of urothelial bladder carcinoma.
Mol Biol Rep. 2023;50:7867-7877.
Abstract
Long-term oncologic and functional outcomes following robot-assisted radical
cystectomy and intracorporeal Padua ileal bladder: results from a single
high-volume center.
World J Urol. 2023;41:2359-2366.
Abstract
Clinical, molecular, and immune correlates of the Immunotherapy Response Score in
patients with advanced urothelial carcinoma under atezolizumab monotherapy:
analysis of the phase II IMvigor210 trial.
ESMO Open. 2023;8:101611.
Abstract
Artificial intelligence to improve cytology performance in urothelial carcinoma
diagnosis: results from validation phase of the French, multicenter, prospective
VISIOCYT1 trial.
World J Urol. 2023;41:2381-2388.
Abstract
Prospective evaluation of functional outcomes in 395 patients with an ileal
neobladder 1 year after radical cystectomy.
World J Urol. 2023;41:2367-2374.
Abstract
A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with
locally advanced or metastatic non-small-cell lung cancer and urothelial
carcinoma.
ESMO Open. 2023;8:101589.
Abstract
Phase II study of a trastuzumab biosimilar in combination with paclitaxel for
HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18.
ESMO Open. 2023;8:101588.
Abstract
Development and external validation of a novel nomogram to predict intravesical
recurrence after radical nephroureterectomy: a multicenter study.
J Cancer Res Clin Oncol. 2023;149:11223-11231.
Abstract
Construction and validation of a cuproptosis-related lncRNA prognosis signature
in bladder carcinoma.
J Cancer Res Clin Oncol. 2023;149:11207-11221.
Abstract
Camrelizumab as adjuvant therapy in urothelial carcinomas after radical surgery
in people living with HIV.
Int J STD AIDS. 2023;34:720-727.
Abstract
Predictive biomarkers of immunotherapy response with pharmacological applications
in solid tumors.
Acta Pharmacol Sin. 2023;44:1879-1889.
Abstract
Immune checkpoint inhibitor-associated thrombosis in patients with bladder and
kidney cancer: a study of the Spanish Society of Medical Oncology (SEOM)
thrombosis and cancer group.
Clin Transl Oncol. 2023;25:3021-3031.
Abstract
Narrow-Band Imaging in Transoral Laser Surgery for Early Glottic Cancer: A
Randomized Controlled Trial.
Otolaryngol Head Neck Surg. 2023;169:606-614.
Abstract
Cox Regression Analysis of Prognostic Factors of Intensity-Modulated Radiotherapy
in Patients with Bladder Cancer.
Arch Esp Urol. 2023;76:411-417.
Abstract
Lobaplatin induces apoptosis in T24 and 5637 bladder cancer cells by regulating
Bcl-2 and Bax expression and inhibiting the PI3K/Akt signaling pathway.
Transl Androl Urol. 2023;12:1296-1307.
Abstract
Re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical
Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guerin for the
Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol
Oncol. In pres
Eur Urol Oncol. 2023 Sep 5:S2588-9311(23)00171-2. doi: 10.1016/j.euo.2023.
Abstract
Protocol for the YORKSURe prospective multistage study testing the feasibility
for early detection of bladder cancer in populations with high disease-specific
mortality risk.
BMJ Open. 2023;13:e076612.
Abstract
Advancing Patient-Centered Outcomes and Equity in Clinical Trials for
BCG-Unresponsive Nonmuscle Invasive Bladder Cancer.
JAMA Oncol. 2023 Sep 7. doi: 10.1001/jamaoncol.2023.3304.
Abstract
Development and experimental validation of a folate metabolism-related gene
signature to predict the prognosis and immunotherapeutic sensitivity in bladder
cancer.
Funct Integr Genomics. 2023;23:291.
Abstract
A preliminary study on the establishment of a cyst and cystic neoplasm
tissue-mimicking model.
J Cancer Res Ther. 2023;19:988-994.
Abstract
High-power green-light laser endoscopic submucosal dissection for
non-muscle-invasive bladder cancer: A technical improvement and its initial
application.
J Cancer Res Ther. 2023;19:945-950.
Abstract
Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies
and immunotherapy.
Front Immunol. 2023;14:1258388.
Abstract
HSD17B1 could serve as a prognostic biomarker for bladder cancer patients.
Asian J Surg. 2023 Sep 4:S1015-9584(23)01094.
Abstract
[Radical cystectomy or trimodal therapy for bladder cancer: where do we stand?].
Urologie. 2023 Sep 5. doi: 10.1007/s00120-023-02194.
Abstract
Duality of the SVIL expression in bladder cancer and its correlation with immune
infiltration.
Sci Rep. 2023;13:14595.
Abstract
AhR diminishes the efficacy of chemotherapy via suppressing STING dependent
type-I interferon in bladder cancer.
Nat Commun. 2023;14:5415.
Abstract
Development and validation of a disulfidptosis and M2 TAM-related classifier for
bladder cancer to explore tumor subtypes, immune landscape and drug treatment.
J Cancer Res Clin Oncol. 2023 Sep 5. doi: 10.1007/s00432-023-05352.
Abstract
Letter to the editor for the article "Comparison between different neoadjuvant
chemotherapy regimens and local therapy alone for bladder cancer: a systematic
review and network meta-analysis of oncologic outcomes".
World J Urol. 2023 Sep 5. doi: 10.1007/s00345-023-04575.
Abstract
Renal function change after radical cystectomy for urothelial carcinoma patients
with a solitary kidney may be independent of urinary diversion type.
Investig Clin Urol. 2023;64:457-465.
Abstract
Pharmacotherapy developments in Autophagy inhibitors for bladder cancer.
Expert Opin Pharmacother. 2023 Sep 5. doi: 10.1080/14656566.2023.2254697.
Abstract
First case report of robot-assisted radical cystectomy for bladder cancer that
developed after salvage radiotherapy following radical prostatectomy for prostate
cancer.
IJU Case Rep. 2023;6:310-313.
Abstract
Sequential Chemotherapy Followed by Radiotherapy Versus Concurrent
Chemo-Radiation in Muscle Invasive Bladder Cancer.
Urol J. 2023 Jul 31. doi: 10.22037/uj.v20i.7525.
Abstract
Biological differences underlying sex and gender disparities in bladder cancer:
current synopsis and future directions.
Oncogenesis. 2023;12:44.
Abstract
Synthetic lethality in human bladder cancer cells by curcumin via concurrent
Aurora A inhibition and autophagy induction.
J Nutr Biochem. 2023 Sep 2:109438. doi: 10.1016/j.jnutbio.2023.109438.
Abstract
miRNA/epithelial-mesenchymal axis (EMT) axis as a key player in cancer
progression and metastasis: A focus on gastric and bladder cancers.
Cell Signal. 2023 Sep 2:110881. doi: 10.1016/j.cellsig.2023.110881.
Abstract
Glucose dysregulation promotes oncogenesis in human bladder cancer by regulating
autophagy and YAP1/TAZ expression.
J Cell Mol Med. 2023 Sep 4. doi: 10.1111/jcmm.17943.
Abstract
RBP7 Regulated by EBF1 Affects Th2 Cells and the Oocyte Meiosis Pathway in Bone
Metastases of Bladder Urothelial Carcinoma.
Front Biosci (Landmark Ed). 2023;28:189.
Abstract
Pyrimidine metabolism regulator-mediated molecular subtypes display tumor
microenvironmental hallmarks and assist precision treatment in bladder cancer.
Front Oncol. 2023;13:1102518.
Abstract
Intravesical chemotherapy synergize with an immune adjuvant by a thermo-sensitive
hydrogel system for bladder cancer.
Bioact Mater. 2023;31:315-332.
Abstract
The function of Foxp1 represses beta-adrenergic receptor transcription in the
occurrence and development of bladder cancer through STAT3 activity.
Open Med (Wars). 2023;18:20230647.
Abstract
A novel cuproptosis pattern and tumor immune microenvironment characterization in
urothelial carcinoma of the bladder.
Front Immunol. 2023;14:1219209.
Abstract
Defining Oligometastatic Bladder Cancer: A Systematic Review.
Eur Urol Open Sci. 2023;55:28-37.
Abstract
Ultrasound Molecular Imaging of Bladder Cancer via Extradomain B
Fibronectin-Targeted Biosynthetic GVs.
Int J Nanomedicine. 2023;18:4871-4884.
Abstract
Combined Mek inhibition and Pparg activation Eradicates Muscle Invasive Bladder
cancer in a Mouse Model of BBN-induced Carcinogenesis.
bioRxiv. 2023 Aug 21:2023.08.19.553961. doi: 10.1101/2023.08.19.553961.
Abstract
Prediction for recurrent non-muscle invasive bladder cancer.
Cancer Biomark. 2023 Aug 15. doi: 10.3233/CBM-220373.
Abstract
The assessment of pathological response to neoadjuvant chemotherapy in
muscle-invasive bladder cancer patients with DCE-MRI and DWI: a systematic review
and meta-analysis.
Br J Radiol. 2023 Sep 3:20230239. doi: 10.1259/bjr.20230239.
Abstract
The role of SOD2 and NOS2 genes in the molecular aspect of bladder cancer
pathophysiology.
Sci Rep. 2023;13:14491.
Abstract
Demethylases of H3 lysine 27 (H3K27) expression in urothelial carcinoma (UC) of
the urinary bladder.
Malays J Pathol. 2023;45:261-269.
Abstract
Circulating tumor DNA based minimal residual disease detection and adjuvant
treatment decision-making for muscle-invasive bladder cancer guided by modern
clinical trials.
Transl Oncol. 2023;37:101763.
Abstract
Paraneoplastic sacroiliitis.
BMJ Case Rep. 2023;16:e252572.
Abstract
Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy
response of metastatic urothelial carcinoma in the POLARIS-03 trial.
J Pathol. 2023;261:198-209.
Abstract
Fourier transform IR imaging of primary tumors predicts lymph node metastasis of
bladder carcinoma.
Biochim Biophys Acta Mol Basis Dis. 2023;1869:166840.
Abstract
Oral 5-aminolevulinic acid administration before transurethral resection of
bladder tumor induces perioperative nausea and vomiting.
Photodiagnosis Photodyn Ther. 2023;43:103707.
Abstract
S100A5 Attenuates Efficiency of Anti-PD-L1/PD-1 Immunotherapy by Inhibiting
CD8(+) T Cell-Mediated Anti-Cancer Immunity in Bladder Carcinoma.
Adv Sci (Weinh). 2023;10:e2300110.
Abstract
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer.
Cancer Discov. 2023;13:1998-2011.
Abstract
Long-Term Oncologic Outcomes of Endoscopic Management of High-Risk Upper Tract
Urothelial Carcinoma: The Fundacio Puigvert's Experience.
J Endourol. 2023;37:973-977.
Abstract
Dual immunocytochemical staining of annexin A10 and p53 in low-grade and
papillary urothelial carcinoma contributes to improvement of diagnostic accuracy
in urine cytology.
Cancer Cytopathol. 2023;131:548-560.
Abstract
Atypical urothelial cells classified according to the Paris System for Reporting
Urinary Cytology: A 2-year experience with histological correlation from a
Finnish tertiary care center-low rate and high risk of malignancy.
Cancer Cytopathol. 2023;131:574-580.
Abstract
Perioperative comparison between robot-assisted and laparoscopic radical
cystectomy: An update meta-analysis.
Asian J Surg. 2023;46:3464-3479.
Abstract
Robot-assisted radical nephroureterectomy for upper tract urothelial carcinoma:
Peri and postoperative outcomes.
Actas Urol Esp (Engl Ed). 2023;47:441-449.
Abstract
An aid to a better understanding of the definitions of BCG failure provided by
the European Urology Association.
Actas Urol Esp (Engl Ed). 2023;47:395-397.
Abstract
Immune-inflammatory-nutritional status predicts oncologic outcomes after radical
cystectomy for urothelial carcinoma of bladder.
Actas Urol Esp (Engl Ed). 2023;47:430-440.
Abstract
Anticancer Effects of Cell-Free Culture Supernatant of Escherichia coli in
Bladder Cancer Cell Line: New Insight into the Regulation of Inflammation.
Gene. 2023 Sep 12:147795. doi: 10.1016/j.gene.2023.147795.
Abstract
Urothelial bladder cancer with cardiac metastasis: Literature review and case
report.
Int J Surg Case Rep. 2023;111:108630.
Abstract
ASO Author Reflections: Cancer-Specific Mortality of Non-Muscle-Invasive Bladder
Cancer.
Ann Surg Oncol. 2023 Sep 14. doi: 10.1245/s10434-023-14301.
Abstract
Role of human papillomavirus and associated viruses in bladder cancer: An updated
review.
J Med Virol. 2023;95:e29088.
Abstract
LRRC59 serves as a novel biomarker for predicting the progression and prognosis
of bladder cancer.
Cancer Med. 2023 Sep 14. doi: 10.1002/cam4.6542.
Abstract
Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from
bench to approval.
Front Immunol. 2023;14:1260498.
Abstract
LncRNA BCCE4 Genetically Enhances the PD-L1/PD-1 Interaction in Smoking-Related
Bladder Cancer by Modulating miR-328-3p-USP18 Signaling.
Adv Sci (Weinh). 2023 Sep 13:e2303473. doi: 10.1002/advs.202303473.
Abstract
Proteogenomics of different urothelial bladder cancer stages reveals distinct
molecular features for papillary cancer and carcinoma in situ.
Nat Commun. 2023;14:5670.
Abstract
177Lu-FAP-2286 Therapy in a Case of Recurrent Bladder Cancer With Multiple
Metastatic Lesions.
Clin Nucl Med. 2023 Sep 13. doi: 10.1097/RLU.0000000000004865.
Abstract
Solitary Axillary Lymph Node Metastasis From Bladder Cancer Detected by FDG
PET/CT.
Clin Nucl Med. 2023 Sep 7. doi: 10.1097/RLU.0000000000004827.
Abstract
Prospective evaluation of return to work, health-related quality of life and
psychosocial distress after radical cystectomy: 1-year follow-up in 230 employed
German bladder cancer patients.
World J Urol. 2023 Sep 13. doi: 10.1007/s00345-023-04570.
Abstract
The current landscape of m6A modification in urological cancers.
PeerJ. 2023;11:e16023.
Abstract
Single-cell profiling of murine bladder cancer identifies sex-specific
transcriptional signatures with prognostic relevance.
iScience. 2023;26:107703.
Abstract
Diagnostic performance of multiparametric MRI based Vesical Imaging-Reporting and
Data System (VI-RADS) scoring in discriminating between non-muscle invasive and
muscle invasive bladder cancer.
Pol J Radiol. 2023;88:e356-e364.
Abstract
Novel potential urinary biomarkers for effective diagnosis and prognostic
evaluation of high-grade bladder cancer.
Transl Cancer Res. 2023;12:1992-2007.
Abstract
A novel genes-based signature with prognostic value and predictive ability to
select patients responsive to Atezolizumab treatment in bladder cancer: an
analysis on data from real-world studies.
Transl Cancer Res. 2023;12:2063-2070.
Abstract
Establishing a prognostic model with ferroptosis-related long non-coding RNAs in
bladder cancer.
Transl Cancer Res. 2023;12:2023-2032.
Abstract
Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond
disease progression.
Cancer Cell. 2023;41:1680-1688.
Abstract
Letter to the editor for the article "5-alpha reductase inhibitors (5-ARi) with
or without alpha-blockers (alpha-B) for Benign Prostatic Hyperplasia do NOT lower the
risk of incident Bladder Cancer: United States insurance claims data".
World J Urol. 2023 Sep 12. doi: 10.1007/s00345-023-04607.
Abstract
A cancer-associated fibroblast subtypes-based signature enables the evaluation of
immunotherapy response and prognosis in bladder cancer.
iScience. 2023;26:107722.
Abstract
The role of Bacillus Calmette-Guerin administration on the risk of dementia in
bladder cancer patients: a systematic review and meta-analysis.
Front Aging Neurosci. 2023;15:1243588.
Abstract
Inhibition of protein kinase C isozymes causes immune profile alteration and
possibly decreased tumorigenesis in bladder cancer.
Am J Cancer Res. 2023;13:3832-3852.
Abstract
Echinatin inhibits tumor growth and synergizes with chemotherapeutic agents
against human bladder cancer cells by activating p38 and suppressing
Wnt/beta-catenin pathways.
Genes Dis. 2023;11:1050-1065.
Abstract
A novel signature constructed by differential genes of muscle-invasive and
non-muscle-invasive bladder cancer for the prediction of prognosis in bladder
cancer.
Front Immunol. 2023;14:1187286.
Abstract
Relationship between Bladder Cancer, Nutritional Supply, and Treatment
Strategies: A Comprehensive Review.
Nutrients. 2023;15:3812.
Abstract
Methylenetetrahydrofolate Reductase C677T (rs1801133) Polymorphism Is Associated
with Bladder Cancer in Asian Population: Epigenetic Meta-Analysis as Precision
Medicine Approach.
Cancers (Basel). 2023;15:4402.
Abstract
Survival Prediction of Patients with Bladder Cancer after Cystectomy Based on
Clinical, Radiomics, and Deep-Learning Descriptors.
Cancers (Basel). 2023;15:4372.
Abstract
Rotatable Bi-Channel En Bloc Resection of Bladder Tumor for Non-Muscle-Invasive
Bladder Cancer in an Ex Vivo Porcine Model.
Cancers (Basel). 2023;15:4255.
Abstract
A Case-Only Genome-Wide Interaction Study of Smoking and Bladder Cancer Risk:
Results from the COBLAnCE Cohort.
Cancers (Basel). 2023;15:4218.
Abstract
Development of Multiplex Polymerase Chain Reaction (PCR)-Based MSA Assay for
Bladder Cancer Detection.
Int J Mol Sci. 2023;24:13651.
Abstract
CircXRN2 suppresses tumor progression driven by histone lactylation through
activating the Hippo pathway in human bladder cancer.
Mol Cancer. 2023;22:151.
Abstract
Adhesion-regulating molecule 1 (ADRM1) can be a potential biomarker and target
for bladder cancer.
Sci Rep. 2023;13:14803.
Abstract
TGM1 could predict overall survival for patients with bladder cancer.
Asian J Surg. 2023 Sep 6:S1015-9584(23)01104.
Abstract
Non-muscle invasive urothelial bladder cancer in a 17-year-old male: A rare case
report.
Int J Surg Case Rep. 2023;110:108728.
Abstract
A Protocol for Organoids from the Urine of Bladder Cancer Patients.
Cells. 2023;12:2188.
Abstract
Avelumab First-Line Maintenance Therapy: Managing Patients With Advanced
Urothelial Carcinoma.
Clin J Oncol Nurs. 2023;27:71-80.
Abstract
Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic
Urothelial Carcinoma.
Adv Ther. 2023;40:4134-4150.
Abstract
Clinicopathological significance of TUBB3 in upper tract urothelial carcinoma and
possible application in urine cytology.
Pathol Int. 2023;73:444-455.
Abstract
Granzymes expression patterns predict immunotherapy response and identify the
heterogeneity of CD8+ T cell subsets.
Cancer Biomark. 2023;38:77-102.
Abstract
Nectin-4 is frequently expressed in primary salivary gland cancer and
corresponding lymph node metastases and represents an important treatment-related
biomarker.
Clin Exp Metastasis. 2023;40:395-405.
Abstract
Coptisine inhibits the malignancy of bladder carcinoma cells and regulates XPO1
expression.
Chem Biol Drug Des. 2023;102:805-814.
Abstract
Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma
Receiving First-Line Systemic Treatment (the IMPACT UC I Study).
Oncologist. 2023;28:790-798.
Abstract
Management of urinary incontinence after radical cystectomy and orthotopic
neobladder: A scoping review of international practices.
Nurs Open. 2023;10:6618-6634.
Abstract
First case of robot-assisted radical cystectomy and intracorporeal neobladder
reconstruction with the Hugo RAS system: step-by-step surgical setup and
technique.
J Robot Surg. 2023;17:2247-2251.
Abstract
Zosteriform cutaneous metastases from urothelial carcinoma: Report of a rare case
and literature review.
J Cutan Pathol. 2023 May 29. doi: 10.1111/cup.14471.
Abstract
The ablative effect of mitomycin reverse thermal gel: Expanding the role for
nephron preservation therapy in low grade upper tract urothelial carcinoma.
Urol Oncol. 2023;41:387.
Abstract
Annual trends of cystectomy complications: A contemporary analysis of the NSQIP
database.
Urol Oncol. 2023;41:390.
Abstract
Association between early postradical cystectomy kidney injury and perioperative
outcome in enhanced recovery era.
Urol Oncol. 2023;41:389.
Abstract
Impact of surgical margin and extent of lymphadenectomy on oncologic outcomes in
plasmacytoid urothelial carcinoma.
Urol Oncol. 2023;41:389.
Abstract
Artifactual Cystic Spaces in Prostatic Transurethral Resections and Related
Specimens: A Potential Diagnostic Confounder.
Int J Surg Pathol. 2023;31:1048-1056.
Abstract
Prognostic variations between "primary" and "progressive" muscle-invasive bladder
cancer following radical cystectomy: A novel propensity score-based multicenter
cohort study.
Int J Surg. 2023 Sep 22. doi: 10.1097/JS9.0000000000000790.
Abstract
International Society of Urological Pathology (ISUP) Consensus Conference on
Current Issues in Bladder Cancer: Working Group 3: Subcategorization of T1
Bladder Cancer.
Am J Surg Pathol. 2023 Sep 22. doi: 10.1097/PAS.0000000000002121.
Abstract
Systematic Evaluation of Imaging Features of Early Bladder Cancer Using Computed
Tomography Performed before Pathologic Diagnosis.
Tomography. 2023;9:1734-1744.
Abstract
Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in a Lebanese
experience: in all aspects.
Gulf J Oncolog. 2023;1:33-39.
Abstract
Clinical and dosimetric outcomes of image-guided, dose-painted radiotherapy in
muscle invasive bladder cancer.
Radiat Oncol. 2023;18:154.
Abstract
Pedal acrometastasis secondary to urothelial carcinoma masquerading as Charcot
arthropathy in a patient with diabetes.
BMJ Case Rep. 2023;16:e254468.
Abstract
Prognosis of patients with T1 low-grade urothelial bladder cancer treated with
bacillus Calmette-Guerin immunotherapy.
Minerva Urol Nephrol. 2023;75:591-599.
Abstract
Chronic Obstructive Pulmonary Disease Mortality in Bladder Cancer Patients: A
SEER-Based Competing Risk Analysis.
Urol J. 2023 Sep 17. doi: 10.22037/uj.v20i.7644.
Abstract
The bladder cancer immune micro-environment in the context of response to immune
checkpoint inhibition.
Front Immunol. 2023;14:1235884.
Abstract
Targeting microRNA-145-mediated progressive phenotypes of early bladder cancer in
a molecularly defined in vivo model.
Mol Ther Nucleic Acids. 2023;33:960-982.
Abstract
A urinary assay for mutation and methylation biomarkers in the diagnosis and
recurrence prediction of non-muscle invasive bladder cancer patients.
BMC Med. 2023;21:357.
Abstract
CAB39 promotes cisplatin resistance in bladder cancer via the LKB1-AMPK-LC3
pathway.
Free Radic Biol Med. 2023 Sep 17:S0891-5849(23)00641.
Abstract
ASO Visual Abstract: Cancer-Specific Survival of Patients with
Non-Muscle-Invasive Bladder Cancer-A Population-Based Analysis.
Ann Surg Oncol. 2023 Sep 19. doi: 10.1245/s10434-023-14286.
Abstract
CT-based deep learning radiomics nomogram for the prediction of pathological
grade in bladder cancer: a multicenter study.
Cancer Imaging. 2023;23:89.
Abstract
Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB
trial).
Sci Rep. 2023;13:15437.
Abstract
Secondary Bladder Cancer After Prostate Cancer Treatment: An Age-matched
Comparison Between Radiation and Surgery.
Eur Urol Focus. 2023 Sep 16:S2405-4569(23)00199.
Abstract
Adherence to the Diabetes Risk Reduction Diet and bladder cancer risk in the
Prostate, Lung, Colorectal, Ovarian (PLCO) cohort.
Cancer Epidemiol Biomarkers Prev. 2023.
Abstract
Bladder cancer course, four genetic high-risk variants, and histopathological
findings.
EXCLI J. 2023;22:867-879.
Abstract
The effect of different timing of blood transfusion on oncological outcomes of
patients undergoing radical cystectomy for bladder cancer: a systematic review
and meta-analysis.
Front Oncol. 2023;13:1223592.
Abstract
Practice change: No benefit of extended lymphadenectomy at radical cystectomy in
patients with muscle invasive bladder cancer.
Semin Oncol. 2023 Sep 14:S0093-7754(23)00064.
Abstract
Mitochondrial-targeted brequinar liposome boosted mitochondrial-related
ferroptosis for promoting checkpoint blockade immunotherapy in bladder cancer.
J Control Release. 2023 Sep 15:S0168-3659(23)00611.
Abstract
The impact of mutational clonality in predicting the response to immune
checkpoint inhibitors in advanced urothelial cancer.
Sci Rep. 2023;13:15287.
Abstract
Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer.
Urol Oncol. 2023 Sep 13:S1078-1439(23)00263.
Abstract
The global landscape of bladder cancer incidence and mortality in 2020 and
projections to 2040.
J Glob Health. 2023;13:04109.
Abstract
Insights into vitamin A in bladder cancer, lack of attention to gut microbiota?
Front Immunol. 2023;14:1252616.
Abstract
Induction therapy with ipilimumab and nivolumab followed by consolidative
chemoradiation as organ-sparing treatment in urothelial bladder cancer: study
protocol of the INDIBLADE trial.
Front Oncol. 2023;13:1246603.
Abstract
Plasma proteomic profiling discovers molecular features associated with upper
tract urothelial carcinoma.
Cell Rep Med. 2023;4:101166.
Abstract
Immunoreactivity of HOXB13 in Neuroendocrine Neoplasms Is a Sensitive and
Specific Marker of Rectal Well-Differentiated Neuroendocrine Tumors.
Endocr Pathol. 2023;34:333-341.
Abstract
Comment on: "Stage-dependent survival in patients treated with neoadjuvant
chemotherapy and radical cystectomy".
Minerva Urol Nephrol. 2023;75:649-651.
Abstract
MicroRNA-145-5p suppresses cell proliferation, migration, and invasion in upper
tract urothelial carcinoma by targeting 5-aminoimidazole-4-carboxamide
ribonucleotide formyltransferase/IMP cyclohydrolase.
J Cell Biochem. 2023;124:1324-1345.
Abstract
Clinical and pathological characteristics of metastatic tumors to the urinary
bladder.
Ann Diagn Pathol. 2023;66:152179.
Abstract
Hyaluronic Acid-Conjugated Fluorescent Probe-Shielded Polydopamine Nanomedicines
for Targeted Imaging and Chemotherapy of Bladder Cancer.
ACS Appl Mater Interfaces. 2023 Sep 28. doi: 10.1021/acsami.3c09564.
Abstract
SQLE Knockdown inhibits bladder cancer progression by regulating the
PTEN/AKT/GSK3beta signaling pathway through P53.
Cancer Cell Int. 2023;23:221.
Abstract
Author Correction: Synthetic Tet-inducible artificial microRNAs targeting
beta-catenin or HIF-1alpha inhibit malignant phenotypes of bladder cancer cells T24 and
5637.
Sci Rep. 2023;13:16331.
Abstract
Elevating Second Near-Infrared Photothermal Conversion Efficiency of Hollow Gold
Nanorod for a Precise Theranostic of Orthotopic Bladder Cancer.
ACS Nano. 2023 Sep 28. doi: 10.1021/acsnano.3c04175.
Abstract
Intracellular Gemcitabine Monophosphate Levels Predict Chemotherapy Efficacy in
Gemcitabine-Treated Patients with Bladder Cancer.
Dokl Biochem Biophys. 2023 Sep 29. doi: 10.1134/S1607672923700503.
Abstract
Bladder Cancer during Pregnancy: A Review of the Literature.
J Pers Med. 2023;13:1418.
Abstract
The Risk of Thromboembolism in Patients with Muscle Invasive Bladder Cancer
before and after Cystectomy Depending on Blood Group and Neoadjuvant
Chemotherapy-A Multicentre Retrospective Cohort Study.
J Pers Med. 2023;13:1355.
Abstract
Radiomic Analysis of Quantitative T2 Mapping and Conventional MRI in Predicting
Histologic Grade of Bladder Cancer.
J Clin Med. 2023;12:5900.
Abstract
Molecular Markers for Bladder Cancer Screening: An Insight into Bladder Cancer
and FDA-Approved Biomarkers.
Int J Mol Sci. 2023;24:14374.
Abstract
GABBR2 as a Downstream Effector of the Androgen Receptor Induces Cisplatin
Resistance in Bladder Cancer.
Int J Mol Sci. 2023;24:13733.
Abstract
Artificial Intelligence in Digital Pathology for Bladder Cancer: Hype or Hope? A
Systematic Review.
Cancers (Basel). 2023;15:4518.
Abstract
Predictors of Response Following Neoadjuvant Cisplatin-Based Chemotherapy for
Muscle Invasive Urothelial Bladder Cancer Using Molecular Profile: A Prospective
Clinical Study.
Clin Genitourin Cancer. 2023 Aug 10:S1558-7673(23)00186.
Abstract
Analysis of Transferrin in the Urine of Patients with Bladder Cancer Using
Nanobodies.
Biochemistry (Mosc). 2023;88:1105-1115.
Abstract
Super-enhancer-associated SNHG15 cooperating with FOSL1 contributes to bladder
cancer progression through the WNT pathway.
Pharmacol Res. 2023 Sep 25:106940. doi: 10.1016/j.phrs.2023.106940.
Abstract
Reply to Letter to Editor: Cancer-Specific Mortality of Non-Muscle-Invasive
Bladder Cancer.
Ann Surg Oncol. 2023 Sep 27. doi: 10.1245/s10434-023-14360.
Abstract
Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in
a Patient with Urothelial Cancer.
Curr Oncol. 2023;30:7802-7809.
Abstract
Selective multimodal bladder-sparing therapy for muscle-invasive bladder cancer:
the present and the future.
Expert Rev Anticancer Ther. 2023 Sep 27:1-13. doi: 10.1080/14737140.2023.2257389
Abstract
Predicting Survival Signature of Bladder Cancer Related to Cancer-Associated
Fibroblast (CAF) Constructed by Intersecting Genes in TCGA and GEO.
Mol Biotechnol. 2023 Sep 25. doi: 10.1007/s12033-023-00892.
Abstract
Health-related quality of life prior to and 1 year after radical cystectomy
evaluated with FACT-G and FACT-VCI questionnaires.
Scand J Urol. 2023;58:76-83.
Abstract
Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk
Non-muscle Invasive Bladder Cancer.
Cureus. 2023;15:e45672.
Abstract
Cancer-Associated Fibroblast-Induced Remodeling of Tumor Microenvironment in
Recurrent Bladder Cancer.
Adv Sci (Weinh). 2023 Sep 24:e2303230. doi: 10.1002/advs.202303230.
Abstract
Inhibition of autophagy can promote the apoptosis of bladder cancer cells induced
by SC66 through the endoplasmic reticulum stress pathway.
Chem Biol Interact. 2023 Sep 21:110725. doi: 10.1016/j.cbi.2023.110725.
Abstract
Identifying possible hub genes and biological mechanisms shared between bladder
cancer and inflammatory bowel disease using machine learning and integrated
bioinformatics.
J Cancer Res Clin Oncol. 2023 Sep 23. doi: 10.1007/s00432-023-05266.
Abstract
Activation of CTNNB1 by deubiquitinase UCHL3-mediated stabilization facilitates
bladder cancer progression.
J Transl Med. 2023;21:656.
Abstract
Loss of ORP3 induces aneuploidy and promotes bladder cancer cell invasion through
deregulated microtubule and actin dynamics.
Cell Mol Life Sci. 2023;80:299.
Abstract
DUSP2 affects bladder cancer prognosis by down-regulating MEK/ERK and P38 MAPK
signaling pathways through PTPN7.
Cell Signal. 2023;112:110893.
Abstract
MCM4 expression is associated with high-grade histology, tumor progression and
poor prognosis in urothelial carcinoma.
Diagn Pathol. 2023;18:106.
Abstract
Association of metabolic syndrome and its components with the risk of urologic
cancers: a prospective cohort study.
BMC Urol. 2023;23:150.
Abstract
Self-reported sleep disorders and the risk of all cancer types: evidence from the
Kailuan Cohort study.
Public Health. 2023;223:209-216.
Abstract
Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in
Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical
Trial.
JAMA Oncol. 2023;9:1205-1213.
Abstract
Mycotic Abdominal Aortic Aneurysm Secondary to BCG Therapy for Non-muscle
Invasive Urothelial Carcinoma of the Bladder.
Vasc Endovascular Surg. 2023;57:776-780.
Abstract
A Case of Immune Thrombocytopenia Occurring after Radiotherapy plus Atezolizumab
Treatment for Bladder Cancer.
Gan To Kagaku Ryoho. 2023;50:985-992.
Abstract
Retracted: MicroRNA-143-3p/TBX3 Axis Represses Malignant Cell Behaviors in
Bladder Cancer.
Comput Math Methods Med. 2023;2023:9763968.
Abstract
Retracted: The Effect of Narrative Nursing Intervention on Shame in Elderly
Patients with Bladder Cancer after Ileal Bladder Replacement: A Cohort Study.
Comput Math Methods Med. 2023;2023:9761783.
Abstract
Glutathione dynamics is a potential predictive and therapeutic trait for
neoadjuvant chemotherapy response in bladder cancer.
Cell Rep Med. 2023 Sep 27:101224. doi: 10.1016/j.xcrm.2023.101224.
Abstract
Does the urinary microbiome profile change after treatment of bladder cancer?
World J Urol. 2023 Oct 5. doi: 10.1007/s00345-023-04627.
Abstract
[Idiopathic Thrombocytopenia Purpura After Pembrolizumab Treatment Against
Locally Recurrent Bladder Cancer : A Case Report].
Hinyokika Kiyo. 2023;69:255-258.
Abstract
[Occurrence of Distant Metastasis During Bladder Presevation in T1 high-grade
Bladder Cancer: Report of Three Cases].
Hinyokika Kiyo. 2023;69:249-254.
Abstract
Organ-sparing precision treatment for muscle-invasive bladder cancer.
Nat Med. 2023 Oct 4. doi: 10.1038/s41591-023-02575.
Abstract
Intravenous administration of BCG in mice promotes natural killer and T
cell-mediated antitumor immunity in the lung.
Nat Commun. 2023;14:6090.
Abstract
Comparison of sequential versus concurrent chemoradiation regimens in
non-metastatic muscle-invasive bladder cancer.
Radiat Oncol J. 2023;41:154-162.
Abstract
Deciphering the immunological and prognostic features of bladder cancer through
platinum-resistance-related genes analysis and identifying potential therapeutic
target P4HB.
Front Immunol. 2023;14:1253586.
Abstract
Exosomal miR-105-5p derived from bladder cancer stem cells targets for GPR12 to
promote the malignancy of bladder cancer.
BMC Urol. 2023;23:155.
Abstract
Treatment impact of newly approved therapeutic agents for metastatic urothelial
carcinoma in Japan: a single-center retrospective study.
Sci Rep. 2023;13:16580.
Abstract
Prevention of local symptoms in muscle invasive bladder cancer patients: clinical
significance of local radiation therapy.
Support Care Cancer. 2023;31:607.
Abstract
Treatment patterns, survival, and healthcare utilisation and costs in patients
with locally advanced and metastatic bladder cancer in Denmark 2015-2020.
Acta Oncol. 2023 Oct 3:1-7. doi: 10.1080/0284186X.2023.2263154.
Abstract
PKMYT1 induced by YAP/TEAD1 gives rise to the progression and worse prognosis of
bladder cancer.
Mol Carcinog. 2023 Oct 3. doi: 10.1002/mc.23643.
Abstract
Urinary microRNA-10a levels in diagnosis and prognosis of urinary bladder cancer.
J Cancer Res Ther. 2023;19:1324-1329.
Abstract
LncRNA LINC00592 mediates the promoter methylation of WIF1 to promote the
development of bladder cancer.
Open Med (Wars). 2023;18:20230788.
Abstract
Preoperative fluorescence in situ hybridization analysis as a predictor of tumor
recurrence in patients with non-muscle invasive bladder cancer: a
bi-institutional study.
J Transl Med. 2023;21:685.
Abstract
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for
muscle-invasive bladder cancer: a phase 2 trial.
Nat Med. 2023 Oct 2. doi: 10.1038/s41591-023-02568.
Abstract
WDR4 promotes the progression and lymphatic metastasis of bladder cancer via
transcriptional down-regulation of ARRB2.
Oncogenesis. 2023;12:47.
Abstract
Sulforaphane and bladder cancer: a potential novel antitumor compound.
Front Pharmacol. 2023;14:1254236.
Abstract
Identification of novel lactate metabolism-related lncRNAs with prognostic value
for bladder cancer.
Front Pharmacol. 2023;14:1215296.
Abstract
Tumorigenic effects of human mesenchymal stromal cells and fibroblasts on bladder
cancer cells.
Front Oncol. 2023;13:1228185.
Abstract
Development and validation of prognostic index based on purine metabolism genes
in patients with bladder cancer.
Front Med (Lausanne). 2023;10:1193133.
Abstract
Cluster of differentiation 147 (CD147) as potential membrane protein biomarker
for bladder cancer cells.
J Pharm Biomed Anal. 2023;236:115729.
Abstract
Comment on: Cancer-Specific Survival of Patients with Non-Muscle-Invasive Bladder
Cancer.
Ann Surg Oncol. 2023 Sep 30. doi: 10.1245/s10434-023-14355.
Abstract
Identification of m6A suppressor EIF4A3 as a novel cancer prognostic and
immunotherapy biomarker through bladder cancer clinical data validation and
pan-cancer analysis.
Sci Rep. 2023;13:16457.
Abstract
Fibroblast growth factor receptor 3 mutation attenuates response to immune
checkpoint blockade in metastatic urothelial carcinoma by driving
immunosuppressive microenvironment.
J Immunother Cancer. 2023;11:e006643.
Abstract
The Evolution of Polyclonal Antibody from Specific Epitope 47kDA for Detection of
Bladder Cancer.
Asian Pac J Cancer Prev. 2023;24:3155-3164.
Abstract
The Association of P53, CK29, and FGFR3 Overexpression with the Characteristics
of Urothelial Cell Carcinoma of the Bladder.
Asian Pac J Cancer Prev. 2023;24:3125-3131.
Abstract
Statins, commonly coprescribed drugs, and concomitant risk factors: A protective,
neutral, or harmful association with common cancer types development: A 10-year
multicentric retrospective lebanese study.
Medicine (Baltimore). 2023;102:e34562.
Abstract
[Organ-sparing treatment of node-positive bladder cancer].
Strahlenther Onkol. 2023 Sep 29. doi: 10.1007/s00066-023-02156.
Abstract
Study on anxiety, depression, and subjective wellbeing of patients with bladder
cancer in their different chemotherapy stages.
Front Psychol. 2023;14:1226712.
Abstract
Heat shock protein family A member 8 is a prognostic marker for bladder cancer:
Evidences based on experiments and machine learning.
J Cell Mol Med. 2023 Sep 28. doi: 10.1111/jcmm.17977.
Abstract
Metformin-Loaded Chitosan Hydrogels Suppress Bladder Tumor Growth in an
Orthotopic Mouse Model via Intravesical Administration.
Molecules. 2023;28:6720.
Abstract
Diagnostic Roles of Immunohistochemical Markers CK20, CD44, AMACR, and p53 in
Urothelial Carcinoma In Situ.
Medicina (Kaunas). 2023;59:1609.
Abstract
Elucidating the Associated Biological Function and Clinical Significance of RHOJ
Expression in Urothelial Carcinoma.
Int J Mol Sci. 2023;24:14081.
Abstract
Advantages of enhanced recovery after surgery program in robot-assisted radical
cystectomy.
Sci Rep. 2023;13:16237.
Abstract
Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Urothelial Cancer.
Clin Genitourin Cancer. 2023;21:509-516.
Abstract
Tumor immune microenvironment and clinical outcomes in stage IV urothelial
cancer: YODO study.
Int J Clin Oncol. 2023;28:1398-1410.
Abstract
Primary Bladder Sarcoma: A multi-institutional experience from the Rare Cancer
Network.
Arch Ital Urol Androl. 2023;95:11533.
Abstract
Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links
to Viral Infection.
Cancer Prev Res (Phila). 2023;16:561-570.
Abstract
Diagnosis and management of complicated urogenital schistosomiasis: a systematic
review of the literature.
Infection. 2023;51:1185-1221.
Abstract
Kidney and Cancer Outcomes with Standard Versus Alternative Chemotherapy Regimens
for First-Line Treatment of Metastatic Urothelial Carcinoma.
Kidney360. 2023;4:e1203-e1211.
Abstract
Incidence of perioperative hypotension in patients undergoing transurethral
resection of bladder tumor after oral 5-aminolevulinic acid administration: a
retrospective multicenter cohort study.
J Anesth. 2023;37:703-713.
Abstract
Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced
Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Clin Genitourin Cancer. 2023;21:574-583.
Abstract
Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy
(PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World"
Experience.
Clin Genitourin Cancer. 2023;21:584-593.
Abstract
Large-scale validation study of an improved semiautonomous urine cytology
assessment tool: AutoParis-X.
Cancer Cytopathol. 2023;131:637-654.
Abstract
Long-term survival after female pelvic organ-sparing radical cystectomy versus
standard radical cystectomy: a multi-institutional propensity score-matched
analysis.
Int J Surg. 2023;109:2742-2750.
Abstract
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in
Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint
Inhibitors or Enfortumab Vedotin.
Clin Genitourin Cancer. 2023;21:e394-e404.
Abstract
Utility and performance of cell blocks in urine cytology: Experience at three
teaching hospitals.
Cancer Cytopathol. 2023;131:614-625.
Abstract
Comparative Genomic Landscape of Urothelial Carcinoma of the Bladder Among
Patients of East and South Asian Genomic Ancestry.
Oncologist. 2023;28:e910-e920.
Abstract
The prognostic Value of Thyroid Hormone Levels in Immunotherapy-Treated Patients
With Metastatic Urothelial Carcinoma.
Clin Genitourin Cancer. 2023;21:e378-e385.
Abstract
Primary Alveolar Soft-Part Sarcoma (ASPS) of the Prostate: Report of a Deceptive
Case.
Int J Surg Pathol. 2023;31:1359-1363.
Abstract
[Cystectomy versus trimodal therapy for bladder cancer].
Urologie. 2023 Oct 12. doi: 10.1007/s00120-023-02195.
Abstract
A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus
Calmette-Guerin Strains in Patients with Intermediate- and High-risk
Non-muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2023 Oct 10:S2588-9311(23)00206.
Abstract
The ceRNA Mechanism of lncRNA MEG3/miR-21-5p/SPRY2 in Cell Proliferation and
Apoptosis in Bladder Cancer.
Crit Rev Eukaryot Gene Expr. 2024;34:55-68.
Abstract
A HER2-targeted Antibody-Drug Conjugate, RC48-ADC, Exerted Promising Antitumor
Efficacy and Safety with Intravesical Instillation in Preclinical Models of
Bladder Cancer.
Adv Sci (Weinh). 2023 Oct 12:e2302377. doi: 10.1002/advs.202302377.
Abstract
Quality of Life in Patients with High-grade Non-muscle-invasive Bladder Cancer
Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guerin
Instillations: The EAU-RF NIMBUS Trial.
Eur Urol Open Sci. 2023;56:15-24.
Abstract
Comparison of trimodality therapy and neoadjuvant chemotherapy combined with
radical cystectomy for the survival of muscle-invasive bladder cancer: a
population-based analysis.
Eur J Med Res. 2023;28:422.
Abstract
Amide Proton Transfer-Weighted MRI and Diffusion-Weighted Imaging in Bladder
Cancer: A Complementary Tool to the VI-RADS.
Acad Radiol. 2023 Oct 9:S1076-6332(23)00472-5. doi: 10.1016/j.acra.2023.
Abstract
Hypophysitis Induced by Sintilimab in the Treatment of Bladder Cancer: A Case
Report.
Endocr Metab Immune Disord Drug Targets. 2023.
Abstract
18F-fluoro-2-deoxy-2-d-glucose PET-CT (FDG PET-CT) in staging of high-risk renal
and urothelial bladder cancers (COPPER-T) trial protocol.
BJUI Compass. 2023;4:662-667.
Abstract
Physical Activity and Bladder Cancer Risk: Findings of the Japan Collaborative
Cohort Study.
Cancer Res Treat. 2023 Oct 6. doi: 10.4143/crt.2023.
Abstract
UCHL1-PKM2 axis dysregulation is associated with promoted proliferation and
invasiveness of urothelial bladder cancer cells.
Aging (Albany NY). 2023;15.
Abstract
[SLC12A8 promotes proliferation, invasiveness, migration and
epithelial-mesenchymal transition of bladder cancer cells by activating JAK/STAT
singaling].
Nan Fang Yi Ke Da Xue Xue Bao. 2023;43:1613-1621.
Abstract
CDCA8 promotes bladder cancer survival by stabilizing HIF1alpha expression under
hypoxia.
Cell Death Dis. 2023;14:658.
Abstract
Corrigendum to "Proposal for a Novel Histological Scoring System as a Potential
Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with
Disease Aggressiveness and Patient Outcomes" [European Urology Oncology (2023)].
Eur Urol Oncol. 2023 Oct 7:S2588-9311(23)00215-8. doi: 10.1016/j.euo.2023.
Abstract
The iBLAD study: patient-reported outcomes in bladder cancer during oncological
treatment: a multicenter national randomized controlled trial.
J Patient Rep Outcomes. 2023;7:99.
Abstract
Endothelial cells are a key target of IFN-g during response to combined
PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer.
iScience. 2023;26:107937.
Abstract
Construction of 3D and 2D contrast-enhanced CT radiomics for prediction of CGB3
expression level and clinical prognosis in bladder cancer.
Heliyon. 2023;9:e20335.
Abstract
The role of cancer-associated fibroblasts in bladder cancer progression.
Heliyon. 2023;9:e19802.
Abstract
[Risk modeling based on HER-2 related genes for bladder cancer survival prognosis
assessment].
Beijing Da Xue Xue Bao Yi Xue Ban. 2023;55:793-801.
Abstract
Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder
Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial
(ANZUP 1502).
Eur Urol Oncol. 2023 Oct 6:S2588-9311(23)00201-8. doi: 10.1016/j.euo.2023.
Abstract
Reply to Francesco Montorsi, Giuseppe Rosiello, and Giorgio Gandaglia's Letter to
the Editor re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al.
Oncological Outcomes for Patients with European Association of Urology Very
High-risk Non-muscl
Eur Urol Oncol. 2023 Oct 6:S2588-9311(23)00210-9. doi: 10.1016/j.euo.2023.
Abstract
Exosome, the glass slipper for Cinderella of cancer-bladder cancer?
J Nanobiotechnology. 2023;21:368.
Abstract
[Research progress in molecular pathology of bladder cancer].
Zhonghua Bing Li Xue Za Zhi. 2023;52:1074-1078.
Abstract
Bladder cancer patient and provider perspectives on smoking cessation.
Urol Oncol. 2023 Oct 5:S1078-1439(23)00292-2. doi: 10.1016/j.urolonc.2023.
Abstract
Corrigendum to "An updated lymphohematopoietic and bladder cancers risk
evaluation for occupational and environmental exposures to 1,3-butadiene" [Chem.
Biol. Interact. 366 (2022) 1-10].
Chem Biol Interact. 2023;385:110736.
Abstract
MRI radiomics for predicting poor disease-free survival in muscle invasive
bladder cancer: the results of the retrospective cohort study.
Abdom Radiol (NY). 2023 Oct 7. doi: 10.1007/s00261-023-04028.
Abstract
Online adaptive radiotherapy for bladder cancer using a simultaneous integrated
boost and fiducial markers.
Radiat Oncol. 2023;18:165.
Abstract
Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by
attenuating CD8(+) T cell infiltration and functional transition.
J Immunother Cancer. 2023;11:e007230.
Abstract
Shared genetic links between bladder cancer and obesity-related traits: A
conjunctional false discovery rate study.
Medicine (Baltimore). 2023;102:e35145.
Abstract
Body mass index and waist circumference in relation to risk of recurrence and
progression after non-muscle invasive bladder cancer.
Cancer Med. 2023 Oct 6. doi: 10.1002/cam4.6620.
Abstract
A cost-consequences and budget impact analysis of blue light-guided cystoscopy
with Hexvix(R) in patients diagnosed with non-muscle-invasive bladder cancer in
France.
J Med Econ. 2023 Oct 6:1-10. doi: 10.1080/13696998.2023.2267929.
Abstract
Downregulation of CRTAC1 in Urothelial Carcinoma Promotes Tumor Aggressiveness
and Confers Poor Prognosis.
Front Biosci (Landmark Ed). 2023;28:217.
Abstract
Astragalus polysaccharide inhibits the development of urothelial carcinoma by
activating AMPK signaling to induce BENC1-xCT complex formation.
Aging (Albany NY). 2023;15:9438-9452.
Abstract
Successful use of Rectal Pregabalin for the Treatment of Chemotherapy-Induced
Neuropathic Pain-a Case Report.
J Palliat Care. 2023;38:412-415.
Abstract
A cluster of grapes: Right atrial masses of uncertain origin.
J Vasc Access. 2023;24:821-823.
Abstract
Identification of pyroptosis-related lncRNA subtype and signature predicts the
prognosis in bladder cancer.
Medicine (Baltimore). 2023;102:e35195.
Abstract
Retracted: Multi-Slice Spiral Computed Tomography Image Features under Hybrid
Iterative Reconstruction Algorithm in Staging Diagnosis of Bladder Cancer.
J Healthc Eng. 2023;2023:9791241.
Abstract
Efficacy and safety of photodynamic therapy for non-muscle-invasive bladder
cancer: a systematic review and meta-analysis.
Front Oncol. 2023;13:1255632.
Abstract
Can Only the Shape Feature in Radiomics Help Machine Learning Show That Bladder
Cancer Has Invaded Muscles?
Cureus. 2023;15:e45488.
Abstract
Comprehensive Analysis of Prognostic Value and Immune Infiltration of TFAP2
Family Members in Bladder Cancer from Database and FFPE Sample.
J Cancer. 2023;14:3050-3065.
Abstract
Digital Tracking of Patients Undergoing Radical Cystectomy for Bladder Cancer:
Daily Step Counts Before and After Surgery Within the iROC Randomised Controlled
Trial.
Eur Urol Oncol. 2023 Oct 16:S2588-9311(23)00213.
Abstract
Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle
invasive bladder cancer (NMIBC) patients with immunomodulating conditions.
Urol Oncol. 2023 Oct 16:S1078-1439(23)00323.
Abstract
Construction and Validation of a Prognostic Model Based on Pyroptosisrelated
Genes in Bladder Cancer.
Comb Chem High Throughput Screen. 2023.
Abstract
Targeting Dna Damage and Repair Machinery via Delivering WEE1 Inhibitor and
Platinum (IV) Prodrugs to Stimulate Sting Pathway for Maximizing
Chemo-immunotherapy in Bladder Cancer.
Adv Mater. 2023 Oct 17:e2308762. doi: 10.1002/adma.202308762.
Abstract
Promoting effect and immunologic role of secretogranin II on bladder cancer
progression via regulating MAPK and NF-kappaB pathways.
Apoptosis. 2023 Oct 17. doi: 10.1007/s10495-023-01898.
Abstract
Computed tomography-based prediction model for identifying patients with high
probability of non-muscle-invasive bladder cancer.
Abdom Radiol (NY). 2023 Oct 17. doi: 10.1007/s00261-023-04069.
Abstract
Selenium and Vitamin E for Prevention of Non-Muscle-Invasive Bladder Cancer
Recurrence and Progression: A Randomized Clinical Trial.
JAMA Netw Open. 2023;6:e2337494.
Abstract
Establishment of prognostic model of bladder cancer based on apoptosis-related
genes, in which P4HB promotes BLCA progression.
BMC Urol. 2023;23:167.
Abstract
Dielectric properties of urine in relation to bladder cancer.
Phys Eng Sci Med. 2023 Oct 16. doi: 10.1007/s13246-023-01341.
Abstract
Real-word efficacy of adjuvant single-agent intravesical gemcitabine for
non-muscle invasive bladder cancer.
Expert Opin Pharmacother. 2023 Oct 16:1-11. doi: 10.1080/14656566.2023.2271396.
Abstract
Haemophagocytic lymphohistiocytosis after intravesical BCG administration for
bladder cancer presenting with multiorgan failure.
Access Microbiol. 2023;5:000670.
Abstract
Complement Regulatory Protein CD46 Manifests a Unique Role in Promoting the
Migration of Bladder Cancer Cells.
Chonnam Med J. 2023;59:160-166.
Abstract
Editorial for "Detecting Muscle Invasion of Bladder Cancer: An Application of
Diffusion Kurtosis Imaging Ratio and Vesical Imaging-Reporting and Data System".
J Magn Reson Imaging. 2023 Oct 15. doi: 10.1002/jmri.29054.
Abstract
Exploiting volatile fingerprints for bladder cancer diagnosis: A scoping review
of metabolomics and sensor-based approaches.
Talanta. 2023;268.
Abstract
Propensity score matched survival analysis of octogenarians with muscle-invasive
bladder cancer: chemoradiation compared to radical cystectomy.
Can J Urol. 2023;30:11686-11691.
Abstract
Re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological
Outcomes for Patients with European Association of Urology Very High-risk
Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin or Early
Radical Cystectomy.
Eur Urol Oncol. 2023 Oct 12:S2588-9311(23)00208.
Abstract
The Role of Checkpoint Inhibitor Expression Directly on Exfoliated Cells from
Bladder Cancer: A Narrative Review.
Diagnostics (Basel). 2023;13:3119.
Abstract
Prognostic Role of Preoperative Neutrophil-To-Lymphocyte Ratio (NLR) and
Recurrence at First Evaluation after Bacillus Calmette-Guerin (BCG) Induction in
Non-Muscle-Invasive Bladder Cancer.
Diagnostics (Basel). 2023;13:3114.
Abstract
Membranous Expression of Heart Development Protein with EGF-like Domain 1 Is
Associated with a Good Prognosis in Patients with Bladder Cancer.
Diagnostics (Basel). 2023;13:3067.
Abstract
Mistletoe Extracts from Different Host Trees Disparately Inhibit Bladder Cancer
Cell Growth and Proliferation.
Cancers (Basel). 2023;15:4849.
Abstract
Genomic Biomarker Discovery in Disease Progression and Therapy Response in
Bladder Cancer Utilizing Machine Learning.
Cancers (Basel). 2023;15:4801.
Abstract
Comparing Robotic-Assisted to Open Radical Cystectomy in the Management of
Non-Muscle-Invasive Bladder Cancer: A Propensity Score Matched-Pair Analysis.
Cancers (Basel). 2023;15:4732.
Abstract
Proteomics Profiling of Bladder Cancer Tissues from Early to Advanced Stages
Reveals NNMT and GALK1 as Biomarkers for Early Detection and Prognosis of BCa.
Int J Mol Sci. 2023;24:14938.
Abstract
Expression of S100A16 Is Associated with Biological Aggressiveness and Poor
Prognosis in Patients with Bladder Cancer Who Underwent Radical Cystectomy.
Int J Mol Sci. 2023;24:14536.
Abstract
Efficacy and safety of HIVEC versus ETFT in non-muscle-invasive bladder cancer: A
systematic review and meta-analysis.
Asian J Surg. 2023 Oct 11:S1015-9584(23)01573.
Abstract
A five necroptosis-related lncRNA signature predicts the prognosis of bladder
cancer and identifies hot or cold tumors.
Medicine (Baltimore). 2023;102:e35196.
Abstract
[Miliary Pulmonary Tuberculosis After Intravesical BCG Instillation in a Patient
with High-Grade Bladder Cancer].
Mikrobiyol Bul. 2023;57:675-681.
Abstract
Role of Maximal Transurethral Resection Preceding Partial Cystectomy for
Muscle-Invasive Bladder Cancer.
Ann Surg Oncol. 2023 Oct 26. doi: 10.1245/s10434-023-14449.
Abstract
Bladder cancer.
Nat Rev Dis Primers. 2023;9:59.
Abstract
Bladder cancer.
Nat Rev Dis Primers. 2023;9:58.
Abstract
Prognostic Significance of HER2 Expression in Patients with Bacillus
Calmette-Guerin-exposed Non-muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2023 Oct 24:S2588-9311(23)00219.
Abstract
Diagnostic and prognostic impact of preoperative thrombocytosis in muscle
invasive bladder cancer: Any role in clinical practice?
J Clin Ultrasound. 2023 Oct 26. doi: 10.1002/jcu.23600.
Abstract
Prognostic value of the systemic immune-inflammation index in patients with upper
tract urothelial carcinoma after radical nephroureterectomy.
World J Surg Oncol. 2023;21:337.
Abstract
Construction and validation of a metabolism-associated gene signature for
predicting the prognosis, immune landscape, and drug sensitivity in bladder
cancer.
BMC Med Genomics. 2023;16:264.
Abstract
Bladder cancer: therapeutic challenges and role of 3D cell culture systems in the
screening of novel cancer therapeutics.
Cancer Cell Int. 2023;23:251.
Abstract
Effectiveness of perioperative chemotherapy and radical cystectomy in treating
bladder cancer.
Urol Oncol. 2023 Oct 23:S1078-1439(23)00332.
Abstract
Preservation of Erectile and Ejaculatory Functions After Tetramodal
Bladder-Sparing Therapy Incorporating Consolidative Partial Cystectomy Against
Muscle Invasive Bladder Cancer.
Urol Res Pract. 2023;49:162-168.
Abstract
Investigation of the Roles of MTHFR (C677T and A1298C) and MMP-2 (-1306C>T )
Variations in Bladder Cancer Development.
Urol Res Pract. 2023;49:33-39.
Abstract
The Impact of Histological Variants on Oncological Outcomes in Patients with
Muscle Invasive Bladder Cancer Treated with Radical Cystectomy.
Urol Res Pract. 2023;49:246-252.
Abstract
A rare case of urothelial carcinoma metastasizing to the gallbladder wall with
manifestations as acute cholecystitis.
Klin Onkol. 2023;36:401-404.
Abstract
A transcriptome study of p53-pathway related prognostic gene signature set in
bladder cancer.
Heliyon. 2023;9:e21058.
Abstract
Sakuranin represses the malignant biological behaviors of human bladder cancer
cells by triggering autophagy via activating the p53/mTOR pathway.
BMC Urol. 2023;23:170.
Abstract
Impact of the COVID-19 pandemic on bladder cancer patients: a multicenter
real-world study.
J Int Med Res. 2023;51:3000605231204465.
Abstract
Erdafitinib in BCG-treated high-risk non-muscle invasive bladder cancer.
Ann Oncol. 2023 Oct 5:S0923-7534(23)04015-2. doi: 10.1016/j.annonc.2023.09.3116.
Abstract
Magnetic resonance radiographic features which might lead to misdiagnosis of
muscle-invasive bladder cancer based on vesical imaging reporting and data
system: the application experience of a single center.
Quant Imaging Med Surg. 2023;13:7258-7268.
Abstract
Tumor Markers as Predictors of Acute Kidney Injury Incidence and Staging of the
Muscle-Invasive Bladder Cancer Receiving Chemoradiation Therapy.
World J Oncol. 2023;14:423-429.
Abstract
Familial Risk and Interaction With Smoking and Alcohol Consumption in Bladder
Cancer: A Population-Based Cohort Study.
World J Oncol. 2023;14:382-391.
Abstract
Integrative analysis of triphenyl phosphate: contextual interpretation of bladder
cancer cohort.
Front Oncol. 2023;13:1260114.
Abstract
Modification of lysine-260 2-hydroxyisobutyrylation destabilizes ALDH1A1
expression to regulate bladder cancer progression.
iScience. 2023;26:108142.
Abstract
Fraxetin inhibits proliferation and induces apoptosis of bladder cancer through
the Akt pathway in vitro and in vivo.
J Biochem Mol Toxicol. 2023 Oct 23:e23556. doi: 10.1002/jbt.23556.
Abstract
Systemic Immune Inflammation Index and T-Staging Predict Prognosis in Patients
with Muscle-Invasive Bladder Cancer.
Arch Esp Urol. 2023;76:511-518.
Abstract
Proteomics, Transcriptomics, and Phosphoproteomics Reveal the Mechanism of
Talaroconvolutin-A Suppressing Bladder Cancer via Blocking Cell Cycle and
Triggering Ferroptosis.
Mol Cell Proteomics. 2023 Oct 20:100672. doi: 10.1016/j.mcpro.2023.100672.
Abstract
Spatial relationship of tertiary lymphoid structures and tumor-associated
neutrophils in bladder cancer and prognostic potential for anti-PD-L1
immunotherapy.
Cancer Commun (Lond). 2023 Oct 20. doi: 10.1002/cac2.12491.
Abstract
Loperamide induces protective autophagy and apoptosis through the ROS/JNK
signaling pathway in bladder cancer.
Biochem Pharmacol. 2023;218:115870.
Abstract
EGR1/LINC00839/SOX5 axis modulates migration, invasion and Gemcitabine resistance
of bladder cancer cells.
Cancer Biol Ther. 2023;24:2270106.
Abstract
[Robot-assisted left-side partial nephrectomy with a segmental resection of left
lower ureter and Boari reconstruction].
Urologiia. 2023;:125-128.
Abstract
[Experience of using Experience of using NefroBest-N for rehabilitation of
patients undergoing radical laparoscopic cystectomy].
Urologiia. 2023;:62-68.
Abstract
[Carboxycryobiopsy and carboxycryoextraction of bladder tumor. Experimental
study].
Urologiia. 2023;:24-29.
Abstract
En bloc resection of bladder tumors (ERBT) revisited 12 years after
reintroduction: too good to be further ignored.
World J Urol. 2023;41:2577-2582.
Abstract
Immunotherapy for advanced or metastatic urothelial carcinoma.
Cochrane Database Syst Rev. 2023;10:CD013774.
Abstract
[Not Available].
Ugeskr Laeger. 2023;185:V04230244.
Abstract
Exploring potential targets of HPV&BC based on network pharmacology and urine
proteomics.
J Pharm Biomed Anal. 2023;236:115694.
Abstract
Use of concomitant proton pump inhibitors, statins or metformin in patients
treated with pembrolizumab for metastatic urothelial carcinoma: data from the
ARON-2 retrospective study.
Cancer Immunol Immunother. 2023;72:3665-3682.
Abstract
The importance of second-look ureteroscopy implementation in the conservative
management of upper tract urothelial carcinoma.
World J Urol. 2023;41:2743-2749.
Abstract
Distance to Treatment With Radical Cystectomy in a Rural State: Long Car Rides,
Equivalent Outcomes.
Urol Pract. 2023;10:588-594.
Abstract
A cost-effectiveness analysis of avelumab plus best supportive care versus best
supportive care alone as first-line maintenance treatment for patients with
locally advanced or metastatic urothelial carcinoma in Taiwan.
Cancer Rep (Hoboken). 2023;6:e1887.
Abstract
The long-term outcome of nephron-sparing surgery versus radical
nephroureterectomy for organ-localized upper urinary tract urothelial carcinoma:
a population-based study of 1969 patients.
J Cancer Res Clin Oncol. 2023;149:14869-14878.
Abstract
En bloc resection of bladder tumour: the rebirth of past through reminiscence.
World J Urol. 2023;41:2599-2606.
Abstract
Endoscopic management of upper tract urothelial cancer in a highly endemic area:
A Taiwan nationwide collaborative study.
Asian J Surg. 2023;46:3058-3065.
Abstract
The genitourinary impacts of electronic cigarette use: a systematic review of the
literature.
World J Urol. 2023;41:2637-2646.
Abstract
Letter to the editor for the article "Molecular urothelial tumor cell subtypes
remain stable during metastatic evolution".
World J Urol. 2023;41:2869-2870.
Abstract
Mutational pattern off homologous recombination repair (HRR)-related genes in
upper tract urothelial carcinoma.
Cancer Med. 2023;12:15304-15316.
Abstract
Impact of a novel immune and nutritional score on prognosis in patients with
upper urinary tract urothelial carcinoma following radical nephroureterectomy.
J Cancer Res Clin Oncol. 2023;149:10893-10909.
Abstract
Impact of Variant Histology on Oncological Outcomes in Upper Tract Urothelial
Carcinoma: Results From the ROBUUST Collaborative Group.
Clin Genitourin Cancer. 2023;21:563-568.
Abstract
A 10-year renaissance of en bloc resection of bladder tumors (ERBT): Are we
approaching the peak or is it back to the trough?
World J Urol. 2023;41:2607-2615.
Abstract
High Infiltration of CD163-Positive Macrophages in Intratumor Compartment
Predicts Poor Prognosis in Patients With Upper Urinary Tract Urothelial Carcinoma
and Radical Nephroureterectomy.
Clin Genitourin Cancer. 2023;21:e386-e393.
Abstract
Prevalence of immune-related adverse events and anti-tumor efficacy in
advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor
treatment.
Clin Transl Oncol. 2023;25:3556-3564.
Abstract
The prognosis and safety of continuous saline bladder irrigation in patients
after transurethral resection of bladder tumors: a systematic review and
meta-analysis of comparative study.
Updates Surg. 2023;75:1795-1806.
Abstract
Bladder Tumors with Multiple Cardiac Metastases, with Elevated Serum Granulocyte
Colony-Stimulating Factor.
Am J Med. 2023;136:e161-e162.
Abstract
Semi-Supervised Bladder Tissue Classification in Multi-Domain Endoscopic Images.
IEEE Trans Biomed Eng. 2023;70:2822-2833.
Abstract
Phyllodes Tumor of the Bladder in a 2-Year-Old Boy - An Exceptional Finding.
Fetal Pediatr Pathol. 2023;42:699-705.
Abstract
Malignancy-related Hypercalcemia Caused by Metameric Cutaneous Metastasis of
Parathyroid Hormone-related Protein-producing Bladder Carcinoma with Squamous
Cell Differentiation: An Autopsy Case of Cobb Syndrome.
Intern Med. 2023 Mar 1. doi: 10.2169/internalmedicine.0893.
Abstract
The DEpth of Endoscopic Perforation scale to assess intraoperative perforations
during transurethral resection of bladder tumor: subgroup analysis of a
randomized controlled trial.
World J Urol. 2023;41:2583-2589.
Abstract
Energy source comparison in en-bloc resection of bladder tumors: subanalysis of a
single-center prospective randomized study.
World J Urol. 2023;41:2591-2597.
Abstract
How do endoscopic bladder tumor resection techniques affect pathology practice?
EAU Section of Uro-Technology (ESUT) and Uropathology (ESUP) survey.
World J Urol. 2023;41:2617-2625.
Abstract
3D laparoscopic treatment of bladder cancer with pelvic multi-organ invasion: a
case report and literature review.
Front Oncol. 2023;13:1249389.
Abstract
Patient-derived organoids identify tailored therapeutic options and determinants
of plasticity in sarcomatoid urothelial bladder cancer.
NPJ Precis Oncol. 2023;7:112.
Abstract
Construction and Validation of a Prognostic Model of Metabolism-Related Genes
Driven by Somatic Mutation in Bladder Cancer.
Front Biosci (Landmark Ed). 2023;28:242.
Abstract
HER2 overexpression predicts pathological T2 stage and improved survival in de
novo muscle-invasive bladder cancer after immediate radical cystectomy: A
retrospective cohort study.
Int J Surg. 2023 Nov 2. doi: 10.1097/JS9.0000000000000859.
Abstract
Detecting Muscle Invasion of Bladder Cancer: An Application of Diffusion Kurtosis
Imaging Ratio and Vesical Imaging-Reporting and Data System.
J Magn Reson Imaging. 2023 Nov 2. doi: 10.1002/jmri.29053.
Abstract
FAM171B stabilizes vimentin and enhances CCL2-mediated TAM infiltration to
promote bladder cancer progression.
J Exp Clin Cancer Res. 2023;42:290.
Abstract
Effect of the TERT mutation on the prognosis of patients with urothelial
carcinoma: a systematic review and meta-analysis.
BMC Urol. 2023;23:177.
Abstract
[Urological Comorbidities in an HIV-Infected Patient: A Case Report].
Hinyokika Kiyo. 2023;69:299-303.
Abstract
Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle-Invasive Bladder
Cancer: Elective and Eligibility Factors Impacting Utilization.
Urol Pract. 2023 Oct 30:101097UPJ0000000000000467.
Abstract
Prognostic significance of preoperative pyuria & Neutrophil to lymphocyte ratio
in patients with non-muscle-invasive bladder cancer: A prospective cohort study.
Urologia. 2023 Nov 1:3915603231203780. doi: 10.1177/03915603231203780.
Abstract
Mathematical modeling of BCG-based bladder cancer treatment using
socio-demographics.
Sci Rep. 2023;13:18754.
Abstract
Factors Influencing Quality of Life and Functional Outcomes in Patients With
Bladder Cancer.
Cancer Control. 2023;30:10732748231212353.
Abstract
Evaluation of a Natural Language Processing Model to Identify and Characterize
Patients in the United States With High-Risk Non-Muscle-Invasive Bladder Cancer.
JCO Clin Cancer Inform. 2023;7:e2300096.
Abstract
Preclinical evaluation of bozepinib in bladder cancer cell lines: modulation of
the NPP1 enzyme.
Purinergic Signal. 2023 Oct 31. doi: 10.1007/s11302-023-09975.
Abstract
Comparative study between mitomycin C versus Bacillus Calmette-Guerin (BCG) in
high-risk non-muscle-invasive bladder cancer.
Urologia. 2023 Oct 31:3915603231206603. doi: 10.1177/03915603231206603.
Abstract
US Clinical Practice Patterns of Intravesical Chemotherapy for Bacillus
Calmette-Guerin-Unresponsive and Bacillus Calmette-Guerin-Exposed
Nonmuscle-Invasive Bladder Cancer.
Urol Pract. 2023 Oct 30:101097UPJ0000000000000481.
Abstract
Knowledge-map analysis of bladder cancer immunotherapy.
Hum Vaccin Immunother. 2023;19:2267301.
Abstract
The relationship between DNA methyltransferase 3B (DNMT3B) and miR 124-3pa
expressions in bladder cancer tissues.
Mol Biol Rep. 2023 Oct 30. doi: 10.1007/s11033-023-08818.
Abstract
The RNA m6A-Binding Protein YTHDC1 Is Downregulated and Associated With M2
Macrophage Infiltration in Muscle-Invasive Bladder Cancer.
Clin Med Insights Oncol. 2023;17:11795549231203150.
Abstract
Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy
of adoptive cell therapy in bladder cancer.
Front Immunol. 2023;14:1275375.
Abstract
Duodenal stenosis caused by locally advanced upper tract urothelial carcinoma: a
case report.
J Int Med Res. 2023;51:3000605231206958.
Abstract
Systematic oxidative stress indices predicts prognosis in patients with
urothelial carcinoma of the upper urinary tract after radical nephroureterectomy.
Eur J Med Res. 2023;28:469.
Abstract
The p38-MITOGEN-ACTIVATED PROTEIN KINASE Signaling Pathway Is Involved in
Leonurus artemisia Extract-Induced Inhibition of the Proliferation of Human
Bladder Cancer BFTC-905 Cells via G1/G0 Arrest and Causes Apoptosis In Vitro.
Pharmaceuticals (Basel). 2023;16:1338.
Abstract
Survival and Enrichment Analysis of Epithelial-Mesenchymal Transition Genes in
Bladder Urothelial Carcinoma.
Genes (Basel). 2023;14:1899.
Abstract
Artificial Intelligence Reveals Distinct Prognostic Subgroups of Muscle-Invasive
Bladder Cancer on Histology Images.
Cancers (Basel). 2023;15:4998.
Abstract
Fractionation versus Adaptation for Compensation of Target Volume Changes during
Online Adaptive Radiotherapy for Bladder Cancer: Answers from a Prospective
Registry.
Cancers (Basel). 2023;15:4933.
Abstract
Oct4 and Hypoxia Dual-Regulated Oncolytic Adenovirus Armed with shRNA-Targeting
Dendritic Cell Immunoreceptor Exerts Potent Antitumor Activity against Bladder
Cancer.
Biomedicines. 2023;11:2598.
Abstract
Serum Leptin Receptor and the rs1137101 Variant of the LEPR Gene Are Associated
with Bladder Cancer.
Biomolecules. 2023;13:1498.
Abstract
Somatic Mutation of the Non-Muscle-Invasive Bladder Cancer Associated with Early
Recurrence.
Diagnostics (Basel). 2023;13:3201.
Abstract
Reconstructing disease dynamics for mechanistic insights and clinical benefit.
Nat Commun. 2023;14:6840.
Abstract
Corrigendum to "MiR-302b regulates cell functions and acts as a potential
biomarker to predict recurrence in bladder cancer" [Life Sciences, 209 (2018)
15-23].
Life Sci. 2023 Oct 25:122169. doi: 10.1016/j.lfs.2023.122169.
Abstract
A candidate prognostic biomarker: TFEB inhibits tumor progression via elevating
CDKN1A in bladder cancer.
Int Immunopharmacol. 2023;125.
Abstract
Plasma Treatment of PDMS for Microcontact Printing (muCP) of Lectins Decreases
Silicone Transfer and Increases the Adhesion of Bladder Cancer Cells.
ACS Appl Mater Interfaces. 2023 Oct 27. doi: 10.1021/acsami.3c09195.
Abstract
Molecular Biomarkers of Bladder Cancer: A Mini-Review.
Physiol Res. 2023;72.
Abstract
Do Histology and Primary Tumor Location Influence Metastatic Patterns in Bladder
Cancer?
Curr Oncol. 2023;30:9078-9089.
Abstract
The Impact of Variant Histology in Patients with Urothelial Carcinoma Treated
with Radical Cystectomy: Can We Predict the Presence of Variant Histology?
Curr Oncol. 2023;30:8841-8852.
Abstract
Influence of the Anesthetic Technique on Circulating Extracellular Vesicles in
Bladder Cancer Patients Undergoing Radical Cystectomy: A Prospective, Randomized
Trial.
Cells. 2023;12:2503.
Abstract
Ferroptosis: An Emerging Target for Bladder Cancer Therapy.
Curr Issues Mol Biol. 2023;45:8201-8214.
Abstract
Brief Report: The Virome of Bladder Tumors Arising in People Living With HIV.
J Acquir Immune Defic Syndr. 2023;94:337-340.
Abstract
[Practical aspects of PD-L1 assessment in the treatment of urothelial carcinoma:
Consensus of the uropathology group of the SEAP].
Rev Esp Patol. 2023;56:261-270.
Abstract
PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in
metastatic urothelial carcinoma.
Oncoimmunology. 2023;12:2267744.
Abstract
Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma
in real-life clinical practice: results of a multicentric, retrospective study.
Sci Rep. 2023;13:17378.
Abstract
Nationwide Study of Real-World Treatment Patterns and Clinical Outcomes in
Patients with Metastatic Urothelial Carcinoma in Hungary.
Adv Ther. 2023;40:5475-5488.
Abstract
LncRNA UCA1 promotes pancreatic cancer cell migration by regulating mitochondrial
dynamics via the MAPK pathway.
Arch Biochem Biophys. 2023;748:109783.
Abstract
A comprehensive pan-cancer analysis of CDH5 in immunological response.
Front Immunol. 2023;14:1239875.
Abstract
Modified Tubeless Ureterocutaneostomy in High-Risk Patients After Radical
Cystectomy and its Long-Term Clinical Outcomes.
Technol Cancer Res Treat. 2023;22:15330338231192906.
Abstract
p16 expression in urothelial carcinoma: Experience from a tertiary care center in
coastal South India.
J Cancer Res Ther. 2023;19:1330-1334.
Abstract
Development and validation of a predictive model for the diagnosis of bladder
tumors using narrow band imaging.
J Cancer Res Clin Oncol. 2023;149:15867-15877.
Abstract
Correlation between androgen and estrogen receptor expression and
clinicopathologic features in carcinoma urinary bladder.
J Cancer Res Clin Oncol. 2023;149:15795-15804.
Abstract
En Bloc Resection of Bladder Tumors (ERBT) using different lasers - Hybrid and
Holmium Laser.
Int Braz J Urol. 2023;49:783-784.
Abstract
Robot-assisted radical cystectomy and ileal conduit with Hugo(TM) RAS system:
feasibility, setting and perioperative outcomes.
Int Braz J Urol. 2023;49:787-788.
Abstract
Lynch syndrome-associated upper tract urothelial carcinoma frequently occurs in
patients older than 60 years: an opportunity to revisit urology clinical
guidelines.
Virchows Arch. 2023;483:517-526.
Abstract
Application of The Paris System in neobladder washing cytology: Comparison
between the original diagnosis and correlation with histopathology.
Diagn Cytopathol. 2023;51:744-750.
Abstract
Are we on track for diagnosing high-grade urothelial carcinoma with a minimum
quantity of five malignant cells in lower tract specimens? Critical analysis of
The Paris System Quantitation Criteria.
Cancer Cytopathol. 2023;131:708-715.
Abstract
Dynamic viral integration patterns actively participate in the progression of BK
polyomavirus-associated diseases after renal transplantation.
Am J Transplant. 2023;23:1694-1708.
Abstract
From mucosal infection to successful cancer immunotherapy.
Nat Rev Urol. 2023;20:682-700.
Abstract
AFM-Based Poroelastic@Membrane Analysis of Cells and its Opportunities for
Translational Medicine.
Small. 2023;19:e2303610.
Abstract
Drug extravasation with Enfortumab vedotin.
J Oncol Pharm Pract. 2023;29:1789-1792.
Abstract
LncRNA MIR4435-2HG drives cancer progression by modulating cell cycle regulators
and mTOR signaling in stroma-enriched subtypes of urothelial carcinoma of the
bladder.
Cell Oncol (Dordr). 2023;46:1509-1527.
Abstract
An Unusual Presentation of Metastatic BK Virus-Associated Urothelial Carcinoma
Arising in the Allograft, Persisting After Transplant Nephrectomy.
Int J Surg Pathol. 2023;31:1586-1592.
Abstract
A Rare Case of Urinary Bladder Hamartoma Clinically Mimicking an Urothelial
Carcinoma: A Case Report and Review of the Literature.
Int J Surg Pathol. 2023;31:1572-1579.
Abstract
Ureteral Metastasis of Colonic Adenocarcinoma with Enteroblastic Differentiation:
A Rare Case to be Distinguished from Clear Cell Adenocarcinoma of the Urinary
Tract.
Int J Surg Pathol. 2023;31:1553-1558.
Abstract
Retracted: Computed Tomography Image Features under Deep Learning Algorithm
Applied in Staging Diagnosis of Bladder Cancer and Detection on Ceramide
Glycosylation.
Comput Math Methods Med. 2023;2023:9842436.
Abstract
Retracted: Applications of Bladder Cancer Data Using a Modified Log-Logistic
Model.
Appl Bionics Biomech. 2023;2023:9789308.
Abstract
Screening for a practical method to monitor the status of patients with
metastatic bladder cancer at the circulating cell-gene level.
Sci Rep. 2023;13:19517.
Abstract
Bladder Cancer and Artificial Intelligence: Emerging Applications.
Urol Clin North Am. 2024;51:63-75.
Abstract
LUCAT1 inhibits ferroptosis in bladder cancer by regulating the mRNA stability of
STAT3.
Gene. 2023 Nov 7:147974. doi: 10.1016/j.gene.2023.147974.
Abstract
Anoikis-associated signatures predict prognosis and immune response in bladder
cancer.
Epigenomics. 2023 Nov 9. doi: 10.2217/epi-2023-0240.
Abstract
The Prevalence of p16 Expression in Urothelial Bladder Cancer in a Tertiary Care
Hospital of Chattogram, Bangladesh.
Iran J Pathol. 2023;18:306-311.
Abstract
Depression and anxiety among patients treated for bladder cancer: examining
clinical, demographic, and psychosocial predictors.
Am J Clin Exp Urol. 2023;11:401-413.
Abstract
Application of contrast-enhanced ultrasound in renal space-occupying lesion
puncture biopsy.
BMC Med Imaging. 2023;23:178.
Abstract
Primary leiomyoma of the bladder radiologically mimicking a retroperitoneal tumor
- a case report.
J Med Invest. 2023;70.
Abstract
Quantitative transcriptomic and proteomic analysis reveals corosolic acid
inhibiting bladder cancer via suppressing cell cycle and inducing mitophagy in
vitro and in vivo.
Toxicol Appl Pharmacol. 2023 Nov 6:116749. doi: 10.1016/j.taap.2023.116749.
Abstract
The diagnostic value of fluorescence in situ hybridization in secondary
electroresection of bladder cancer.
Bladder (San Franc). 2023;10:e21200006.
Abstract
Advances in the bladder cancer research using 3D culture models.
Bladder (San Franc). 2023;10:e21200005.
Abstract
Laparoscopic and Robotic-Assisted Extended Pelvic Lymph Node Dissection for
Invasive Bladder Cancer: A Review.
Bladder (San Franc). 2023;10:e21200004.
Abstract
Alternative polyadenylation-related genetic variants contribute to bladder cancer
risk.
J Biomed Res. 2023 Nov 15:1-13. doi: 10.7555/JBR.37.20230063.
Abstract
MicroRNA-367-3p directly targets RAB23 and inhibits proliferation, migration and
invasion of bladder cancer cells and increases cisplatin sensitivity.
J Cancer Res Clin Oncol. 2023 Nov 8. doi: 10.1007/s00432-023-05484.
Abstract
POLR3G promotes EMT via PI3K/AKT signaling pathway in bladder cancer.
FASEB J. 2023;37:e23260.
Abstract
WTAP enhances the instability of SYTL1 mRNA caused by YTHDF2 in bladder cancer.
Histol Histopathol. 2023 Oct 23:18671. doi: 10.14670.
Abstract
Small-molecule nanoprodrug with high drug loading and EGFR, PI3K/AKT
dual-inhibiting properties for bladder cancer treatment.
Exploration (Beijing). 2023;3:20220141.
Abstract
Differences in clinical features between focal and extensive types of cystitis
glandularis in patients without a previous history of urinary tract malignancy.
Investig Clin Urol. 2023;64:597-605.
Abstract
Impact of rural residence on the presentation, management and survival of
patients with non-metastatic muscle-invasive bladder carcinoma.
Investig Clin Urol. 2023;64:561-571.
Abstract
The effect of immediate neoadjuvant electromotive instillation of mitomycin C
with Bacillus Calmette-Guerin versus BCG alone in non-muscle-invasive bladder
cancer: A randomized controlled trial.
Investig Clin Urol. 2023;64:554-560.
Abstract
Accuracy of Vesical Imaging-Reporting and Data System for muscle-invasive bladder
cancer detection from multiparametric magnetic resonance imaging.
Investig Clin Urol. 2023;64:546-553.
Abstract
Human amniotic membrane inhibits migration and invasion of muscle-invasive
bladder cancer urothelial cells by downregulating the FAK/PI3K/Akt/mTOR
signalling pathway.
Sci Rep. 2023;13:19227.
Abstract
The relationship between BCG immunotherapy and oxidative stress parameters in
patients with nonmuscle invasive bladder cancer.
Urol Oncol. 2023 Nov 4:S1078-1439(23)00321-6. doi: 10.1016/j.urolonc.2023.
Abstract
Radiotherapy combined with deep regional hyperthermia in elderly and frail
patients with muscle-invasive bladder cancer: quality analysis of hyperthermia
and impact on clinical results.
Int J Hyperthermia. 2023;40:2275540.
Abstract
Comparative real-world survival outcomes of muscle-invasive bladder cancer
treated with bladder-only vs. whole-pelvis concurrent chemoradiation.
Can Urol Assoc J. 2023 Oct 23. doi: 10.5489/cuaj.8386.
Abstract
A case of bladder cancer after bilateral lung transplantation following bone
marrow transplantation.
IJU Case Rep. 2023;6:471-474.
Abstract
Pretreatment PLR Is Preferable to NLR and LMR as a Predictor in Locally Advanced
and Metastatic Bladder Cancer.
Cancer Diagn Progn. 2023;3:706-715.
Abstract
Multiparametric MRI-based VI-RADS: can it predict 1- to 5-year recurrence of
bladder cancer?
Eur Radiol. 2023 Nov 6. doi: 10.1007/s00330-023-10387.
Abstract
Corrigendum to "PRMT5-activated c-Myc promote bladder cancer proliferation and
invasion through up-regulating NF-kappaB pathway" [Tissue Cell 76 (2022) 101788].
Tissue Cell. 2023 Nov 1:102221. doi: 10.1016/j.tice.2023.102221.
Abstract
Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guerin (BCG) Versus
Upfront Induction BCG After TUR in High-risk Non-muscle-invasive Bladder Cancer:
Feasibility Phase of a Randomized Controlled Study.
Eur Urol Focus. 2023 Nov 1:S2405-4569(23)00236-5. doi: 10.1016/j.euf.2023.
Abstract
High-precision bladder cancer diagnosis method: 2D Raman spectrum figures based
on maintenance technology combined with automatic weighted feature fusion
network.
Anal Chim Acta. 2023;1282:341908.
Abstract
Ipsilateral synchronous papillary renal neoplasm with reverse polarity and
urothelial carcinoma in a renal transplant recipient: a rare case report with
molecular analysis and literature review.
Diagn Pathol. 2023;18:120.
Abstract
Cancer trial results show power of weaponized antibodies.
Nature. 2023;623:231-232.
Abstract
Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.
N Engl J Med. 2023;389:1778-1789.
Abstract
A new era in the treatment of urothelial carcinoma.
Urol Oncol. 2023;41:395-397.
Abstract
Peripheral Blasts in a Patient Receiving Chemotherapy.
JAMA. 2023;330:1581-1582.
Abstract
Experts' recommendations in laser use for the treatment of upper tract urothelial
carcinoma: a comprehensive guide by the European Section of Uro-Technology (ESUT)
and Training Research in Urological Surgery and Technology (T.R.U.S.T.) group.
World J Urol. 2023;41:3367-3376.
Abstract
Perioperative, renal function and oncological outcomes of robot-assisted radical
nephroureterectomy for patients with upper tract urothelial carcinoma.
World J Urol. 2023;41:3001-3007.
Abstract
[Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for
patients with metastatic urothelial carcinoma].
Urologie. 2023;62:1193-1199.
Abstract
Preoperative urine sediment chromosomal instability level predicts urothelial
cancer prognosis.
Urol Oncol. 2023;41:433.
Abstract
Feasibility and tissue concordance of genomic sequencing of urinary cytology in
upper tract urothelial carcinoma.
Urol Oncol. 2023;41:433.
Abstract
Selective targeting of lectins and their macropinocytosis in urothelial tumours:
translation from in vitro to ex vivo.
Histochem Cell Biol. 2023;160:435-452.
Abstract
Conditional survival following radical cystectomy for urothelial carcinoma of the
bladder.
Urol Oncol. 2023;41:432.
Abstract
Differentiation of urothelial carcinoma and neuroendocrine carcinoma in the
urinary bladder based on CT texture analysis.
Asian J Surg. 2023;46:5053-5054.
Abstract
Antibody-drug conjugates for urothelial carcinoma.
Urol Oncol. 2023;41:420-428.
Abstract
Pelvic lipomatosis with mucinous adenocarcinoma: A case report and literature
review.
Asian J Surg. 2023;46:4889-4890.
Abstract
A carcinoma in situ was inadvertently discovered after surgery for urinary
bladder contracture.
Asian J Surg. 2023;46:4897-4898.
Abstract
The patient experience with localized upper tract urothelial cancer.
Urol Oncol. 2023;41:431.
Abstract
The role of perioperative chemotherapy for upper tract urothelial carcinoma
patients treated with radical nephroureterectomy.
World J Urol. 2023;41:3205-3230.
Abstract
The management of toxicities from immune, targeted and ADCs treatments in
patients with urothelial cancer.
Urol Oncol. 2023;41:410-419.
Abstract
Gene expression profiles to analyze the anticancer and carcinogenic effects of
arsenic in bladder cancer.
Am J Transl Res. 2023;15:5984-5996.
Abstract
A sialyltransferases-related gene signature serves as a potential predictor of
prognosis and therapeutic response for bladder cancer.
Eur J Med Res. 2023;28:515.
Abstract
Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The
evolving role of PD-(L)1 inhibition.
Urol Oncol. 2023 Nov 13:S1078-1439(23)00342.
Abstract
Identification and validation of a dysregulated TME-related gene signature for
predicting prognosis, and immunological properties in bladder cancer.
Front Immunol. 2023;14:1213947.
Abstract
Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive
urothelial bladder cancer: diagnostic performance and outcomes using biparametric
vs. multiparametric MRI.
Cancer Imaging. 2023;23:110.
Abstract
Engineered Macrophages Tune Intratumoral Cytokines through Precisely Controlled
Self-Pyroptosis to Enhance Bladder Cancer Immunotherapy.
Small. 2023 Nov 14:e2306699. doi: 10.1002/smll.202306699.
Abstract
Enfortumab vedotin as a salvage option as 5th line therapy for metastatic
urothelial bladder cancer.
Aktuelle Urol. 2023 Nov 14. doi: 10.1055/a-2148-5799.
Abstract
Three versus four cycles of neoadjuvant chemotherapy for muscle-invasive bladder
cancer: a systematic review and meta-analysis.
Ann Med. 2023;55:2281654.
Abstract
Identification of potential phytochemical for the inhibition of non-muscle
invasive bladder cancer (NMIBC).
J Biomol Struct Dyn. 2023 Nov 14:1-9. doi: 10.1080/07391102.2023.2280914.
Abstract
Postoperative Metachronous Metastasis of Bladder Cancer to Penis: A Case Report.
Arch Esp Urol. 2023;76:622-626.
Abstract
Exploring the Shared Gene Signatures and Molecular Mechanisms between Bladder
Urothelial Carcinoma and Metabolic Syndrome.
Arch Esp Urol. 2023;76:605-621.
Abstract
HMG co-reductase expression and response to intravesical Bacillus Calmette-Guerin
in patients with high grade non-muscle invasive urinary bladder cancer receiving
statins.
Scott Med J. 2023 Nov 13:369330231213935. doi: 10.1177/00369330231213935.
Abstract
Evidence-Based Analysis of the Critical Steps of Radical Cystectomy for Bladder
Cancer.
J Clin Med. 2023;12:6845.
Abstract
The Characterization of Non-oncologic Chronic Drug Therapy in Bladder Cancer
Patients and the Impact on Recurrence-Free and Cancer-Specific Survival: A
Prospective Study.
J Clin Med. 2023;12:6749.
Abstract
Chitinase 3-like-1 Expression in the Microenvironment Is Associated with
Neutrophil Infiltration in Bladder Cancer.
Int J Mol Sci. 2023;24:15990.
Abstract
Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for
Urological Cancers.
Int J Mol Sci. 2023;24:15795.
Abstract
Gelsolin, an Actin-Binding Protein: Bioinformatic Analysis and Functional
Significance in Urothelial Bladder Carcinoma.
Int J Mol Sci. 2023;24:15763.
Abstract
The Role of Longevity Assurance Homolog 2/Ceramide Synthase 2 in Bladder Cancer.
Int J Mol Sci. 2023;24:15668.
Abstract
Exosomal Long Non-Coding Ribonucleic Acid Ribonuclease Component of Mitochondrial
Ribonucleic Acid Processing Endoribonuclease Is Defined as a Potential
Non-Invasive Diagnostic Biomarker for Bladder Cancer and Facilitates
Tumorigenesis via the miR-206
Cancers (Basel). 2023;15:5305.
Abstract
FAM111B Acts as an Oncogene in Bladder Cancer.
Cancers (Basel). 2023;15:5122.
Abstract
A New Scoring System to Differentiate Bladder Cancer from Intravesical Prostatic
Protrusion in the Bladder Neck: BCa-IPP Score.
Curr Med Imaging. 2023 Nov 10. doi: 10.2174/0115734056241577231023064014.
Abstract
Nitrogen isotopic composition as a gauge of tumor cell anabolism-to-catabolism
ratio.
Sci Rep. 2023;13:19796.
Abstract
Status of PD-1 and PD-L1 expression in invasive urothelial carcinoma
of the bladder with mismatch repair protein deficiency.
Pol J Pathol. 2023;74:161-170.
Abstract
Identification of tryptophan metabolism- and immune-related genes signature and
prediction of immune infiltration landscape in bladder urothelial carcinoma.
Front Immunol. 2023;14:1283792.
Abstract
Initial management and survival of patients with primary metastatic bladder
cancer before the immunotherapy era: a population-based study from Norway.
Scand J Urol. 2023;58:101-108.
Abstract
Pelvic lymphadenectomy: Evaluating nodal stage migration and will rogers effect
in bladder cancer.
Urol Oncol. 2023 Nov 10:S1078-1439(23)00324.
Abstract
Identification of the role of MCM6 in bladder cancer prognosis, immunotherapy
response, and in vitro experimental investigation using multi-omics analysis.
Life Sci. 2023;335:122253.
Abstract
Collaborating single-cell and bulk RNA sequencing for comprehensive
characterization of the bladder cancer intratumor heterogeneity and prognostic
model development for bladder cancer.
Aging (Albany NY). 2023;15.
Abstract
Assessing the prognostic impact of prostatic urethra involvement and developing a
nomogram for T1 stage bladder cancer.
BMC Urol. 2023;23:182.
Abstract
Tumor microenvironment heterogeneity in bladder cancer identifies biologically
distinct subtypes predicting prognosis and anti-PD-L1 responses.
Sci Rep. 2023;13:19563.
Abstract
The vascular and morphological characteristics of tumors under narrow-band
imaging as predictors for the grade and stage of bladder cancer: a prospective
and multi-center study.
Ann Med. 2023;55:2281656.
Abstract
Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment
Landscape: Insights from Italian Experts.
Curr Oncol Rep. 2023;25:1345-1362.
Abstract
Invasive urothelial carcinoma with chordoid features or abundant myxoid stroma: A
reappraisal of morphologic spectrum and risk stratification based on molecular
classification.
Pathol Res Pract. 2023;251:154839.
Abstract
Lymph Node Dissection in Upper Tract Urothelial Carcinoma: Current Status and
Future Perspectives.
Curr Oncol Rep. 2023;25:1327-1344.
Abstract
Efficient Augmented Intelligence Framework for Bladder Lesion Detection.
JCO Clin Cancer Inform. 2023;7:e2300031.
Abstract
Robot-Assisted Repair of Ureteroenteric Strictures After Cystectomy with Urinary
Diversion: Technique Description and Outcomes from the European Robotic Urology
Section Scientific Working Group.
J Endourol. 2023;37:1209-1215.
Abstract
BK Polyomavirus-Associated Urothelial Carcinoma of the Bladder with a Background
of BK Polyomavirus Nephropathy in a Kidney Transplant Recipient.
Nephron. 2023;147 Suppl 1:53-60.
Abstract
LncRNA UCA1 could regulate the progression of neuropathic pain by regulating
miR-135a-5p.
Mutat Res. 2023;827:111833.
Abstract
Genomic Alterations of Signaling and DNA Damage Repair Pathways in Non-muscle
Invasive Bladder Cancer.
Cancer Invest. 2023 Nov 24:1-10. doi: 10.1080/07357907.2023.2288640.
Abstract
Comprehensive analysis of Transferrin receptor (TFRC): A prognostic biomarker for
patients with bladder cancer.
Asian J Surg. 2023 Nov 22:S1015-9584(23)01835.
Abstract
Health-related Quality of Life During the First 4 Years After Non-Muscle-invasive
Bladder Cancer Diagnosis: Results of a Large Multicentre Prospective Cohort.
Eur Urol Oncol. 2023 Nov 22:S2588-9311(23)00252.
Abstract
Construction and evaluation of a novel prognostic risk model of aging-related
genes in bladder cancer.
Curr Urol. 2023;17:236-245.
Abstract
Predictors of time-to-nadir serum creatinine after drainage of bilaterally
obstructed kidneys due to bladder cancer.
Curr Urol. 2023;17:246-250.
Abstract
Depth of invasion to the bladder wall as a prognostic factor and its association
with circulating cell-free DNA levels in patients with muscle-invasive bladder
cancer.
Curr Urol. 2023;17:229-235.
Abstract
The association between postvoid residual and response to standard therapy in
male and female patients with non-muscle-invasive bladder cancer.
Curr Urol. 2023;17:251-256.
Abstract
Patient-derived bladder cancer organoid model to predict sensitivity and
feasibility of tailored precision therapy.
Curr Urol. 2023;17:221-228.
Abstract
Quinolone Prophylaxis in Conjunction with Bacillus Calmette-Guerin Instillations
for Bladder Cancer: Time To Reconsider the Evidence and Open the Quinolone Box?
Eur Urol Focus. 2023 Nov 21:S2405-4569(23)00249.
Abstract
Patient reported treatment burden and attitudes towards in-home intravesical
therapy among patients with bladder cancer.
Urol Oncol. 2023 Nov 21:S1078-1439(23)00306.
Abstract
Engineering redirected NF-kappaB/OIP5 expression programs to enhance tumor responses
to chemotherapy in bladder cancer.
Sci Bull (Beijing). 2023 Nov 14:S2095-9273(23)00781.
Abstract
ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer.
Sci Adv. 2023;9:eadg2263.
Abstract
A software package for efficient patient trajectory analysis applied to analyzing
bladder cancer development.
PLOS Digit Health. 2023;2:e0000384.
Abstract
Patients With Muscle-Invasive Bladder Cancer With Lymphovascular Invasion in
Transurethral Resection Specimen Benefits Most From Platinum-Based Neoadjuvant
Chemotherapy.
Clin Genitourin Cancer. 2023 Nov 2:S1558-7673(23)00234.
Abstract
Molecular mechanism of microRNAs, long noncoding RNAs, and circular RNAs
regulating lymphatic metastasis of bladder cancer.
Urol Oncol. 2023 Nov 20:S1078-1439(23)00351.
Abstract
Impact of consensus molecular subtypes on survival with and without adjuvant
chemotherapy in muscle-invasive urothelial bladder cancer.
J Clin Pathol. 2023 Nov 21:jcp-2023-208973. doi: 10.1136/jcp-2023-208973.
Abstract
Clinical significance and immune landscape of angiogenesis-related genes in
bladder cancer.
Aging (Albany NY). 2023;15.
Abstract
Is there a promoting role for artificial sweeteners in the evolution of bladder
cancer? A meta-analysis of current literature.
Minerva Surg. 2023 Nov 21. doi: 10.23736/S2724-5691.23.10000.
Abstract
[Morphological variants of the invasive urothelial cell carcinoma.].
Orv Hetil. 2023;164:1567-1582.
Abstract
E-Cigarettes and Associated Health Risks: An Update on Cancer Potential.
Adv Respir Med. 2023;91:516-531.
Abstract
Abandoning testing for asymptomatic microscopic haematuria in Sweden - a
long-term follow-up.
Scand J Urol. 2023;58:109-114.
Abstract
Thulium fiber laser as a novel technique with shallow and accurate cutting,
high-quality hemostasis, and no ballistic effect in the treatment of non-muscle
invasive bladder cancer.
Urologia. 2023 Nov 20:3915603231211982. doi: 10.1177/03915603231211982.
Abstract
Knowledge-map analysis and bladder cancer immunotherapy: Comment.
Hum Vaccin Immunother. 2023;19:2285094.
Abstract
CircFSCN1 induces tumor progression and triggers epithelial-mesenchymal
transition in bladder cancer through augmentation of MDM2-mediated p53 silencing.
Cell Signal. 2023 Nov 17:110982. doi: 10.1016/j.cellsig.2023.110982.
Abstract
Phase II trial of Concurrent Nivolumab and Radiation therapy in Elderly or
Chemotherapy ineligible Muscle Invasive Bladder Cancer.
Int J Radiat Oncol Biol Phys. 2023 Nov 17:S0360-3016(23)08152.
Abstract
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of
Immune Checkpoint Inhibitors in Bladder Cancer.
Mol Cancer. 2023;22:185.
Abstract
METTL3 regulates the proliferation, metastasis and EMT progression of bladder
cancer through P3H4.
Cell Signal. 2023;113:110971.
Abstract
Re: Katharina Bruck, Richard P. Meijer, Joost L. Boormans, et al. Disease-free
Survival of Patients with Muscle-invasive Bladder Cancer Treated with Radical
Cystectomy Versus Bladder-preserving Therapy: A Nationwide Study. Int J Radiat
Oncol Biol Phys
Eur Urol Oncol. 2023 Nov 15:S2588-9311(23)00238.
Abstract
Radiogenomics uncovers an interplay between angiogenesis and clinical outcomes in
bladder cancer.
Environ Toxicol. 2023 Nov 17. doi: 10.1002/tox.24038.
Abstract
Young population bladder neoplasms.
Eur Rev Med Pharmacol Sci. 2023;27:10454-10461.
Abstract
A novel nomogram based on body composition and nutritional indicators to predict
the prognosis of patients with muscle-invasive bladder cancer undergoing radical
cystectomy.
Cancer Med. 2023 Nov 16. doi: 10.1002/cam4.6712.
Abstract
Geriatric assessment-derived deficit accumulation and patient-reported treatment
burden in older adults with bladder cancer.
J Am Geriatr Soc. 2023 Nov 16. doi: 10.1111/jgs.18676.
Abstract
Prognostic value of preoperative De Ritis ratio on oncological outcomes in
patients with muscle-invasive bladder cancer.
J Surg Oncol. 2023 Nov 16. doi: 10.1002/jso.27517.
Abstract
The impact of second transurethral resection on survival outcomes in patients
with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin
therapy.
Jpn J Clin Oncol. 2023 Nov 16:hyad155. doi: 10.1093.
Abstract
[Not Available].
Aktuelle Urol. 2023;54:438-440.
Abstract
[Not Available].
Aktuelle Urol. 2023;54:428-430.
Abstract
[Not Available].
Aktuelle Urol. 2023;54:428.
Abstract
Comment on: Vitamin C and catheter-related bladder discomfort after transurethral
resection of bladder tumor: A double-blind, randomized, placebo-controlled study.
J Clin Anesth. 2024;92:111273.
Abstract
miR-628-5p is a Potential Novel Prognosis Biomarker, Associated with Immune
Infiltration in Bladder Urothelial Carcinoma.
Curr Pharm Des. 2023;29:2477-2488.
Abstract
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
N Engl J Med. 2023;389:1961-1971.
Abstract
Perioperative cortical hand stroke syndrome mimicking peripheral neuropathy: a
case report.
Can J Anaesth. 2023;70:1839-1844.
Abstract
Gene of the month: GATA3.
J Clin Pathol. 2023;76:793-797.
Abstract
Harnessing potent therapies with care: enfortumab vedotin plus pembrolizumab for
advanced-stage urothelial carcinoma.
Nat Rev Clin Oncol. 2023;20:818-819.
Abstract
Deubiquitinating enzyme PSMD7 promotes bladder cancer development: Involvement of
RAB1A stabilization.
Cell Signal. 2023 Nov 29:110996. doi: 10.1016/j.cellsig.2023.110996.
Abstract
Heterogeneous MXene Hybrid-Oriented Exosome Isolation and Metabolic Profiling for
Early Screening, Subtyping and Follow-up Evaluation of Bladder Cancer.
ACS Nano. 2023 Dec 1. doi: 10.1021/acsnano.3c08391.
Abstract
SPI1-mediated CXCL12 expression in bladder cancer affects the recruitment of
tumor-associated macrophages.
Mol Carcinog. 2023 Dec 1. doi: 10.1002/mc.23663.
Abstract
Novel immunotherapeutic options for BCG-unresponsive high-risk
non-muscle-invasive bladder cancer.
Cancer Med. 2023 Dec 1. doi: 10.1002/cam4.6768.
Abstract
Corrigendum to "EGCG inhibited bladder cancer SW780 cell proliferation and
migration both in vitro and in vivo via down-regulation of NF-kappaB and MMP-9"
[Journal of Nutritional Biochemistry 41 (2017) 56-64].
J Nutr Biochem. 2023 Nov 29:109530. doi: 10.1016/j.jnutbio.2023.109530.
Abstract
Evaluation of proteolytic activity and serine proteases distribution in plasma
from patients with bladder cancer.
Front Med (Lausanne). 2023;10:1276882.
Abstract
mRNA expression of CRF family members in urothelial bladder cancer.
Oncol Lett. 2023;27:13.
Abstract
Association of obesity and different metabolic status with prognosis in patients
with bladder cancer: a retrospective cohort study.
Ther Adv Urol. 2023;15:17562872231213720.
Abstract
Evaluation of the safety and feasibility of electrochemotherapy with intravenous
bleomycin as local treatment of bladder cancer in dogs.
Sci Rep. 2023;13:21078.
Abstract
Long-term cardiovascular mortality risk in patients with bladder cancer: a
real-world retrospective study of 129,765 cases based on the SEER database.
Front Cardiovasc Med. 2023;10:1142417.
Abstract
LINC-PINT Inhibited Malignant Progression of Bladder Cancer by Targeting
miR-155-5p [Retraction].
Cancer Manag Res. 2023;15:1267-1268.
Abstract
Genetic Polymorphisms Involved in Bladder Cancer: A Global Review.
Oncol Rev. 2023;17:10603.
Abstract
m(6)A epitranscriptome analysis reveals differentially methylated transcripts
that drive early chemoresistance in bladder cancer.
NAR Cancer. 2023;5:zcad054.
Abstract
Is the Urinary and Gut Microbiome Associated With Bladder Cancer?
Clin Med Insights Oncol. 2023;17:11795549231206796.
Abstract
Metastatic bladder cancer forming a sigmoidorectal fistula after enfortumab
vedotin therapy: a case report.
Front Oncol. 2023;13:1274494.
Abstract
Comprehensive analysis of PRPF19 immune infiltrates, DNA methylation,
senescence-associated secretory phenotype and ceRNA network in bladder cancer.
Front Immunol. 2023;14:1289198.
Abstract
Clinicopathological characteristics, molecular landscape, and biomarker landscape
for predicting the efficacy of PD-1/PD-L1 inhibitors in Chinese population with
mismatch repair deficient urothelial carcinoma: a real-world study.
Front Immunol. 2023;14:1269097.
Abstract
Erratum: Transcriptional cofactor Mask2 is required for YAP-induced cell growth
and migration in bladder cancer cell: Erratum.
J Cancer. 2023;14:3521-3522.
Abstract
Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for
Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based Therapy.
Eur Urol Open Sci. 2023;57:22-29.
Abstract
[Bladder cancer : a comprehensive follow-up for an efficient and personalized
care].
Rev Med Suisse. 2023;19:2250-2253.
Abstract
[Radical cystectomy in the geriatric population. Tools for screening
postoperative complications].
Rev Med Suisse. 2023;19:2247-2249.
Abstract
Can uric acid affect the immune microenvironment in bladder cancer? A
single-center multi-omics study.
Mol Carcinog. 2023 Nov 29. doi: 10.1002/mc.23664.
Abstract
The value of ATAD3A as a potential biomarker for bladder cancer.
Cancer Med. 2023 Nov 28. doi: 10.1002/cam4.6759.
Abstract
Identifying prognostic characteristics of m6A-related glycolysis gene and
predicting the immune infiltration landscape in bladder cancer.
Cancer Cell Int. 2023;23:300.
Abstract
CD271 promotes proliferation and migration in bladder cancer.
Genes Cells. 2023 Nov 28. doi: 10.1111/gtc.13087.
Abstract
MYLK and CALD1 as molecular targets in bladder cancer.
Medicine (Baltimore). 2023;102:e36302.
Abstract
Correction: Synthetic tetracycline-controllable shRNA targeting long non-coding
RNA HOXD-AS1 inhibits the progression of bladder cancer.
J Exp Clin Cancer Res. 2023;42:321.
Abstract
Inflammatory bowel disease and bladder cancer risk: based on a Mendelian
randomization study.
BMC Urol. 2023;23:195.
Abstract
Reparameterized multiobjective control of BCG immunotherapy.
Sci Rep. 2023;13:20850.
Abstract
Identification of bladder cancer subtypes and predictive model for prognosis,
immune features, and immunotherapy based on neutrophil extracellular trap-related
genes.
Sci Rep. 2023;13:20791.
Abstract
Chronic polyradiculoneuropathy associated with pembrolizumab for bladder cancer.
Acta Neurol Belg. 2023 Nov 27. doi: 10.1007/s13760-023-02439.
Abstract
ERVK13-1/miR-873-5p/GNMT Axis Promotes Metastatic Potential in Human Bladder
Cancer though Sarcosine Production.
Int J Mol Sci. 2023;24:16367.
Abstract
Characterization of a miRNA Signature with Enhanced Diagnostic and Prognostic
Power for Patients with Bladder Carcinoma.
Int J Mol Sci. 2023;24:16243.
Abstract
Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin.
Int J Mol Sci. 2023;24:16109.
Abstract
Cell Line-Based Human Bladder Organoids with Bladder-like Self-Organization-A New
Standardized Approach in Bladder Cancer Research.
Biomedicines. 2023;11:2958.
Abstract
Multiparametric MRI in Era of Artificial Intelligence for Bladder Cancer
Therapies.
Cancers (Basel). 2023;15:5468.
Abstract
Cancer-associated fibroblasts-derived CXCL12 enhances immune escape of bladder
cancer through inhibiting P62-mediated autophagic degradation of PDL1.
J Exp Clin Cancer Res. 2023;42:316.
Abstract
The classification of the bladder cancer based on Vision Transformers (ViT).
Sci Rep. 2023;13:20639.
Abstract
Neoadjuvant Chemoradiotherapy Followed by Radical Cystectomy for Muscle-Invasive
Bladder Cancer: Analysis of Efficacy and Safety in 119 Patients.
Clin Genitourin Cancer. 2023 Nov 2:S1558-7673(23)00232.
Abstract
Association between cigarette smoke exposure and urinary bladder cancer in
Scottish terriers in a cohort study.
Vet J. 2023 Nov 22:106044. doi: 10.1016/j.tvjl.2023.106044.
Abstract
Development and validation of a nomogram for predicting suicide risk and
prognostic factors in bladder cancer patients following diagnosis: A
population-based retrospective study.
J Affect Disord. 2023;347:124-133.
Abstract
Impact of urinary diversion type on urethral recurrence following radical
cystectomy for bladder cancer: Propensity score matched and weighted analyses of
retrospective cohort.
Int J Surg. 2023 Nov 23. doi: 10.1097/JS9.0000000000000904.
Abstract
VI-RADS scoring system for predicting 1- to 5-year recurrence of bladder cancer.
Eur Radiol. 2023 Nov 24. doi: 10.1007/s00330-023-10458.
Abstract
Seminal papers in urology: maintenance Bacillus Calmette-Guerin (BCG)
immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell
carcinoma of the bladder: a randomized southwest oncology group study
(SWOG-8507).
BMC Urol. 2023;23:194.
Abstract
Omics sciences and precision medicine in Urothelial Carcinoma.
Clin Ter. 2023;174.
Abstract
Incidence, mortality and survival of transitional cell carcinoma in the urinary
system: A population-based analysis.
Medicine (Baltimore). 2023;102:e36063.
Abstract
[Not Available].
Aktuelle Urol. 2023;54:434.
Abstract
Altered p53/p16 expression is linked to urothelial carcinoma progression but
largely unrelated to prognosis in muscle-invasive tumors.
Acta Oncol. 2023;62:1880-1889.
Abstract
Risk assessment of cancer patients based on HLA-I alleles, neobinders and
expression of cytokines.
Comput Biol Med. 2023;167:107594.
Abstract
Bladder-sparing neoadjuvant therapy for MIBC.
Nat Rev Urol. 2023;20:703.
Abstract
Current trends in the promising immune checkpoint inhibition and radiotherapy
combination for locally advanced and metastatic urothelial carcinoma.
Int J Clin Oncol. 2023;28:1573-1584.
Abstract
Occupational exposures of firefighting and urinary tract cancer risk among men in
the Norwegian Fire Departments Cohort.
Occup Environ Med. 2023;80:659-666.
Abstract
Mucosal damage and gamma-H2AX formation in the rat urinary bladder induced by
aromatic amines with structures similar to o-toluidine and o-anisidine.
Arch Toxicol. 2023;97:3197-3207.
Abstract
Low-to-Moderate Arsenic Exposure and Urothelial Tract Cancers with a Long Latent
Period of Follow-Up in an Arseniasis Area.
J Epidemiol Glob Health. 2023;13:807-815.
Abstract
11-item modified frailty index and outcomes after radical cystectomy.
J Geriatr Oncol. 2023;14:101627.
Abstract
Does Chemo-Radiotherapy Improve Survival Outcomes vs. Radiotherapy Alone for
High-Grade cT1 Urothelial Carcinoma of the Bladder?
Clin Genitourin Cancer. 2023;21:653-659.
Abstract
EV-301 long-term outcomes: 24-month findings from the phase III trial of
enfortumab vedotin versus chemotherapy in patients with previously treated
advanced urothelial carcinoma.
Ann Oncol. 2023;34:1047-1054.
Abstract
Urothelial bladder carcinoma recurrence in the uterine cervix: Cytological
findings on a cervical cytology test.
Cytopathology. 2023;34:645-648.
Abstract
Clinicopathologic features and prognostic significance of mixed (Low and
high-grade) papillary urothelial carcinoma comparison with low and high-grade
papillary urothelial carcinoma.
Virchows Arch. 2023;483:621-634.
Abstract
Primary Urinary Bladder Tumors in Three Guinea Pigs (Cavia Porcellus).
Top Companion Anim Med. 2023;56-57:100805.
Abstract
Tumor contact length with bladder wall provides effective risk stratification for
lesions with a VIRADS score of 2-3.
Eur Radiol. 2023;33:8417-8425.
Abstract
Trends of Lymph Node Outcomes in Partial Cystectomy for Muscle-Invasive
Urothelial Carcinoma of the Bladder.
Clin Genitourin Cancer. 2023;21:703-709.
Abstract
Clinicopathologic and Survival After Cystectomy Outcomes in Squamous Cell
Carcinoma of the Bladder.
Clin Genitourin Cancer. 2023;21:631-638.
Abstract
HALP Score as a New Prognostic Factor for Patients with Metastatic Bladder
Cancer.
J Coll Physicians Surg Pak. 2023;33:1405-1409.
Abstract
ALOX5 deficiency contributes to bladder cancer progression by mediating
ferroptosis escape.
Cell Death Dis. 2023;14:800.
Abstract
Innate Lymphoid Cells in Bladder Cancer: From Mechanisms of Action to Immune
Therapies.
Cancer Immunol Res. 2023 Dec 7:OF1-OF12. doi: 10.1158/2326-6066.CIR-23-0414.
Abstract
Comprehensive identification of onco-exaptation events in bladder cancer cell
lines revealed L1PA2-SYT1 as a prognosis-relevant event.
iScience. 2023;26:108482.
Abstract
EIF5A2 Promotes Doxorubicin Resistance in Bladder Cancer Cells through the TGF-beta
Signaling Pathway.
Discov Med. 2023;35:1167-1176.
Abstract
Current and Potential Roles of Ferroptosis in Bladder Cancer.
Curr Med Sci. 2023 Dec 7. doi: 10.1007/s11596-023-2814.
Abstract
Vesical imaging reporting and data system (VI-RADS) could predict the survival of
bladder-cancer patients who received radical cystectomy.
Sci Rep. 2023;13:21502.
Abstract
Identification of a novel ferroptosis-inducing micropeptide in bladder cancer.
Cancer Lett. 2023 Dec 4:216515. doi: 10.1016/j.canlet.2023.216515.
Abstract
C15:0 and C17:0 partially mediate the association of milk &dairy products with
bladder cancer risk.
J Dairy Sci. 2023 Dec 4:S0022-0302(23)00830-5. doi: 10.3168/jds.2023-24186.
Abstract
Recurrence of non-muscle invasive bladder carcinoma after transurethral resection
with hexaminolevulinate photodynamic diagnosis or regular cystoscopy.
Scand J Urol. 2023;58:120-125.
Abstract
Preoperative systemic immune-inflammation index as a prognostic indicator for
patients with urothelial carcinoma.
Front Immunol. 2023;14:1275033.
Abstract
Oncological impact of perioperative blood transfusion in bladder cancer patients
undergoing radical cystectomy: Do we need to consider storage time of blood
units, donor age, or gender matching?
Transfusion. 2023 Dec 6. doi: 10.1111/trf.17618.
Abstract
Clinical Effect of the Combination of Compound Kushen Injection and Gemcitabine
on Postoperative Patients with Non-Muscle Invasive Bladder Cancer and Its
Influence on Serum-Related Factors.
Arch Esp Urol. 2023;76:657-665.
Abstract
Metabolic changes preceding bladder cancer occurrence among Korean men: a nested
case-control study from the KCPS-II cohort.
Cancer Metab. 2023;11:23.
Abstract
Integrative approach for classifying male tumors based on DNA methylation 450K
data.
Math Biosci Eng. 2023;20:19133-19151.
Abstract
Erratum to: ARID1A Inactivation Increases Expression of circ0008399 and Pro-motes
Cisplatin Resistance in Bladder Cancer.
Curr Med Sci. 2023 Dec 4. doi: 10.1007/s11596-023-2819.
Abstract
Hub biomarkers in ultrasound-guided bladder cancer and osteosarcoma: Myosin light
chain kinase and caldesmon.
Medicine (Baltimore). 2023;102:e36414.
Abstract
Development of a prognostic model to predict BLCA based on anoikis-related gene
signature: preliminary findings.
BMC Urol. 2023;23:199.
Abstract
Effect and Mechanism of Curdione Combined with Gemcitabine on Migration and
Invasion of Bladder Cancer.
Biochem Genet. 2023 Dec 5. doi: 10.1007/s10528-023-10584.
Abstract
Bladder Preservation and Immunotherapy: Rebel Without A Cause?
Int J Radiat Oncol Biol Phys. 2024;118:50-51.
Abstract
Trimodal Therapy Using an MR-guided Radiation Therapy Partial Bladder Tumor Boost
in Muscle Invasive Bladder Cancer.
Adv Radiat Oncol. 2023;8:101268.
Abstract
Delayed Recurrence of Gall Bladder Cancer as Port-site Metastases with Occult
Primary Detected on Fluorodeoxyglucose Positron Emission Tomography-Computed
Tomography: A Tale of Two Cases.
Indian J Nucl Med. 2023;38:273-275.
Abstract
Inflection points in urology as witnessed by Mark Soloway. Part 1: bladder
cancer.
Cent European J Urol. 2023;76:263-268.
Abstract
Framework for a living systematic review and meta-analysis for the surgical
treatment of bladder cancer: introducing EVIglance to urology.
Int J Surg Protoc. 2023;27:9-15.
Abstract
Bladder cancer risk stratification with the Oncuria 10-plex bead-based urinalysis
assay using three different Luminex xMAP instrumentation platforms.
Res Sq. 2023 Nov 25:rs.3.rs-3635581. doi: 10.21203/rs.3.rs-3635581.
Abstract
Boosting chemotherapy of bladder cancer cells by ferroptosis using intelligent
magnetic targeting nanoparticles.
Colloids Surf B Biointerfaces. 2023;234:113664.
Abstract
Use of in vivo Raman spectroscopy and cryoablation for diagnosis and treatment of
bladder cancer.
Spectrochim Acta A Mol Biomol Spectrosc. 2023;308:123707.
Abstract
Does Bladder Cancer Subtype Influence Pathologic Complete Response (pCR) and
Pelvic Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Response Evaluation
After Neoadjuvant Chemotherapy? Pathological Perspective.
Clin Genitourin Cancer. 2023 Nov 10:S1558-7673(23)00240.
Abstract
Quality of life after definitive treatment for bladder cancer: A systematic
review and meta-analysis.
Radiother Oncol. 2023;190:110038.
Abstract
Co-delivery of oxaliplatin prodrug liposomes with Bacillus Calmette-Guerin for
chemo-immunotherapy of orthotopic bladder cancer.
J Control Release. 2023;365:640-653.
Abstract
Autophagy modulation changes mechano-chemical sensitivity of T24 bladder cancer
cells.
Biomed Pharmacother. 2023;170:115942.
Abstract
Prognostic significance and immunoinfiltration analysis of genes associated with
epithelial-mesenchymal transition and energy metabolism in bladder urothelial
carcinoma.
Aging (Albany NY). 2023;15:13312-13328.
Abstract
The complementary and alternative roles of elemene injection in cancer: An
umbrella review.
Pharmacol Res. 2023;198:107007.
Abstract
Positioning the role of urine cytology within the diagnostic pathway for UTUC:
supportive but inconclusive.
World J Urol. 2023;41:3429-3435.
Abstract
Nephron-sparing ureteroscopic surgery vs. radical nephroureterectomy: comparable
survival-outcomes in upper tract urothelial carcinoma.
World J Urol. 2023;41:3585-3591.
Abstract
Influence of preoperative body mass index on prognosis for patients with upper
urinary tract urothelial carcinoma treated with radical nephroureterectomy.
World J Urol. 2023;41:3575-3583.
Abstract
Rational peri-operative management of antithrombotic therapy in patients
undergoing radical cystectomy: A 30-day morbidity analysis based on the updated
European Association of Urology guidelines for standardized complication
reporting.
Eur J Surg Oncol. 2023;49:107123.
Abstract
Eliminating the routine use of postoperative drain placement in patients
undergoing robotic-assisted radical cystectomy with intracorporeal urinary
diversion.
Urol Oncol. 2023;41:457.
Abstract
Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination
with a TLR3-Specific Adjuvant.
Cancer Immunol Res. 2023;11:1656-1670.
Abstract
Comparative Effectiveness Analysis of Treatment Strategies for Surgically
Resectable Neuroendocrine Carcinoma of the Urinary Tract.
Eur Urol Oncol. 2023;6:611-620.
Abstract
Consultation on UTUC II Stockholm 2022: diagnostic and prognostic methods-what's
around the corner?
World J Urol. 2023;41:3405-3411.
Abstract
Patient-specific targeted analysis of circulating tumour DNA in plasma is
feasible and may be a potential biomarker in UTUC.
World J Urol. 2023;41:3421-3427.
Abstract
Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and
Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract
urothelial cancer: the iNDUCT trial (NCT04617756).
World J Urol. 2023;41:3413-3420.
Abstract
Sequential intravesical gemcitabine/docetaxel provides a durable remission in
recurrent high-risk NMIBC following BCG therapy.
Urol Oncol. 2023;41:458.
Abstract
Consultation on UTUC II Stockholm 2022: diagnostics, prognostication, and
follow-up-where are we today?
World J Urol. 2023;41:3395-3403.
Abstract
Incidence and predictors of deep incisional and organ/space surgical site
infection following radical cystectomy.
Urol Oncol. 2023;41:455.
Abstract
Racial and sex differences in tumor genomics in urothelial carcinoma.
Urol Oncol. 2023;41:456.
Abstract
Diagnostic validity of the vesical imaging-reporting and data system (VI-RADS): a
real-world study.
Actas Urol Esp (Engl Ed). 2023;47:638-644.
Abstract
Mitomycin Gel (UGN-101) as a Kidney-sparing Treatment for Upper Tract Urothelial
Carcinoma in Patients with Imperative Indications and High-grade Disease.
Eur Urol Focus. 2023;9:807-812.
Abstract
Surgical treatment of urachal remnants in an adult population-a single-centre
experience.
Ir J Med Sci. 2023;192:3023-3027.
Abstract
Lower Detrusor Apron-sparing Robot-assisted Radical Cystectomy and Intracorporeal
Neobladder Reconstruction: Technique and Preliminary Outcomes.
Eur Urol Focus. 2023;9:760-764.
Abstract
The causal relationship between osteoarthritis and bladder cancer: A Mendelian
randomization study.
Cancer Med. 2023 Dec 15. doi: 10.1002/cam4.6829.
Abstract
Assessment of Prostate and Bladder Cancer Genomic Biomarkers Using Artificial
Intelligence: a Systematic Review.
Curr Urol Rep. 2023 Dec 15. doi: 10.1007/s11934-023-01193.
Abstract
Assessment of aggressive bladder cancer mutations in plasma cell-free DNA.
Front Oncol. 2023;13:1270962.
Abstract
DOK7, a target of miR-299-5p, suppresses the progression of bladder cancer.
Aging (Albany NY). 2023;15.
Abstract
An estimation of physiochemical properties of bladder cancer drugs via
degree-based chemical bonding topological descriptors.
J Biomol Struct Dyn. 2023 Dec 14:1-9. doi: 10.1080/07391102.2023.2292792.
Abstract
Global research trends of the application of artificial intelligence in bladder
cancer since the 21st century: a bibliometric analysis.
Front Oncol. 2023;13:1227152.
Abstract
Retracted: CASC1 Expression in Bladder Cancer Is Regulated by Exosomal miRNA-150:
A Comprehensive Pan-Cancer and Bioinformatics Study.
Comput Math Methods Med. 2023;2023:9867274.
Abstract
Deep learning signature based on multiphase enhanced CT for bladder cancer
recurrence prediction: a multi-center study.
EClinicalMedicine. 2023;66:102352.
Abstract
Cuproptosis-related long noncoding RNAs predicts overall survival and reveal
immune microenvironment of bladder cancer.
Heliyon. 2023;9:e21153.
Abstract
INTEGRATING NOVEL IMMUNOTHERAPEUTIC APPROACHES IN ORGAN-PRESERVING THERAPIES FOR
BLADDER CANCER.
Br J Pharmacol. 2023 Dec 13. doi: 10.1111/bph.16300.
Abstract
MM-SFENet: multi-scale multi-task localization and classification of bladder
cancer in MRI with spatial feature encoder network.
Phys Med Biol. 2023 Dec 13. doi: 10.1088/1361-6560/ad1548.
Abstract
The values of HER-2 expression in the non-muscle-invasive bladder cancer: a
retrospective clinical study.
Front Oncol. 2023;13:1243118.
Abstract
Symptom management and nursing interventions for postoperative bladder
instillation chemotherapy in bladder cancer patients.
Minerva Surg. 2023 Dec 13. doi: 10.23736/S2724-5691.23.10162.
Abstract
Interruptions in bladder cancer care during the COVID-19 public health emergency.
Urol Oncol. 2023 Dec 11:S1078-1439(23)00362.
Abstract
Investigating the prognostic value of mTORC1 signaling in bladder cancer via
bioinformatics evaluation.
Sci Rep. 2023;13:22066.
Abstract
Upper Urinary Tract Urothelial Cancer After Radical Cystectomy for Bladder
Cancer: Survival Outcomes After Radical Nephroureterectomy.
Ann Surg Oncol. 2023 Dec 12. doi: 10.1245/s10434-023-14710.
Abstract
Advanced bladder cancer management: history in the making.
Future Oncol. 2023 Dec 12. doi: 10.2217/fon-2023-0908.
Abstract
G3BP1 and SLU7 Jointly Promote Immune Evasion by Downregulating MHC-I via
PI3K/Akt Activation in Bladder Cancer.
Adv Sci (Weinh). 2023 Dec 12:e2305922. doi: 10.1002/advs.202305922.
Abstract
Early-stage diagnosis of bladder cancer using surface-enhanced Raman spectroscopy
combined with machine learning algorithms in a rat model.
Biosens Bioelectron. 2023;246:115915.
Abstract
Retracted: Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for
Preventing Non-Muscle-Invasive Bladder Cancer Recurrence.
J Healthc Eng. 2023;2023:9801404.
Abstract
Retracted: Effects of Nursing Care for the Treatment of Patients with Bladder
Cancer: A Systematic Review and Meta-analysis.
Comput Math Methods Med. 2023;2023:9876720.
Abstract
A Spatial Comparison of Molecular Features Associated with Resistance to
Pembrolizumab in BCG Unresponsive Bladder Cancer.
medRxiv. 2023 Nov 29:2023.11.28.23299093. doi: 10.1101/2023.11.28.23299093.
Abstract
Assessment tool based on fatty acid metabolic signatures for predicting the
prognosis and treatment response in bladder cancer.
Heliyon. 2023;9:e22768.
Abstract
Trimodal therapy versus radical cystectomy for cT2N0M0 urothelial muscle-invasive
bladder cancer: Single-center experience.
Urol Ann. 2023;15:406-411.
Abstract
Bacille Calmette-Guerin preparation and intravesical administration to patients
with bladder cancer: Risks to healthcare personnel and patients, and mitigation
strategies.
Infect Control Hosp Epidemiol. 2023 Dec 11:1-6. doi: 10.1017/ice.2023.
Abstract
A new immune-related gene signature predicts the prognosis and immune escape of
bladder cancer.
Cancer Biomark. 2023 Nov 7. doi: 10.3233/CBM-230190.
Abstract
Tumor-derived exosomal miR-1247-3p promotes angiogenesis in bladder cancer by
targeting FOXO1.
Cancer Biol Ther. 2024;25:2290033.
Abstract
Does the Presence of Heavy Metals Influence the Gene Expression and Oxidative
Stress in Bladder Cancer?
Biol Trace Elem Res. 2023 Dec 11. doi: 10.1007/s12011-023-03950.
Abstract
Identification and validation of telomerase related lncRNAs signature to predict
prognosis and tumor immunotherapy response in bladder cancer.
Sci Rep. 2023;13:21816.
Abstract
MicroRNA-152 specifically targets kinesin family member 14 to suppress the
advancement of bladder cancer cells via PI3K/AKT pathway.
Biochem Biophys Res Commun. 2023;692:149337.
Abstract
Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive
Bladder Cancer.
Int J Mol Sci. 2023;24:16578.
Abstract
Identification of SPP1 as a Prognostic Biomarker and Immune Cells Modulator in
Urothelial Bladder Cancer: A Bioinformatics Analysis.
Cancers (Basel). 2023;15:5704.
Abstract
Adaptation Time as a Determinant of the Dosimetric Effectiveness of Online
Adaptive Radiotherapy for Bladder Cancer.
Cancers (Basel). 2023;15:5629.
Abstract
Immune Predictors of Response after Bacillus Calmette-Guerin Treatment in
Non-Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2023;15:5554.
Abstract
Bladder Cancer and Probiotics: What Do We Know So Far?
Cancers (Basel). 2023;15:5551.
Abstract
CD4, CD20 and PD-L1 as Markers of Recurrence in Non-Muscle-Invasive Bladder
Cancer.
Cancers (Basel). 2023;15:5529.
Abstract
Clinical efficacy and safety of percutaneous drainage for post-operative fluid
collection in patients with bladder cancer undergoing radical cystectomy and
urinary diversion.
Medicine (Baltimore). 2023;102:e36488.
Abstract
A "One Arrow Three Eagle" Strategy to Improve CM-272 Primed Bladder Cancer
Immunotherapy.
Adv Mater. 2023 Dec 8:e2310522. doi: 10.1002/adma.202310522.
Abstract
Multiple programmed cell death patterns and immune landscapes in bladder cancer:
Evidence based on machine learning and multi-cohorts.
Environ Toxicol. 2023 Dec 8. doi: 10.1002/tox.24066.
Abstract
Hypoxia is correlated with the tumor immune microenvironment: Potential
application of immunotherapy in bladder cancer.
Cancer Med. 2023 Dec 8. doi: 10.1002/cam4.6617.
Abstract
[Significance of TERT promoter mutation in differential diagnosis of non-invasive
inverted urothelial lesions of bladder].
Zhonghua Bing Li Xue Za Zhi. 2023;52:1216-1222.
Abstract
Enhancing the image quality of blue light cystoscopy through green-hue correction
and fogginess removal.
Sci Rep. 2023;13:21484.
Abstract
Ileal conduit to small intestine fistula following extensive abdominopelvic
resection and radiation for metastatic colon cancer.
BMJ Case Rep. 2023;16:e254170.
Abstract
Comparison of neoadjuvant and adjuvant chemotherapy for upper tract urothelial
carcinoma in real-world practice: a multicenter retrospective study.
Jpn J Clin Oncol. 2023;53:1208-1214.
Abstract
Comparing trimodal therapy with radical cystectomy in muscle-invasive bladder
cancer: an updated meta-analysis.
Front Surg. 2023;10:1276746.
Abstract
Overexpression of MTHFD2 represents an inflamed tumor microenvironment and
precisely predicts the molecular subtype and immunotherapy response of bladder
cancer.
Front Immunol. 2023;14:1326509.
Abstract
The Use of Hospital Services by Patients With Muscle Invasive Bladder Cancer in
the Last Year of Life: Identifying the Areas to Improve Care.
Cureus. 2023;15:e49175.
Abstract
Effect of subsequent bladder cancer on survival in upper tract urothelial
carcinoma patients post-radical nephroureterectomy: a systematic review and
meta-analysis.
BMC Urol. 2023;23:212.
Abstract
Author Correction: Theophylline controllable RNAi-based genetic switches regulate
expression of lncRNA TINCR and malignant phenotypes in bladder cancer cells.
Sci Rep. 2023;13:22896.
Abstract
Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and
predictive factors in bladder cancer and to generate real-world data on treatment
patterns, resource use and quality of life.
BMJ Open. 2023;13:e075942.
Abstract
[Overall survival and cancer-specific mortality in patients with very high-risk
non-muscle-invasive bladder cancer (NMIBC) : Retrospective analysis of a US
American single-center cohort].
Urologie. 2023 Dec 21. doi: 10.1007/s00120-023-02252.
Abstract
Letter to the editor for the article "Does the urinary microbiome profile change
after treatment of bladder cancer?".
World J Urol. 2023;42:2.
Abstract
Perioperative and oncological outcomes of distal ureter management during
nephroureterectomy for upper urinary tract urothelial carcinoma: a systematic
review and meta-analysis.
Minerva Urol Nephrol. 2023;75:672-682.
Abstract
Retracted: Comparative Analysis of the Efficacy of Transurethral Bipolar Plasma
Needle Electrode and Ring Electrode in the Treatment of Non-Muscle-Invasive
Bladder Cancer.
Comput Intell Neurosci. 2023;2023:9824189.
Abstract
Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance
in bladder cancer.
Chem Biol Interact. 2023 Dec 18:110840. doi: 10.1016/j.cbi.2023.110840.
Abstract
Quality of care perceived by patients during cystoscopy and affecting factors.
Medicine (Baltimore). 2023;102:e36314.
Abstract
Bioinformatics analysis of CMTM family in pan-cancer and preliminary exploration
of CMTM6 in bladder cancer.
Cell Signal. 2023 Dec 17:111012. doi: 10.1016/j.cellsig.2023.111012.
Abstract
Real-world data of atezolizumab in patients with previously treated locally
advanced or metastatic urothelial bladder cancer.
Int J Clin Pharm. 2023 Dec 19. doi: 10.1007/s11096-023-01667.
Abstract
Comparative assessment of disease recurrence after transurethral resection of
non-muscle-invasive bladder cancer with and without a photodynamic diagnosis
using 5-aminolevulinic acid: a propensity score-matching analysis.
Int J Clin Oncol. 2023 Dec 19. doi: 10.1007/s10147-023-02447.
Abstract
A case series of urinary bladder rhabdomyosarcoma in seven dogs.
Open Vet J. 2023;13:1498-1503.
Abstract
Targeted therapies in bladder cancer: signaling pathways, applications, and
challenges.
MedComm (2020). 2023;4:e455.
Abstract
Analysis of prognostic factors in patients diagnosed with bladder cancer
complicated by hemorrhage treated by drug-eluting bead embolization.
Transl Androl Urol. 2023;12:1697-1707.
Abstract
Recurring cystitis cystica and cystitis glandularis masquerading as urothelial
carcinoma.
Can J Urol. 2023;30:11752-11755.
Abstract
Impact of COVID-19 pandemic on ambulatory urologic oncology surgeries.
Can J Urol. 2023;30:11714-11723.
Abstract
Author Correction: Screening for a practical method to monitor the status of
patients with metastatic bladder cancer at the circulating cell-gene level.
Sci Rep. 2023;13:22350.
Abstract
Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune
responses that correlate with safety and may be associated to therapy potential.
J Immunother Cancer. 2023;11:e008020.
Abstract
The cancer physician who helped to deliver a life-extending treatment.
Nature. 2023;624:508.
Abstract
[Thoracic Endovascular Aortic Repair for Mycotic Thoracic Aortic Aneurysm After
BCG Intravesical Therapy].
Kyobu Geka. 2023;76:1083-1089.
Abstract
Postradical cystectomy delayed urethral recurrence: a rare presentation posing
diagnostic dilemma.
BMJ Case Rep. 2023;16:e256700.
Abstract
The role of HIF in angiogenesis, lymphangiogenesis, and tumor microenvironment in
urological cancers.
Mol Biol Rep. 2023;51:14.
Abstract
Quest to develop a standard screening method for urothelial carcinoma using
liquid-based cytology (The Paris System) and CK20.
Indian J Pathol Microbiol. 2023;66:720-726.
Abstract
The expression of SP263 in muscle invasive bladder carcinoma and its relationship
with clinicopathological features.
Indian J Pathol Microbiol. 2023;66:702-707.
Abstract
Koopman-based Impulsive Model Predictive Control of BCG Immunotherapy.
Annu Int Conf IEEE Eng Med Biol Soc. 2023;2023:1-4.
Abstract
[High expression of long noncoding RNA UCA1 promotes invasion, migration and
epithelial-mesenchymal transition of trophoblasts in vitro].
Nan Fang Yi Ke Da Xue Xue Bao. 2023;43:1984-1988.
Abstract
Tumor-killing viruses score rare success in late-stage trial.
Science. 2023;382:1101-1102.
Abstract
Preoperative optimization of the radical cystectomy patient: Current state and
future directions.
J Surg Oncol. 2024;129:138-144.
Abstract
Development and validation of a nomogram based on geriatric nutritional risk
index for predicting prognosis and postoperative complications in surgical
patients with upper urinary tract urothelial carcinoma.
J Cancer Res Clin Oncol. 2023;149:18185-18200.
Abstract
Canine urothelial carcinoma: a pilot study of microRNA detection in
formalin-fixed, paraffin-embedded tissue samples and in normal urine.
J Vet Diagn Invest. 2024;36:70-77.
Abstract
Role of Contrast-Enhanced Ultrasound With the Enhancement Pattern and Qualitative
Analysis for Differentiating Hypovascular Solid Renal Lesions.
Ultrasound Med Biol. 2024;50:295-303.
Abstract
The efficacy and safety of chemotherapy with or without anti-PD-1 for the
first-line treatment of advanced urothelial carcinoma.
Cancer Med. 2023;12:21129-21137.
Abstract
Molecular characterization of plasmacytoid urothelial carcinoma and the impact on
treatment implications.
Cancer Treat Res Commun. 2023;37:100779.
Abstract
Optimal interval timing between transurethral resection of bladder tumors and
Bacillus Calmette-Guerin perfusion.
Cancer Med. 2023;12:21279-21286.
Abstract
Progress in systemic therapy for advanced-stage urothelial carcinoma.
Nat Rev Clin Oncol. 2024;21:8-27.
Abstract
Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1
inhibitors for patients with locally advanced or metastatic urothelial carcinoma:
A multicenter, retrospective clinical study.
Cancer Med. 2023;12:21159-21171.
Abstract
Bone targeting agents, but not radiation therapy, improves survival in patients
with bone metastases from advanced urothelial carcinoma receiving pembrolizumab:
results from the ARON-2 study.
Clin Exp Med. 2023;23:5413-5422.
Abstract
UC Trials Get Standing Ovation.
Cancer Discov. 2023;13:2496.
Abstract
Budgetary Impact of Including the Urinary Genomic Marker Cxbladder Detect in the
Evaluation of Microhematuria Patients.
Urol Pract. 2024;11:54-60.
Abstract
The effect of body mass index on quality of life in modified single stoma
cutaneous ureterostomy or ileal conduit after radical cystectomy.
Cancer Med. 2023;12:20930-20939.
Abstract
Predictive models of long-term survival outcomes following radical cystectomy.
Cancer Med. 2023;12:21118-21128.
Abstract
HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder
(aBSCC): A comprehensive genomic profiling (CGP) study.
Urol Oncol. 2023;41:486.
Abstract
PDGFRA exhibits potential as an indicator of angiogenesis within the tumor
microenvironment and is up-regulated in BLCA.
Microvasc Res. 2024;151:104614.
Abstract
Case-control matching-guided exposure-efficacy relationship for avelumab in
patients with urothelial carcinoma.
CPT Pharmacometrics Syst Pharmacol. 2023;12:2001-2012.
Abstract
Inflammatory myofibroblastic tumors of the bladder in a 20-year-old female.
Asian J Surg. 2023;46:5567-5568.
Abstract
Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict
outcome of pembrolizumab.
Cancer Sci. 2023;114:4622-4631.
Abstract
Development of a nomogram for predicting overall survival in patients with
urinary bladder carcinoma in situ based on SEER database analysis.
Asian J Surg. 2023;46:6015-6017.
Abstract
Large cell neuroendocrine carcinoma of the urinary bladder: A case report and
literature review.
Asian J Surg. 2023;46:6049-6050.
Abstract
Genetic testing and innovative surgery for familial urinary bladder
paraganglioma: Report of two cases and literature review.
Asian J Surg. 2023;46:6053-6055.
Abstract
Primary pure bladder large cell neuroendocrine carcinoma: A case report.
Asian J Surg. 2023;46:5454-5455.
Abstract
Synchronous renal pelvic urothelial carcinoma and oncocytoma: A case report.
Asian J Surg. 2023;46:5952-5953.
Abstract
The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta/T1
urothelial carcinoma before and after BCG treatment.
Urol Oncol. 2023;41:486.
Abstract
High grade urothelial carcinoma in kidney transplant patients with a history of
BK viremia - Just a coincidence?
Clin Transplant. 2023 Aug 31:e15113. doi: 10.1111/ctr.15113.
Abstract
Impact of pathological response on oncological outcomes in patients with upper
tract urothelial cancer receiving neo-adjuvant chemotherapy.
J Formos Med Assoc. 2023;122:1274-1281.
Abstract
Immunotherapy for advanced urothelial carcinoma (UC): rational and current
evidence.
Ann Palliat Med. 2023;12:1345-1354.
Abstract
Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer
Patients Treated With Immune Checkpoint Inhibitors.
Oncologist. 2023;28:1072-1078.
Abstract
Route of Administration for UGN-101 and Impact on Oncological and Safety
Outcomes.
Eur Urol Focus. 2023;9:1052-1058.
Abstract
Complications After Radical Cystectomy: A Systematic Review and Meta-analysis of
Randomized Controlled Trials with a Meta-regression Analysis.
Eur Urol Focus. 2023;9:920-929.
Abstract
Disseminated Bacillus Calmette-Guerin Infection with Rhabdomyolysis, Acute Kidney
Injury, and Interstitial Pneumonia after Bacillus Calmette-Guerin Intravesical
Instillation Therapy.
Intern Med. 2023;62:3707-3712.
Abstract
For Which Patients Should Bladder Preservation Be Considered After a Complete
Response to Neoadjuvant Chemotherapy.
Eur Urol Focus. 2023;9:900-902.
Abstract
Investigating the inhibitory and penetrating properties of three novel anticancer
and antimicrobial scorpion peptides via molecular docking and molecular dynamic
simulation.
J Biomol Struct Dyn. 2023;41:15354-15385.
Abstract
Correlation between PD-L1 expression of the tumour cells and lymphocytes
infiltration in the invasive front of urothelial carcinoma.
J Clin Pathol. 2023;77:61-67.
Abstract
Unusual Cervical Lymph Node Metastasis of Papillary Urothelial Carcinoma.
Ear Nose Throat J. 2024;103:NP4-NP6.
Abstract
Environmental and Occupational Exposures and Prognosis in Patients with
Non-Muscle Invasive Bladder Cancer in the Be-Well Study.
Am J Epidemiol. 2023 Dec 5:kwad236. doi: 10.1093.
Abstract
Artesunate Exhibits Synergy With Cisplatin and Cytotoxicity for Upper Tract and
Bladder Urothelial Carcinoma Cells.
Anticancer Res. 2023;43:1175-1184.
Abstract
First-line Chemotherapy Response Is Associated With Clinical Outcome During
Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real
World Retrospective Study.
Anticancer Res. 2023;43:1331-1339.
Abstract
Effect of Adjuvant Systemic Chemotherapy on Intravesical Recurrence After Radical
Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma.
Anticancer Res. 2023;43:1725-1730.
Abstract
Expression of Eukaryotic Translation Initiation Factors in the Urothelial
Carcinoma of the Bladder.
Anticancer Res. 2023;43:1437-1448.
Abstract
The Regulatory Role of Nuclear Respiratory Factor 1 in Bladder Cancer Cells.
Anticancer Res. 2023;43:1521-1531.
Abstract
Efficacy and Tolerability of Second-line Pembrolizumab With Radiation Therapy in
Advanced Urothelial Carcinoma.
Anticancer Res. 2023;43:2119-2126.
Abstract
Factors Related to Overactive Bladder-like Symptoms in Bladder Cancer.
Anticancer Res. 2023;43:3607-3613.
Abstract
Investigation on the Usefulness of Photodynamic Diagnosis-assisted Targeted
Bladder Biopsy: Japanese Real-world Study.
Anticancer Res. 2023;43:3615-3621.
Abstract
Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial
Carcinoma: Early Experience in the Real World.
Anticancer Res. 2023;43:4055-4060.
Abstract
Comparison of Testosterone Level of Seminal Vesicle Fluid in Patients With
Prostate Cancer Versus Other Malignancies.
Anticancer Res. 2023;43:4249-4254.
Abstract
PD-L1 mRNA Detection in Immunohistochemically Negative Patients: A Complementary
Method for a Better Treatment Selection?
Anticancer Res. 2023;43:4365-4371.
Abstract
Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in
Treatment Outcomes According to the Primary Site.
Anticancer Res. 2023;43:5041-5050.
Abstract
Organ-specific Tumor Response to Avelumab Maintenance Therapy for Advanced
Urothelial Carcinoma: A Multicenter Retrospective Study.
Anticancer Res. 2023;43:5689-5698.
Abstract
Clinical presentation of bacille Calmette-Guerin (BCG) infections after BCG
instillation therapy.
BJU Int. 2023;131:306-312.
Abstract
Letter to the editor regarding the article 'Do we need repeat transurethral
resection after en-bloc resection for pathological T1 bladder cancer?
BJU Int. 2023 Mar 10. doi: 10.1111/bju.16005.
Abstract
Intravesical Oncolytic Virotherapy and Immunotherapy for Non-Muscle Invasive
Bladder Cancer Mouse Model.
BJU Int. 2023 Mar 24. doi: 10.1111/bju.16012.
Abstract
Antegrade administration of mitomycin gel for upper tract urothelial carcinoma
via percutaneous nephrostomy tube: a multi-institutional retrospective cohort
study.
BJU Int. 2023;131:471-476.
Abstract
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial
carcinoma.
BJU Int. 2023;131:477-485.
Abstract
Inflammatory Markers and Type 2 Diabetes as Prognostic Risk Factors in Low-Risk
Bladder Cancer.
BJU Int. 2023 Apr 5. doi: 10.1111/bju.16026.
Abstract
Reply to Huseyin Besiroglu's Letter to the editor regarding the article 'Do we
need repeat transurethral resection after en-bloc resection for pathological T1
bladder cancer?'.
BJU Int. 2023 Apr 24. doi: 10.1111/bju.16035.
Abstract
Oncological and safety profiles in patients undergoing simultaneous transurethral
resection (TUR) of bladder tumour and TUR of the prostate.
BJU Int. 2023;131:571-580.
Abstract
Financial toxicity from newly approved second-/third-line agents in metastatic
urothelial carcinoma.
BJU Int. 2023;131:691-693.
Abstract
Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral
cancers: real-world findings from NHS England between 2013 and 2019.
BJU Int. 2023;131:734-744.
Abstract
Diagnostic evaluation of upper tract urothelial carcinoma: can we safely omit
diagnostic ureteroscopy?
BJU Int. 2023;131:755-762.
Abstract
Surgical checklist adherence across urology expertise levels impacts
transurethral resection of bladder tumour quality indicators.
BJU Int. 2023;131:712-719.
Abstract
BCG unresponsive non-muscle invasive bladder cancer: Are the sub-groups equal?
BJU Int. 2023 May 28. doi: 10.1111/bju.16087.
Abstract
Staging FDG-PET/CT for muscle-invasive bladder cancer: A nationwide
population-based study.
BJU Int. 2023 May 28. doi: 10.1111/bju.16091.
Abstract
Big trials in prostate cancer | predicting drug response in bladder cancer |
immune checkpoint inhibitors for urothelial carcinoma | hydrochlorothiazide in
the prevention of kidney stone recurrence.
BJU Int. 2023;132:2-3.
Abstract
Teaching robotic cystectomy: prospective pilot clinical validation of the ERUS
training curriculum.
BJU Int. 2023;132:84-91.
Abstract
Bladder cancer grading using the four-tier combination of the World Health
Organization (WHO) 1973 and WHO 2004 classifications.
BJU Int. 2023 Jul 6. doi: 10.1111/bju.16100.
Abstract
Impact of age >70 years on oncological outcomes in patients with
non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin.
BJU Int. 2023 Jul 13. doi: 10.1111/bju.16127.
Abstract
Urinary function in female patients after traditional, organ-and nerve-sparing
radical cystectomy for bladder cancer: a systematic review and pooled analyses.
BJU Int. 2023 Aug 10. doi: 10.1111/bju.16152.
Abstract
Voiding and renal function 10 years after radical cystectomy and orthotopic
neobladder in women.
BJU Int. 2023;132:291-297.
Abstract
Robot-assisted radical cystectomy with intracorporeal urinary diversion: a Danish
11-year series.
BJU Int. 2023;132:428-434.
Abstract
VI-RADS use predicting the outcome of neoadjuvant pembrolizumab in
muscle-invasive bladder cancer.
BJU Int. 2023 Oct 6. doi: 10.1111/bju.16191.
Abstract
Alternative instillation techniques of sequential intravesical gemcitabine and
docetaxel for non-muscle-invasive bladder cancer.
BJU Int. 2023 Oct 19. doi: 10.1111/bju.16208.
Abstract
Impact of the Extent of Lymph Node Dissection on Survival Outcomes in Clinically
Lymph Node-Positive Bladder Cancer.
BJU Int. 2023 Oct 30. doi: 10.1111/bju.16210.
Abstract
Quality of life after a diagnosis of Bladder Cancer: Longitudinal survey over the
first year.
BJU Int. 2023 Nov 29. doi: 10.1111/bju.16242.
Abstract
Open versus robot-assisted radical cystectomy: pentafecta and trifecta
achievement comparison from a randomised controlled trial.
BJU Int. 2023;132:671-677.
Abstract
Patient Experience of Surveillance Following Radical Treatment for
Muscle-Invasive Bladder Cancer.
BJU Int. 2023 Dec 14. doi: 10.1111/bju.16261.
Abstract
Long-term outcomes and cost savings of office fulguration of papillary Ta
low-grade bladder cancer.
BJU Int. 2023 Dec 17. doi: 10.1111/bju.16269.
Abstract
Multicentric validation of nomograms based on BC-116 and BC-106 urine peptide
biomarker panels for bladder cancer diagnostics and monitoring in two prospective
cohorts of patients.
Br J Cancer. 2023 Mar 1. doi: 10.1038/s41416-023-02142.
Abstract
Irradiation plus myeloid-derived suppressor cell-targeted therapy for overcoming
treatment resistance in immunologically cold urothelial carcinoma.
Br J Cancer. 2023;128:2197-2205.
Abstract
Exposure to benzene and other hydrocarbons and risk of bladder cancer among male
offshore petroleum workers.
Br J Cancer. 2023 Jul 18. doi: 10.1038/s41416-023-02357.
Abstract
A clinically practical model for the preoperative prediction of lymph node
metastasis in bladder cancer: a multicohort study.
Br J Cancer. 2023 Aug 4. doi: 10.1038/s41416-023-02383.
Abstract
Exposure to low-level ambient air pollution and the relationship with lung and
bladder cancer in older men, in Perth, Western Australia.
Br J Cancer. 2023 Sep 8. doi: 10.1038/s41416-023-02411.
Abstract
Urine-derived bladder cancer organoids (urinoids) as a tool for cancer
longitudinal response monitoring and therapy adaptation.
Br J Cancer. 2023 Dec 15. doi: 10.1038/s41416-023-02494.
Abstract
Cancer-associated fibroblast-derived miR-146a-5p generates a niche that promotes
bladder cancer stemness and chemoresistance.
Cancer Res. 2023 Mar 20:CAN-22-2213. doi: 10.1158/0008-5472.CAN-22-2213.
Abstract
The m6A reader YTHDF2 promotes bladder cancer progression by suppressing
RIG-I-mediated immune response.
Cancer Res. 2023 Mar 20:CAN-22-2485. doi: 10.1158/0008-5472.CAN-22-2485.
Abstract
NAT10 drives cisplatin chemoresistance by enhancing ac4C-associated DNA repair in
bladder cancer.
Cancer Res. 2023 Mar 20:CAN-22-2233. doi: 10.1158/0008-5472.CAN-22-2233.
Abstract
Correction: ARF Confers a Context-Dependent Response to Chemotherapy in
Muscle-Invasive Bladder Cancer.
Cancer Res. 2023;83:1159.
Abstract
FGFR3 alterations in bladder cancer stimulate serine synthesis to induce
immune-inert macrophages that suppress T-cell recruitment and activation.
Cancer Res. 2023 Sep 28. doi: 10.1158/0008-5472.CAN-23-1065.
Abstract
SUMOylation-driven mRNA circularization enhances translation and promotes
lymphatic metastasis of bladder cancer.
Cancer Res. 2023 Nov 22. doi: 10.1158/0008-5472.CAN-23-2278.
Abstract
Pan-cancer analysis of G6PD carcinogenesis in human tumors.
Carcinogenesis. 2023;44:525-534.
Abstract
Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin
Resistance.
Clin Cancer Res. 2023;29:1377-1380.
Abstract
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of
Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
Clin Cancer Res. 2023;29:1496-1505.
Abstract
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial
Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.
Clin Cancer Res. 2023;29:2052-2065.
Abstract
Urinary tumor DNA MRD analysis to identify responders to neoadjuvant
immunotherapy in muscle-invasive bladder cancer.
Clin Cancer Res. 2023 Aug 3:CCR-23-0513. doi: 10.1158/1078-0432.CCR-23-0513.
Abstract
PET Imaging of Nectin-4: A Promising Tool for Personalized/Precision Oncology.
Clin Cancer Res. 2023;29:3259-3261.
Abstract
First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET/CT
Imaging of Advanced Urothelial Carcinoma.
Clin Cancer Res. 2023;29:3395-3407.
Abstract
Development and Multicenter Case-Control Validation of Urinary Comprehensive
Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and
Risk-Prediction.
Clin Cancer Res. 2023;29:3668-3680.
Abstract
A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive
Urothelial Carcinoma In Situ of the Bladder.
Clin Cancer Res. 2023;29:3875-3881.
Abstract
Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing
Chemoradiation Therapy for Bladder Cancer.
Clin Cancer Res. 2023 Oct 19. doi: 10.1158/1078-0432.CCR-23-0792.
Abstract
A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is
Associated with Checkpoint Inhibitor Resistance.
Clin Cancer Res. 2023;29:4242-4255.
Abstract
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab
Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II
Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial
Carcinoma).
Clin Cancer Res. 2023;29:4373-4384.
Abstract
Association of Molecular Subtypes with Pathologic Response, PFS and OS in a Phase
II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-Invasive Bladder
Cancer.
Clin Cancer Res. 2023 Nov 15. doi: 10.1158/1078-0432.CCR-23-0602.
Abstract
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and
Treatment Outcomes with Erdafitinib: A Real-World Experience.
Clin Cancer Res. 2023;29:4586-4595.
Abstract
Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from
Biological Analysis and Extended Clinical Follow-up.
Clin Cancer Res. 2023;29:4797-4807.
Abstract
PET in bladder cancer imaging.
Curr Opin Urol. 2023 Mar 7. doi: 10.1097/MOU.0000000000001090.
Abstract
Extended pelvic lymph node dissection in muscle invasive bladder cancer.
Curr Opin Urol. 2023 Apr 7. doi: 10.1097/MOU.0000000000001096.
Abstract
Prevention and management of urinary tract infections after cystectomy.
Curr Opin Urol. 2023 Mar 3. doi: 10.1097/MOU.0000000000001085.
Abstract
Current methods facilitating diagnosis of upper tract urothelial carcinoma: a
comprehensive literature review.
Curr Opin Urol. 2023;33:230-238.
Abstract
Recent developments in perioperative combination therapy in muscle-invasive
bladder cancer.
Curr Opin Urol. 2023 Jun 3. doi: 10.1097/MOU.0000000000001107.
Abstract
Need for and extent of lymph node dissection for upper tract urothelial
carcinoma: an updated review in 2023.
Curr Opin Urol. 2023;33:258-268.
Abstract
Bladder-sparing strategies in patients with clinically localized muscle-invasive
bladder cancer.
Curr Opin Urol. 2023 Jul 3. doi: 10.1097/MOU.0000000000001113.
Abstract
Use of genomic markers to improve epidemiologic and clinical research in urology.
Curr Opin Urol. 2023;33:414-420.
Abstract
AI-powered radiomics: revolutionizing detection of urologic malignancies.
Curr Opin Urol. 2024;34:1-7.
Abstract
Overview of current applications and trends in artificial intelligence for
cystoscopy and transurethral resection of bladder tumours.
Curr Opin Urol. 2024;34:27-31.
Abstract
Neo-Adjuvant immunotherapies: Bladder cancer as a platform for drug development
targeting mucosal immunity.
Eur J Cancer. 2023;187:58-64.
Abstract
Erratum to "European Association of Urology (EAU) Prognostic Factor Risk Groups
for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016
and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC
Guidelines Panel
Eur Urol. 2023 Feb 23:S0302-2838(23)02579-4. doi: 10.1016/j.eururo.2023.
Abstract
High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of
Tumour Delineation.
Eur Urol. 2023;83:193-194.
Abstract
Corrigendum to "Assessment of Predictive Genomic Biomarkers for Response to
Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer" [Eur Urol
2023;83:313-17].
Eur Urol. 2023 Mar 10:S0302-2838(23)02641-6. doi: 10.1016/j.eururo.2023.
Abstract
ADAPT and Improvise: Overcoming Bacillus Calmette-Guerin Unresponsiveness in
Non-muscle-invasive Bladder Cancer.
Eur Urol. 2023 Mar 8:S0302-2838(23)02627-1. doi: 10.1016/j.eururo.2023.
Abstract
In Patients with Advanced Urothelial Carcinoma, Immune Checkpoint Inhibition
Prior to Enfortumab Vedotin Is Associated with High-grade Skin Toxicity.
Eur Urol. 2023;83:377-378.
Abstract
Time to Rethink Quality of Life Assessment in Patients with Urothelial Cancer in
the Current Therapeutic Era?
Eur Urol. 2023;83:329-330.
Abstract
Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line
Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for
Advanced Urothelial Carcinoma.
Eur Urol. 2023;83:320-328.
Abstract
First-line Intravesical Chemotherapy for Non-muscle-invasive Bladder Cancer:
Chimera or "Ne Plus Ultra"?
Eur Urol. 2023 Mar 18:S0302-2838(23)02637-4. doi: 10.1016/j.eururo.2023.
Abstract
Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately
Before Transurethral Resection of Bladder Tumor in Patients with
Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective,
Randomized Phase II Study.
Eur Urol. 2023 Mar 24:S0302-2838(23)02649-0. doi: 10.1016/j.eururo.2023.
Abstract
Results from HIVEC-II for Intermediate-risk Non-muscle-invasive Bladder Cancer:
Is This a Dead End for Mitomycin C Hyperthermia?
Eur Urol. 2023 Mar 23:S0302-2838(23)02643-X. doi: 10.1016/j.eururo.2023.
Abstract
Re: Alberto Gil-Jimenez, Jeroen van Dorp, Alberto Contreras-Sanz, et al.
Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based
Neoadjuvant Chemotherapy in Bladder Cancer. Eur Urol. 2023;83:313-7.
Eur Urol. 2023 Mar 24:S0302-2838(23)02653-2. doi: 10.1016/j.eururo.2023.
Abstract
Corrigendum to "First-line Intravesical Chemotherapy for Non-muscle-invasive
Bladder Cancer: Chimera or "Ne Plus Ultra"?" [Eur Urol 2023].
Eur Urol. 2023 Apr 17:S0302-2838(23)02714-8. doi: 10.1016/j.eururo.2023.
Abstract
Disease-free Survival Analysis for Patients with High-risk Muscle-invasive
Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined
Positive Score and Tumor Cell Score.
Eur Urol. 2023;83:432-440.
Abstract
Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors.
Eur Urol. 2023 May 15:S0302-2838(23)02707-0. doi: 10.1016/j.eururo.2023.
Abstract
Re: Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors
Is as Good as Conventional Inpatient Photodynamic Diagnosis-guided Transurethral
Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder
Tumors.
Eur Urol. 2023;83:582.
Abstract
Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus
Study Endorsed by the European Association of Urology, European Society for
Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary
Faculty.
Eur Urol. 2023 May 20:S0302-2838(23)02810-5. doi: 10.1016/j.eururo.2023.
Abstract
Genome-wide Association Study of Bladder Cancer Reveals New Biological and
Translational Insights.
Eur Urol. 2023 May 18:S0302-2838(23)02780-X. doi: 10.1016/j.eururo.2023.
Abstract
Patient and Carer Experiences with Bladder Cancer: Results from a Global Survey
in 45 Countries.
Eur Urol. 2023 May 24:S0302-2838(23)02801-4. doi: 10.1016/j.eururo.2023.
Abstract
Re: DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection
with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a
Randomized Controlled Trial.
Eur Urol. 2023 Jun 1:S0302-2838(23)02873-7. doi: 10.1016/j.eururo.2023.
Abstract
Re: Addition of Nintedanib or Placebo to Neoadjuvant Gemcitabine and Cisplatin in
Locally Advanced Muscle-invasive Bladder Cancer (NEOBLADE): A Double-blind,
Randomised, Phase 2 Trial.
Eur Urol. 2023 Jun 9:S0302-2838(23)02871-3. doi: 10.1016/j.eururo.2023.
Abstract
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma:
Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3
Trial.
Eur Urol. 2023;84:95-108.
Abstract
European Association of Urology Guidelines on Upper Urinary Tract Urothelial
Carcinoma: 2023 Update.
Eur Urol. 2023;84:49-64.
Abstract
Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the
USA.
Eur Urol. 2023;84:117-126.
Abstract
Identification of Lineage-specific Transcriptional Factor-defined Molecular
Subtypes in Small Cell Bladder Cancer.
Eur Urol. 2023 Jun 27:S0302-2838(23)02830-0. doi: 10.1016/j.eururo.2023.
Abstract
Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis
Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in
FGFR3-mutated Tumors.
Eur Urol. 2023 Jun 27:S0302-2838(23)02885-3. doi: 10.1016/j.eururo.2023.
Abstract
A Pilot Study on Hyperthermic Intraperitoneal Chemotherapy after Radical or
Partial Cystectomy with Pelvic Lymph Node Dissection for High-risk
Muscle-invasive Bladder Cancer.
Eur Urol. 2023 Jun 21:S0302-2838(23)02900-7. doi: 10.1016/j.eururo.2023.
Abstract
A Step Closer to Predicting Progression After Bacillus Calmette-Guerin
Immunotherapy in High-risk Non-muscle-invasive Bladder Cancer.
Eur Urol. 2023 Jul 1:S0302-2838(23)02948-2. doi: 10.1016/j.eururo.2023.
Abstract
Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for
Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695).
Eur Urol. 2023 Jul 4:S0302-2838(23)02945-7. doi: 10.1016/j.eururo.2023.
Abstract
Oligometastatic Bladder Cancer: Defining a Novel Entity.
Eur Urol. 2023 Jul 4:S0302-2838(23)02898-1. doi: 10.1016/j.eururo.2023.
Abstract
Re: Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder
Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis.
Eur Urol. 2023 Jul 12:S0302-2838(23)02962-7. doi: 10.1016/j.eururo.2023.
Abstract
The Impact of Lineage-specific Transcriptional Factors in Small-cell Bladder
Cancer in the Patient Selection Process in Future Clinical Trials.
Eur Urol. 2023 Jul 25:S0302-2838(23)02969-X. doi: 10.1016/j.eururo.2023.
Abstract
Re: Rakesh Heer, Rebecca Lewis, Thenmalar Vadiveloo, et al. A Randomized Trial of
PHOTOdynamic Surgery in Non-muscle-invasive Bladder Cancer. NEJM Evid
2022;1:EVIDoa2200092.
Eur Urol. 2023 Aug 12:S0302-2838(23)03017-8. doi: 10.1016/j.eururo.2023.
Abstract
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guerin-unresponsive High-risk
Non-muscle-invasive Bladder Cancer: SWOG S1605.
Eur Urol. 2023 Aug 16:S0302-2838(23)03019-1. doi: 10.1016/j.eururo.2023.
Abstract
Reply to Thomas Seisen, Morgan Roupret, and Pierre Blanchard's Letter to the
Editor re: Alexandre R. Zlotta, Leslie K. Ballas, Andrzej Niemierko, et al.
Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer:
A Multi-institut
Eur Urol. 2023 Sep 1:S0302-2838(23)03066-X. doi: 10.1016/j.eururo.2023.
Abstract
Re: Alexandre R. Zlotta, Leslie K. Ballas, Anderzej Niemierko, et al. Radical
Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A
Multi-institutional Propensity Score Matched and Weighted Analysis. Lancet Oncol
2023;24:669-81.
Eur Urol. 2023 Aug 31:S0302-2838(23)03065-8. doi: 10.1016/j.eururo.2023.
Abstract
Re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of
Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell
Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023.
Eur Urol. 2023 Sep 9:S0302-2838(23)03085-3. doi: 10.1016/j.eururo.2023.
Abstract
Field Cancerization Is Associated with Tumor Development, T-cell Exhaustion, and
Clinical Outcomes in Bladder Cancer.
Eur Urol. 2023 Sep 15:S0302-2838(23)03014-2. doi: 10.1016/j.eururo.2023.
Abstract
Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic
Review and Meta-analysis of Perioperative, Oncological, and Quality of Life
Outcomes Using Randomized Controlled Trials.
Eur Urol. 2023;84:393-405.
Abstract
Reply to Kentaro Inamura's Letter to the Editor re: Mingxiao Feng, Andres Matoso,
Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional
Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In
press. https://do
Eur Urol. 2023 Sep 27:S0302-2838(23)03097-X. doi: 10.1016/j.eururo.2023.
Abstract
SWOG S1605: Moving Beyond Systemic Immune Checkpoint Inhibitor Monotherapy in
Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer.
Eur Urol. 2023 Oct 4:S0302-2838(23)03138-X. doi: 10.1016/j.eururo.2023.
Abstract
Re: First-in-Human Study of the Radioligand (68)Ga-N188 Targeting Nectin-4 for
PET/CT Imaging of Advanced Urothelial Carcinoma: Navigating Metastatic Urothelial
Cancer with Nectin-4 PET/CT.
Eur Urol. 2023;84:514-515.
Abstract
European Association of Urology Guidelines on Muscle-invasive and Metastatic
Bladder Cancer: Summary of the 2023 Guidelines.
Eur Urol. 2023 Oct 17:S0302-2838(23)03073-7. doi: 10.1016/j.eururo.2023.
Abstract
Re: Martin Swinton, Neethu Billy Graham Mariam, Jean Ling Tan, et al.
Bladder-Sparing Treatment with Radical Dose Radiotherapy Is an Effective
Alternative to Radical Cystectomy in Patients with Clinically Node-positive
Nonmetastatic Bladder Cancer. J
Eur Urol. 2023 Oct 19:S0302-2838(23)03163-9. doi: 10.1016/j.eururo.2023.
Abstract
Reply to Thomas Seisen, Morgan Roupret, Quoc-Dien Trinh, and Joaquim Bellmunt's
Letter to the Editor re: Martin Swinton, Neethu Billy Graham Mariam, Jean Ling
Tan, et al. Bladder-Sparing Treatment with Radical Dose Radiotherapy Is an
Effective Alterna
Eur Urol. 2023 Oct 19:S0302-2838(23)03162-7. doi: 10.1016/j.eururo.2023.
Abstract
Checkpoint Inhibitors in Urothelial Carcinoma-Future Directions and Biomarker
Selection.
Eur Urol. 2023;84:473-483.
Abstract
Robot-assisted Radical Cystectomy with Orthotopic Neobladder Reconstruction:
Techniques and Functional Outcomes in Males.
Eur Urol. 2023;84:484-490.
Abstract
Re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of
Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell
Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023.
Eur Urol. 2023 Oct 31:S0302-2838(23)03169-X. doi: 10.1016/j.eururo.2023.
Abstract
The 2023 European Association of Urology Guidelines on Muscle-invasive and
Metastatic Bladder Cancer: A Critical Appraisal.
Eur Urol. 2023 Oct 31:S0302-2838(23)03208-6. doi: 10.1016/j.eururo.2023.
Abstract
Spatial Relationships in the Tumor Microenvironment Demonstrate Association with
Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder
Cancer.
Eur Urol. 2023 Dec 12:S0302-2838(23)03261-X. doi: 10.1016/j.eururo.2023.
Abstract
Re: Bhavan P. Rai, Jose Luis Dominguez Escrig, Luis Vale, et al. Systematic
Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell
Carcinoma Among Patients with Haematuria. Eur Urol 2022;82:182-92.
Eur Urol. 2024;85:e17-e18.
Abstract
Reply to Qingpeng Xie and Dianqiu Shen's Letter to the Editor re: Bhavan P. Rai,
Jose Luis Dominguez Escrig, Luis Vale, et al. Systematic Review of the Incidence
of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among
Patients with H
Eur Urol. 2024;85:e15-e16.
Abstract
Long-term prevention of bladder cancer progression by alpha1-oleate alone or in
combination with chemotherapy.
Int J Cancer. 2023 Mar 9. doi: 10.1002/ijc.34500.
Abstract
Bladder cancer risk in relation to occupations held in a nationwide case-control
study in Iran.
Int J Cancer. 2023 May 9. doi: 10.1002/ijc.34560.
Abstract
Genome-wide exploration of genetic interactions for bladder cancer risk.
Int J Cancer. 2023 Aug 28. doi: 10.1002/ijc.34690.
Abstract
Metastasis and recurrence patterns in the molecular subtypes of urothelial
bladder cancer.
Int J Cancer. 2023 Sep 6. doi: 10.1002/ijc.34715.
Abstract
Evaluating interactions of polygenic risk scores and NAT2 genotypes with tobacco
smoking in bladder cancer risk.
Int J Cancer. 2023 Sep 20. doi: 10.1002/ijc.34736.
Abstract
[Retracted] MicroRNA‑24 upregulation inhibits proliferation, metastasis and
induces apoptosis in bladder cancer cells by targeting CARMA3.
Int J Oncol. 2023;62:67.
Abstract
Tumor suppressive functions of hsa‑miR‑34a on cell cycle, migration and
protective autophagy in bladder cancer.
Int J Oncol. 2023;62:66.
Abstract
Exosomes from PYCR1 knockdown bone marrow mesenchymal stem inhibits aerobic
glycolysis and the growth of bladder cancer cells via regulation of the
EGFR/PI3K/AKT pathway.
Int J Oncol. 2023;63:84.
Abstract
CUDC?101 is a potential target inhibitor for the EGFR?overexpression bladder
cancer cells.
Int J Oncol. 2023;63:131.
Abstract
Editorial Comment on Transurethral lidocaine (100 mg) bladder irrigation
(TULI100) reduces the incidence of catheter-related bladder discomfort in TURBT:
A randomized, double-blind, controlled trial.
Int J Urol. 2023;30:270-271.
Abstract
Trends of radical cystectomy and comparisons of surgical outcomes among surgical
approaches focusing on robot-assisted radical cystectomy: A Japanese nationwide
database study.
Int J Urol. 2023;30:258-263.
Abstract
Chemotherapy with gemcitabine and cisplatin downregulates tumor expression level
of nectin-4 in a syngeneic model of murine MBT2 urothelial cancer cell line and
C3H mice.
Int J Urol. 2023;30:328-330.
Abstract
Transurethral lidocaine (100 mg) bladder irrigation (TULI100) reduces the
incidence of catheter related bladder discomfort in transurethral resection of
bladder tumors: A randomized, double blind, controlled trial.
Int J Urol. 2023;30:264-270.
Abstract
Editorial Comment on Validation of the risk stratification newly defined in the
Japanese Urological Association guidelines 2019 for non-muscle invasive bladder
cancer: A multi-institutional collaborative study.
Int J Urol. 2023 Mar 16. doi: 10.1111/iju.15177.
Abstract
Editorial Comment on Impact of functional impairment and cognitive status on
perioperative outcomes and costs after radical cystectomy: The role of Barthel
Index.
Int J Urol. 2023;30:373-374.
Abstract
Impact of functional impairment and cognitive status on perioperative outcomes
and costs after radical cystectomy: The role of Barthel Index.
Int J Urol. 2023;30:366-373.
Abstract
Editorial Comment to Significance of dorsal bladder neck involvement in
predicting the progression of non-muscle-invasive bladder cancer.
Int J Urol. 2023 May 10. doi: 10.1111/iju.15200.
Abstract
Editorial Comment to Impact of the coronavirus disease-2019 pandemic on the
number of patients undergoing radical nephroureterectomy and postoperative
adjuvant systematic therapy for upper tract urothelial carcinomas in Japan: A
multicenter retrospect
Int J Urol. 2023;30:471-472.
Abstract
Impact of the coronavirus disease 2019 pandemic on the number of undergoing
radical nephroureterectomy and postoperative adjuvant systematic therapy for
upper tract urothelial carcinomas in Japan: A multicenter retrospective study.
Int J Urol. 2023;30:464-471.
Abstract
Recent advancements in the diagnosis and treatment of non-muscle invasive bladder
cancer: Evidence update of surgical concept, risk stratification, and BCG-treated
disease.
Int J Urol. 2023 Jul 31. doi: 10.1111/iju.15263.
Abstract
Editorial Comment to Learning from the past and present to change the future:
Endoscopic management of upper urinary tract urothelial carcinoma.
Int J Urol. 2023;30:647-648.
Abstract
Learning from the past and present to change the future: Endoscopic management of
upper urinary tract urothelial carcinoma.
Int J Urol. 2023;30:634-647.
Abstract
Editorial Comment to Impact of nephroureterectomy on postoperative renal function
in upper tract urothelial carcinoma: A multicenter retrospective study.
Int J Urol. 2023;30:657.
Abstract
Editorial Comment to Impact of nephroureterectomy on postoperative renal function
in upper tract urothelial carcinoma: A multicenter retrospective study.
Int J Urol. 2023;30:658.
Abstract
Impact of nephroureterectomy on postoperative renal function in upper tract
urothelial carcinoma: A multicenter retrospective study.
Int J Urol. 2023;30:649-657.
Abstract
Necessity of prophylactic drainage tube in retroperitoneal laparoscopic
nephroureterectomy with open distal ureterectomy: A matched-pair analysis.
Int J Urol. 2023;30:579-584.
Abstract
Trends in the age of hospitalized patients with urological cancers: A 17-year
experience.
Int J Urol. 2023;30:572-578.
Abstract
Editorial Comment to Recent advancements in the diagnosis and treatment of
non-muscle invasive bladder cancer: Evidence update of surgical concept, risk
stratification, and BCG-treated disease.
Int J Urol. 2023 Aug 22. doi: 10.1111/iju.15286.
Abstract
Impact on Japanese healthcare economics of photodynamic diagnosis-assisted
transurethral resection of bladder tumor for non-muscle invasive bladder cancer:
A multicenter retrospective cohort study.
Int J Urol. 2023 Aug 22. doi: 10.1111/iju.15283.
Abstract
Identification of tumor immunophenotypes associated with immunotherapy response
in bladder cancer.
Int J Urol. 2023 Aug 21. doi: 10.1111/iju.15276.
Abstract
Editorial Comment to Identification of tumor immunophenotypes associated with
immunotherapy response in bladder cancer.
Int J Urol. 2023 Sep 4. doi: 10.1111/iju.15296.
Abstract
Improving compliance with guidelines may lead to favorable clinical outcomes for
patients with non-muscle-invasive bladder cancer: A retrospective multicenter
study.
Int J Urol. 2023 Sep 4. doi: 10.1111/iju.15294.
Abstract
Editorial Comment to "The poor antitumor effect of pembrolizumab in advanced
upper urothelial carcinoma with renal parenchymal invasion".
Int J Urol. 2023;30:786-787.
Abstract
The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma
with renal parenchymal invasion.
Int J Urol. 2023;30:779-786.
Abstract
Differential impact of proton pump inhibitor on survival outcomes of patients
with advanced urothelial carcinoma treated with chemotherapy versus
pembrolizumab.
Int J Urol. 2023;30:738-745.
Abstract
Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial
carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
Int J Urol. 2023;30:696-703.
Abstract
Editorial comment to real-world outcomes of pembrolizumab for platinum refractory
advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit
patients.
Int J Urol. 2023;30:704.
Abstract
Editorial Comment to "Improving compliance with guidelines may lead to favorable
clinical outcomes for patients with non-muscle-invasive bladder cancer: A
retrospective multicenter study".
Int J Urol. 2023 Sep 27. doi: 10.1111/iju.15311.
Abstract
Editorial Comment to Impact on Japanese healthcare economics of photodynamic
diagnosis-assisted transurethral resection of bladder tumor for non-muscle
invasive bladder cancer: A multicenter retrospective cohort study.
Int J Urol. 2023 Sep 22. doi: 10.1111/iju.15308.
Abstract
Editorial Comments to "Preoperative risk classification for intravesical
recurrence after laparoscopic radical nephroureterectomy for upper tract
urothelial carcinoma in a multi-institutional cohort".
Int J Urol. 2023;30:859.
Abstract
Risk stratification and management of non-muscle-invasive bladder cancer: A
physician survey in six Asia-Pacific territories.
Int J Urol. 2023 Oct 6. doi: 10.1111/iju.15309.
Abstract
Urethrectomy via parapenile incision to complete robot-assisted radical
cystectomy in a spine position for male patients.
Int J Urol. 2023;30:936-938.
Abstract
Preoperative risk classification for intravesical recurrence after laparoscopic
radical nephroureterectomy for upper tract urothelial carcinoma in a
multi-institutional cohort.
Int J Urol. 2023;30:853-858.
Abstract
Editorial Comment from Dr. Mori to texture feature analysis using dynamic
computed tomography for preoperative risk stratification in upper urinary tract
urothelial carcinoma.
Int J Urol. 2023;30:1059.
Abstract
Surgical outcomes of robot-assisted radical cystectomy in octogenarian or older
patients: A Japanese nationwide study.
Int J Urol. 2023;30:1014-1019.
Abstract
Texture feature analysis using dynamic computed tomography for preoperative risk
stratification in upper urinary tract urothelial carcinoma.
Int J Urol. 2023;30:1056-1058.
Abstract
Urinary markers for bladder cancer diagnosis: A review of current status and
future challenges.
Int J Urol. 2023 Nov 15. doi: 10.1111/iju.15338.
Abstract
Editorial comment-Risk stratification and management of nonmuscle-invasive
bladder cancer: A physician survey in six Asia-Pacific territories.
Int J Urol. 2023 Nov 15. doi: 10.1111/iju.15340.
Abstract
Epigenetic alterations in urothelial bladder cancer associated with disease
outcomes.
Int J Urol. 2023 Nov 14. doi: 10.1111/iju.15335.
Abstract
Editorial Comment to Enfortumab vedotin versus platinum rechallenge in
post-platinum post-pembrolizumab advanced urothelial carcinoma: A multicenter
propensity score-matched study.
Int J Urol. 2023;30:1186-1187.
Abstract
Enfortumab vedotin versus platinum rechallenge in post-platinum,
post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity
score-matched study.
Int J Urol. 2023;30:1180-1186.
Abstract
Recent advances in immune checkpoint inhibitors in the treatment of urothelial
carcinoma: A review.
Int J Urol. 2023;30:1068-1077.
Abstract
Editorial Comment on Urinary markers for bladder cancer diagnosis: A review of
current status and future challenges.
Int J Urol. 2023 Dec 10. doi: 10.1111/iju.15360.
Abstract
Editorial Comment on Epigenetic alterations in urothelial bladder cancer
associated with disease outcomes.
Int J Urol. 2023 Dec 10. doi: 10.1111/iju.15361.
Abstract
Cancer risk in bladder diverticula: a large institutional analysis of risk and
management.
Int Urol Nephrol. 2023;55:541-546.
Abstract
Comparable survival benefits of partial ureterectomy to radical
nephroureterectomy in non-metastatic ureter carcinoma: a population-matched
study.
Int Urol Nephrol. 2023;55:579-588.
Abstract
Letter to the editor re: "assessing bladder cancer prognosis through circulating
tumor cell analysis and Ki-67 measurement".
Int Urol Nephrol. 2023 Mar 3. doi: 10.1007/s11255-023-03538.
Abstract
Increased co-expression of stromal HHLA2 and fibroblast activation protein in
upper tract urothelial carcinoma.
Int Urol Nephrol. 2023;55:867-874.
Abstract
The comparison between contrast-enhanced ultrasound and contrast-enhanced
magnetic resonance imaging in diagnosing bladder urothelial carcinoma.
Int Urol Nephrol. 2023;55:1073-1079.
Abstract
Evaluation of comprehensive complication index versus Clavien-Dindo
classification in prediction of overall survival after radical cystectomy.
Int Urol Nephrol. 2023;55:1459-1465.
Abstract
The prediction of cancer-specific mortality in T1 non-muscle-invasive bladder
cancer: comparison of logistic regression and artificial neural network: a SEER
population-based study.
Int Urol Nephrol. 2023 Jun 6. doi: 10.1007/s11255-023-03655.
Abstract
The relationship between microRNAs and bladder cancer: are microRNAs useful to
predict bladder cancer in suspicious patients?
Int Urol Nephrol. 2023 Jun 20. doi: 10.1007/s11255-023-03666.
Abstract
Ileal conduit versus single stoma uretero-cutanoustomy after radical cystectomy
in patients >/= 75 years; which technique is better? a prospective randomized
comparative study.
Int Urol Nephrol. 2023;55:1719-1726.
Abstract
Upper tract heparin instillation for maintenance of ureteral stent patency.
Int Urol Nephrol. 2023;55:1893-1897.
Abstract
Endocrine immune-related adverse events in patients with metastatic renal and
urothelial cancer treated with immune checkpoint-inhibitors.
Int Urol Nephrol. 2023;55:1943-1949.
Abstract
Natural killer cells strengthen antitumor activity of cisplatin by
immunomodulation and ameliorate cisplatin-induced side effects.
Int Urol Nephrol. 2023;55:1957-1970.
Abstract
Bladder perforation as a complication of transurethral resection of bladder
tumors: the predictors, management, and its impact in a series of 1570 at a
tertiary urology institute.
Int Urol Nephrol. 2023;55:2161-2167.
Abstract
Comparison of the risks of renal cell carcinoma or urothelial cancer between
hemodialysis and peritoneal dialysis patients.
Int Urol Nephrol. 2023;55:2267-2274.
Abstract
Safety, feasibility, and quality of thulium laser en-bloc resection for treatment
of non-muscle invasive bladder cancer.
Int Urol Nephrol. 2023 Aug 28. doi: 10.1007/s11255-023-03752.
Abstract
Device-assisted intravesical chemotherapy versus bacillus Calmette-Guerin for
intermediate or high-risk non-muscle invasive bladder cancer: a systematic
reviewer and meta-analysis.
Int Urol Nephrol. 2023 Sep 2. doi: 10.1007/s11255-023-03765.
Abstract
Immunohistochemical expression of CD117/KIT, HER2, and Erbeta in schistosomal and
non-schistosomal urothelial carcinoma of Egyptian patients.
Int Urol Nephrol. 2023;55:2473-2481.
Abstract
Development of a prognostic signature for immune-associated genes in bladder
cancer and exploring potential drug findings.
Int Urol Nephrol. 2023 Sep 23. doi: 10.1007/s11255-023-03796.
Abstract
Pan-immune-inflammation value as a prognostic tool for overall survival and
disease-free survival in non-metastatic muscle-invasive bladder cancer.
Int Urol Nephrol. 2023 Sep 29. doi: 10.1007/s11255-023-03812.
Abstract
Effect of obturator nerve block during transurethral resection of bladder tumors
on the disease recurrence, progression and surgery outcomes.
Int Urol Nephrol. 2023;55:2765-2772.
Abstract
Effects of delayed diagnosis on tumor size, stage and grade in bladder cancer.
Int Urol Nephrol. 2023 Oct 17. doi: 10.1007/s11255-023-03829.
Abstract
Multi-omics analysis reveals critical metabolic regulators in bladder cancer.
Int Urol Nephrol. 2023 Oct 26. doi: 10.1007/s11255-023-03841.
Abstract
Comparison of hyperthermic intravesical chemotherapy and Bacillus Calmette-Guerin
therapy in high-risk non-muscle invasive bladder cancer: a matched-pair analysis.
Int Urol Nephrol. 2023 Oct 25. doi: 10.1007/s11255-023-03849.
Abstract
Clinical impact of the intensity of follow-up cystoscopy in patients with
high-risk non-muscle-invasive bladder cancer.
Int Urol Nephrol. 2023 Nov 1. doi: 10.1007/s11255-023-03851.
Abstract
Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive
bladder cancer: impact on prognosis?
Int Urol Nephrol. 2023 Nov 19. doi: 10.1007/s11255-023-03867.
Abstract
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant
Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma.
J Clin Oncol. 2023;41:1618-1625.
Abstract
Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on
Immune Checkpoint Blockade.
J Clin Oncol. 2023;41:3225-3235.
Abstract
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From
the JAVELIN Bladder 100 Trial After >/=2 Years of Follow-Up.
J Clin Oncol. 2023;41:3486-3492.
Abstract
Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results
in 1,054 Patients.
J Clin Oncol. 2023;41:3772-3781.
Abstract
JCO Flashback: Long-Term Outcomes of Radical Cystectomy in Patients With Invasive
Bladder Cancer (2001).
J Clin Oncol. 2023;41:3771.
Abstract
Flashback Foreword: Radical Cystectomy in the Treatment of Bladder Cancer.
J Clin Oncol. 2023;41:3769-3770.
Abstract
Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective
Alternative to Radical Cystectomy in Patients With Clinically Node-Positive
Nonmetastatic Bladder Cancer.
J Clin Oncol. 2023 Jul 21:JCO2300725. doi: 10.1200/JCO.23.00725.
Abstract
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and
Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large,
Randomized, Multinational, Multicenter, Phase III Study.
J Clin Oncol. 2023;41:3881-3890.
Abstract
Flashback Foreword: Gemcitabine/Cisplatin Versus Methotrexate, Vinblastine,
Doxorubicin, and Cisplatin in Transitional Cell Carcinoma.
J Clin Oncol. 2023;41:3879-3880.
Abstract
Combinations, Sequencing, and the Contribution of Components: New Frontline
Standards for Metastatic Urothelial Carcinoma.
J Clin Oncol. 2023;41:4084-4086.
Abstract
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer:
Recommendations From the Society for Immunotherapy of Cancer and the
International Bladder Cancer Group.
J Clin Oncol. 2023 Oct 4:JCO2300307. doi: 10.1200/JCO.23.00307.
Abstract
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial
Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
J Clin Oncol. 2023;41:5131-5139.
Abstract
Controversy Surrounding Bladder-Sparing Radical Dose Radiotherapy as an
Alternative to Radical Cystectomy for Clinically Node-Positive Nonmetastatic
Bladder Cancer.
J Clin Oncol. 2023 Dec 5:JCO2301920. doi: 10.1200/JCO.23.01920.
Abstract
Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately
Before Transurethral Resection of Bladder Tumor in Patients With
Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective,
Randomized Phase II Study.
J Urol. 2023 Mar 9:101097JU0000000000003407. doi: 10.1097/JU.0000000000003407.
Abstract
Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of
Cxbladder Tests and Improves Patient Risk Stratification. Letter.
J Urol. 2023;209:676-677.
Abstract
Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of
Cxbladder Tests and Improves Patient Risk Stratification.
J Urol. 2023;209:762-772.
Abstract
Non-risk Adapted Sequential Intravesical Gemcitabine and Docetaxel for Non-muscle
Invasive Bladder Cancer: The Time is Now.
J Urol. 2023 Mar 31:101097JU0000000000003438. doi: 10.1097/JU.0000000000003438.
Abstract
Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical
Cystectomy Is Prognostic but Not Therapeutic. Letter.
J Urol. 2023 Apr 10:101097JU0000000000003455. doi: 10.1097/JU.0000000000003455.
Abstract
Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With
Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent
Therapy: A Phase 1 Study.
J Urol. 2023;209:890-900.
Abstract
Will Patient-reported Outcomes Be the Key to Demonstrating the Value of Robotic
Cystectomy? Data Are Accumulating but Clarity Is Not.
J Urol. 2023;209:833-835.
Abstract
A Urine-based DNA Methylation Marker Test to Detect Upper Tract Urothelial
Carcinoma: A Prospective Cohort Study.
J Urol. 2023;209:854-862.
Abstract
Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy
in a Large, Multi-institutional Cohort.
J Urol. 2023;209:882-889.
Abstract
Final Results of a Phase I Trial of WST-11 (TOOKAD Soluble) Vascular-targeted
Photodynamic Therapy for Upper Tract Urothelial Carcinoma.
J Urol. 2023;209:863-871.
Abstract
Health-related Quality of Life After Robotic-assisted vs Open Radical Cystectomy:
Analysis of a Randomized Trial.
J Urol. 2023;209:901-910.
Abstract
Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After
Complete Endoscopic Management of Upper Tract Urothelial Carcinoma.
J Urol. 2023;209:872-881.
Abstract
Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma:
AUA/SUO Guideline.
J Urol. 2023;209:1071-1081.
Abstract
Long-term Urological Outcomes in Pelvic Genitourinary Rhabdomyosarcoma: A 48-Year
Single-center Experience.
J Urol. 2023;209:1202-1209.
Abstract
Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical
Cystectomy Is Prognostic but Not Therapeutic. Reply.
J Urol. 2023 May 22:101097JU0000000000003553. doi: 10.1097/JU.0000000000003553.
Abstract
PD44-11 Neoadjuvant Chemotherapy Increases Urinary and Bowel Anastomotic Failure
in PT2-T4 Bladder Cancer Undergoing Radical Cystectomy.
J Urol. 2023;210:222.
Abstract
Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical
Cystectomy Is Prognostic But Not Therapeutic. Letter.
J Urol. 2023 Jul 6:101097JU0000000000003613. doi: 10.1097/JU.0000000000003613.
Abstract
International Bladder Cancer Group Intermediate-risk Non-muscle Invasive Bladder
Cancer (IBCG IR-NMIBC) Scoring System Predicts Outcomes of Patients on Active
Surveillance.
J Urol. 2023 Aug 3:101097JU0000000000003639. doi: 10.1097/JU.0000000000003639.
Abstract
Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with
UGN-102 +/- Transurethral Resection of Bladder Tumor (TURBT) Compared to TURBT
Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).
J Urol. 2023 Aug 7:101097JU0000000000003645. doi: 10.1097/JU.0000000000003645.
Abstract
Health-related Quality of Life After Robotic-assisted vs Open Radical Cystectomy:
Analysis of a Randomized Trial. Reply.
J Urol. 2023;210:408.
Abstract
Health-related Quality of Life After Robotic-assisted vs Open Radical Cystectomy:
Analysis of a Randomized Trial. Letter.
J Urol. 2023;210:407-408.
Abstract
Primary Chemoablation for Intermediate-Risk Low-Grade Bladder Cancer: New
Paradigm or Added Uncertainty? Letter.
J Urol. 2023 Sep 28:101097JU0000000000003729. doi: 10.1097/JU.0000000000003729.
Abstract
Primary Chemoablation for Intermediate-risk Low-grade Bladder Cancer: New
Paradigm or Added Uncertainty?
J Urol. 2023 Sep 27:101097JU0000000000003702. doi: 10.1097/JU.0000000000003702.
Abstract
Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical
Cystectomy Is Prognostic but Not Therapeutic. Reply.
J Urol. 2023 Sep 25:101097JU0000000000003704. doi: 10.1097/JU.0000000000003704.
Abstract
Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical
Cystectomy Is Prognostic but Not Therapeutic. Reply.
J Urol. 2023 Sep 25:101097JU0000000000003705. doi: 10.1097/JU.0000000000003705.
Abstract
Long-Term Oncological Outcomes in Patients Diagnosed with Non-Metastatic
Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson
Cancer Center Experience.
J Urol. 2023 Nov 3:101097JU0000000000003778. doi: 10.1097/JU.0000000000003778.
Abstract
Regulation of CD8(+) T cells infiltration and immunotherapy by circMGA/HNRNPL
complex in bladder cancer.
Oncogene. 2023 Mar 3. doi: 10.1038/s41388-023-02637.
Abstract
Epigenomic mapping identifies an enhancer repertoire that regulates cell identity
in bladder cancer through distinct transcription factor networks.
Oncogene. 2023 Mar 22. doi: 10.1038/s41388-023-02662.
Abstract
Retraction Note: Mesenchymal stem cells-derived exosomal microRNA-139-5p
restrains tumorigenesis in bladder cancer by targeting PRC1.
Oncogene. 2023 May 30. doi: 10.1038/s41388-023-02726.
Abstract
M6A-mediated-upregulation of lncRNA BLACAT3 promotes bladder cancer angiogenesis
and hematogenous metastasis through YBX3 nuclear shuttling and enhancing NCF2
transcription.
Oncogene. 2023 Aug 23. doi: 10.1038/s41388-023-02814.
Abstract
The urothelial gene regulatory network: understanding biology to improve bladder
cancer management.
Oncogene. 2023 Nov 23. doi: 10.1038/s41388-023-02876.
Abstract
TRAIP suppresses bladder cancer progression by catalyzing K48-linked
polyubiquitination of MYC.
Oncogene. 2023 Dec 20. doi: 10.1038/s41388-023-02922.
Abstract
METTL3/YTHDF2 m6A axis promotes the malignant progression of bladder cancer by
epigenetically suppressing RRAS.
Oncol Rep. 2023;49:94.
Abstract
CircRPPH1 accelerates the proliferation and migration of bladder cancer via
enhancing the STAT3 signaling pathway.
Oncol Rep. 2023;49:103.
Abstract
Long non‑coding RNA BLACAT2/miR‑378a‑3p/YY1 feedback loop promotes the
proliferation, migration and invasion of uterine corpus endometrial carcinoma.
Oncol Rep. 2023;49:108.
Abstract
CUDC‑907 suppresses epithelial‑mesenchymal transition, migration and invasion in
a 3D spheroid model of bladder cancer.
Oncol Rep. 2023;49:130.
Abstract
Forkhead box F1 functions as a novel prognostic biomarker and induces
caspase‑dependent apoptosis in bladder cancer.
Oncol Rep. 2023;50:173.
Abstract
Regulation of Drp1 and enhancement of mitochondrial fission by the
deubiquitinating enzyme PSMD14 facilitates the proliferation of bladder cancer
cells.
Oncol Rep. 2024;51:6.
Abstract
SYNPO2 promotes the development of BLCA by upregulating the infiltration of
resting mast cells and increasing the resistance to immunotherapy.
Oncol Rep. 2024;51:14.
Abstract
[Retracted] Isoquercitrin inhibits bladder cancer progression in vitro and
in vivo by regulating the PI3K/Akt and PKC signaling pathways.
Oncol Rep. 2024;51:25.
Abstract
[Pathological pelvic lymph node involvement in muscle-invasive bladder cancer
patients treated with radical cystectomy: A narrative review].
Prog Urol. 2023;33:145-154.
Abstract
[Evaluation of the efficacy and safety of HIVEC intravesical thermochemotherapy
with intermediate-risk and high-risk non-muscle-invasive bladder cancer].
Prog Urol. 2023 Mar 9:S1166-7087(23)00062-3. doi: 10.1016/j.purol.2023.
Abstract
Photodynamic cystoscopy for bladder cancer diagnosis and for NMIBC follow-up: An
overview of systematic reviews and meta-analyses.
Prog Urol. 2023 Apr 21:S1166-7087(23)00083-0. doi: 10.1016/j.purol.2023.
Abstract
[Preoperative chemotherapy for patients with upper tract urothelial carcinoma:
Impact on renal function].
Prog Urol. 2023;33.
Abstract
Management of high-grade papillary Ta or T1 bladder cancer after restaging
transurethral resection: A retrospective study comparing Bacillus Calmette-Guerin
therapy upfront versus a third resection.
Prog Urol. 2023 Nov 16:S1166-7087(23)00238-5. doi: 10.1016/j.purol.2023.
Abstract
[Profile and immune environment of upper tract urothelial carcinoma].
Prog Urol. 2023;33.
Abstract
[Bladder tumors in the Herault department: Results of the Herault tumor registry
registration from1987 to 2019].
Prog Urol. 2023;33.
Abstract
Hsa_circ_0008035 Knockdown Inhibits Bladder Cancer Progression through
miR-1184/RAP2B Axis.
Urol Int. 2023 Mar 23:1-14. doi: 10.1159/000527873.
Abstract
Short-Term and Long-Term Morbidity after Radical Cystectomy in Patients with
NMIBC and Comparison with MIBC: Identifying Risk Factors for Severe Short-Term
Complications.
Urol Int. 2023;107:246-256.
Abstract
Low Skeletal Muscle Mass Predicts Relevant Outcomes in Palliative Urological
Oncology: A Systematic Review and Meta-Analysis.
Urol Int. 2023;107:219-229.
Abstract
ANLN Serves as an Oncogene in Bladder Urothelial Carcinoma via Activating JNK
Signaling Pathway.
Urol Int. 2023;107:310-320.
Abstract
Association between Operative Time and Short-Term Radical Cystectomy
Complications.
Urol Int. 2023;107:273-279.
Abstract
Patient Compliance in Assessing Electronic Patient-Reported Outcome Measures
after Urologic Surgery.
Urol Int. 2023;107:280-287.
Abstract
Increasing Biomarker Guidance in the Treatment of Urothelial Carcinoma:
Systematic Review of International Clinical Trials.
Urol Int. 2023;107:480-488.
Abstract
The Influence of Preoperative Hydronephrosis on the Prognosis after Radical
Cystectomy among Patients with Different Pathological Stages of Bladder Cancer.
Urol Int. 2023 Jun 2:1-8. doi: 10.1159/000531080.
Abstract
Predicting Complexity in Transurethral Resection of Bladder Tumours: External
Validation and Modification of the Bladder Complexity Score.
Urol Int. 2023;107:583-590.
Abstract
The Misdiagnosis of Intravesical Ectopic Prostatic Tissue as a Tumor.
Urol Int. 2023;107:738-741.
Abstract
Prognostic Ability of Nutritional Indices for Outcomes of Bladder Cancer: A
Systematic Review and Meta-Analysis.
Urol Int. 2023 Aug 29:1-9. doi: 10.1159/000531884.
Abstract
The Role of Specificity Protein 1 (SP1) in Bladder Cancer Progression through
PTEN-Mediated AKT/mTOR Pathway.
Urol Int. 2023 Sep 4:1-9. doi: 10.1159/000532128.
Abstract
The Role of Urine and Washing Cytology in Primary Transurethral Resection of
Bladder Tumours.
Urol Int. 2023;107:792-800.
Abstract
Letter to the Editor regarding the Article "Postoperative Mortality Rate after
Radical Cystectomy: A Systematic Review of Epidemiologic Series".
Urol Int. 2023;107:839-840.
Abstract
Urological Tumor: A Narrative Review of Tertiary Lymphatic Structures.
Urol Int. 2023;107:841-847.
Abstract
Successful Kidney-Sparing Systemic Therapy for a High-Risk Ureteral Carcinoma
Case.
Urol Int. 2023;107:895-898.
Abstract
Laparoscopic Radical Cystectomy With Ileal Orthotopic Neobladder for Bladder
Cancer: Current Indications and Outcomes.
Urol Int. 2023 Nov 23. doi: 10.1159/000535032.
Abstract
U-Net-Based Assistive Identification of Bladder Cancer: A Promising Approach for
Improved Diagnosisc.
Urol Int. 2023 Dec 11. doi: 10.1159/000535652.
Abstract
Transurethral Hem-o-lok Clip Ligation of the Distal Ureter in Retroperitoneal
Laparoscopic Radical Nephroureterectomy.
Urol Int. 2023;107.
Abstract
Double-Layered Hand-Sewn versus Stapled Intestinal Anastomosis in Patients Who
Underwent Ileal Urinary Diversion in Radical Cystectomy: A Comparative and Cost
Effective Study.
Urol Int. 2023;107.
Abstract
Variation in Statewide Intravesical Treatment Rates for Non-Muscle Invasive
Bladder Cancer During the BCG Drug Shortage.
Urology. 2023 Mar 25:S0090-4295(23)00267-4. doi: 10.1016/j.urology.2023.
Abstract
Evaluation of Women With a Positive Urine Cytology and no Demonstrable Disease in
the Urinary Tract.
Urology. 2023;173:10-16.
Abstract
Association of Increased Age With Decreased Response to Intravesical Instillation
of Bacille Calmette-Guerin in Patients With High-Risk Non-Muscle Invasive Bladder
Cancer: Retrospective Multi-Institute Results From the Japanese Urological
Oncology Res
Urology. 2023;173:229.
Abstract
Insurance type and area deprivation are associated with worse overall mortality
for patients with muscle-invasive bladder cancer.
Urology. 2023 Apr 5:S0090-4295(23)00270-4. doi: 10.1016/j.urology.2023.
Abstract
Contemporary Systemic Therapies in Urothelial Carcinoma.
Urology. 2023;174:150-158.
Abstract
Upper Tract Tumor En Bloc Enucleation: A Novel Approach to the Diagnosis and
Management of Upper Tract Urothelial Carcinoma.
Urology. 2023;174:196-200.
Abstract
Total Intracorporeal Versus Open Bladder Cuffing in Robotic Radical
Nephroureterectomy for Upper Tract Urothelial Carcinoma.
Urology. 2023;174:111-117.
Abstract
Gender, racial and ethnic differences in pathologic response following
neoadjuvant chemotherapy for bladder cancer patients.
Urology. 2023 May 23:S0090-4295(23)00446-6. doi: 10.1016/j.urology.2023.
Abstract
Editorial Comment On: Variation in Statewide Intravesical Treatment Rates for
Non-Muscle Invasive Bladder Cancer During the BCG Drug Shortage.
Urology. 2023 May 19:S0090-4295(23)00371-0. doi: 10.1016/j.urology.2023.
Abstract
Bilateral Adrenal and testicular Tumours; When a Simple Diagnosis Becomes
Complicated.
Urology. 2023;175:e11-e12.
Abstract
An Atypical Bladder Mass: Extra Adrenal Paraganglioma.
Urology. 2023;176:e8-e9.
Abstract
Increased Plasma Ignition Distance Practice may Prevent the Obturator Reflex
Occurrences and Compare of its Effectiveness Versus Obturator Block: A
Prospective, Randomized, Controlled Study.
Urology. 2023;176:226-231.
Abstract
Reply: Gender, Racial and Ethnic Differences in Pathologic Response Following
Neoadjuvant Chemotherapy for Bladder Cancer Patients.
Urology. 2023 Jul 11:S0090-4295(23)00448-X. doi: 10.1016/j.urology.2023.
Abstract
Impact of Race, Ethnicity, and Gender on Response to Neoadjuvant Chemotherapy and
Survival in Patients With Muscle-invasive Bladder Cancer.
Urology. 2023 Jul 11:S0090-4295(23)00447-8. doi: 10.1016/j.urology.2023.
Abstract
Clinical Challenge in Urology: Late Genitourinary Toxicity Following Intravesical
Bacillus Calmette-Guerin.
Urology. 2023;177:e8-e9.
Abstract
Analysis of Transurethral Resection of Bladder Tumor Efficiency Utilizing
Nonprocedural Operating Room Times.
Urology. 2023;177:6-11.
Abstract
Prophylactic Mesh Placement With Ileal Conduit: A Cost-effectiveness Analysis.
Urology. 2023;177:197-203.
Abstract
Survival and Analysis of Prognostic Factors for Bladder Malignancies in Children
and Adolescents: A Population-based Study.
Urology. 2023;177:156-161.
Abstract
Ileal Ureter Utilization in Patients With Previous Urinary Diversions.
Urology. 2023;177:184-188.
Abstract
Surveillance for Non-Muscle Invasive Bladder Cancer: Identifying the point of
Diminishing Returns.
Urology. 2023 Aug 19:S0090-4295(23)00697-0. doi: 10.1016/j.urology.2023.
Abstract
Outcomes of Hematuria Evaluation by Advanced Practice Providers and Urologists.
Urology. 2023;178:67-75.
Abstract
Accurate Documentation Contributes to Guideline-concordant Surveillance of
Non-Muscle Invasive Bladder Cancer: a Multi-site VA Study.
Urology. 2023 Sep 1:S0090-4295(23)00729-X. doi: 10.1016/j.urology.2023.
Abstract
Cutaneous Ureterostomy Following Radical Cystectomy for Bladder Cancer: A
Contemporary Series.
Urology. 2023 Sep 7:S0090-4295(23)00733-1. doi: 10.1016/j.urology.2023.
Abstract
The Impact of Agent Orange Exposure on Non-Muscle Invasive Bladder Cancer
Outcomes.
Urology. 2023 Sep 18:S0090-4295(23)00794-X. doi: 10.1016/j.urology.2023.
Abstract
Acute Kidney Injury within 90 days of Radical Cystectomy for Bladder Cancer:
Incidence and Risk Factors.
Urology. 2023 Sep 22:S0090-4295(23)00807-5. doi: 10.1016/j.urology.2023.
Abstract
Microbial trends in infection-related readmissions following radical cystectomy
for bladder cancer.
Urology. 2023 Sep 22:S0090-4295(23)00805-1. doi: 10.1016/j.urology.2023.
Abstract
Genital Sparing Robot-Assisted Radical Cystectomy with Intracorporeal Neobladder
& Paravaginal Repair.
Urology. 2023;179:202-203.
Abstract
Reply by Authors: Acute Kidney Injury Within 90Days of Radical Cystectomy for
Bladder Cancer: Incidence and Risk Factors.
Urology. 2023 Oct 21:S0090-4295(23)00810-5. doi: 10.1016/j.urology.2023.
Abstract
Editorial Comment to Acute Kidney Injury Within 90Days of Radical Cystectomy for
Bladder Cancer: Incidence and Risk Factors.
Urology. 2023 Oct 21:S0090-4295(23)00809-9. doi: 10.1016/j.urology.2023.
Abstract
Does Alexis(c) wound protector/retractor reduce the risk of surgical site
infections after open radical cystectomy for bladder cancer? Results from a
single center, comparative study.
Urology. 2023 Nov 6:S0090-4295(23)00951-2. doi: 10.1016/j.urology.2023.
Abstract
Use of Perirectal Hyaluronic Acid Spacer Prior to Radiotherapy in a Pediatric
Patient With Bladder Rhabdomyosarcoma: A Case Report.
Urology. 2023;181:136-140.
Abstract
Recurrent Papillary Bladder Tumors in a Boy With Lynch Syndrome.
Urology. 2023;181:133-135.
Abstract
A Multipronged Intervention to Reduce Readmissions and Readmission Intensity
After Radical Cystectomy.
Urology. 2023;182:155-160.
Abstract
Editorial Comment: Does Alexis Wound Protector/Retractor Reduce the Risk of
Surgical Site Infections After Open Radical Cystectomy for Bladder Cancer?
Results From a Single Center, Comparative Study.
Urology. 2023 Dec 14:S0090-4295(23)00958-5. doi: 10.1016/j.urology.2023.
Abstract
Efficacy and safety of transurethral resection of bladder tumour combined with
chemotherapy and immunotherapy in bladder-sparing therapy in patients with T1
high-grade or T2 bladder cancer: a protocol for a randomized controlled trial.
BMC Cancer. 2023;23:320.
Abstract
Pan-cancer analysis and experimental validation of DTL as a potential diagnosis,
prognosis and immunotherapy biomarker.
BMC Cancer. 2023;23:328.
Abstract
Identification of immunotherapy-related lncRNA signature for predicting
prognosis, immunotherapy responses and drug candidates in bladder cancer.
BMC Cancer. 2023;23:355.
Abstract
Optimizing identification of consensus molecular subtypes in muscle-invasive
bladder cancer: a comparison of two sequencing methods and gene sets using FFPE
specimens.
BMC Cancer. 2023;23:504.
Abstract
The CHASIT study: sequential chemo-immunotherapy in patients with locally
advanced urothelial cancer - a non-randomized phase II clinical trial.
BMC Cancer. 2023;23:539.
Abstract
Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with
unresectable urothelial carcinoma: a nation-wide post-marketing surveillance.
BMC Cancer. 2023;23:565.
Abstract
Prognostic models for upper urinary tract urothelial carcinoma patients after
radical nephroureterectomy based on a novel systemic immune-inflammation score
with machine learning.
BMC Cancer. 2023;23:574.
Abstract
Elevated levels of MMP12 sourced from macrophages are associated with poor
prognosis in urothelial bladder cancer.
BMC Cancer. 2023;23:605.
Abstract
Upregulation of dihydropyrimidinase-like 3 (DPYSL3) protein predicts poor
prognosis in urothelial carcinoma.
BMC Cancer. 2023;23:599.
Abstract
Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in
muscle-invasive bladder cancer.
BMC Cancer. 2023;23:661.
Abstract
TUBA1C is a potential new prognostic biomarker and promotes bladder urothelial
carcinoma progression by regulating the cell cycle.
BMC Cancer. 2023;23:716.
Abstract
A novel metabolic subtype with S100A7 high expression represents poor prognosis
and immuno-suppressive tumor microenvironment in bladder cancer.
BMC Cancer. 2023;23:725.
Abstract
PD-L1 protein expression by Combined Positive Score (CPS) in patients with muscle
invasive or advanced urothelial carcinoma: a single institution experience.
BMC Cancer. 2023;23:817.
Abstract
The prognostic significance of histologic variant on survival outcomes in
patients with metastatic urothelial carcinoma receiving immune checkpoint
inhibitor therapy.
BMC Cancer. 2023;23:871.
Abstract
GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in
gastric cancer.
BMC Cancer. 2023;23:925.
Abstract
Identification of characteristics predictive of long-term survival with
durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma.
BMC Cancer. 2023;23:919.
Abstract
Genetic factors, adherence to healthy lifestyle behaviors, and risk of bladder
cancer.
BMC Cancer. 2023;23:965.
Abstract
MiR-205-3p suppresses bladder cancer progression via GLO1 mediated P38/ERK
activation.
BMC Cancer. 2023;23:956.
Abstract
Prevalence and characteristics of patients with upper urinary tract urothelial
carcinoma having potential Lynch syndrome identified by immunohistochemical
universal screening and Amsterdam criteria II.
BMC Cancer. 2023;23:940.
Abstract
Circular RNA CCT3 is a unique molecular marker in bladder cancer.
BMC Cancer. 2023;23:977.
Abstract
The optimal intravesical maintenance chemotherapy scheme for the
intermediate-risk group non-muscle-invasive bladder cancer.
BMC Cancer. 2023;23:1018.
Abstract
Identification of a basement membrane-related genes signature with immune
correlation in bladder urothelial carcinoma and verification in vitro.
BMC Cancer. 2023;23:1021.
Abstract
Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for
muscle-invasive bladder cancer: a systematic review and meta-analysis.
BMC Cancer. 2023;23:1066.
Abstract
A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic
body radiation therapy in patients with metastatic multiorgan cancer.
BMC Cancer. 2023;23:1080.
Abstract
Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment
Options (CISTO) study: a pragmatic, prospective multicenter observational cohort
study of recurrent high-grade non-muscle invasive bladder cancer.
BMC Cancer. 2023;23:1127.
Abstract
Whole exome sequencing analysis of canine urothelial carcinomas without BRAF
V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative
mechanisms for MAPK pathway disruption.
PLoS Genet. 2023;19:e1010575.
Abstract
Postoperative complications and hospital costs following open radical cystectomy:
A retrospective study.
PLoS One. 2023;18:e0282324.
Abstract
CDCP1 (CUB domain containing protein 1) is a potential urine-based biomarker in
the diagnosis of low-grade urothelial carcinoma.
PLoS One. 2023;18:e0281873.
Abstract
Detection of cytological abnormalities in urothelial cells from individuals
previously exposed or currently infected with Schistosoma haematobium.
PLoS One. 2023;18:e0278202.
Abstract
Expression of Concern: The prognostic significance of long noncoding RNAs in
bladder cancer: A meta-analysis.
PLoS One. 2023;18:e0284938.
Abstract
The expression of stem cells markers and its effects on the propensity for
recurrence and metastasis in bladder cancer: A systematic review.
PLoS One. 2023;18:e0269214.
Abstract
Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all
combined positive score indications.
PLoS One. 2023;18:e0285764.
Abstract
Exploring the mechanism of BK polyomavirus-associated nephropathy through
consensus gene network approach.
PLoS One. 2023;18:e0282534.
Abstract
Predictive role of pretreatment skeletal muscle mass index for long-term survival
of bladder cancer patients: A meta-analysis.
PLoS One. 2023;18:e0288077.
Abstract
Pre-analytical handling conditions and protein marker recovery from urine
extracellular vesicles for bladder cancer diagnosis.
PLoS One. 2023;18:e0291198.
Abstract
Transperitoneal vs extraperitoneal radical cystectomy: A systematic review and
meta-analysis.
PLoS One. 2023;18:e0294809.
Abstract
The association between BCG treatment in patients with bladder cancer and
subsequent risk of developing Alzheimer and other dementia.-A Swedish nationwide
cohort study from 1997 to 2019.
PLoS One. 2023;18:e0292174.
Abstract
IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against
bladder cancer.
Proc Natl Acad Sci U S A. 2023;120:e2306782120.
Abstract
Somatic mutations of MLL4/COMPASS induce cytoplasmic localization providing
molecular insight into cancer prognosis and treatment.
Proc Natl Acad Sci U S A. 2023;120:e2310063120.
Abstract
Thank you for your interest in scientific medicine.